CHEMICAL COMPOUNDS

BACKGROUND OF THE INVENTION

The present invention relates to compounds which demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.

Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiple resistant Enterococcus faecium.

The preferred clinically effective antibiotic for treatment of last resort of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with various toxicities, including nephrotoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens. There is also now increasing resistance appearing towards agents such as β-lactams, quinolones and macrolides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H. influenzae and M. catarrhalis.

Consequently, in order to overcome the threat of widespread multi-drug resistant organisms, there is an on-going need to develop new antibiotics, particularly those with either a novel mechanism of action and/or containing new pharmacophoric groups.

Deoxyribonucleic acid (DNA) gyrase is a member of the type II family of topoisomerases that control the topological state of DNA in cells (Champoux, J. J.; 2001. Ann. Rev. Biochem. 70: 369-413). Type II topoisomerases use the free energy from adenosine triphosphate (ATP) hydrolysis to alter the topology of DNA by introducing transient double-stranded breaks in the DNA, catalyzing strand passage through the break and resealing the DNA. DNA gyrase is an essential and conserved enzyme in bacteria and is unique among topoisomerases in its ability to introduce negative supercoils into DNA. The enzyme consists of two subunits, encoded by gyrA and gyrB, forming an A₂B₂tetrameric complex. The A subunit of gyrase (GyrA) is involved in DNA breakage and resealing and contains a conserved tyrosine residue that forms the transient covalent link to DNA during strand passage. The B subunit (GyrB) catalyzes the hydrolysis of ATP and interacts with the A subunit to translate the free energy from hydrolysis to the conformational change in the enzyme that enables strand-passage and DNA resealing.

Another conserved and essential type II topoisomerase in bacteria, called topoisomerase IV, is primarily responsible for separating the linked closed circular bacterial chromosomes produced in replication. This enzyme is closely related to DNA gyrase and has a similar tetrameric structure formed from subunits homologous to Gyr A and to Gyr B. The overall sequence identity between gyrase and topoisomerase IV in different bacterial species is high. Therefore, compounds that target bacterial type II topoisomerases have the potential to inhibit two targets in cells, DNA gyrase and topoisomerase IV; as is the case for existing quinolone antibacterials (Maxwell, A. 1997, Trends Microbiol. 5: 102-109).

DNA gyrase is a well-validated target of antibacterials, including the quinolones and the coumarins. The quinolones (e.g. ciprofloxacin) are broad-spectrum antibacterials that inhibit the DNA breakage and reunion activity of the enzyme and trap the GyrA subunit covalently complexed with DNA (Drlica, K., and X. Zhao, 1997, Microbiol. Molec. Biol. Rev. 61: 377-392). Members of this class of antibacterials also inhibit topoisomerase IV and as a result, the primary target of these compounds varies among species. Although the quinolones are successful antibacterials, resistance generated primarily by mutations in the target (DNA gyrase and topoisomerase IV) is becoming an increasing problem in several organisms, including S. aureus and Streptococcus pneumoniae (Hooper, D. C., 2002, The Lancet Infectious Diseases 2: 530-538). In addition, quinolones, as a chemical class, suffer from toxic side effects, including arthropathy that prevents their use in children (Lipsky, B. A. and Baker, C. A., 1999, Clin. Infect. Dis. 28: 352-364). Furthermore, the potential for cardiotoxicity, as predicted by prolongation of the QT, interval, has been cited as a toxicity concern for quinolones.

There are several known natural product inhibitors of DNA gyrase that compete with ATP for binding the GyrB subunit (Maxwell, A. and Lawson, D. M. 2003, Curr. Topics in Med. Chem. 3: 283-303). The coumarins are natural products isolated from Streptomyces spp., examples of which are novobiocin, chlorobiocin and coumermycin A1. Although these compounds are potent inhibitors of DNA gyrase, their therapeutic utility is limited due to toxicity in eukaryotes and poor penetration in Gram-negative bacteria (Maxwell, A. 1997, Trends Microbiol. 5: 102-109). Another natural product class of compounds that targets the GyrB subunit is the cyclothialidines, which are isolated from Streptomyces filipensis (Watanabe, J. et al 1994, J. Antibiot. 47: 32-36). Despite potent activity against DNA gyrase, cyclothialidine is a poor antibacterial agent showing activity only against some eubacterial species (Nakada, N, 1993, Antimicrob. Agents Chemother. 37: 2656-2661).

Synthetic inhibitors that target the B subunit of DNA gyrase and topoisomeraseIV are known in the art. For example, coumarin-containing compounds are described in patent application number WO 99/35155,5,6-bicyclic heteroaromatic compounds are described in patent application WO 02/060879, and pyrazole compounds are described in patent application WO 01/52845 (U.S. Pat. No. 6,608,087).

We have discovered a new class of compounds which are useful for inhibiting DNA gyrase and topoisomerase IV.

SUMMARY OF THE INVENTION

Therefore the present invention provides a compound of formula (I):

embedded image

wherein:

R¹is selected from hydrogen, nitro, hydroxy, halo, cyano, C_1-4alkyl, C_1-4alkoxy, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkanoyl, C_1-4alkylS(O)_awherein a is 0 to 2 and C_3-6cycloalkyl; wherein R¹may be optionally substituted on carbon by one or more halo or cyclopropyl;

R³is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C_1-4alkyl, C_1-4alkyl, C_1-4alkoxy, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkanoyl, C_1-4alkylS(O)_awherein a is 0 to 2 and C_3-6cycloalkyl; wherein R³may be optionally substituted on carbon by one or more halo or C_3-6cycloalkyl;

W is —O—, —N(R⁶)— or —C(R⁷)(R⁸)—;

X is a direct bond, —CH₂—, —C(O)— or S(O)_q— (wherein q is 1 or 2);

Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R⁴and R⁵are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, C_1-4alkoxyiminomethyl, N-hydroxyformamido, C_1-4hydrazino, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂-amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, N—(C_1-4alkoxy)carbamoyl, N′—(C_1-4alkyl)ureido, N′,N′—(C_1-4alkyl)₂ureido, N—(C_1-4alkyl)-N—(C_1-4alkoxy)carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, C_1-4alkoxycarbonylamino, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkylsulphonylaminocarbonyl, N′—(C_1-4alkyl)hydrazinocarbonyl, N′,N′—(C_1-4alkyl)₂hydrazinocarbonyl, carbocyclyl-R¹⁰— or heterocyclyl-R¹¹—; wherein R⁴and R⁵independently of each other may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁶, R⁷and R⁸are independently selected from hydrogen or C_1-4alkyl;

n is 1-4; wherein the values of R⁴may be the same or different;

m is 0-4; wherein the values of R⁵may be the same or different;

R¹²is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂amino, C_1-4alkanoylamino, N—(C_1-4alkyl)₂carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkoxycarbonylamino, carbocyclyl-R¹⁴— or heterocyclyl-R¹⁵—; wherein R¹²independently of each other may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

R⁹, R¹³and R¹⁷are independently selected from C_1-4alkyl, C_1-4alkanoyl, C_1-4alkylsulphonyl, C_1-4alkoxycarbonyl, carbamoyl, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R¹⁰, R¹¹, R¹⁴and R¹⁵are independently selected from a direct bond, —O—, —N(R¹⁸)—, —C(O)—, —N(R¹⁹)C(O)—, —C(O)N(R²⁰)—, —S(O)_p—, —SO₂N(R²¹)— or —N(R²²)SO₂—; wherein R¹⁸, R¹⁹, R²⁰, R²¹and R²²are independently selected from hydrogen or C_1-4alkyl and p is 0-2;

R¹⁶is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;

or a pharmaceutically acceptable salt thereof.

The present invention also provides a compound of formula (IA):

embedded image

wherein:

R²is selected from hydrogen, nitro, hydroxy, halo, cyano, C_1-4alkyl, C_1-4alkoxy, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkanoyl, C_1-4alkylS(O)_awherein a is 0 to 2 and C_3-6cycloalkyl; wherein R²may be optionally substituted on carbon by one or more halo or C_3-6cycloalkyl; R³is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C_1-4alkyl, C_1-4alkyl, C_1-4alkoxy, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkanoyl, C_1-4alkylS(O)_awherein a is 0 to 2 and C_3-6cycloalkyl; wherein R³may be optionally substituted on carbon by one or more halo or C_3-6cycloalkyl; X is a direct bond, —CH₂—, —C(O)— or S(O)_q— (wherein q is 1 or 2);

Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R⁴and R⁵are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂-amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, N—(C_1-4alkoxy)carbamoyl, N′—(C_1-4alkyl)ureido, N′,N′—(C_1-4alkyl)₂ureido, N—(C_1-4alkyl)-N—(C_1-4alkoxy)carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, C_1-4alkoxycarbonylamino, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkylsulphonylaminocarbonyl, N′—(C_1-4alkyl)hydrazinocarbonyl, N′,N′—(C_1-4alkyl)₂hydrazinocarbonyl, carbocyclyl-R¹⁰— or heterocyclyl-R¹¹—; wherein R⁴and R⁵independently of each other may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁶, R⁷and R⁸are independently selected from hydrogen or C_1-4alkyl;

n is 1-4; wherein the values of R⁴may be the same or different;

m is 0-4; wherein the values of R⁵may be the same or different;

R¹²is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkoxycarbonylamino, carbocyclyl-R¹⁴— or heterocyclyl-R¹⁵—; wherein R¹²independently of each other may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

or a pharmaceutically acceptable salt thereof.

The present invention also provides a compound of formula (IB):

embedded image

wherein:

Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R⁴and R⁵are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂-amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, N—(C_1-4alkoxy)carbamoyl, N′—(C_1-4alkyl)ureido, N′,N′—(C_1-4alkyl)₂ureido, N—(C_1-4alkyl)-N—(C_1-4alkoxy)carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, C_1-4alkoxycarbonylamino, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkylsulphonylaminocarbonyl, N′—(C_1-4alkyl)hydrazinocarbonyl, N′,N′—(C_1-4alkyl)₂hydrazinocarbonyl, carbocyclyl-R¹⁰— or heterocyclyl-R¹¹—; wherein R⁴and R⁵independently of each other may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁶, R⁷and R⁸are independently selected from hydrogen or C_1-4alkyl;

n is 1-4; wherein the values of R⁴may be the same or different;

m is 0-4; wherein the values of R⁵may be the same or different;

R¹²is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkoxycarbonylamino, carbocyclyl-R¹⁴— or heterocyclyl-R¹⁵—; wherein R¹²independently of each other may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

R¹⁰, R¹¹, R¹⁴and R¹⁵are independently selected from a direct bond, —O—, —N(R¹⁸)—, —C(O)—, —N(R¹⁹)C(O)—, —C(O)N(R²⁰)—, —S(O)_p—, —SO₂N(R²¹)— or —N(R²²)SO₂—; wherein R¹⁸, R¹⁹, R²⁰, R²¹, and R²²are independently selected from hydrogen or C_1-4alkyl and p is 0-2;

or a pharmaceutically acceptable salt thereof.

The present invention also provides a compound of formula (IC):

embedded image

wherein:

Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R⁴and R⁵are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂-amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, N—(C_1-4alkoxy)carbamoyl, N′—(C_1-4alkyl)ureido, N′,N′—(C_1-4alkyl)₂ureido, N—(C_1-4alkyl)-N—(C_1-4alkoxy)carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, C_1-4alkoxycarbonylamino, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkylsulphonylaminocarbonyl, N′—(C_1-4alkyl)hydrazinocarbonyl, N′,N′—(C_1-4alkyl)₂hydrazinocarbonyl, carbocyclyl-R¹⁰— or heterocyclyl-R¹¹—; wherein R⁴and R⁵independently of each other may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁶, R⁷and R⁸are independently selected from hydrogen or C_1-4alkyl;

m is 0-4; wherein the values of R⁵may be the same or different; R¹²is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkoxycarbonylamino, carbocyclyl-R¹⁴— or heterocyclyl-R¹⁵—; wherein R¹²independently of each other may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

R¹⁰, R¹¹, R¹⁴and R¹⁵are independently selected from a direct bond, —O—, —N(R¹⁸)—, —C(O)—, —N(R¹⁹)C(O)—, —C(O)N(R²⁰)—, —S(O)_p—, —SO₂N(R²¹)— or —N(R²²)SO₂—; wherein R¹⁸, R¹⁹, R²⁰, R²¹, and R²²are independently selected from hydrogen or C_1-4alkyl and p is 0-2;

or a pharmaceutically acceptable salt thereof.

The present invention also provides a compound of formula (IC):

embedded image

wherein:

Ring A is heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R⁴and R⁵are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂-amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, N—(C_1-4alkoxy)carbamoyl, N′—(C_1-4alkyl)ureido, N′,N′—(C_1-4alkyl)₂ureido, N—(C_1-4alkyl)-N—(C_1-4alkoxy)carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, C_1-4alkoxycarbonylamino, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkylsulphonylaminocarbonyl, N′—(C_1-4alkyl)hydrazinocarbonyl, N′,N′—(C_1-4alkyl)₂hydrazinocarbonyl, carbocyclyl-R¹⁰— or heterocyclyl-R¹¹—; wherein R⁴and R⁵independently of each other may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁶, R⁷and R⁸are independently selected from hydrogen or C_1-4alkyl;

m is 0-4; wherein the values of R⁵may be the same or different;

R¹²is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkoxycarbonylamino, carbocyclyl-R¹⁴— or heterocyclyl-R¹⁵—; wherein R¹²independently of each other may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

or a pharmaceutically acceptable salt thereof.

The present invention also provides a compound of formula (IE):

embedded image

wherein: Y is NH, N(C_1-4alkyl) or S;

X is a direct bond, —CH₂—, —C(O)— or S(O)_q— (wherein q is 1 or 2);

Ring A is heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R⁴is a substitutent on carbon selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂-amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, N—(C_1-4alkoxy)carbamoyl, N′—(C_1-4alkyl)ureido, N′,N′—(C_1-4alkyl)₂ureido, N—(C_1-4alkyl)-N—(C_1-4alkoxy)carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, C_1-4alkoxycarbonylamino, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkylsulphonylamino carbonyl, N′—(C_1-4alkyl)hydrazinocarbonyl, N′,N′—(C_1-4alkyl)₂hydrazinocarbonyl, carbocyclyl-R¹⁰— or heterocyclyl-R¹¹—; wherein R⁴and R⁵independently of each other may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R^5aand R^5bare substituents as defined for R⁴or taken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups which may be the same or different and which are selected from R⁵;

R⁶, R⁷and R⁸are independently selected from hydrogen or C_1-4alkyl;

R¹²is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkoxycarbonylamino, carbocyclyl-R¹⁴— or heterocyclyl-R¹⁵—; wherein R¹²independently of each other may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

or a pharmaceutically acceptable salt thereof.

The present invention also provides a compound of formula (IF):

embedded image

wherein:

X is a direct bond, —CH₂—, —C(O)— or S(O)_q— (wherein q is 1 or 2);

R⁶, R⁷and R⁸are independently selected from hydrogen or C_1-4alkyl;

or a pharmaceutically acceptable salt thereof.

The invention also provides a compound which is

2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[(1S)-2-methoxy-1-methylethyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(methylamino)carbonyl]-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-methyl-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid;
4-acetyl-2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[(1R)-2-methoxy-1-methylethyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2S)-2-methoxypropyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2R)-2-methoxypropyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(1R,2S)-2-fluorocyclopropyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-benzothiazole-7-carboxylic acid;
Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(methoxymethyl)-1,3-thiazole-5-carboxylic acid;
Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinic acid;
2-((3S,4R)-4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-benzothiazole-7-carboxylic acid;
Cis(±)-2-(3-chloro-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidin-1-yl)-4-(methoxymethyl)-1,3-thiazole-5-carboxylic acid;
2-((3S,4R)-4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-4-methyl-1,3-thiazole-5-carboxylic acid;
Cis(±)-2-[4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(prop-2-yn-1-yloxy)piperidin-1-yl]-1,3-thiazole-5-carboxylic acid;
Cis(±)2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-4-carboxylic acid; or
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[2-methoxy-1-(methoxymethyl)ethyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;

or a pharmaceutically acceptable salt thereof.

The invention also provides a pharmaceutical composition that comprises a compound of formula I, IA, IB, IC, or IE or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.

The invention also provides a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, or IE, or a pharmaceutically-acceptable salt thereof.

The invention also provides a method for inhibiting bacterial DNA gyrase in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, or IE or a pharmaceutically acceptable salt.

The invention also provides a compound of formula I, IA, IB, IC, or IE and pharmaceutically acceptable salts thereof for use as a medicament.

The invention also provides the use of a compound of formula I, IA, IB, IC, or IE, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.

The invention also provides the use of a compound of formula I, IA, IB, IC, or IE, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.

The present invention also provides a process for preparing compounds of formula (I) or pharmaceutically-acceptable salts thereof, comprising:

Process a) for compounds of formula (I) wherein W is —C(R⁷)(R⁸)—; converting a compound of formula (II):

embedded image

wherein R^ais cyano and R^bis dimethyamino or diethylamino; or R^aand R^bare independently selected from C_1-4alkylthio; or R^aand R^btogether form 1,3-dithianyl or 1,3-dithiolanyl; into a compound of formula (I);

Process b) for compounds of formula (I) wherein W is —O—; reacting a compound of formula (III):

embedded image

with a compound of formula (IV):

embedded image

Process c) for compounds of formula (I) wherein W is —N(R⁶)—; reacting a compound of formula (V):

embedded image

with a compound of formula (IV) or an activated acid derivative thereof;

Process d) for compounds of formula (I) wherein W is —C(R⁷)(R⁸)—; reacting a compound of formula (VI):

embedded image

wherein L is a displaceable group; with a compound of formula (VII):

embedded image

Process e) for compounds of formula (I) wherein W is —C(R⁷)(R⁸)—; reacting a compound of formula (VIII):

embedded image

wherein M is an organometallic group; with a compound of formula (IX):

embedded image

wherein L is a displaceable group;

Process f) reacting a compound of formula (X):

embedded image

with a compound of formula (XI):

embedded image

wherein D is a displaceable group;

Process g) for compounds of formula (I) wherein X is —C(O)—; reacting a compound of formula (X) with a compound of formula (XII):

embedded image

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt.

DETAILED DESCRIPTION OF THE INVENTION
Definitions

In this specification the term alkyl includes both straight and branched chain alkyl groups. For example, “C_1-4alkyl” includes methyl, ethyl, propyl, isopropyl and t-butyl. However references to individual alkyl groups such as propyl are specific for the straight chain version only. An analogous convention applies to other generic terms.

Where optional substituents are chosen from one or more groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

A “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a —CH₂-group can optionally be replaced by a —C(O)— and a ring nitrogen and/or a ring sulphur atom may be optionally oxidised to form the N- or S-oxide(s). In one aspect of the invention a “heterocyclyl” is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a —CH₂— group can optionally be replaced by a —C(O)— and a ring sulphur atom may be optionally oxidised to form the S-oxides. In a further aspect of the invention a “heterocyclyl” is an unsaturated, carbon-linked, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen. Examples and suitable values of the term “heterocyclyl” are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, N-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-N-oxide and quinoline-N-oxide. Further examples and suitable values of the term “heterocyclyl” are thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl and pyridinyl.

A “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a —CH₂— group can optionally be replaced by a —C(O)—. Particularly “carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for “carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. A particular example of “carbocyclyl” is phenyl.

An example of “C_1-4alkanoyloxy” is acetoxy. Examples of “C_1-4alkoxycarbonyl” include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of “C_1-4alkoxycarbonylamino” include methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino. Examples of “C_1-4alkoxy” include methoxy, ethoxy and propoxy. Examples of “C_1-4alkanoylamino” include formamido, acetamido and propionylamino. Examples of “C_1-4alkylS(O)_awherein a is 0 to 2” include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of “C_1-4alkanoyl” include propionyl and acetyl. Examples of “N—(C_1-4alkyl)amino” include methylamino and ethylamino. Examples of “N,N—(C_1-4alkyl)₂-amino” include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino. Examples of “C_2-4alkenyl” are vinyl, allyl and 1-propenyl. Examples of “C_2-4alkynyl” are ethynyl, 1-propynyl and 2-propynyl. Examples of “N—(C_1-4alkyl)sulphamoyl” are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of “N,N—(C_1-4alkyl)₂sulphamoyl” are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl. Examples of “N—(C_1-4alkyl)carbamoyl” are methylaminocarbonyl and ethylaminocarbonyl. Examples of “N,N—(C_1-4alkyl)₂carbamoyl” are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of “N—(C_1-4alkoxy)carbamoyl” are methoxyaminocarbonyl and isopropoxyaminocarbonyl. Examples of “N—(C_1-4alkyl)-N—(C_1-4alkoxy)carbamoyl” are N-methyl-N-methoxyaminocarbonyl and N-methyl-N-ethoxyaminocarbonyl. Examples of “C_3-6cycloalkyl” are cyclopropyl, cyclobutyl, cyclopropyl and cyclohexyl. Examples of “N′—(C_1-4alkyl)ureido” are N′-methylureido and N′-isopropylureido. Examples of “N′,N′—(C_1-4alkyl)₂ureido” are N′N′-dimethylureido and N′-methyl-N′-isopropylureido. Examples of “N′—(C_1-4alkyl)hydrazinocarbonyl” are N′-methylhydrazinocarbonyl and N′-isopropylhydrazinocarbonyl. Examples of “N′,N′—(C_1-4alkyl)₂hydrazinocarbonyl” are N′N′-dimethylhydrazinocarbonyl and N′-methyl-N′-isopropylhydrazinocarbonyl. Examples of “C_1-4alkylsulphonylamino” include methylsulphonylamino, isopropylsulphonylamino and t-butylsulphonylamino. Examples of “C_1-4alkylsulphonylaminocarbonyl” include methylsulphonylaminocarbonyl, isopropylsulphonylaminocarbonyl and t-butylsulphonylaminocarbonyl. Examples of “C_1-4alkylsulphonyl” include methylsulphonyl, isopropylsulphonyl and t-butylsulphonyl.

A compound of formula (I) may form stable acid or basic salts, and in such cases administration of a compound as a salt may be appropriate, and pharmaceutically acceptable salts may be made by conventional methods such as those described following.

Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, tosylate, α-glycerophosphate, fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably) hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine, tris-(2-hydroxyethyl)amine, tromethamine, N-methyl d-glucamine and amino acids such as glycine or lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is the sodium salt.

However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.

Within the present invention it is to be understood that a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits DNA gyrase and/or topoisomeraseIV and is not to be limited merely to any one tautomeric form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein. The same applies to compound names. It will be appreciated by those skilled in the art that certain compounds of formula (I) contain an asymmetrically substituted carbon and/or sulphur atom, and accordingly may exist in, and be isolated in, optically-active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, which form possesses properties useful in the inhibition of DNA gyrase and/or topoisomeraseIV, it being well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase) and how to determine efficacy for the inhibition of DNA gyrase and/or topoisomeraseIV by the standard tests described hereinafter.

It is also to be understood that certain compounds of the formula (I) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which inhibit DNA gyrase and/or topoisomeraseIV.

Particular and suitable values for certain substituents and groups referred to in this specification are listed below. These values may be used where appropriate with any of the definitions and embodiments disclosed herein. Each stated species represents a particular and independent aspect of the invention.

Referring to a compound of formula I, R¹is C_1-4alkyl. R¹is methyl. R¹is halo. R¹is hydrogen.

R²is C_1-4alkyl. R²is methyl. R²is halo. R²is fluoro or chloro. R²is hydrogen. R²is chloro.

R³is C_1-4alkyl. R³is methyl. R³is halo. R³is fluoro or chloro. R³is hydrogen. R³is CN. R³is C═N—OH. R³is chloro.

W is —O—. W is —N(R⁶)—. W is —NH—. W is —C(R⁷)(R⁸)—.

X is a direct bond. X is —CH₂—. X is —C(O)—. X is S(O)_q— (wherein q is 1 or 2).

Ring A is carbocyclyl. Ring A is heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R⁹. Ring A is heterocyclyl. Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl. Ring A is thiazol-2-yl, quinolin-4-yl, benzothiazol-2-yl, pyrimidin-4-yl, pyridin-2-yl or pyridin-4-yl.

R⁴is a substituent on carbon and is selected from halo, hydroxy, carboxy, C_1-4alkyl, C_1-4alkoxy, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, N—(C_1-4alkyl)-N—(C_1-4alkoxy)carbamoyl, C_1-4alkoxycarbonyl or heterocyclyl-R¹¹—; wherein R⁴may be optionally substituted on carbon by one or more R¹². R¹²is selected from hydroxy, C_2-4alkenyl, C_1-4alkoxy, N—(C_1-4alkyl)amino or N,N—(C_1-4alkyl)₂-amino; and R¹¹is —C(O)—.

Alternatively, R⁴is a substituent on carbon and is selected from fluoro, hydroxy, carboxy, methyl, methoxy, propoxy, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N-methyl-N-methoxycarbamoyl, methoxycarbonyl or morpholino-R¹¹—; wherein R⁴may be optionally substituted on carbon by one or more R¹². R¹²is selected from hydroxy, ethenyl, methoxy, N-methylamino or N,N-dimethylamino; and R¹¹is —C(O)—.

Alternatively, R⁴is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, N-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, N-methyl-N-methoxyxcarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfinyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy, oxyacetic acid, ethylaminocarbonyloxy, allylaminocarbonyloxy, pyridinylmethoxy, hydroxypropoxy, methoxy(methyl)amino, and azido.

Alternatively R⁴is halo, particularly fluoro.

R⁵is a substituent on carbon and is selected from halo, carboxy, carbamoyl, C_1-4alkyl, C_1-4alkoxy, N—(C_1-4alkyl)carbamoyl, N—(C_1-4alkoxy)carbamoyl or C_1-4alkoxycarbonyl; wherein R⁵may be optionally substituted on carbon by one or more R¹². R¹²is selected from C_1-4alkoxy or carbocyclyl-R¹⁴—; and R¹⁴is a direct bond.

Alternatively, R⁵is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxy, N-(isopropyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl; wherein R⁵may be optionally substituted on carbon by one or more R¹². R¹²is selected from methoxy or phenyl-R¹⁴—; and R¹⁴is a direct bond.

Alternatively, R⁵is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(1-methyl-1-phenylethyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl. Alternatively, R⁵is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(1-methyl-1-phenylethyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, N-methoxycarbamoyl, formyl, (methoxyimino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy-1-methylethyl, amino, methoxycarbonylamino, methylsulfonylamino, N-(1-methyl-1-phenylethyl)carbamoyl, N-2-morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N-methylcarbamoyl, N-2-hydroxyethylcarbamoyl, N-2-methoxyethylcarbamoyl, N-2-hydroxypropylcarbamoyl, N-2-hydroxy-1-methylethylcarbamoyl, N-isoxazolylcarbamoyl, N-2,2-difluoroethylcarbamoyl, N-tetrahydrofuran-3-ylcarbamoyl, N-cyclopropylcarbamoyl, N-1-cyanocyclopropylcarbamoyl, N-2-fluorocyclopropylcarbamoyl, N-2-hydroxy-1,1-dimethylethylcarbamoyl, N-1-cyano-1-methylethylcarbamoyl, N-1-(hydroxymethyl-2-methoxy-2-oxoethylcarbamoyl, N-1,3-dioxolan-2-ylmethylcarbamoyl, N-3-(2-oxopyrrolidin-1-ylpropylcarbamoyl, N-pyridin-2-ylmethylcarbamoyl, N-2-(methylthio)ethylcarbamoyl, N-1,3-oxazol-2-ylmethylcarbamoyl, N-2-fluoroethylcarbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, morpholin-4-ylmethyl, tert-butylaminomethyl, piperidine-1-ylmethyl, (3-hydroxypyrrolidin-1-yl)methyl, (hydroxyimino)methyl, 1,1-difluoromethyl, azidomethyl, cyano(morpholin-4-yl)methyl, N-2-(methylsulfonyl)ethylcarbamoyl, cyano, 1-hydroxy-1-methylethyl, cyclopropylmethyl, N-methylcarbamoyl, N-1-carboxycycloproylcarbamoyl, N-isoxazol-3-ylcarbamoyl, N-prop-2-yn-lylcarbamoyl, N-1-carboxy-2-hydroxymethylcarbamoyl, N-[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, N-methoxy-N-methylcarbamoyl, N-2-(methylsulfonyl)ethylcarbamoyl, N-methoxypropylcarbamoyl, and methoxymethyl)ethyl]amino}carbamoyl.

Alternatively R⁵is carboxy.

R⁶is hydrogen.

n is 1.

m is 1 or 2; wherein the values of R⁵may be the same or different. m is 1. m is 2.

In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

R¹is selected from C_1-4alkyl;

R²is selected from halo.

R³is selected from hydrogen or halo;

W is —N(R⁶)—;

X is a direct bond;

Ring A is heterocyclyl;

R⁵is a substituent on carbon and is selected from halo, carboxy, carbamoyl, C_1-4alkyl, C_1-4alkoxy, N—(C_1-4alkyl)carbamoyl, N—(C_1-4alkoxy)carbamoyl or C_1-4alkoxycarbonyl; wherein

R⁵may be optionally substituted on carbon by one or more R¹²;

R⁶is hydrogen;

R¹¹is —C(O)—;

R¹²is selected from hydroxy, C_2-4alkenyl, C_1-4alkoxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂-amino or carbocyclyl-R¹⁴—;

R¹⁴is a direct bond;

n is 1; and

m is 1 or 2; wherein the values of R⁵may be the same or different;

or a pharmaceutically acceptable salt thereof.

In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

R¹is selected from methyl;

R²is fluoro or chloro;

R³is selected from hydrogen, fluoro or chloro;

W is —NH—;

X is a direct bond;

Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl;

n is 1; and

m is 1 or 2; wherein the values of R⁵may be the same or different;

or a pharmaceutically acceptable salt thereof.

In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

R¹is selected from hydrogen or methyl;

R²is hydrogen, bromo, fluoro, chloro, CN, or —C═NOMe;

R³is selected from hydrogen, fluoro or chloro;

W is —NH—;

X is a direct bond;

Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl;

R⁴is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, N-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, N-methyl-N-methoxyxcarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfinyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy, oxyacetic acid, ethylaminocarbonyloxy, allylaminocarbonyloxy, pyridinylmethoxy, hydroxypropoxy, methoxy(methyl)amino, and azido;

R⁵is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(1-methyl-1-phenylethyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, N-methoxycarbamoyl, formyl, (methoxyimino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy-1-methylethyl, amino, methoxycarbonylamino, methylsulfonylamino, N-(1-methyl-1-phenylethyl)carbamoyl, N-2-morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N-methylcarbamoyl, N-2-hydroxyethylcarbamoyl, N-2-methoxyethylcarbamoyl, N-2-hydroxypropylcarbamoyl, N-2-hydroxy-1-methylethylcarbamoyl, N-isoxazolylcarbamoyl, N2,2-difluoroethylcarbamoyl, N-tetrahydrofuran-3-ylcarbamoyl, N-cyclopropylcarbamoyl, N-1-cyanocyclopropylcarbamoyl, N-2-fluorocyclopropylcarbamoyl, N-2-hydroxy-1,1-dimethylethylcarbamoyl, N-1-cyano-1-methylethylcarbamoyl, N-1-(hydroxymethyl-2-methoxy-2-oxoethylcarbamoyl, N-1,3-dioxolan-2-ylmethylcarbamoyl, N-3-(2-oxopyrrolidin-1-ylpropylcarbamoyl, N-pyridin-2-ylmethylcarbamoyl, N-2-(methylthio)ethylcarbamoyl, N-1,3-oxazol-2-ylmethylcarbamoyl, N-2-fluoroethylcarbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, morpholin-4-ylmethyl, tert-butylaminomethyl, piperidine-1-ylmethyl, (3-hydroxypyrrolidin-1-yl)methyl, (hydroxyimino)methyl, 1,1-difluoromethyl, azidomethyl, cyano(morpholin-4-yl)methyl, N-2-(methylsulfonyl)ethylcarbamoyl, cyano, 1-hydroxy-1-methylethyl, cyclopropylmethyl, N-methylcarbamoyl, N-1-carboxycycloproylcarbamoyl, N-isoxazol-3-ylcarbamoyl, N-prop-2-yn-lylcarbamoyl, N-1-carboxy-2-hydroxymethylcarbamoyl, N-[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, N-methoxy-N-methylcarbamoyl, N-2-(methylsulfonyl)ethylcarbamoyl, N-methoxypropylcarbamoyl, and methoxymethyl)ethyl]amino}carbamoyl;

n is 1; and

m is 1 or 2; wherein the values of R⁵may be the same or different;

or a pharmaceutically acceptable salt thereof.

In a further aspect of the invention, there is provided a compound of the invention which is a compound of formula (IA)

embedded image

wherein:

R¹is selected from hydrogen, halo, cyano, or C_1-4alkyl;

R²is selected from hydrogen, halo, cyano, or C_1-4alkyl;

R³is selected from hydrogen, halo, cyano, C_1-4alkyl, or —C═N—OH;

X is a direct bond, —CH₂—, —C(O)— or S(O)_q— (wherein q is 1 or 2);

Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R⁶is hydrogen or C_1-4alkyl;

n is 1-4; wherein the values of R⁴may be the same or different;

m is 0-4; wherein the values of R⁵may be the same or different;

R¹²is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_1-4alkyl, C_2-4alkenyl, C_2-4alkynyl, C_1-4alkoxy, C_1-4alkanoyl, C_1-4alkanoyloxy, N—(C_1-4alkyl)amino, N,N—(C_1-4alkyl)₂amino, C_1-4alkanoylamino, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)₂carbamoyl, C_1-4alkylS(O)_awherein a is 0 to 2, C_1-4alkoxycarbonyl, N—(C_1-4alkyl)sulphamoyl, N,N—(C_1-4alkyl)₂sulphamoyl, C_1-4alkylsulphonylamino, C_1-4alkoxycarbonylamino, carbocyclyl-R¹⁴— or heterocyclyl-R¹⁵—; wherein R¹²independently of each other may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

or a pharmaceutically acceptable salt thereof.

In a further aspect of the invention, there is provided a compound of formula (IA) which is a compound of formula (IB):

embedded image

wherein:

n is 1; wherein the values of R⁴may be the same or different; and

m is 1 or 2; wherein the values of R⁵may be the same or different.

In a further aspect of the invention, there is provided a compound of formula (IB) which is a compound of formula (IC).

embedded image

In a further aspect of the invention, there is provided a compound of formula (IC)

embedded image

wherein:

Ring A is heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from C_1-4alkyl, C_1-4alkanoyl, C_1-4alkylsulphonyl, C_1-4alkoxycarbonyl, carbamoyl, N—(C_1-4alkyl)carbamoyl, N,N—(C_1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl.

In a further aspect of the invention, there is provided a compound of formula (IC) which is a compound of formula (IE):

embedded image

wherein:

Y is N—H, N—C_1-4alkyl, S, or O;

R^5ais H or as defined for R⁵;

R^5bis H or as defined for R⁵; or

R^5aand R^5btaken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups selected from R⁵which may be the same or different.

In a further aspect of the invention, there is provided a compound of formula (IE) which is a compound of formula (IF):

embedded image

Particular compounds of the invention are the compounds of the Examples, each of which provides a further independent aspect of the invention. In further aspects, the present invention also comprises any two or more compounds of the Examples.

In one embodiment of the invention are provided compounds of formula (I), in an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (I).

In a further aspect the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt thereof.

Thus, the present invention also provides that the compounds of the formula (I) and pharmaceutically-acceptable salts thereof, can be prepared by a process as follows (wherein the variables are as defined above unless otherwise stated):

Process a) for compounds of formula (I) wherein W is —C(R⁷)(R⁸)—; converting a compound of formula (II):

embedded image

with a compound of formula (IV):

embedded image

Process c) for compounds of formula (I) wherein W is —N(R⁶)—; reacting a compound of formula (V):

embedded image

with a compound of formula (IV) or an activated acid derivative thereof;

Process d) for compounds of formula (I) wherein W is —C(R⁷)(R⁸)—; reacting a compound of formula (VI):

embedded image

wherein L is a displaceable group; with a compound of formula (VII):

embedded image

Process e) for compounds of formula (I) wherein W is —C(R⁷)(R⁸)—; reacting a compound of formula (VIII):

embedded image

wherein M is an organometallic group; with a compound of formula (IX):

embedded image

wherein L is a displaceable group;

Process f) reacting a compound of formula (X):

embedded image

with a compound of formula (XI):

embedded image

wherein D is a displaceable group;

Process g) for compounds of formula (I) wherein X is —C(O)—; reacting a compound of formula (X) with a compound of formula (XII):

embedded image

L is a displaceable group. Suitable values for L include halo, for example chloro and bromo, pentafluorophenoxy and 2,5-oxopyrrolidin-1-yloxy.

D is a displaceable group. Suitable values for D include halo, for example chloro, bromo and iodo, tosylate and mesylate.

M is an organometallic group, suitable values for M include organocuprates, for example CuLi, organozincs, Zn, or a Grignard reagent for example MgG where G is halo for example chloro.

Specific reaction conditions for the above reaction are as follows.

Process a) Compounds of formula (II) may be converted into compounds of formula (I):

(i) where R^ais cyano and R^bis dimethyamino or diethylamino; in the presence of a base for example sodium hydroxide, in a suitable solvent for example aqueous methanol at room temperature.

(ii) wherein or R^aand R^bare independently selected from C_1-4alkylthio; or R^aand R^btogether form 1,3-dithianyl or 1,3-dithiolanyl; in the presence of a reagent such as a mercury, copper or silver salt for example Hg(ClO₄)₂, CuCl₂or AgNO₃/Ag₂O in the presence of a suitable solvent for example methanol, acetone or ethanol from a temperature ranging from room temperature to reflux.

Compounds of formula (II) may be prepared according to Scheme 1:

embedded image

wherein Pg is a hydroxy protecting group as defined hereinbelow; and D is a displaceable group as defined hereinabove.

Deprotection of hydroxy protecting groups are well known in the art. Examples of such deprotections are given hereinbelow.

FGI stands for Functional Group Interconversion. In the above scheme such conversions between a hydroxy group and a D group are well known in the art and are well within the capabilities of a person skilled in the art.

Compounds of formula (IIa) and (IId) are known in the literature, or they are prepared by standard processes known in the art.

Process b) Compounds of formula (III) and (IV) may be reacted together may be reacted together in the presence of a coupling reagent, for example dicyclohexylcarbodiimide or EDC, in a suitable solvent, for example dichloromethane, THF or diethylether.

Compounds of formula (III) may be prepared according to Scheme 2:

embedded image

wherein Pg is a hydroxy protecting group as defined hereinbelow.

Deprotection of hydroxy protecting groups are well known in the art. Examples of such deprotections are given hereinbelow.

Compounds of formula (IIIa) and (IV) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process c) Compounds of formula (V) and (IV) may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di-alkyl-pyridines such as 2,6-lutidine or 2,6-di-tert-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of −40 to 40° C.

Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of −40 to 40° C.

Compounds of formula (V) may be prepared according to Scheme 3:

embedded image

wherein Pg is a amino protecting group as defined hereinbelow. The skilled reader will appreciate that where R⁶is hydrogen, this hydrogen also needs protecting by way of a suitable protecting group.

Deprotection of amino protecting groups are well known in the art. Examples of such deprotections are given hereinbelow.

Compounds of formula (Va) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process d) Compounds of formula (VI) and (VII) may be reacted in a suitable solvent such a DCM or 1,2-dichloroethane, optionally in the presence of a Lewis acid, for example AlCl₃, from 0° C. to room temperature.

Compounds of formula (VI) may be prepared according to Scheme 4:

embedded image

wherein R^aOC(O) is an ester group.

Suitable values for R^ainclude C_1-6alkyl. Deprotection of the R^acarboxy protecting group may be achieved under standard conditions, for example acid or base hydrolysis, such as those conditions give hereinbelow.

FGI stands for Functional Group Interconversion. In the above scheme such conversions between an acid group and a —C(O)L group are well known in the art and are well within the capabilities of a person skilled in the art.

Compounds of formula (VIa) and (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process e) Compounds of formula (VIII) and (IX) may be reacted in a suitable aprotic solvent such as THF or ether, at temperatures in the range of −78° C. to 0° C.

Compounds of formula (VIII) may be prepared from compounds of formula (IIc) under standard conditions known in the art. For example where M is an organocuprous reagent such compounds could be prepared according to Scheme 5:

embedded image

Compounds of formula (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process f) Compounds of formula (X) and (XI) may be reacted in a suitable solvent such as DMF, N-methylpyrrolidinone or dimethylacetamide in the presence of a base such as triethylamine or diisopropylethylamine under thermal conditions or a microwave reactor.

Compounds of formula (X) may be prepared according to Scheme 6:

embedded image

wherein M is an organometallic group as defined hereinabove.

Compounds of formula (Xa), (Xb) and (XI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process g) Compounds of formula (X) and (XII) may be coupled together under the conditions outlined in Process c).

Compounds of formula (XII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

The formation of a pharmaceutically-acceptable salt is within the skill of an ordinary organic chemist using standard techniques.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. The reagents used to introduce such ring substituents are either commercially available or are made by processes known in the art.

Introduction of substituents into a ring may convert one compound of the formula (I) into another compound of the formula (I). Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents, oxidation of substituents, esterification of substituents, amidation of substituents, formation of heteroaryl rings. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of alkoxides, diazotization reactions followed by introduction of thiol group, alcohol group, halogen group. Examples of modifications include; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

The skilled organic chemist will be able to use and adapt the information contained and referenced within the above references, and accompanying Examples therein and also the Examples herein, to obtain necessary starting materials, and products. If not commercially available, the necessary starting materials for the procedures such as those described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the above described procedure or the procedures described in the examples. It is noted that many of the starting materials for synthetic methods as described above are commercially available and/or widely reported in the scientific literature, or could be made from commercially available compounds using adaptations of processes reported in the scientific literature. The reader is further referred to Advanced Organic Chemistry, 4^thEdition, by Jerry March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in compounds. The instances where protection is necessary or desirable are known to those skilled in the art, as are suitable methods for such protection. Conventional protecting groups may be used in accordance with standard practice (for illustration see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991).

Examples of a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, a silyl group such as trimethylsilyl or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively a silyl group such as trimethylsilyl may be removed, for example, by fluoride or by aqueous acid; or an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation in the presence of a catalyst such as palladium-on-carbon.

A suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine or 2-hydroxyethylamine, or with hydrazine.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art, or they may be removed during a later reaction step or work-up.

When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.

Similarly, when a pure regioisomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure.

Enzyme Potency Testing Methods

Compounds were tested for inhibition of GyrB ATPase activity using an ammonium molybdate/malachite green-based phosphate detection assay (Lanzetta, P. A., L. J. Alvarez, P. S. Reinach, and O. A. Candia, 1979, 100: 95-97). Assays were performed in multiwell plates in 100 μl reactions containing: 50 mM TRIS buffer pH 7.5, 75 mM ammonium acetate, 5.5 mM magnesium chloride, 0.5 mM ethylenediaminetetraacetic acid, 5% glycerol, 1 mM 1,4-Dithio-DL-threitol, 200 nM bovine serum albumin, 16 μg/ml sheared salmon sperm DNA, 4 nM E. coli GyrA, 4 nM E. coli GyrB, 250 μM ATP, and compound in dimethylsulfoxide. Reactions were quenched with 150 μl of ammonium molybdate/malachite green detection reagent containing 1.2 mM malachite green hydrochloride, 8.5 mM ammonium molybdate tetrahydrate, and 1 M hydrochloric acid. Plates were read in an absorbance plate reader at 625 nm and percent inhibition values were calculated using dimethylsulfoxide (2%)-containing reactions as 0% inhibition and novobiocin-containing (2 μM) reactions as 100% inhibition controls. Compounds were tested for inhibition of topoisomeraseIV ATPase activity as described above for GyrB except the 100 μl reactions contained the following: 20 mM TRIS buffer pH 8, 50 mM ammonium acetate, 8 mM magnesium chloride, 5% glycerol, 5 mM 1,4-Dithio-DL-threitol, 0.005% Brij-35, 5 μg/ml sheared salmon sperm DNA, 10 nM E. coli GyrA, 10 nM E. coli GyrB, 160 μM ATP, and compound in dimethylsulfoxide. Compound potency was based on IC₅₀measurements determined from reactions performed in the presence of 10 different compound concentrations.

Compounds of the Examples generally have IC₅₀values of <20 μg/ml.

Bacterial Susceptibility Testing Methods

Compounds were tested for antimicrobial activity by susceptibility testing in liquid media. Compounds were dissolved in dimethylsulfoxide and tested in 10 doubling dilutions in the susceptibility assays. The organisms used in the assay were grown overnight on suitable agar media and then suspended in a liquid medium appropriate for the growth of the organism. The suspension was a 0.5 McFarland and a further 1 in 10 dilution was made into the same liquid medium to prepare the final organism suspension in 100 μL. Plates were incubated under appropriate conditions at 37 degrees C. for 24 hrs prior to reading. The Minimum Inhibitory Concentration was determined as the lowest drug concentration able to reduce growth by 80% or more.

Example 48 had an MIC of 0.13 μg/ml against Streptococcus pneumoniae. Other examples are provided in the following table.

Example
MIC
MIC
MIC
MIC
MIC

No.
HIN446
MCA445
SPN548
SAU516
EFM073

333
4
0.13
0.063
2
0.5

60
4
0.25
2
2
8

315
2
0.13
0.5
4
4

345
0.25
0.031
0.03
0.5
0.13

294
0.031
0.001
0.0039
0.031
0.016

According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.

We have found that compounds of the present invention inhibit bacterial DNA gyrase and topoisomeraseIV and are therefore of interest for their antibacterial effects.

According to a further feature of the present invention there is provided a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof.

According to a further feature of the invention there is provided a method for inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.

According to a further feature of the invention there is provided a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.

A further feature of the present invention is a compound of formula (I) and pharmaceutically acceptable salts thereof for use as a medicament. Suitably the medicament is an antibacterial agent.

According to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.

According to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal such as a human being.

Thus according to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.

According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.

According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal such as a human being.

Thus according to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.

In order to use a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, (hereinafter in this section relating to pharmaceutical composition “a compound of this invention”) for the therapeutic (including prophylactic) treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition that comprises a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.

According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in producing an anti-bacterial effect in an warm-blooded animal, such as a human being.

According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in an warm-blooded animal, such as a human being.

According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a bacterial infection in an warm-blooded animal, such as a human being.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain or be co-administered (simultaneously, sequentially or separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, macrolides, quinolones, β-lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin). These may include carbapenems, for example meropenem or imipenem, to broaden the therapeutic effectiveness. Compounds of this invention may also contain or be co-administered with bactericidal/permeability-increasing protein (BPI) products or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

In addition to its use in therapeutic medicine, compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in-vitro and in-vivo test systems for the evaluation of the effects of inhibitors of DNA gyrase in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other, pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and particular embodiments of the compounds of the invention described herein also apply.

EXAMPLES

The invention is now illustrated but not limited by the following Examples in which unless otherwise stated:—

(i) evaporations were carried out by rotary evaporation in-vacuo and work-up procedures were carried out after removal of residual solids by filtration;

(ii) operations were carried out at ambient temperature, that is typically in the range 18-26° C. and without exclusion of air unless otherwise stated, or unless the skilled person would otherwise work under an inert atmosphere;

(iii) column chromatography (by the flash procedure) was used to purify compounds and was performed on Merck Kieselgel silica (Art. 9385) unless otherwise stated;

(iv) yields are given for illustration only and are not necessarily the maximum attainable;

(v) the structure of the end-products of the invention were generally confirmed by NMR and mass spectral techniques [proton magnetic resonance spectra is quoted and was generally determined in DMSO-d₆unless otherwise stated using a Bruker DRX-300 spectrometer operating at a field strength of 300 MHz. Chemical shifts are reported in parts per million downfield from tetramethysilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; d, doublet; AB or dd, doublet of doublets; dt, doublet of triplets; dm, doublet of multiplets; t, triplet, m, multiplet; br, broad; fast-atom bombardment (FAB) mass spectral data were generally obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected] or using Agilent 1100series LC/MSD equipped with Sedex 75ELSD, run in APCI mode and, where appropriate, either positive ion data or negative ion data were collected; optical rotations were determined at 589 nm at 20° C. using a Perkin Elmer Polarimeter 341; reverse phase HPLC was carried out using YMC Pack ODS-AQ(100×20 mmID, S-5μ particle size, 12 nm pore size);

(vi) each intermediate was purified to the standard required for the subsequent stage and was characterised in sufficient detail to confirm that the assigned structure was correct; purity was assessed by HPLC, TLC, or NMR and identity was determined by infra-red spectroscopy (IR), mass spectroscopy or NMR spectroscopy as appropriate;

(vii) in which the following abbreviations may be used:—

DMF is N,N-dimethylformamide; DMA is N,N-dimethylacetamide; TLC is thin layer chromatography; HPLC is high pressure liquid chromatography; DMSO is dimethylsulfoxide; CDCl₃is deuterated chloroform; MS is mass spectroscopy; APCI is atmospheric pressure chemical ionisation; EtOAc is ethyl acetate; MeOH is methanol; DIEA is diisopropylethlamine; TFA is trifluoroacetic acid; HATU is N-[(dimethylamino)-1H,2,3-triazolo[4,5-b-]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide; HOAT is 1-hydroxy-7-azabenzotriazole; NMP is N-methylpyrrolidinone; THF is tetrahydrofuran; EtOH is ethanol; LCMS is liquid chromatography/mass spectrometry; DCM is dichloromethane;

(viii) temperatures are quoted as ° C.;

(ix) Smith Microwave Synthesizer refers to an equipment that uses microwave energy to heat organic reactions in a short period of time; it was used according to the manufacturers instruction and was obtained from Personal Chemistry Uppsala AB;

(x) Kugelrohr distillation refers to a piece of equipment that distils liquids and heats sensitive compounds using air-bath oven temperature; it was used according to the manufacturers instruction and was obtained from Buchi, Switzerland or Aldrich, Milwaukee, USA;

(xi) Where cis(±) or trans(±) is used it is to be understood that this refers to a racemic mixture of the cis or the trans isomers, (−) or (+) refers to the single enantiomer as does R,R or S,S where quoted. Rotations were measured for the first chiral compound in the synthetic scheme (see for example Intermediates 57 and 58) by measuring the rotation of the effluent from the chiral column, using a Perkin Elmer Polarimeter 341, at the point at which the enantiomer eluted, the nomenclature cis(−) or cis (+) was then continued for all the compounds in the synthesis (for example, Example 42 is the final compound in the synthesis which started from Intermediate 57); and

(xii) GCMS is Gas phase chromatography (model 6890N) with Mass Spectrometer(model 5973) manufactured by Agilent and was used according to manufacturers instructions.

Example 1

Cis(±)methyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate

embedded image

Method 1

Cis(±)3,4-dichloro-N-(3-methoxypiperidin-4-yl)-5-methyl-1H-pyrrole-2-carboxamide (Intermediate 50; 380 mg), methyl 2-bromo-1,3-thiazole-5-carboxylate (276 mg), were dissolved in anhydrous DMA (5 ml). DIEA (216 μl) was added and the mixture was heated at 120° C. for 7 hours (h). The mixture was diluted with EtOAc, washed well with citrate buffer, water, brine, and dried over Na₂SO₄. The organic phase was concentrated in vacuo to give the title compound as a brown solid (337 mg).

Method 2

Alternatively the title compounds were prepared using a Smith Microwave Synthesizer by subjecting the reaction mixture to single-mode microwave at 150° C. for 30 minutes (min.) or until the reaction is complete as judged by LCMS, using polar aprotic solvent such as DMA, NMP or 1-butyl-3-methyl imidazolium-tetrafluoroborate as reaction solvents. MS (ES) MH⁺: 447 for C₁₇H₂₀Cl₂N₄O₄S; NMR: 1.65 (m, 2H), 2.09 (s, 3H), 3.07 (m, 3H), 3.48 (m, 1H), 3.63 (s, 3H), 3.86 (m, 1H), 4.15 (m, 2H), 6.91 (d, 1H), 7.45 (s, 1H), 11.19 (s, 1H).

Examples 2-33

The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

2
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 447 for
Intermediate 51 and

dichloro-5-methyl-1H-
C₁₇H₂₀Cl₂N₄O₄S; NMR: 1.87
methyl 2-bromo-1,3-

pyrrol-2-
(m, 2H), 2.05 (m, 2H), 2.27 (s,
thiazole-5-

yl)carbonyl]amino}-3-
3H), 3.01 (m, 2H), 3.25 (s,
carboxylate

methoxypiperidin-1-yl)-1,3-
3H), 3.65 (m, 1H), 3.83 (s,

thiazole-5-carboxylate
3H), 4.12 (m, 1H), 4.46 (m,

2H), 7.40 (d, 1H), 8.00 (s, 1H),

12.38 (s, 1H)

3
methyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH⁺: 447 for
Intermediate 52 and

dichloro-5-methyl-1H-
C₁₇H₂₀Cl₂N₄O₄S; NMR: 1.89
methyl 2-bromo-1,3-

pyrrol-2-
(m, 2H), 2.11 (m, 2H), 2.23 (s,
thiazole-5-

yl)carbonyl]amino}-3-
3H), 3.33 (m, 2H), 3.46 (s,
carboxylate

methoxypiperidin-1-yl)-1,3-
3H), 3.59 (m, 1H), 3.85 (s,

thiazole-5-carboxylate
3H), 4.09 (m, 1H), 4.46 (m,

2H), 7.31 (d, 1H), 7.92 (s, 1H),

12.30 (s, 1H)

4
Cis(±)methyl 2-(4-{[(3,4-
MS (ES) MH⁺: 414 for
Intermediate 56 and

difluoro-5-methyl-1H-
C₁₇H₂₀F₂N₄O₄S; NMR: 1.72
methyl 2-bromo-1,3-

pyrrol-2-
(m, 2H), 1.79 (s, 3H), 2.3 (m,
thiazole-5-

yl)carbonyl]amino}-3-
2H), 3.45 (s, 3H), 3.61 (s, 1H),
carboxylate

methoxypiperidin-1-yl)-1,3-
3.8 (s, 3H), 4.08 (m, 1H), 4.41

thiazole-5-carboxylate
(m, 2H), 6.88 (d, 1H), 8.00 (s,

1H), 11.5 (brs, 1H)

5
Cis(±)methyl 2-(4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-3- propoxypiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 475 for C₁₉H₂₄Cl₂N₄O₄S; NMR: 0.89 (m, 3H), 1.54 (m, 2H), 1.87 (m, 2H), 2.26 (s, 3H), 3.37 (m, 2H), 3.71 (m, 2H), 3.81 (s, 3H), 4.15 (m, 1H), 4.42 (m, 2H), 7.18 (d, 1H), 7.98 (s, 1H), 12.29 (s, 1H)
Intermediate 53 and methyl 2-bromo-1,3- thiazole-5- carboxylate

6
Cis(±)methyl 2-(3-
MS (ES) MH⁺: 473 for
Intermediate 54 and

(allyloxy)-4-{[(3,4-
C₁₉H₂₂Cl₂N₄O₄S; NMR: 1.94
methyl 2-bromo-1,3-

dichloro-5-methyl-1H-
(m, 2H), 2.23 (s, 3H), 3.56 (m,
thiazole-5-

pyrrol-2-
2H), 3.58 (m, 2H), 3.8 (s,
carboxylate

yl)carbonyl]amino}piperidin-
3H), 4.07 (m, 2H), 4.21 (m,

1-yl)-1,3-thiazole-5-
1H), 4.46 (m, 2H), 5.37 (m,

carboxylate
2H), 5.95 (m, 1H), 7.29 (d,

1H), 7.96 (s, 1H), 12.32 (s,

1H)

7
Cis(±)ethyl 4-(3-(allyloxy)-
MS (ES) MH⁺: 531 for
Intermediate 54 and

4-{[(3,4-dichloro-5-methyl-
C₂₆H₂₈Cl₂N₄O₄
Intermediate 10

1H-pyrrol-2-

yl)carbonyl]amino}piperidin-

1-yl)quinoline-2-

carboxylate

8
Cis(±)ethyl 4-(4-{[(3,4-
MS (ES) MH⁺: 533 for
Intermediate 53 and

dichloro-5-methyl-1H-
C₂₆H₃₀Cl₂N₄O₄
Intermediate 10

pyrrol-2-

yl)carbonyl]amino}-3-

propoxypiperidin-1-

yl)quinoline-2-carboxylate

9
Cis(±)methyl-2-(4-{[(3,4-
MS (ES) MH⁺: 435, 437 for
Intermediate 32 and

dichloro-5-methyl-1H-
C₁₆H₁₇Cl₂FN₄O₃S; NMR:
methyl 2-bromo-1,3-

pyrrol-2-
1.77-1.79 (m, 2H), 2.12 (s,
thiazole-5-

yl)carbonyl]amino}-3-
3H), 3.25-3.27 (m, 2H), 3.49-
carboxylate

fluoropiperidin-1-yl)-1,3-
3.62 (dd, 1H), 3.68 (s, 3H),

thiazole-5-carboxylate
3.95 (m, 1H), 4.00-4.24 (m,

1H), 4.82-4.99 (m, 1H), 7.21

(d, 1H), 7.79 (s, 1H), 12.05

(brs, 1H)

10
Trans(±)methyl-2-(4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 435, 437 for C₁₆H₁₇Cl₂FN₄O₃S
Intermediate 34 and methyl 2-bromo-1,3- thiazole-5- carboxylate

11
methyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH⁺: 435, 437 for
Intermediate 33 and

dichloro-5-methyl-1H-
C₁₆H₁₇Cl₂FN₄O₃S; NMR:
methyl 2-bromo-1,3-

pyrrol-2-
1.77-1.79 (m, 2H), 2.12 (s,
thiazole-5-

yl)carbonyl]amino}-3-
3H), 3.25-3.27 (m, 2H), 3.49-
carboxylate

fluoropiperidin-1-yl)-1,3-
3.62 (dd, 1H), 3.68 (s, 3H),

thiazol-5-carboxylate
3.95 (m, 1H), 4.00-4.24 (m,

1H), 4.82-4.99 (m, 1H), 7.21

(d, 1H), 7.79 (s, 1H), 12.05

(brs, 1H)

12
Cis(±)ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 499, 501 for
Intermediate 32 for

dichloro-5-methyl-1H-
C₁₆H₁₇Cl₂FN₄O₃S
ethyl 2-bromo-1,3-

pyrrol-2-

benzothiazole-7-

yl)carbonyl]amino}-3-

carboxylate (U.S. Pat.

fluoropiperidin-1-yl)-1,3-

No. 5770758)

benzothiazole-7-

carboxylate

13
Cis(±)Ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 511, 513 for
Intermediate 50 and

dichloro-5-methyl-1H-
C₂₂H₂₄Cl₂N₄O₄S; NMR: 1.45
ethyl 2-bromo-1,3-

pyrrol-2-
(t, 3H), 1.87 (m, 2H), 3.44 (s,
benzothiazole-7-

yl)carbonyl]amino}-3-
3H), 3.46 (m, 2H), 3.67 (m,
carboxylate (U.S. Pat.

methoxypyridin-1-yl)-1,3-
1H), 4.23 (m, 1H), 4.28 (m,
No. 5770758)

benzothiazole-7-
1H), 4.36 (m, 1H), 4.47 (q,

carboxylate
2H), 7.27 (d, 1H), 7.50 (t, 1H),

7.77 (t, 1H0, 12.26 (s, 1H)

14
Cis(±)Methyl 2-chloro-6-
MS (ES) MH⁺: 477, 479 for
Intermediate 50 and

(4-{[(3,4-dichloro-5-
C₁₈H₂₀Cl₃N₅O₄; NMR: 1.62
methyl 2,6-

methyl-1H-pyrrol-2-
(m, 1H), 1.77 (m, 1H), 2.18 (s,
dichloropyrimidine-

yl)carbonyl]amino}-3-
3H), 3.15 (m, 1H), 3.28 (s,
4-carboxylate

methoxypyridin-1-
3H), 3.56 (m, 1H), 3.87 (s,

yl)pyrimidine-4-carboxylate
3H), 4.11 (m, 1H), 4.30 (m,

1H), 5.00 (m, 1H), 7.15 (m,

1H0, 7.36-7.48 (m, 1H), 12.16

(m, 1H)

15
Cis(±)Ethyl 2-(4-{[(4- chloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-4-carboxylate embedded image

MS (ES) MH⁺: 427, 429 for C₁₈H₂₃ClN₄O₃; NMR: 1.27 (t, 3H), 1.60 (m, 1H), 1.93 (m, 1H), 2.14 (s, 3H), 3.23 (m, 1H), 3.28 (s, 3H), 3.43 (m, 1H), 3.53 (m, 1H), 3.85 (m, 1H), 4.12 (m, 1H), 4.24 (m, 2H), 6.89 (s, 1H)
Intermediate 55 and ethyl 2-bromo-1,3- thiazole-4- carboxylate

16
Cis(±)ethyl 2-(4-{[(3,4-
MS (ES) (M +H): 461, 463 for
Intermediate 50 and

dichloro-5-methyl-1H-
C₁₈H₂₂Cl₂N₄O₄S
ethyl 2-bromo-1,3-

pyrrol-2-

thiazole-4-

yl)carbonyl]amino}-3-

carboxylate

methoxypiperidin-1-yl)-1,3-

thiazole-4-carboxylate

17
Cis(±)ethyl 4-(4-{[(3,4-
MS (ES) MH⁺: 455 for
Intermediate 50 and

dichloro-5-methyl-1H-
C₂₀H₂₄Cl₂N₄O₄
ethyl 4-

pyrrol-2-

chloropyridine-2-

yl)carbonyl]amino}-3-

carboxylate (WO

methoxypiperidin-1-

2004007657)

yl)pyridine-2-carboxylate

18
Cis(±)methyl 2-(4-{[(3,4-
MS (ES) MH⁺: 461 for
Intermediate 74 and

dichloro-5-methyl-1H-
C₁₈H₂₂Cl₂N₄O₄S
methyl-2-

pyrrol-2-

bromothiazole-5-

yl)carbonyl]amino}-3-

carboxylate

(methoxymethyl)piperiin-

1-yl]-1,3-thiazole-5-

carboxylate

19
Cis(±)methyl-2-{4-{[(3,4-
MS (ES) MH⁺: 460 for
Intermediate 75 and

dichloro-5-methyl-1H-
C₁₈H₂₃Cl₂N₅O₃S
methyl-2-

pyrrol-2-

bromothiazole-5-

yl)carbonyl]amino}-3-

carboxylate

[(methylamino)methyl]

piperidin-1-yl}-1,3-thiazole-5-

carboxylate

20
Cis(±)methyl 2-{4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-3- [(dimethylamino)methyl] piperidin-1-yl}-1,3-thiazole- 5-carboxylate embedded image

MS (ES) MH⁺: 474 for C₁₉H₂₅Cl₂N₅O₃S
Intermediate 76 and methyl-2- bromothiazole-5- carboxylate

21
Cis(±)methyl-2-(4-{[(4-
MS (ES) MH⁺: 574 for
Intermediate 16 and

chloro-5-methyl-1H-pyrrol-
C₂₇H₃₂ClN₅O₅S
Intermediate 55

2-yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-4-

{[(1-methyl-1-

phenylethyl)amino]carbonyl}-

1,3-thiazole-5-

carboxylate

22
Cis(±)methyl-2-(4-{[(4-
MS (ES) MH⁺: 413 for
Intermediate 55 and

chloro-5-methyl-1H-pyrrol-
C₁₇H₂₁ClN₄O₄S; NMR: 1.63
methyl 2-bromo-1,3-

2-yl)carbonyl]amino}-3-
(s, 1H), 1.90 (s, 1H), 2.14 (s,
thiazole-5-

methoxypiperidin-1-yl)-1,3-
3H), 3.28 (s, 3H), 3.39 (s, 1H),
carboxylate

thiazole-5-carboxylate
3.47 (s, 2H), 3.74 (s, 3H), 3.93

(s, 1H), 4.21 (s, 2H), 6.89 (d,

J = 2.64 Hz, 1H), 7.71 (d,

J = 7.91 Hz, 1H), 7.84 (s, 1H),

11.64 (s, 1H)

23
Cis(±)methyl-2-chloro-6-
MS (ES) MH⁺: 442 for
Intermediate 55 and

(4-{[(4-chloro-5-methyl-
C₁₈H₂₁Cl₂N₅O₄; NMR: 1.63 (s,
methyl 2,6-

1H-pyrrol-2-
1H), 1.79 (s, 1H), 2.09-2.20
dichloropyrimidine-

yl)carbonyl]amino}-3-
(m, 3H), 3.08 (s, 1H), 3.17 (d,
4-carboxylate

methoxypiperidin-1-
J = 5.27 Hz, 1H), 3.25 (s, 3H),

yl)pyrimidine-4-carboxylate
3.30-3.81-3.89 (m, 3H), 4.22

(s, 2H), 4.91 (s, 1H), 6.87 (d,

J = 2.64 Hz, 1H), 7.37 (s, 1H),

7.67 (d, J = 7.72 Hz, 1H), 11.62

(s, 1H)

24
Cis(±)methyl-2-(4-{[(4-
MS (ES) MH⁺: 457 for
Intermediate 55 and

chloro-5-methyl-1H-pyrrol-
C₁₉H₂₅ClN₄O₅S; NMR: 1.63
Intermediate 17

2-yl)carbonyl]amino}-3-
(s, 1H), 1.84-1.99 (m, 1H),

methoxypiperidin-1-yl)-4-
2.12-2.19 (m, 3H), 3.33 (s,

(methoxymethyl)-1,3-
3H), 3.35-3.38 (m, 1H), 3.52-

thiazole-5-carboxylate
3.57 (m, 1H), 3.72 (s, 3H),

3.97 (s, 1H), 4.15-4.29 (m,

3H), 4.52-4.61 (m, 2H), 6.89

(d, J = 2.64 Hz, 1H), 7.70 (d,

J = 7.91 Hz, 1H), 11.63 (s, 1H)

25
Cis(±)methyl-2-(4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- (methoxymethyl)-1,3- thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 491 for C₁₉H₂₄Cl₂N₄O₅S; NMR: 1.66- 1.81 (m, 2H), 2.14-2.22 (m, 3H), 3.29 (s, 3H), 3.33 (s, 2H), 3.36 (s, 3H), 3.55 (s, 1H), 3.73 (s, 3H), 3.97 (s, 1H), 4.20- 4.35 (m, 2H), 4.57 (d, J = 1.32 Hz, 2H), 7.15 (d, J = 8.29 Hz, 1H), 12.15 (s, 1H)
Intermediate 50 and Intermediate 17

26
Cis(±)ethyl 4-(4-{[(4-
MS (ES) MH⁺: 471 for
Intermediate 55 and

chloro-5-methyl-1H-pyrrol-
C₂₄H₂₇ClN₄O₄; NMR: 1.38 (t,
Intermediate 10

2-yl)carbonyl]amino}-3-
J = 7.06 Hz, 3H), 1.80 (s, 1H),

methoxypiperidin-1-
2.15 (s, 3H), 3.27 (s, 3H), 3.36-

yl)quinoline-2-carboxylate
3.42 (m, 3H), 3.64 (s, 3H),

3.84 (s, 1H), 4.41 (q, J = 7.10

Hz, 2H), 6.95 (d, J = 2.64 Hz,

1H), 7.57 (s, 1H), 7.69 (d,

J = 7.16 Hz, 1H), 7.73-7.82

(m, 2H), 8.11 (dd, J = 17.14,

8.29 Hz, 2H), 11.65 (s, 1H)

27
Cis(±)ethyl-2-(4-{[(3,4-
MS (ES) MH⁺: 455 for
Intermediate 50 and

dichloro-5-methyl-1H-
C₂₀H₂₄Cl₂N₄O₄; NMR: 1.32 (t,
ethyl 2-

pyrrol-2-
J = 7.06 Hz, 3H), 1.72 (d,
fluoroisonicotinate

yl)carbonyl]amino}-3-
J = 0.75 Hz, 2H), 2.18 (s, 3H),
(Konno, Akinori J.

methoxypiperidin-1-
3.13 (d, J = 13.38 Hz, 2H), 3.29-
Fluorine Chemistry

yl)isonicotinate
3.31 (m, 3H), 3.50 (s, 1H),
(1998), 87(2), 137-

4.23 (s, 2H), 4.32 (q, J = 7.03
140)

Hz, 2H), 4.67 (s, 1H), 6.97 (dd,

J = 5.09, 0.94 Hz, 1H), 7.14 (d,

J = 8.10 Hz, 1H), 7.23 (s, 1H),

8.24 (d, J = 5.09 Hz, 1H), 12.15

(s, 1H)

28
Cis(±)ethyl-4-(4-{[(4-
MS (ES) MH⁺: 421 for
Intermediate 55 and

chloro-5-methyl-1H-pyrrol-
C₂₀H₂₅ClN₄O₄; NMR: 1.31 (t,
ethyl 4-

2-yl)carbonyl]amino}-3-
J = 7.06 Hz, 3H), 1.61 (s, 1H),
chloropyridine-2-

methoxypiperidin-1-
1.85 (s, 1H), 2.12-2.18 (m,
carboxylate (WO

yl)pyridine-2-carboxylate
3H), 3.23 (s, 3H), 3.50 (s, 1H),
2004007657)

3.89 (s, 2H), 4.19 (s, 3H), 4.30

(q, J = 7.16 Hz, 2H), 6.89 (d,

J = 2.83 Hz, 1H), 7.05 (dd,

J = 6.03, 2.64 Hz, 1H), 7.44 (d,

J = 2.64 Hz, 1H), 7.67 (d,

J = 8.10 Hz, 1H), 8.20 (d,

J = 5.84 Hz, 1H), 11.63 (s, 1H)

29
Cis(±)3,4-dichloro-N-[3-
MS (ES) MH⁺: 447 for
Intermediate 50 and

methoxy-1-(2-
C₂₂H₂₄Cl₂N₄O₂
4-chloro-2-

methylquinolin-4-

methylquinoline

yl)piperidin-4-yl]-5-methyl-

1H-pyrrole-2-carboxyamide

30
Cis(±)Methyl 4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-1-[5- (methoxycarbonyl)-1,3- thiazol-2-yl]piperidine-3- carboxylate embedded image

MS (ES) MH⁺: 474 C₁₈H₂₂ClN₅O₅S; NMR: 1.98 (m, 2H), 2.23 (s, 3H), 3.08 (m, 1H), 3.24 (m, 1H), 3.55 (m, 1H), 3.66 (s, 3H), 3.79 (s, 3H), 3.97 (m, 1H), 4.23 (m, 1H), 4.63 (m, 1H), 7.64 (d, 1H), 7.95 (s, 1H), 12.01 (s, 1H)
Intermediate 35 and methyl 2-bromo-1,3- thiazole-5- carboxylate

31
Cis(±)ethyl 2-(4-{[(4-
MS(ES) MH⁺: 477, 479 for
Intermediate 55 and

chloro-5-methyl-1H-pyrrol-
C₂₂H₂₅ClN₄O₄S; NMR: 1.33 (t,
ethyl 2-bromo-1,3-

2-yl)carbonyl]amino}-3-
3H), 1.76 (m, 1H), 1.83 (m,
benzothiazole-7-

methoxypiperidin-1-yl)-1,3-
1H), 2.10 (s, 3H), 3.37 (m,
carboxylate (U.S. Pat.

benzothiazole-7-
2H), 3.45 (s, 3H), 3.54 (m,
No. 5770758)

carboxylate
1H), 4.21-4.29 (m, 3H), 4.36

(q, 2H), 6.86 (m, 1H), 7.38 (t,

1H), 7.62-7.69 (m, 3H), 11.60

(s, 1H)

32
Cis(±)ethyl 4-(4-{[(3,4-
MS (ES) MH: 472 for for
Intermediate 56 and

difluoro-5-methyl-1H-
C₂₄H₂₆F₂N₄O₄
Intermediate 10

pyrrol-2-

yl)carbonyl]amino}-3-

methoxypiperidin-1-

yl)quinoline-2-carboxylate

33
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 435, 437 for
Intermediate 36 and

dichloro-5-methyl-1H-
C₁₆H₁₇Cl₂FN₄O₃S; NMR: 1.77-
methyl 2-bromo-1,3-

pyrrol-2-
1.79 (m, 2H), 2.12 (s, 3H),
thiazole-5-

yl)carbonyl]amino}-3-
3.25-3.27 (m, 2H), 3.49-3.62
carboxylate

fluoropiperidin-1-yl)-1,3-
(dd, 1H), 3.68 (s, 3H), 3.95 (m,

thiazole-5-carboxylate
1H), 4.00-4.24 (m, 1H), 4.82-

4.99 (m, 1H), 7.21 (d, 1H),

7.79 (s, 1H), 12.05 (br s, 1H)

Example 34
Cis(±)methyl 4-(aminocarbonyl)-2-(4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate

Cis(±)methyl-2-(4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-1,3-thiazole-5-carboxylate (Example 21; 0.058 g, 0.1 mmol) was dissolved in equal volumes of TFA and DCM. The reaction was heated in a sealed tube to an external temperature of 85° C. overnight. The reaction mixture was concentrated to remove the DCM and excess TFA. The residue was partitioned with EtOAc and NaHCO₃and the organic extracts were dried with MgSO₄and concentrated to a yellow solid (0.050 g, 100%). MS (ES) MH⁺: 456 for C₁₈H₂₂ClN₅O₅S.

Example 35
Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid

embedded image

Cis(±)methyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate (Example 1; 200 mg) was dissolved in THF (50 ml). 2N LiOH (100 ml) was added and the mixture was heated at 50° C. for 18 h. The reaction mixture was cooled to ambient and acidified with 20% aqueous citric acid. The aqueous phase was extracted with EtOAc and the organic phase was washed with water, brine, dried over Na₂SO₄. The organic phase was concentrated in vacuo and triturated with diethyl ether to give the title compound as an off white solid. (164 mg). MS (ES) MH⁺: 433, 431 for C₁₆H₁₈Cl₂N₄O₄S; NMR: 1.87 (m, 2H), 2.28 (s, 3H), 3.32 (m, 6H), 3.63 (s, 1H), 3.87 (m, 1H), 4.45 (m, 2H), 7.04 (d, 1H), 7.90 (s, 1H), 11.97 (s, 1H), 12.30 (s, 1H).

Examples 36-71

The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.

Ex
Compound
NMR
m/z
SM

36
Cis(±)2-(4-{[(3,4-dichloro-5-
0.87 (m, 3H), 1.57 (m, 2H),
461
Example 5

methyl-1H-pyrrol-2-
1.93 (m, 2H), 2.24 (s, 3H),

yl)carbonyl]amino}-3-
2.6 (m, 2H), 3.45 (m, 2H),

propoxypiperidin-1-yl)-1,3-
3.69 (m, 2H), 4.36 (m, 2H),

thiazole-5-carboxylic acid
7.23 (d, 1H), 7.87 (s, 1H),

12.34 (s, 1H)

37
Cis(±)2-(3-(allyloxy)-4-{[(3,4-
1.79 (m, 2H), 2.20 (s, 3H),
459
Example 6

dichloro-5-methyl-1H-pyrrol-2-
3.38 (m, 2H), 3.71 (s, 1H),

yl)carbonyl]amino}piperidin-1-
3.95 (m, 2H), 4.15 (m, 2H),

yl)-1,3-thiazole-5-carboxylic
5.26 (m, 2H), 5.91 (m, 1H),

acid
7.18 (d, 1H), 7.76 (s, 1H),

12.19 (s, 1H)

38
Cis(±)4-(3-(allyloxy)-4-{[(3,4-
2.06 (m, 2H), 2.20 (s, 3H),
503
Example 7

dichloro-5-methyl-1H-pyrrol-2-
3.1-4.0 (m, 4H), 4.51 (m,

yl)carbonyl]amino}piperidin-1-
3H), 5.18 (m, 2H), 5.82 (m,

yl)quinoline-2-carboxylic acid
1H), 7.29 (d, 1H), 7.57 (s,

1H), 7.71 (m, 1H), 7.95 (m,

1H), 8.36 (m, 2H), 12.23 (s,

1H)

39
Cis(±)4-(4-{[(3,4-dichloro-5-
0.62 (t, 3H), 1.35 (m, 2H),
505
Example 8

methyl-1H-pyrrol-2-
2.13 (s, 3H), 5.36 (m, 2H),

yl)carbonyl]amino}-3-
3.5-4.0 (m, 4H), 4.05 (m,

propoxypiperidin-1-
2H), 4.43 (m, 2H), 7.20 (d,

yl)quinoline-2-carboxylic acid
1H), 7.55 (s, 1H), 7.71 (m,

1H), 8.00 (m, 1H), 8.22 (m,

2H), 12.24 (s, 1H)

40
Cis(±)2-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylic acid embedded image

1.75-1.79 (m, 2H), 2.13 (s, 3H), 3.39-3.57 (m, 2H), 3.93- 3.96 (d, 1H), 4.25 (m, 2H), 4.81-4.97 (m, 1H), 7.28 (d, 1H), 7.63 (s, 1H), 12.12 (s, 1H)
421, 423
Example 9

41
Trans(±)2-(4-{[(3,4-dichloro-5-
1.74-1.79 (m, 2H), 2.11 (s,
421,
Example 10

methyl-1H-pyrrol-2-
3H), 3.49-3.58 (m, 2H), 3.86-
423

yl)carbonyl]amino}-3-
3.92 (d, 1H), 4.22 (m, 2H),

fluoropiperidin-1-yl)-1,3-
4.84-4.97 (m, 1H), 7.26 (d,

thiazole-5-carboxylic acid
1H), 7.61 (s, 1H), 12.11 (s,

1H)

42
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.62-1.90 (m, 2H), 2.12 (s,
421,
Example 33

methyl-1H-pyrrol-2-
3H), 3.23 (m, 1H), 3.50 (dd,
423

yl)carbonyl]amino}-3-
1H), 3.83-4.03 (m, 1H), 4.12-

fluoropiperidin-1-yl)-1,3-
4.43 (m, 2H), 4.90 (d, 1H),

thiazole-5-carboxylic acid
7.21 (d, 1H), 7.69 (s, 1H),

12.04 (s, 1H), 12.61 (brs, 1H)

43
2-((3R,4S)-4-{[(3,4-dichloro-5-
1.63-1.92 (m, 2H), 2.13 (s,
421,
Example 11

methyl-1H-pyrrol-2-
3H), 3.21 (m, 1H), 3.50 (dd,
423

yl)carbonyl[amino]}-3-
1H), 3.87-4.02 (m, 1H), 4.14-

fluoropiperidin-1-yl)-1,3-
4.42 (m, 2H), 4.90 (d, 1H),

thiazole-5-carboxylic acid
7.21 (d, 1H), 7.69 (s, 1H),

12.04 (s, 1H), 12.61 (brs, 1H)

44
Cis(±)2-(4-{[(3,4-dichloro-5-
1.82 (m, 2H), 2.13 (s, 3H),
471,
Example 12

methyl-1H-pyrrol-2-
3.48-3.67 (m, 2H), 4.12-4.41 473

yl)carbonyl]amino}-3-
(m, 3H), 4.92 (d, 1H), 7.22 (d,

fluoropiperidin-1-yl)-1,3-
1H), 7.34 (t, 1H), 7.62 (m,

benzothiazole-7-carboxylic acid
1H), 12.06 (s, 1H), 13.45 (brs,

1H)

45
Cis(±)2-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- benzothiazole-7-carboxylic acid embedded image

1.86 (m, 2H), 2.25 (s, 3H), 3.46 (s, 3H), 3.48 (m, 2H), 3.65 (m, 1H), 4.35 (m, 2H), 4.46 (m, 1H), 7.25 (d, 1H), 7.48 (t, 1H), 7.73 (t, 1H), 12.26 (s, 1H)
483, 485
Example 13

46
Cis(±)2-(4-{[(4-chloro-5-
1.60 (m, 1H), 1.83 (m, 1H),
449,
Example 31

methyl-1H-pyrrol-2-
2.07 (s, 3H), 3.25 (s, 3H),
451

yl)carbonyl]amino}-3-
3.35 (m, 2H), 3.52 (m, 1H),

methoxypiperidin-1-yl)-1,3-
4.09-4.17 (m, 3H), 6.84 (d,

benzothiazole-7-carboxylic acid
1H), 7.37 (t, 1H), 7.58-7.67

(m, 3H), 11.58 (s, 1H)

47
Cis(±)2-(4-{[(3,4-dichloro-5-
1.74 (m, 2H), 2.17 (s, 3H),
433,
Example 16

methyl-1H-pyrrol-2-
3.26 (m, 2H), 3.35 (s, 3H),
435

yl)carbonyl]amino}-3-
3.52 (m, 1H), 3.84 (m, 1H),

methoxypiperidin-1-yl)-1,3-
4.21 (m, 2H), 7.13 (d, 1H),

thiazole-4-carboxylic acid
7.57 (s, 1H), 12.15 (s, 1H),

12.61 (brs, 1H)

48
Cis(±)2-Chloro-6-(4-{[(3,4-
1.59 (m, 1H), 1.77 (m, 1H),
463,
Example 14

dichloro-5-methyl-1H-pyrrol-2-
2.18 (s, 3H), 3.16 (m, 1H),
465

yl)carbonyl]amino}-3-
3.17 (m, 1H), 3.56 (m, 1H),

methoxypiperidin-1-
4.11 (m, 1H), 4.30 (m, 1H),

yl)pyrimidine-4-carboxylic acid
4.55 (m, 1H), 4.98 (m, 1H),

7.15 (m, 1H), 7.38 (m, 1H),

12.10 (m, 1H)

49
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.85 (m, 2H), 2.24 (s, 3H),
433
Example 2

methyl-1H-pyrrol-2-
3.32 (s, 3H), 3.42 (m, 2H),

yl)carbonyl]amino}-3-
3.69 (s, 1H), 4.07 (m, 1H),

methoxypiperidin-1-yl)-1,3-
4.49 (m, 2H), 7.31 (d, 1H),

thiazole-5-carboxylic acid
7.87 (s, 1H), 12.27 (s, 1H),

12.69 (s, 1H)

50
Cis(±)2-(4-{[(4-chloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-4-carboxylic acid embedded image

1.61 (m, 1H), 1.92 (m, 1H), 2.14 (s, 3H), 3.24 (m, 1H), 3.28 (s, 3H), 3.43 (m, 1H), 3.53 (m, 1H), 3.84 (m, 1H), 4.10 (m, 1H), 4.21 (m, 1H), 6.91 (s, 1H), 7.51 (s, 1H), 7.69 (m, 1H), 11.64 (s, 1H)
399, 401
Example 15

51
2-((3S,4S)-4-{[(3,4-Dichloro-5-
1.64 (m, 1H), 1.88 (m, 1H),
433,
Example 86

methyl-1H-pyrrol-2-
2.11 (s, 3H), 3.13-3.20 (m,
435

yl)carbonyl]amino}-3-
3H), 3.29 (s, 3H), 3.68 (m,

methoxypiperidin-1-yl)-1,3-
1H), 4.03 (m, 1H), 7.29 (d,

thiazole-5-carboxylic acid
1H0, 7.71 (s, 1H), 11.95 (s,

1H), 12.63 (brs, 1H)

52
2-((3R,4R)-4-{[(3,4-Dichloro-5-
1.63 (m, 1H), 1.88 (m, 1H),
433,
Example 85

methyl-1H-pyrrol-2-
2.11 (s, 3H), 3.16-3.27 (m,
435

yl)carbonyl[amino}-3-
3H), 3.29 (s, 3H), 3.69 (m,

methoxypiperidin-1-yl)-1,3-
1H), 4.03-4.07 (m, 2H), 7.37

thiazole-5-carboxylic acid
(d, 1H), 7.69 (s, 1H), 12.03 (s,

1H)

53
Cis(±)2-[4-{[(3,4-dichloro-5-
1.62 (m, 1H), 2.03 (m, 1H),
447
Example 18

methyl-1H-pyrrol-2-
2.16 (s, 3H), 2.98 (m, 1H),

yl)carbonyl]amino}-3-
3.21 (s, 3H), 3.25 (m, 3H),

(methoxymethyl)piperidin-1-
3.41 (dd, 1H), 3.89 (m, 2H),

y1]-1,3-thiazole-5-carboxylic
4.06 (dd, 1H), 7.51 (d, 1H),

acid
7.63 (s, 1H)

54
Cis(±)2-{4-{[(3,4-dichloro-5-
1.63 (m, 1H), 1.83 (m, 1H),
446
Example 19

methyl-1H-pyrrol-2-
1.97 (m, 1H), 2.18 (s, 3H),

yl)carbonyl]amino}-3-
2.44 (s, 3H), 2.64 (m, 1H),

[(methylamino)methyl]piperidin-
2.79 (m, 1H), 2.98 (m, 2H),

1-y1}-1,3-thiazole-5-carboxylic
3.87 (m, 1H), 4.07 (m, 2H),

acid
7.33 (s, 1H), 8.14 (d, 1H)

55
Cis(±)2-{4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- [(dimethylamino)methyl]piperidin- 1-yl}-1,3-thiazole-5- carboxylic acid embedded image

1.66 (m, 1H), 1.88 (m, 1H0, 2.05 (m, 1H), 2.16 (s, 3H), 2.26 (s, 6H), 2.40 (m, 2H), 2.94 (t, 1H), 3.18 (t, 1H), 3.86 (m, 1H), 3.98 (dd, 2H), 7.63 (s, 1H), 7.67 (d, 1H), 12.3 (brs, 1H)
460
Example 20

56
Cis(±)2-(4-{[(4-chloro-5-
1.63 (d, J = 3.39 Hz, 1H), 1.84-
399
Example 22

methyl-1H-pyrrol-2-
1.99 (m, 1H), 2.14 (s, 3H),

yl)carbonyl]amino}-3-
3.28 (s, 3H), 3.54 (s, 1H),

methoxypiperidin-1-yl)-1,3-
3.91 (s, 1H), 4.15-4.29 (m,

thiazole-5-carboxylic acid
1H), 6.90 (d, J = 2.83 Hz, 1H),

7.71 (d, J = 8.10 Hz, 1H), 7.74

(s, 1H), 11.64 (d, J = 1.70 Hz,

1H), 12.62 (s, 1H)

57
Cis(±)2-chloro-6-{4-{[(4-
1.64 (s, 1H), 1.78 (s, 1H),
428
Example 23

chloro-5-methyl-1H-pyrrol-2-
2.13 (s, 3H), 3.13 (s, 1H),

yl)carbonyl]amino}-3-
3.25 (s, 3H), 3.54 (s, 1H),

methoxypiperidin-1-
4.22 (s, 2H), 4.60 (s, 1H),

yl)pyrimidine-4-carboxylic acid
4.93 (s, 1H), 6.87 (d, J = 2.45

Hz, 1H), 7.34 (s, 1H), 7.65 (s,

1H), 11.62 (s, 1H), 13.69 (s,

1H)

58
Cis(±)2-(4-{[(4-chloro-5-
1.62 (s, 1H), 1.93 (s, 1H),
443
Example 24

methyl-1H-pyrrol-2-
2.14 (s, 3H), 3.28 (d, J = 2.26

yl)carbonyl]amino}-3-
Hz, 3H), 3.36 (s, 3H), 3.54 (s,

methoxypiperidin-1-yl)-4-
2H), 3.91 (s, 1H), 4.19 (s,

(methoxymethyl)-1,3-thiazole-
2H), 4.56 (s, 2H), 6.89 (s,

5-carboxylic acid
1H), 7.69 (s, 1H), 11.63 (s,

1H)

59
Cis(±)2-(4-{[(3,4-dichloro-5-
1.75 (s, 2H), 2.18 (s, 3H),
477
Example 25

methyl-1H-pyrrol-2-
3.28 (s, 3H), 3.37 (s, 3H),

yl)carbonyl]amino}-3-
3.54 (s, 3H), 3.91 (s, 1H),

methoxypiperidin-1-y1)-4-
4.26 (s, 2H), 4.56 (s, 2H),

(methoxymethyl)-1,3-thiazole-
7.14 (s, 1H), 12.15 (s, 1H)

5-carboxylic acid

60
Cis(±)4-(4-{[(4-chloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1- yl)quinoline-2-carboxylic acid embedded image

1.80 (s, 1H), 2.15 (s, 3H), 3.15 (s, 3H), 3.64 (s, 3H), 3.80 (s, 2H), 4.09 (s, 1H), 4.30 (s, 1H), 6.93 (d, J = 2.45 Hz, 1H), 7.57 (s, 1H), 7.68 (s, 1H), 7.85 (s, 2H), 8.19 (s, 2H), 11.65 (s, 1H)
443
Example 26

61
Cis(±)4-(4-{[(3,4-dichloro-5-
1.67 (s, 1H), 1.81 (s, 1H),
393
Example 17

methyl-1H-pyrrol-2-
2.18 (s, 3H), 3.28 (s, 3H),

yl)carbonyl]amino}-3-
3.59 (s, 2H), 4.20 (s, 2H),

methoxypiperidin-1-
4.32 (s, 1H), 4.55 (d, J = 12.43

yl)pyridine-2-carboxylic acid
Hz, 1H), 7.14 (d, J = 8.29 Hz,

1H), 7.18 (dd, J = 7.06, 2.92

Hz, 1H), 7.44 (d, J = 2.64 Hz,

1H), 7.97 (d, J = 6.97 Hz, 1H),

12.18 (s, 1H)

62
Cis(±)2-(4-{[(3,4-dichloro-5-
1.72 (s, 2H), 2.18 (s, 3H),
427
Example 27

methyl-1H-pyrrol-2-
3.04-3.18 (m, 2H), 3.30 (s,

yl)carbonyl]amino}-3-
3H), 3.49 (s, 1H), 4.25 (s,

methoxypiperidin-1-
2H), 4.66 (s, 1H), 6.97 (d,

yl)isonicotinic acid
J = 4.71 Hz, 1H), 7.16 (s, 1H),

7.24 (s, 1H), 8.22 (d, J = 4.90

Hz, 1H), 12.16 (s, 1H), 13.39

(s, 1H)

63
Cis(±)2-[4-{[(3,4-Dichloro-5-
MS (ES⁺): 516, 518 for

Example 78

methyl-1H-pyrrol-2-
C₂₀H₂₃Cl₂N₄O₅S; NMR: 1.82

yl)carbonyl]amino}-3-
(m, 2H), 2.15 (s, 3H), 3.32

(morpholin-4-
(m, 6H), 3.61 (m, 5H), 3.99

ylcarbonyl)piperidin-1-yl]-1,3-
(t, 2H), 4.40 (m, 1H), 7.18 (d,

thiazole-5-carboxylic acid
1H), 7.78 (s, 1H), 12.03 (s,

1H), 12.8 (brs, 1H)

64
Cis(±)2-{4-{[(3,4-Dichloro-5-
1.75 (m, 1H), 1.89 (m, 1H),
474,
Example 79

methyl-1H-pyrrol-2-
2.14 (s, 3H), 2.87 (s, 3H),
476

yl)carbonyl]amino}-3-
3.09 (s, 3H), 3.36 (m [under

[(dimethylamino)carbonyl]piperidin-
water peak], 3H), 4.00 (m,

1-yl}-1,3-thiazole-5-
2H), 4.36 (m, 1H), 7.19 (d,

carboxylic acid
1H), 7.78 (s, 1H), 11.98 (s,

1H), 12.71 (brs, 1H)

65
Cis(±)2-{4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- [(ethylamino)carbonyl]piperidin- 1-yl}-1,3-thiazole-5-carboxylic acid embedded image

0.92 (t, 3H), 1.58 (m 1H), 1.99 (d, 1H), 2.15 (s, 3H), 2.62 (dd, 1H), 3.02 (m, 2H), 3.30 (q, 2H), 3.92 (d, 1H), 4.07 (d, 1H), 4.27 (m, 1H), 7.03 (d, 1H), 7.77 (s, 1H), 7.92 (t, 1H), 12.01 (s, 1H), 12.71 (brs, 1H)
474, 476
Example 80

66
Cis(±)2-(4-{[(3,4-dichloro-5-
1.50 (m, 1H), 1.96 (d, 1H),
490,
Example 81

methyl-1H-pyrrol-2-
2.41 (s, 3H), 2.61 (m, 1H),
492

yl)carbonyl]amino}-3-{[(2-
3.07 (m, 2H), 3.26 (q, 2H),

hydroxyethyl)amino]carbonyl}
3.32 (under water peak, 2H),

piperidin-1-yl)-1,3-thiazole-5-
3.89 (d, 1H), 4.04 (d, 1H),

carboxylic acid
4.22 (m, 1H), 4.72 (brs, 1H),

7.39 (brs, 1H), 7.62 (s, 1H),

8.07 (t, 1H), 12.32 (brs, 1H)

67
Cis(±)2-(4-{[(3,4-dichloro-5-
1.66 (m, 1H), 1.85 (m, 1H),
490,
Example 82

methyl-1H-pyrrol-2-
2.14 (s, 3H), 3.08 (m, 1H),
492

yl)carbonyl]amino}-3-
3.09 (s, 3H), 3.15 (m, 1H),

{[methoxy(methyl)amino]
3.33 (under water peak, 1H),

carbonyl}piperidin-1-yl)-1,3-
3.74 (brs, 3H), 3.83 (m, 1H),

thiazole-5-carboxylic acid
4.00 (m, 1H), 4.33 (m, 1H),

7.19 (s, 1H), 7.81 (brs, 1H),

12.98 (brs, 1H)

68
Cis(±)4-(aminocarbonyl)-2-(4-
1.63 (s, 1H), 1.90 (s, 1H),
442
Example 34

{[(4-chloro-5-methyl-1H-
2.14 (s, 3H), 3.17 (s, 1H),

pyrrol-2-yl)carbonyl]amino}-3-
3.37 (s, 3H), 3.54 (s, 2H),

methoxypiperidin-1-yl)-1,3-
4.14-4.28 (m, 2H), 6.90 (s,

thiazole-5-carboxylic acid
1H), 7.72 (s, 1H), 8.93 (s,

2H), 11.63 (s, 1H)

69
2-((3R,4S)-4-{[(3,4-dichloro-5-
1.89 (m, 2H), 2.11 (s, 3H),
433
Example 3

methyl-1H-pyrrol-2-
2.23 (s, 3H), 3.33 (m, 2H),

yl)carbonyl]amino}-3-
3.46 (s, 3H), 3.59 (s, 1H),

methoxypiperidin-1-yl)-1,3-
4.09 (m, 1H), 4.46 (m, 2H),

thiazole-5-carboxylic acid
7.31 (d, 1H), 7.92 (s, 1H),

12.28 (s, 1H), 12.67 (brs, 1H)

70
Cis(±)2-(4-{[(3,4-difluoro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-5-carboxylic acid embedded image

1.75 (m, 2H), 2.13 (s, 3H), 3.33 (s, 3H), 3.36 (m, 2H), 3.54 (s, 1H), 3.89 (m, 1H), 3.94 (m, 2H), 6.73 (d, 1H), 7.90 (s, 1H), 11.40 (s, 1H)
441
Example 4

71
Cis(±)4-(4-{[(3,4-difluoro-5-
1.69 (m, 2H), 2.01 (s, 3H),
444
Example 32

methyl-1H-pyrrol-2-
3.16 (m, 1H), 3.16 (s, 3H),

yl)carbonyl]amino}-3-
3.8-4.02 (m, 2H), 4.18-4.38

methoxypiperidin-1-
(m, 2H), 6.57-6.84 (d, 1H),

yl)quinoline-2-carboxylic acid
7.44-7.56 (s, 1H), 7.56-7.72

(m, 1H), 7.78-7.94 (m, 1H),

8.04-8.27 (m, 2H), 11.23 (br,

1H)

Example 72
Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-N-methoxy-1,3-thiazole-5-carboxamide

Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (Example 35; 100 mg) was dissolved in anhydrous DMA (2 ml). HATU (97 mg), HOAT (31 mg), DIEA (41 μl) were added and the mixture was stirred for 30 min. N-Methoxyamine hydrochloride (19.3 mg) was added followed by DIEA (41 μl), and the mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc, washed with H₂O, 20% citric acid solution, H₂O, sat. NaHCO₃, H₂O, brine and dried over Na₂SO₄. The organic phase was concentrated in vacuo to give the title compound as an off-white solid (82 mg). MS (ES) (MH⁺): 462, 460 for C₁₇H₂₁Cl₂N₅O₄S; NMR: 1.64 (m, 2H), 1.85 (m, 1H), 2.05 (s, 3H), 2.83 (m, 1H), 3.33 (m, 5H), 3.73 (s, 3H), 4.07 (m, 1H), 4.38 (m, 2H), 7.24 (d, 1H), 7.74 (s, 1H), 11.39 (s, 1H), 12.05 (s, 1H).

Example 73

The following Example was prepared by the procedure described in Example 72 from the starting material (SM) indicated.

Ex
Compound
Data
SM

73
2-((3R,4R)-4-{[(3,4-Dichloro-
MS (ES) (M + H): 462, 464
Example 52

5-methyl-1H-pyrrol-2-
(M + H), for C₁₇H₂₁Cl₂N₅O₄S;

yl)carbonyl]amino}-3-
NMR: 1.61 (m, 1H), 1.87 (m,

methoxypiperidin-1-yl)-N-
1H), 2.11 (s, 3H), 3.14 (m,

methoxy-1,3-thiazole-5-
1H), 3.29 (s, 3H), 3.33 (m,

carboxamide
1H), 3.59 (s, 3H), 3.64 (m,

1H), 3.95-4.06 (m, 3H), 7.29

(d, 1H), 7.66 (s, 1H), 11.31

(brs, 1H), 11.95 (s, 1H)

Example 74
Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-hydroxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid

Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (Example 35; 100 mg) was suspended in anhydrous DCM. BBr₃/DCM (15 ml) was added and the mixture was heated at 40° C. for 18 h. The reaction mixture was cooled to −50° C. and water was added. The mixture was extracted with EtOAc and the organic phase was washed with water, dried over Na₂SO₄. The organic phase was concentrated in vacuo to yield a pale brown solid which was dissolved in acetonitrile/water mixture and was lyophilized (46 mg). MS (ES) MH⁺: 419 for C₁₅H₁₆Cl₂N₄O₄S; NMR: 1.87 (m, 2H), 2.20 (s, 3H), 3-4 (brm, 6H), 6.9 (d, 1H), 7.51 (s, 1H), 12.19 (s, 1H).

Example 75

The following Example was prepared by the procedure described in Example 74 from the starting material (SM) indicated.

Ex
Compound
Data
SM

75
Cis(±)4-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- hydroxypiperidin-1- yl)quinoline-2-carboxylic acid embedded image

MS (ES) MH⁺: 463 for C₂₁H₂₀Cl₂N₄O₄; NMR: 1.24 (m, 2H), 2.13 (m, 2H), 2.38 (s, 3H), 3.54 (m, 2H), 4.14 (m, 2H), 4.57 (m, 1H), 7.07 (s, 1H), 7.87 (m, 1H), 8.23 (m, 2H), 8.52 (m, 2H), 12.06 (s, 1H)
Example 76

Example 76
Cis(±)-4-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)quinoline-2-carboxylic acid

Cis(±)3,4-dicholoro-N-[3-methoxy-1-(2-methylquinolin-4-yl)piperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide (Example 29; 170 mg) was dissolved in pyridine (5 ml). Selenium dioxide (211 mg) was added and the mixture was heated at 130° C. for 3 h. The brown solution was cooled to room temperature, diluted with water and filtered through a bed of celite. The filtrate was extracted with EtOAc, washed with water and dried over Na₂SO₄, concentrated in vacuo. The brown solid that separated was triturated with Et₂O, filtered, washed well with n-hexanes and dried in vacuo to give the title compound as a brown solid (176 mg). MS (ES) MH⁺: 477 for C₂₂H₂₂Cl₂N₄O₄; NMR: 1.34 (m, 1H), 2.01 (m, 1H), 2.28 (s, 3H), 3.10 (s, 3H), 3.42 (m, 3H), 3.72 (m, 2H), 4.23 (m, 1H), 7.36 (d, 1H), 7.63 (s, 1H), 7.78 (m, 1H), 7.92 (m, 1H), 8.30 (m, 2H), 12.30 (brs, 1H).

Example 77
Cis(±)4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-[5-(methoxycarbonyl)-1,3-thiazol-2-yl]piperidine-3-carboxylic acid

Cis(±)4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-3-carboxylic acid hydrochloride (Intermediate 79; 1.84 g) was dissolved in anhydrous DMF (20 ml) under an argon atmosphere in a 100-ml round bottom flask. Methyl 2-bromothiazole-5-carboxylate (1.43 g) was added followed by N,N-diisopropylethylamine (3.6 ml) at room temperature. The reaction was heated to 55° C. for 14 h cooled to room temperature. The reaction mixture was diluted with EtOAc (250 ml) and washed with a saturated aqueous ammonium chloride solution (125 ml), followed by a saturated aqueous sodium chloride solution (100 ml). The EtOAc solution was dried over anhydrous MgSO₄and concentrated in vacuo. The crude product was purified by silica gel chromatography using 0-10% CH₃OH in DCM. The recovered product was recrystallised from EtOAc to further enhance the diastereomeric excess, increasing it from a 90:10 cis:trans mixture to a 96:4 cis:trans mixture (by HPLC analysis). The recrystallised product was carried on to the next reaction (2 g). MS (ES−(M+H)⁺): 461, 463 for C₁₇H₁₈Cl₂N₄O₅S; NMR: 1.71 (m, 1H), 1.91 (m, 1H), 2.16 (s, 3H), 2.81 (dt, 1H), 3.42 (m, 2H), 3.74 (s, 3H), 3.86 (m, 1H), 4.34 (m, 2H), 7.43 (d, 1H), 7.88 (s, 1H), 8.50 (brs, 1H), 12.06 (s, 1H).

Example 78
Cis(±)methyl 2-[4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(morpholin-4-ylcarbonyl)piperidin-1-yl]-1,3-thiazole-5-carboxylate

The title compound was prepared in a manner analogous to (Intermediate 37) starting from cis(±)4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-[5-(methoxycarbonyl)-1,3-thiazol-2-yl]piperidine-3-carboxylic acid (Example 77) and morpholine. MS (ES⁺): 530, 532 for C₂₁H₂₅Cl₂N₅O₅S.

Examples 79-82

The following compounds were synthesized by an analogous method to Example 78 from Example 77 and the starting materials given in the table below.

Ex
Compound
m/z
SM

79
Cis(±)methyl 2-{4-{[(3,4-
M/z 488, 490
Dimethylamine

dichloro-5-methyl-1H-pyrrol-2-

(2M in THF)

yl)carbonyl]amino}-3-

[(dimethylamino)carbonyl]

piperidin-1-yl}-1,3-thiazole-5-

carboxylate

80
Cis(±)methyl 2-{4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- [(ethylamino)carbonyl]piperidin- 1-yl}-1,3-thiazole-5-carboxylate embedded image

M/z 488, 490
Ethylamine (2M in THF)

81
Cis(±)methyl 2-(4-{[(3,4-
M/z 504, 506
Ethanolamine

dichloro-5-methyl-1H-pyrrol-2-

yl)carbonyl]amino}-3-{[(2-

hydroxyethyl)amino]carbonyl}

piperidin-1-yl)-1,3-thiazole-5-

carboxylate

82
Cis(±)methyl 2-(4-{[(3,4-
M/z 504, 506; NMR: 1.78 (m,
N,O-Dimethyl-

dichloro-5-methyl-1H-pyrrol-2-
1H), 1.93 (m, 1H), 2.14 (s, 3H),
hydroxylamine

yl)carbonyl]amino]-3-
3.06 (brs, 3H), 3.24 (m, 1H), 3.32
hydrochloride

{[methoxy(methyl)amino]
(s, 1H), 3.38 (m, 1H), 3.72 (brs,

carbonyl}piperidin-1-yl)-
1H), 3.74 (s, 3H), 3.98 (m, 1H),

1,3-thiazole-5-carboxylate
4.12 (m, 1H), 4.38 (m, 1H), 7.19

(d, 1H), 7.88 (s, 1H), 11.99 (s, 1H)

Example 83
Cis(±)-6-(4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-2-methoxypyrimidine-4-carboxylic acid

Cis(±)methyl 2-chloro-6-(4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)pyrimidine-4-carboxylate (Example 23; 0.12 g, 0.27 mmol) was dissolved in 0.5 M sodium methoxide in MeOH (5.4 ml, 2.7 mmol) and heated in the microwave for 1.5 h at 85° C. The reaction mixture was acidified with 1N HCl and the product was extracted with EtOAc, dried with MgSO₄and concentrated to a solid which was purified by reverse phase chromatography (gradient elution from 20-50% CH₃CN in water with 0.5% TFA). Freeze drying yielded product as a white solid. MS (ES) MH⁺: 424 for C₁₈H₂₂ClN₅O₅; NMR: 1.62 (s, 1H), 1.75 (s, 1H), 2.14 (s, 3H), 3.26 (s, 3H), 3.53 (m, 3H), 3.87 (s, 3H), 4.22 (s, 2H), 6.88 (d, J=2.64 Hz, 1H), 7.07 (s, 1H), 7.66 (d, J=7.91 Hz, 1H), 11.63 (s, 1H).

Example 84

The following compound was prepared by the procedure of Example 83 from the starting material (SM) indicated.

Ex
Compound
NMR
M/z
SM

84
Cis(±)6-(4-{[(3,4-dichloro-5-
1.61 (m, 1H), 1.74 (m, 1H), 2.18
458,
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.21 (m, 1H), 3.33 (s, 3H),
460
14

yl)carbonyl]amino}-3-
3.51 (m, 1H), 3.53 (m, 1H), 3.85

methoxypiperidin-1-yl)-2-
(s, 3H), 4.28 (m, 2H), 5.10 (m,

memoxypyrimidine-4-
1H), 7.03 (m, 1H), 7.12 (m, 1H),

carboxylic acid
12.15 (m, 1H)

Examples 85-86

The following compounds were prepared by the procedure of Intermediate 37 using the starting materials (SM) indicated.

Ex
Compound
Data
SM

85
Methyl 2-((3R,4R)-4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 447 for C₁₇H₂₀ClN₄O₄S; NMR: 1.71 (m, 1H), 1.93 (m, 1H), 2.18 (s, 3H), 3.24-3.28 (m, 2H), 3.31 (s, 3H), 3.75 (s, 3H), 3.79 (m, 1H), 4.02- 4.11 (m, 2H), 7.35 (d, 1H), 7.88 (s, 1H0, 12.00 (s, 1H)
Intermediate 30 and Intermediate 1

86
Methyl 2-((3S,4S)-4-{[(3,4-
MS (ES) MH⁺: 447 for
Intermediate 31 and

dichloro-5-methyl-1H-
C₁₇H₂₀ClN₄O₄S; NMR: 1.71 (m,
Intermediate 1

pyrrol-2-
1H), 1.93 (m, 1H), 2.18 (s, 3H),

yl)carbonyl]amino}-3-
3.24-3.28 (m, 2H), 3.31 (s, 3H),

methoxypiperidin-1-yl)-1,3-
3.75 (s, 3H), 3.79 (m, 1H), 4.02-

thiazole-5-carboxylate
4.11 (m, 2H), 7.35 (d, 1H), 7.88 (s,

1H0, 12.00 (s, 1H)

Preparation of Starting Materials for Examples 1-86
Intermediate 1
3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxylic acid

embedded image

Ethyl 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 2; 7.765 g, 0.03496 mol) was dissolved in MeOH (80 ml) and DCM (10 ml) and slowly added to a 70° C. solution of 2 N LiOH (105 ml, 0.21 mol). After 2 h, the reaction mixture was cooled to room temperature and then in an ice bath, followed by acidification with 2 N HCl. The mixture was stirred at 0° C. for 1 h, and a purple solid was filtered, washed with water and lyophilized overnight to give 4.314 g (0.0222 mol, 64% yield) of the desired product. MS (ES⁻): 192.13, 194.13 for C₆H₅Cl₂NO₂; NMR: 2.17 (s, 3H).

Intermediate 2
Ethyl 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylate
Method 1

A solution of ethyl 5-methyl-1H-pyrrole-2-carboxylate (Intermediate 3; 7.00 g, 0.0457 mol) in tetrachloromethane (30 ml) was cooled to 0° C. under nitrogen. The rubber septum used in the apparatus was pierced with a needle, and SO₂Cl₂(7.8 ml, 0.096 mol) was then added dropwise over 25 min. Within 1 h, the reaction mixture had formed a slurry. The solid was collected by suction filtration, washed with cold tetrachloromethane, and dried under vacuum overnight to give the title product as a peach coloured solid (7.84 g, 0.0353 mol, 77% yield). MS (ES⁻): 222.00, 224.00 for C₈H₉Cl₂NO₂; NMR: 1.34-1.40 (t, 3H), 2.28 (s, 3H), 4.32-4.38 (m, 2H).

Method 2

A 4-neck 22 L round bottom flask equipped with an overhead stirrer, reflux condenser, nitrogen inlet and an internal temperature probe was charged with (Intermediate 253, 1000 g, 3.9 mol), 1-methyl-2-pyrrolidinone (10 L) and sodium cyanoborohydride (382 g, 6.1 mol, 1.56 eq). The resulting solution was heated at 75-80° C. for 6 h and allowed to cool to ambient overnight. Reaction solution was poured into water (20 L) resulting in a light brown suspension and product was extracted with methyl tert-butyl ether (2×10 L). Organic layer was dried with sodium sulfate and concentrated under reduced pressure to a thick slurry, which was filtered and solid dried in convection oven yielding 4 (518 g, 60%) as a light brown solid.

Intermediate 3
Ethyl 5-methyl-1H-pyrrole-2-carboxylate

Sodium (2.79 g, 0.121 mmol) was dissolved in anhydrous EtOH (100 ml), then 2,2,2-trichloro-1-(5-methyl-1H-pyrrol-2-yl)ethanone (Intermediate 4; 22.5 g, 0.099 mmol) was added in small portions. The dark brown solution was stirred at room temperature for 30 min then concentrated under vacuum to a small volume. The mixture was cooled in an ice bath and 3 N HCl was added slowly then extracted with diethyl ether (3×100 ml). The ether extracts were washed with 10% NaHCO₃, water and brine, dried over Na₂SO₄and concentrated in vacuo to give the title compound as a brown solid. (15.04 g). NMR: 1.32 (t, 3H), 2.1 (s, 3H), 4.371 (q, 2H), 5.96 (dd, 1H), 6.78 (dd, 1H), 11.67 (s, 1H).

Intermediate 4
2,2,2-Trichloro-1-(5-methyl-1H-pyrrol-2-yl)ethanone

2-Methyl-1H-pyrrole (Intermediate 5; 10 g, 0.123 mmol) in anhydrous diethyl ether (30 ml) was added dropwise over 1 h to a stirred solution of triacetyl chloride (29 g, 0.16 mmol) in anhydrous Et₂O (100 ml). The mixture was stirred for a further 1 h then K₂CO₃(10 g/30 ml) was added slowly through a dropping funnel. The organic phase was dried over Na₂SO₄and treated with decolourizing charcoal (3 g) for 30 min at room temperature. The resulting purple solution was concentrated and triturated with n-hexanes to give the title compound as a purple solid. (16.72 g). NMR (CDCl₃): 2.36 (s, 3H), 6.04 (dd, 1H), 7.45 (dd, 1H), 10.344 (s, 1H).

Intermediate 5
2-Methyl-1H-pyrrole

Potassium hydroxide (50 g, 0.89 mmol) was added to a solution of ethylene glycol (750 ml) and 1H-pyrrole-2-carbaldehyde (50 g, 0.53 mmol). Hydrazine hydrate (37 ml, 0.745 mmol) was added slowly over 15 min. The reaction mixture was refluxed at 90° C. for 90 min. The mixture was cooled to room temperature and cold water (250 ml) was added. The aqueous mixture was extracted with DCM (250 ml). The organic phase was washed with water (250 ml), dried over Na₂SO₄and concentrated in vacuo. Kugelrohr distillation gave the title compound as a clear colourless liquid (29.75 g). NMR: 2.1 (s, 3H), 5.77 (s, 1H), 5.9 (dd, 1H), 6.25 (dd, 1H), 10.54 (s, 1H).

Intermediate 6
4-Chloro-5-methyl-1H-pyrrole-2-carboxylic acid

embedded image

Lithium hydroxide (2 M, 4 ml) was warmed to 50° C. and a solution of ethyl 4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 7; 0.30 g, 1.60 mmol) in MeOH was added to it. The reaction was heated to 80° C. and stirred for two hours. The MeOH was removed and the aqueous solution was cooled to 0° C. and acidified with 30% HCl. The precipitated product (0.23 g, 92%) was filtered and dried. MS (ES): 160 (M+1) for C₆H₆ClNO₂; NMR (CDCl₃) □: 2.25 (s, 3H), 6.85 (s, 1H), 8.98 (brs, 1H).

Intermediate 7
Ethyl 4-chloro-5-methyl-1H-pyrrole-2-carboxylate

N-Chlorosuccinimide (0.67 g, 5.08 mmol) was added to a solution of ethyl 5-methyl-1H-pyrrole-2-carboxylate (Intermediate 3; 0.65 g, 4.23 mmol) in chloroform (20 ml). The reaction was warmed to 40° C. and stirred for 4 h, then poured to a beaker containing 2 N NaOH (20 ml) at 0° C. The layers were separated and the aqueous layer was extracted with chloroform (×3). The combined organic extracts were dried over magnesium sulfate and concentrated. The resultant off-white solid was purified by flash chromatography (hexanes/EtOAc, 16:1) to give the title product as a white solid (0.3 g, 38%). MS (ES): 188 (M+1) for C₈H₁₀ClNO₂; NMR (CDCl₃) □: 1.34 (t, 3H), 2.27 (s, 3H), 4.30 (q, 2H), 6.76 (s, 1H), 9.07 (brs, 1H)

Intermediate 8
3,4-Difluoro-2-methyl-1H-pyrrole

BH₃THF (400 ml, 1M in THF) was added dropwise to a solution of 3,4-difluoro-1H-pyrrole-2-carbaldehyde (Intermediate 19; 3.82 g) in THF (50 ml) cooled in an ice-water bath under N₂. The reaction mixture was stirred at room temperature for 3 days. MeOH was added slowly to quench excess of BH₃and then the solvent was removed in vacuo at 0° C. The resulting yellow oil was triturated with hexanes/DCM and the yellow precipitate was removed by filtration. The filtrate was washed with NaHCO₃, H₂O and brine, dried over Na₂SO₄, filtered and concentrated at 0° C. in vacuo to give a pale yellow oil (3.8 g). MS (ES) MH⁺: 116 for C₅H₅F₂N; NMR (CDCl₃): 2.15 (s, 3H), 6.22 (m, 1H).

Intermediate 9
1-tert-Butyl-3-methyl-4-hydroxy-5,6-dihydropyridine-1,3-(2H)-dicarboxylate

Methyl-4-hydroxy-1,2,5,6-tetrahydropyridine-3-carboxylate-hydrochloride (25 g) was suspended in DCM (250 ml). DIEA (41.6 g) was added in a single portion and the resultant homogeneous solution was cooled to 0° C. A DCM solution of di-tert-butyl dicarbonate (29.5 g, 1.05 moles) was added dropwise over a 1 h period. After the addition, the reaction was warmed to room temperature and stirred overnight. The reaction mixture was concentrated to one-half the volume and washed with water, brine, dried over Na₂SO₄, filtered and concentrated in vacuo to an oil. The crude product was purified by flash column chromatography eluting with (20% EtOAc/80% hexanes) to give the title product (33 g). NMR (CDCl₃): 1.48 (s, 9H), 2.37 (m, 2H), 3.57 (t, 2H), 3.78 (s, 3H), 4.06 (brs, 2H), 11.9 (s, 1H).

Intermediate 10
Ethyl 4-chloroquinoline-2-carboxylate

embedded image

Phosphorous oxychloride (5 ml) was added to ethyl 4-hydroxyquinoline-2-carboxylate (1.01 g). The reaction mixture was subjected to single-mode microwave at 100° C. for 30 min using a Smith Microwave Synthesizer. The solvent was removed in vacuo and recrystallized with acetone to gave the title compound as a white solid (1.90 g). MS (ES) MH⁺: 235, 237 for C₁₂H₁₀ClNO₂; NMR (CDCl₃): 1.44 (t, 3H, J=7.16), 4.51 (q, 2H, J=7.16), 7.19 (s, 1H), 7.71 (m, 1H), 7.81 (m, 1H), 8.22 (m, 1H), 8.36 (d, 1H, J=8.29).

Intermediate 11
2-(Methylthio)-1,3-thiazole-4-carboxylic acid

Ethyl 2-(methylthio)-1,3-thiazole-4-carboxylate (5.0 g) (Sinha, Subhash C et al. Tet. Lett. 2000, 41 (43), 8243-8246) was dissolved in MeOH (50 ml) and 2N LiOH (74 ml) was added. After stirring at room temperature for five minutes the reaction mixture was concentrated to remove MeOH and the residue was suspended in water and acidified with conc. HCl to pH 3. The white precipitate was filtered and dried to yield the title compound (3.42 g). NMR: 2.72 (s, 3H), 8.35 (s, 1H).

Intermediate 12
2-(Methylthio)-4-thiazolecarbonyl chloride

2-(Methylthio)-1,3-thiazole-4-carboxylic acid (Intermediate 11; 1.0 g) in thionyl chloride (10 ml) was heated to reflux for 30 min. The solution was cooled to room temperature and concentrated in vacuo. The residue was washed with anhydrous THF and concentrated to yield a black solid which was dried and stored cold under nitrogen (1.2 g). NMR (CDCl₃): 2.76 (s, 3H), 8.32 (s, 1H).

Intermediate 13
N-(1-Methyl-1-phenylethyl)-2-(methylthio)-1,3-thiazole-4-carboxamide

Triethylamine (2.24 ml) was added to a solution of cumylamine (3.2 ml) in anhydrous THF (30 ml). After stirring for 15 min, a solution of 2-(methylthio)-4-thiazolecarbonyl chloride (Intermediate 12; 3.1 g) in anhydrous THF was added and the reaction mixture was concentrated in vacuo after 15 min. The residue was partitioned with EtOAc and water, dried with MgSO₄, and concentrated to an orange oil. Flash purification on silica gel with isocratic elution of DCM yielded the product as a yellow oil (3.7 g). MS (ES) MH⁺: 293 for C_1-4H₁₆N₂OS₂; NMR: 1.68 (s, 6H), 2.76 (s, 3H), 7.20 (d, J=7.16 Hz, 1H), 7.29 (t, J=7.54 Hz, 2H), 7.36-7.41 (m, 2H), 8.04 (s, 1H), 8.08 (s, 1H).

Intermediate 14
4-{[(1-Methyl-1-phenylethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylic acid

Diisopropylamine (4.2 ml) was dissolve in anhydrous THF (100 ml) was cooled to −78° C. and to this was added n-butyl lithium (12 ml) slowly. The solution was slowly warmed to 0° C. and then cooled back to −78° C. A solution of N-(1-methyl-1-phenylethyl)-2-(methylthio)-1,3-thiazole-4-carboxamide (Intermediate 13; 2.8 g) in anhydrous THF was added slowly maintaining the temperature below −70° C. After stirring for 30 min, a solution of methyl cyano formate (1.6 ml) in anhydrous THF was added in one portion and the reaction was stirred at −78° C. for 30 min followed by slow warming to room temperature. The reaction mixture was diluted with water and extracted with ether. The aqueous portion was acidified with conc. HCl, extracted with EtOAc, dried with MgSO₄and concentrated to an orange solid (0.9 g). MS (ES) MH⁺: 337 for C₁₅H₁₆N₂O₃S₂; NMR: 1.66-1.74 (m, 6H), 2.80 (s, 3H), 7.23 (d, J=7.16 Hz, 1H), 7.33 (t, J=7.54 Hz, 2H), 7.45 (s, 2H), 9.07 (s, 1H).

Intermediate 15
Methyl 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylate

embedded image

Potassium carbonate (0.37 g) and iodomethane (0.17 ml) were added to a solution of 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylic acid (Intermediate 14; 0.9 g) in DMF (20 ml) and heated in a sealed tube at an external temperature of 85° C. for 30 min. The reaction mixture was concentrated to remove DMF and partitioned with EtOAc and water. The combined organic extracts were washed with water, dried with MgSO₄, and concentrated to an orange solid (0.63 g). NMR: 1.60-1.65 (m, 6H), 2.76 (s, 3H), 3.78-3.83 (m, 3H), 7.22 (d, J=7.16 Hz, 1H), 7.33 (t, J=7.63 Hz, 2H), 7.46 (d, J=7.35 Hz, 2H), 8.75 (s, 1H).

Intermediate 16
Methyl 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2-(methylsulfonyl)-1,3-thiazole-5-carboxylate

3-Chloroperbenzoic acid (0.89 g) was added to a solution of methyl 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylate (Intermediate 15; 0.63 g) in DCM (25 ml). After stirring overnight the reaction was complete. Aqueous sodium bisulfite was added to quench any unreacted peroxides and the solution was washed with sat. NaHCO₃. The organic portion was dried with MgSO₄and concentrated to a yellow solid (0.6 g). NMR: 1.63-1.68 (m, 6H), 3.58 (s, 3H), 3.89 (s, 3H), 7.23 (d, J=7.16 Hz, 1H), 7.34 (t, J=7.63 Hz, 2H), 7.47 (d, J=7.54 Hz, 2H), 8.91 (s, 1H).

Intermediate 17
Methyl-2-chloro-4-(methoxymethyl)-1,3-thiazole-5-carboxylate

tert-Butyl nitrite (2.2 ml, 18.6 mmol) and cuprous chloride (1.5 g) were suspended in anhydrous CH₃CN (100 ml). Methyl 2-amino-4-(methoxymethyl)-1,3-thiazole-5-carboxylate (2.5 g) prepared as described in (Kennedy, Alan R. et al. Acta Crystallographica, Section C: Crystal Structure Communications (1999, C55 (7) 2) was added in one portion. The mixture was stirred at room temperature for 2 h and the temperature was raised to 70° C. for 1 h. The mixture was cooled to room temperature and filtered. The filtrate was poured into 6 N HCl, extracted with EtOAc, dried with MgSO₄and concentrated to a black oil. Flash purification on silica gel with gradient elution (hexane to EtOAc) yielded product as a yellow liquid (0.82 g). NMR: 3.31 (s, 3H), 3.85 (s, 3H), 4.71 (s, 2H).

Intermediate 18
3,4-Difluoro-1H-pyrrole

3,4-Difluoro-1H-pyrrole was prepared as described in Eric K. Woller et al., J. Org. Chem., 1998 63(16), 5706-5707) and references therein. Thus, to a solution of 3,3,4,4-tetrafluoro-pyrrolidine hydrochloride (30.2 g) in dry DMSO (250 ml) cooled in an ice-water bath, t-BuOK was added (100 g) under N₂. After the addition was complete (˜0.5 h), the reaction mixture was stirred at room temperature for another 0.5 h. It was cooled to 0° C. and quenched with ice water (300 ml). After the solid dissolved, the mixture was diluted to ˜1.5 l with water, neutralized to pH 7 with HCl, and extracted with DCM. The combined DCM extracts were washed with water, brine, dried over MgSO₄and filtered. DCM was removed in vacuo at 0° C., and the resulting orange oil was dissolved in pentane at room temperature, cooled to −20° C. overnight and filtered under N₂to give the title compound as golden crystals (4.6 g). NMR (CDCl₃): 6.38 (d, 1H), 6.41 (d, 1H).

Intermediate 19
3,4-Difluoro-1H-pyrrole-2-carbaldehyde

DMF (4.3 ml) was cooled in ice-water bath under N₂and POCl₃(5.2 ml) was added dropwise. The mixture was stirred at room temperature for 10 min. The ice-water bath was replaced, and the mixture was diluted with DCM (45 ml). A solution of 3,4-difluoro-1H-pyrrole (Intermediate 18; 4.57 g) in DCM (45 ml) was added dropwise. The mixture was refluxed for 30 min, cooled to room temperature and a solution of NaOAc (23 g) in water (60 ml) was added slowly. The resulting mixture was refluxed for 30 min, organic phase was separated and aqueous phase was extracted with DCM. The combined organic phase was washed with NaHCO₃, dried over Na₂SO₄, and concentrated in vacuo. The crude solid was triturated with DCM (20 ml)/pentane (100 ml), and then cooled to −20° C. to give the title compound as pale brown needles (4.73 g). NMR (CDCl₃): 6.87 (m, 1H), 9.6 (m, 1H).

Intermediate 20
3,4-Difluoro-5-methyl-1H-pyrrole-2-carboxylic acid

embedded image

2,2,2-Trichloro-1-(3,4-di fluoro-5-methyl-1H-pyrrol-2-yl)ethanone (Intermediate 80; 1.03 g) was added to an aqueous solution of NaOH (18 ml) at 0° C. under N₂. The mixture was stirred at room temperature for a further 2 h, cooled to 0° C. and acidified with HCl to ˜pH 2. A brown precipitate of product was collected by filtration. The crude product was purified by column chromatography on silica gel elution with EtOAc/hexanes (1:1). Trituration with DCM (1 ml)/pentane (6 ml) gave the title compound as a pale brown solid (306 mg). M.p. 140° C. (dec.). MS (ES) MH⁺: 160, 161 for C₆H₅F₂NO₂; NMR (CDCl₃): 2.15 (s, 3H), 11.5 (s, 1H), 12.8 (brs, 1H).

Intermediate 21

Cis(±)ethyl 4-amino-3-methoxypiperidine-1-carboxylate hydrochloride salt The title compound can be prepared as described in Lee, C. et al. Synth. Comm. 2001, 31(7), 10881-10890 and/or WO 94/12494 or from Intermediate 157 by the following procedure;

To a stirred solution of the benzylamine (36.45 g, 125 mmol) and 10% palladium on activated carbon (50% wet; approximately 4 g) in methanol (250 mL), at room temperature and under an atmosphere of N₂, was added ammonium formate (31.50 g, 500 mmol) as a solid. Temperature was increased to 70° C.; the reaction was stirred overnight at this temperature, under an atmosphere of N₂. Complete conversion was suggested by TLC (6% methanol in ethyl acetate; Rf˜0.06 in a solution of 15% methanol and 30% acetone in methylene chloride) in the morning. The reaction mixture was filtered through Celite and concentrated under vacuum. To the residue was added approximately 50 mL water; from this mixture was extracted the crude product with a solution of ˜3% methanol in chloroform (4×300 mL). Organic layers were combined, dried over magnesium sulfate, and concentrated. Obtained 24.18 g (96%) of an off-white solid.

MS (ES) MH⁺: 202 for C₉H₁₈N₂O₃.

Intermediate 22
Cis(±)ethyl 4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate

Benzyl chloroformate (3.3 ml) was added dropwise to a cold solution of Cis(±)ethyl 4-amino-3-methoxypiperidine-1-carboxylate hydrochloride salt (Intermediate 21; 5 g) in saturated NaHCO₃. The mixture was stirred at room temperature for 14 h. The white precipitate was filtered, washed well with water, dried in vacuo to give the title compound as a white solid (6.66 g). MS (ES) MH⁺: 336 for C₁₇H₂₄N₂O₅; NMR: 1.21 (t, 3H), 1.52-1.67 (m, 2H), 3.08 (m, 2H), 3.28 (s, 3H), 3.41 (s, 2H), 3.74-3.92 (m, 2H), 3.96 (m, 2H), 4.14 (m, 1H), 5.10 (s, 2H), 7.24 (d, 1H), 7.44 (m, 5H).

Intermediate 23 and Intermediate 24
ethyl(3R,4S)-4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylateand ethyl (3S,4R)-4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate

Cis(±)ethyl 4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate (Intermediate 22; 6.2 g) were separated into its enantiomers by chiral chromatography over a Chiralcel OJ column (eluant: hexanes/MeOH/EtOH;70/15/15;0.1% diethylamine). The fractions corresponding to the first chromatographic peak (Cis(−)isomer) were collected and evaporated yielding the title compound as a white solid (2.62 g). The fractions corresponding to the second chromatographic peak (Cis(+)isomer) were collected and evaporated yielding the title compound as a white solid (2.71 g). MS (ES) (M+Na)⁺: 360 for C₁₇H₂₄N₂O₅; NMR: 1.21 (t, 3H), 1.52-1.67 (m, 2H), 3.08 (m, 2H), 3.28 (s, 3H), 3.41 (s, 2H), 3.74-3.92 (m, 2H), 3.96 (m, 2H), 4.14 (m, 1H), 5.10 (s, 2H), 7.24 (d, 1H), 7.44 (m, 5H).

Intermediate 25
ethyl(3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate

embedded image

Cis(+)ethyl 4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate (Intermediate 24; 3.98 g) was dissolved in MeOH (100 ml) and 1N HCl (50 ml). 10% Pd-charcoal (600 mg) was added, degassed and hydrogenolysed under an atmosphere of H₂gas at room temperature for 3 h. The catalyst was filtered through a bed of celite, concentrated in vacuo and lyophilized giving the title compound (2.8 g). MS (ES) MH⁺: 202 for C₉H₁₈N₂O₃.

Intermediate 26

The title compound was prepared in a manner analogous to Intermediate 25 from the starting material indicated.

Int
Compound
MS
SM

26
ethyl (3R,4S)-4-amino-3-
MS (ES) MH⁺: 202
Intermediate

methoxypiperidine-1-carboxylate
for C₉H₁₈N₂O₃
23

Intermediate 27
Cis(±)ethyl-3-(allyloxy)-4-[(tert-butoxycarbonyl)amino]piperidine-1-carboxylate

A 50% aqueous solution of sodium hydroxide (3 ml) was added to a suspension of allyl bromide (693 mg, 5.70 mmol), cis(±)ethyl 4-[(tert-butoxycarbonyl)amino]-3-hydroxypiperidine-1-carboxylate (reference: C. H. Lee et al. Syn. Commun., 2001, 31, 1081.), (750 mg, 2.6 mmol), benzyltriethylammonium chloride (4 mg, cat.) and toluene (8 ml). The resultant mixture was stirred overnight at room temperature. The reaction mixture was diluted with EtOAc (150 ml) and water (35 ml). The organic phase was separated and the aqueous phase was back extracted with EtOAc (2×30 ml). The combined organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated. The crude residue was purified by flash column chromatography (hexane/EtOAc, 3:2) to yield 734 mg of the title compound. MS (ES) (M+H): 329. for C₁₆H₂₈N₂O₅; NMR□: 1.28 (t, 3H), 1.47 (s, 9H), 1.68 (m, 2H), 2.88 (brt, 2H), 3.50 (m, 1H), 3.68 (m, 1H), 3.90 (m, 1H), 4.00-4.45 (m, 3H), 4.10 (q, 2H), 4.92 (brs, 1H), 5.20 (m, 2H), 5.86 (m, 1H).

Intermediate 28
Cis(±)ethyl-3-(allyloxy)-4-amino]piperidine-1-carboxylate hydrochloride salt

4N HCl/dioxane (20 ml) was added to cis(±)ethyl-3-(allyloxy)-4-[(tert-butoxycarbonyl)amino]piperidine-1-carboxylate (Intermediate 27; 572 mg). The mixture was stirred at room temperature for 90 min. The solvent was removed in vacuo, dried in vacuo to give the title compound as an oily foam which was used without further purification (449 mg). MS (ES) (M+H): 228. for C₁₁H₂₀N₂O₃.

Intermediates 29-36

The following compounds were prepared in a manner analogous to Intermediate 28 from the starting material (SM) indicated.

Int
Compound
Data
SM

29
Cis(±)ethyl-4-amino-3-
MS (ES)(M + H): 220 for
Intermediate 81

propyoxypiperidine-1-carboxylate
C₁₁H₂₂N₂O₃

hydrochloride salt

30
Methyl 2-[(3R,4R)-4-amino-3- methoxypiperidin-1-yl]-1,3- thiazole-5-carboxylate hydrochloride salt embedded image

NMR: 1.63 (m, 1H), 2.08 (d, 1H), 2.97-3.01 (m, 1H), 3.21-3.24 (m, 2H), 3.25 (m, 2H), 3.40 (s, 3H), 3.73 (s, 3H), 3.88 (d, 1H), 4.34 (m, 1H), 7.87 (s, 1H), 8.28 (brs, 3H)
Intermediate 68

31
Methyl 2-[(3S,4S)-4-amino-3-
NMR: 1.63 (m, 1H), 2.08 (d,
Intermediate 69

methoxypiperidin-1-yl]-1,3-
1H), 2.97-3.01 (m, 1H),

thiazole-5-carboxylate
3.21-3.24 (m, 2H), 3.25 (m,

hydrochloride salt
2H), 3.40 (s, 3H), 3.73 (s,

3H), 3.88 (d, 1H), 4.34 (m,

1H), 7.87 (s, 1H), 8.28 (brs,

3H)

32
Cis(±)3,4-dichloro-N-[3-
NMR: 1.92-1.96 (m, 2H),
Intermediate 49

fluoropiperidin-4-y1]-5-methyl-1H-
2.20 (s, 3H), 3.10 (m, 1H),

pyrrole-2-carboxamide
3.43-3.51 (m, 2H), 3.64 (m,

hydrochloride salt
1H), 4.27-4.38 (m, 1H), 5.05

(d, 1H), 7.58 (d, 1H), 8.75

(brs, 1H), 9.43 (brs, 1H),

12.32 (s, 1H)

33
3,4-dichloro-N-[(3R,4S)-3-
MS (ES) (M + H): 294, 296
Intermediate 45

fluoropiperidin-4-yl]-5-methyl-1H-
for C₁₁H₁₄Cl₂FN₃O

pyrrole-2-carboxamide

hydrochloride

34
Trans(±)3,4-dichloro-N-[3-
MS (ES)(M + H): 294, 296
Intermediate 44

fluoropiperidin-4-yl]-5-methyl-1H-
for C₁₁H₁₄Cl₂FN₃O

pyrrole-2-carboxamide

hydrochloride

35
Cis(±)methyl 4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}piperidine-3- carboxylate hydrochloride salt embedded image

MS (ES)(M + H): 332 for Cl₃H₁₇Cl₂N₃O₃
Intermediate 46

36
3,4-dichloro-N-[(3S,4R)-3-
MS(ES)M + H): 294, 296 for
Intermediate 48

fluoropiperidin-4-yl]-5-methyl-1H-
C₁₁H₁₄Cl₂FN₃O

pyrrole-2-carboxamide

hydrochloride

Intermediate 37
Cis(±)ethyl 4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidine-1-carboxylate

3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (Intermediate 1; 304 mg) was dissolved in anhydrous DMF. HATU (596 mg), HOAT (213 mg) and DIEA (274 μl) were added and stirred at ambient for 15 min. Cis(±)ethyl 4-amino-3-methoxypiperidine-1-carboxylate (Intermediate 21; 317 mg) was added and the mixture was stirred at ambient for 18 h. The mixture was diluted with EtOAc and washed with water, 1N HCl, bicarbonate buffer, water, brine and dried over Na₂SO₄. The solution was concentrated in vacuo to give the title compound as a brown solid (503 mg). MS (ES) MH⁺: 378, 380 for C₁₅H₂₁Cl₂N₃O₄; NMR: 1.29 (t, 3H), 1.79 (m, 2H), 2.27 (s, 3H), 3.12 (m, 2H), 3.30 (s, 3H), 3.37 (m, 1H), 3.83-4.16 (m, 5H), 7.25 (d, 1H), 12.23 (s, 1H).

Intermediates 38-49

The following compounds were prepared in a manner analogous to Intermediate 37 from the starting material (SM) indicated.

Int
Compound
Data
SM

38
Cis(±)ethyl-4-{[(3,4-difluoro-5-
MS (ES) MH⁺: 344 for
Intermediate 20

methyl-1H-pyrrol-2-
C₁₅H₂₁F₂N₃O₄; NMR: 1.3 (t,
and Intermediate

yl)carbonyl]amino}-3-
3H), 1.69 (m, 2H), 2.21 (s,
21

methoxypiperidine-1-
3H), 3.11 (m, 2H), 3.22 (s,

carboxylate
3H), 3.39 (m, 2H), 3.85 (q,

2H), 4.41 (m, 1H), 6.83 (d,

1H), 11.54 (s, 1H)

39
ethyl (3S,4R)-4-{[(3,4-dichloro-
MS (ES) MH⁺: 377 for
Intermediate 25

5-methyl-1H-pyrrol-2-
C₁₅H₂₁Cl₂N₃O₄; NMR: 1.32 (t,
and Intermediate 1

yl)carbonyl]amino}-3-
3H), 1.74 (m, 2H), 2.31 (s,

methoxypiperidine-1-
3H), 3.14 (m, 2H), 3.18-3.52

carboxylate
(s, 3H), 3.75-4.44 (m, 5H),

7.30 (d, 1H), 12.39 (s, 1H)

40
ethyl (3R,4S)-4-{[(3,4-dichloro- 5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidine-1- carboxylate embedded image

MS (ES) MH⁺: 377 for C₁₅H₂₁Cl₂N₃O₄; NMR: 1.32 (t, 3H), 1.74 (m, 2H), 2.31 (s, 3H), 3.14 (m, 2H), 3.18-3.52 (s, 3H), 3.75-4.44 (m, 5H), 7.30 (d, 1H), 12.39 (s, 1H)
Intermediate 26 and Intermediate 1

41
Ethyl 4-{[(4-chloro-5-methyl-
MS (ES) MH⁺: for
Intermediate 21

1H-pyrrol-2-
C₁₅H₂₂ClN₃O₄; NMR: 1.18 (t,
and Intermediate 6

yl)carbonyl]amino}-3-
J = 7.06 Hz, 3H), 1.48 (d,

methoxypiperidine-1-
J = 3.58 Hz, 1H), 1.75 (td,

carboxylate
J = 12.29, 7.82 Hz, 1H), 2.10-

2.18 (m, 3H), 2.95 (d, J = 13.38

Hz, 2H), 3.20-3.27 (m, 3H),

3.27-3.35 (m, 2H), 3.38 (s,

1H), 3.97-4.09 (m, J = 10.53,

7.08, 7.08, 3.39 Hz, 2H), 4.19

(s, 1H), 6.88 (d, J = 2.64 Hz,

1H), 7.62 (d, J = 7.91 Hz, 1H),

11.60 (s, 1H)

42
Cis(±)ethyl 3-(allyloxy)-4-
MS (ES) MH⁺: 402, 404 for
Intermediate 1 and

{[(3,4-dichloro-5-methyl-1H-
C₁₇H₂₃Cl₂N₃O₄
Intermediate 28

pyrrol-2-

yl)carbonyl]amino}piperidine-

1-carboxylate

43
Cis(±)ethyl 4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 404, 406 for
Intermediate 1 and

methyl-1H-pyrrol-2-
C₁₇H₂₅Cl₂N₃O₄
Intermediate 29

yl)carbonyl]amino}-3-

propoxypiperidine-1-

carboxylate

44
Trans(±)tert-butyl-4-{[(3,4-
MS (ES) (M + Na): 416, 418
Intermediate 60

dichloro-5-methyl-1H-pyrrol-2-
for C₁₆H₂₂Cl₂FN₃O₃
and Intermediate 1

yl)carbonyl]amino}-3-

fluoropiperidine-1-carboxylate

45
tent-butyl (3R,4S)-4-{[(3,4-
MS (ES) (M + Na): 416, 418
Intermediate 61

dichloro-5-methyl-1H-pyrrol-2-
for C₁₆H₂₂Cl₂FN₃O₃
and Intermediate 1

yl)carbonyl]amino}-3-

fluoropiperidine-1-carboxylate

46,
1-tert-Butyl 3-methyl 4-{[(3,4-
46: MS (ES-(M + H)⁺): 434,
Intermediate 70

47
dichloro-5-methyl-1H-pyrrol-2-
436 for C₁₈H₂₅Cl₂N₃O₅; NMR
and Intermediate 1

yl)carbonyl]amino}piperidine-
1.45 (s, 9H), 2.16 (m, 1H),

1,3-dicarboxylate
2.27 (s, 3H), 2.55 (dt, 1H),

Note for Examples 46 and 47:
2.93 (m, 1H), 3.09 (m, 2H),

The resultant crude mixture
3.66 (s, 3H), 4.08 (m, 1H),

dissolved in DCM, added to a
4.29 (m, 2H), 6.68 (d, 1H),

silica gel column, and was
9.66 (s, 1H)

purified using a gradient of 10-
47: MS (ES) MH)⁺: 434, 436

50% EtOAc in hexanes. The
for C₁₈H₂₅Cl₂N₃O₅; NMR:

recovered mixture of
1.44 (s, 9H), 1.75 (m, 1H),

diastereomers were taken up in
2.09 (m, 1H), 2.26 (s, 3H),

EtOAc (200 ml), heated to
2.86 (m, 1H), 2.98 (m, 1H),

50° C., and filtered. The solid
3.17 (dd, 1H), 3.71 (s, 3H),

was washed with EtOAc and
4.04 (m, 1H), 4.44 (m, 2H),

dried, to show a 90:10 cis:trans
7.57 (d, 1H), 9.53 (s, 1H)

mixture of diastereomers (2.3 g,

30.6% yield) (Intermediate 46).

The filtrate was then subjected

to a recrystallisation using

EtOAc and n-heptane, and a

90:10 trans:cis mixture (2.65 g,

35.3% yield) (Intermediate 47)

was recovered.

48
tert-butyl (3S,4R)-4-{[(3,4-
MS (ES) (M + Na): 416, 418
Intermediate 64

dichloro-5-methyl-1H-pyrrol-2-
for C₁₆H₂₂Cl₂FN₃O₃
and Intermediate 1

yl)carbonyl]amino}-3-

fluoropiperidine-1-carboxylate

49
Cis(±)tert-butyl-4-{[(3,4-
NMR (CDCl₃): 1.47 (s, 9H),
Intermediate 59

dichloro-5-methyl-1H-pyrrol-2-
1.84-1.88 (m, 2H), 2.28 (s,
and Intermediate 1

yl)carbonyl]amino}-3-
3H), 2.76-3.02 (m, 2H), 4.11-

fluoropiperidine-1-carboxylate
4.26 (m, 2H), 4.43-4.51 (m,

1H), 4.77 (d, 1H)

Intermediate 50
Cis(±)3,4-dichloro-N-(3-methoxypiperidin-4-yl)-5-methyl-1H-pyrrole-2-carboxamide

embedded image

The title compound was prepared by the methods described below:

Method A

Cis(±)ethyl 4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidine-1-carboxylate (Intermediate 37; 503 mg) was dissolved in MeOH (30 ml). 1 M NaOH was added and the mixture was heated at 100° C. for 12 h. The reaction mixture was cooled to ambient and extracted with EtOAc, washed with water, dried over Na₂SO₄and concentrated in vacuo to give the title compound as a brown oily gum which was used without further purification (336 mg).

Method B

Cis(±)ethyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidine-1-carboxylate (Intermediate 37; 3.85 g) was suspended in anhydrous CH₃CN. Iodotrimethylsilane (2.2 ml) was added slowly. The reaction was heated to reflux for several hours until complete by LCMS. The crude reaction mixture was diluted with water and acidified with 1N HCl to pH 3. The solution was extracted with EtOAc. The aqueous layer was basified with 50% NaOH to pH 10. The aqueous layer as saturated with sodium chloride and extracted with THF, dried with MgSO₄and concentrated to a tan solid (2.1 g). MH⁺: 306 for C₁₂H₁₇Cl₂N₃O₂; NMR: 1.61 (d, J=3.77 Hz, 2H), 1.76 (dt, J=6.50, 3.16 Hz, 1H), 2.16-2.20 (m, 3H), 2.56-2.69 (m, 2H), 2.90 (d, J=13.19 Hz, 1H), 3.18 (dd, J=13.75, 3.01 Hz, 1H), 3.30-3.35 (m, 3H), 3.56-3.64 (m, 1H), 4.04-4.15 (m, J=8.10, 7.72, 7.72, 3.01 Hz, 1H), 7.14 (d, J=8.29 Hz, 1H).

Intermediates 51-56

The following Intermediates were prepared as described by the general methods described in Intermediate 50 from the starting materials (SM) indicated.

Int
Compound
Data
SM

51
3,4-dichloro-N-(3S,4R)[3-
M/z 306; 1.73 (m, 2H), 2.31 (s, 3H), 2.64 (m,
Intermediate

methoxypiperidin-4-yl]-5-
1H), 2.98 (m, 1H), 3.22 (m, 1H), 3.34 (m,
39

methyl-1H-pyrrole-2-
1H), 3.34 (s, 3H), 3.42 (m, 2H), 4.25 (m,

carboxamide
1H), 7.31 (d, 1H).

52
3,4-dichloro-N-(3R,4S)[3-
M/z 306; 1.73 (m, 2H), 2.31 (s, 3H), 2.64 (m,
Intermediate

methoxypiperidin-4-yl]-5-
1H), 2.98 (m, 1H), 3.22 (m, 1H), 3.34 (m,
40

methyl-1H-pyrrole-2-
1H), 3.34 (s, 3H), 3.42 (m, 2H), 4.25 (m,

carboxamide
1H), 7.31 (d, 1H).

53
Cis(±)3,4-dichloro-5-
M/z 334
Intermediate

methyl-N-(3-

43

propoxypiperidin-4-yl)-1H-

pyrrole-2-carboxamide

54
Cis(±)3,4-dichloro-5-
M/z 332
Intermediate

methyl-N-(3-

42

allyoxypiperidin-4-yl)-1H-

pyrrole-2-carboxamide

55
Cis(±)4-chloro-N-(3-
M/z 272; 1.41 (s, 1H), 1.67 (s, 1H), 2.13 (s,
Intermediate

methoxypiperidin-4-yl)-5-
3H), 2.47 (s, 1H), 2.55 (s, 1H), 2.86 (s, 1H),
41

methyl-1H-pyrrole-2-
3.08 (d, J = 13.19 Hz, 1H), 3.25 (s, 3H), 3.31

carboxamide
(s, 1H), 6.89 (d, J = 2.45 Hz, 1H), 7.52 (s,

1H), 11.59 (s, 1H)

56
Cis(±)3,4-difluoro-N-(3-
M/z 273; 1.74 (m, 2H), 2.24 (s, 3H), 3.00 (m,
Intermediate

methoxypiperidin-4-yl)-5-
1H), 3.21 (m, 1H), 3.36 (s, 3H), 3.42 (m,
38

methyl-1H-pyrrole-2-
4H), 4.20 (brm, 1H), 6.74 (brm, 1H), 11.60

carboxamide
(brs, 1H).

Intermediate 57 and Intermediate 58
tert-Butyl-(3S,4R)-4-(benzylamino)-3-fluoropiperidine-1-carboxylate and tert-Butyl-(3R,4S)-4-(benzylamino)-3-fluoropiperidine-1-carboxylate

embedded image

Cis(±)tert-butyl-4-(benzylamino)-3-fluoropiperidine-1-carboxylate (Intermediate 82; 2.2 g) was separated into the title compounds using chiral HPLC, in a manner analogous to Intermediate 23 and Intermediate 24 over a Chiralpak AD column (eluent: hexanes/MeOH/EtOH; 90/2.5/2.5; 0.1% diethylamine). The fractions corresponding to the first chromatographic peak (Cis(+) isomer; Intermediate 57) were collected and evaporated yielding the title compound as a white solid (942 mg). The fractions corresponding to the second chromatographic peak (Cis(−) isomer; Intermediate 58) were collected and evaporated yielding the title compound as a white solid (980 mg). NMR (CDCl₃): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, 1H), 4.66 (d, 1H).

Intermediate 59
Cis(±)tert-butyl-4-amino-3-fluoropiperidine-1-carboxylate

Cis(±)tert-butyl-4-(benzylamino)-3-fluoropiperidine-1-carboxylate (Intermediate 82; 711 mg), ammonium formate (582 mg), and 10% Pd/C (200 mg) in MeOH (10 ml) was heated to 50° C. for 1 h. The reaction mixture was cooled to room temperature, filtered through diatomaceous earth and concentrated under reduced pressure to give the title compound (503 mg, quantitative). NMR (CDCl₃): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, 1H), 4.66 (d, 1H).

Intermediates 60-64

The following Intermediates were prepared by the procedure described in Intermediate 59 from the starting materials (SM) indicated.

Int
Compound
Data
SM

60
Trans(±)tert-butyl-4-amino-3- fluoropiperidine-1-carboxylate embedded image

NMR (CDCl3): 1.38 (s, 9H), 1.88 (m, 2H), 2.87 (m, 2H), 3.59 (m, 2H), 3.77 (m, 1H), 4.66 (d, 1H)
Intermediate 65

61
tert-butyl (3R,4S)-4-amino-3-
NMR (CDCl₃): 1.40 (s, 9H),
Intermediate 58

fluoropiperidine-1-carboxylate
1.88 (m, 2H), 3.01 (m, 2H), 3.55

(m, 2H), 3.77 (m, 1H), 4.66 (d,

1H)

62
tert-Butyl [(3R,4R)-3-
NMR (CDCl₃): 1.45 (s, 9H),
Intermediate 66

methoxypiperidin-4-
2.43 (m, 1H), 2.50-2.57 (m,

yl]carbamate
1H), 2.59-2.66 (m, 1H), 2.89

(m, 1H), 3.01 (m, 1H), 3.24 (m,

1H), 3.41 (s, 3H), 3.67 (m, 1H),

4.71 (m, 1H)

63
tert-Butyl [(3S,4S)-3-
NMR (CDCl₃): 1.45 (s, 9H),
Intermediate 67

methoxypiperidin-4-
2.43 (m, 1H), 2.50-2.57 (m,

yl]carbamate
1H), 2.59-2.66 (m, 1H), 2.89

(m, 1H), 3.01 (m, 1H), 3.24 (m,

1H), 3.41 (s, 3H), 3.67 (m, 1H),

4.71 (m, 1H)

64
tert-butyl (3S,4R)-4-amino-3-
NMR (CDCl₃): 1.40 (s, 9H),
Intermediate 57

fluoropiperidine-1-carboxylate
1.88 (m, 2H), 3.01 (m, 2H), 3.55

(m, 2H), 3.77 (m, 1H), 4.66 (d,

1H)

Intermediate 65
Trans(±)tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate

embedded image

The title compound was prepared as described in Monique B. van Neil et al. J. Med. Chem., 1999, 42, 2087-2104 and the references therein. NMR (CDCl₃): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, 1H), 4.66 (d, 1H).

Intermediate 66
tert-Butyl[(3R,4R)-1-benzyl-3-methoxypiperidin-4-yl]carbamate

The title compound (150 mg) was prepared from tert-butyl[(3R,4R)-1-benzyl-3-hydroxypiperidin-4-yl]carbamate by the procedure described (for similar compounds) in Synth. Commun., 2001, 31, 1081-1089. NMR (CDCl₃): 1.44 (s, 9H), 1.97-2.11 (m, 3H), 2.68 (d, 1H), 3.07-3.12 (m, 2H), 3.36 (s, 3H), 3.41 (m, 1H), 3.52 (m, 2H), 4.51 (m, 1H), 7.23-7.32 (m, 5H).

Intermediate 67
tert-Butyl[(3S,4S)-1-benzyl-3-methoxypiperidin-4-yl]carbamate

The title compound (426 mg) was prepared from tert-butyl[(3S,4S)-1-benzyl-3-hydroxypiperidin-4-yl]carbamate by the procedure described (for similar compounds) in Synth. Commun., 2001, 31, 1081-1089. NMR (CDCl₃): 1.44 (s, 9H), 1.97-2.11 (m, 3H), 2.68 (d, 1H), 3.07-3.12 (m, 2H), 3.36 (s, 3H), 3.41 (m, 1H), 3.52 (m, 2H), 4.51 (m, 1H), 7.23-7.32 (m, 5H).

Intermediates 68-69

The following Intermediates were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.

Int
Compound
Data
SM

68
2-{(3R,4R)-4-[(tert-
MS (ES) (M + Na): 394 for
Intermediate 62 and

Butoxycarbonyl)amino]-3-
C₁₆H₂₅N₃O₅S; NMR (CDCl₃):
methyl 2-bromo-

methoxypiperidin-1-yl}-1,3-
1.46 (s, 9H), 1.66 (m, 1H), 1.89
1,3-thiazole-5-

thiazole-5-carboxylate
(m, 1H), 2.29 (m, 1H), 3.13-3.20
carboxylate

(m, 3H), 3.47 (s, 3H), 3.75 (m,

1H), 3.83 (s, 3H), 4.20 (m, 1H),

4.60 (brs, 1H), 7.85 (s, 1H)

69
2-{(3S,4S)-4-[(tert-
MS (ES) (M + Na): 394 for
Intermediate 63 and

Butoxycarbonyl)amino]-3-
C₁₆H₂₅N₃O₅S; NMR (CDCl₃):
methyl 2-bromo-

methoxypiperidin-1-yl}-1,3-
1.46 (s, 9H), 1.66 (m, 1H), 1.89
1,3-thiazole-5-

thiazole-5-carboxylate
(m, 1H), 2.29 (m, 1H), 3.13-3.20
carboxylate

(m, 3H), 3.47 (s, 3H), 3.75 (m,

1H), 3.83 (s, 3H), 4.20 (m, 1H),

4.60 (brs, 1H), 7.85 (s, 1H)

Intermediate 70
1-tert-Butyl-3-methyl-4-aminopiperidine-1,3-dicarboxylate

embedded image

The title compound was prepared according to (Cordero, F. M et al. Gazz. Chim. Ital. 1997, 127, 25-29). Thus, 1-tert-butyl-3-methyl-4-hydroxy-5,6-dihydropyridine-1,3-(2H)-dicarboxylate (Intermediate 9; 33 g) and NH₄OAc (100 g) were dissolved in dry MeOH (250 ml). NaCNBH₃(8.1 g) was added in three equal portions at 1 h intervals. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by GC/MS and additional NH₄OAc (2.5 equiv.) and NaCNBH₃(0.25 equiv.) were added until reaction was completed. The reaction was cooled to −10° C. and acidified to pH=2 with concentrated HCl and solvent was removed in vacuo. The solid residue was dissolved in water, and extracted with Et₂O. The pH of the aqueous phase was adjusted to 8-9 with solid KOH, solution saturated with NaCl and extracted with EtOAc. The organic layer was dried over K₂CO₃, filtered and concentrate to an oil (25 g). GC/MS: 258 for C₁₂H₂₂N₂O₄.

Intermediate 71
Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(hydroxymethyl)piperidine-1-carboxylate

Cis(±)1-tert-butyl-3-methyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-piperidine-1,3-dicarboxylate (Intermediate 46; 4.26 g) and LiBH₄(321 mg) were combined in dry THF (20 ml). MeOH (600 μl) was added in a single portion. The reaction was heated to reflux for 1 h. The mixture was cooled to room temperature, diluted with EtOAc and washed with 0.5% HCl. The organic layer was dried over Na₂SO₄, filtered and concentrated to a solid which was purified by flash column chromatography eluting with (60% EtOAc/40% hexanes), to yield title compound (3.11 g). MS (ES) (MH⁺): 406 for C₁₇H₂₅Cl₂N₃O₄; NMR (CDCl₃): 1.47 (s, 9H), 1.56 (m, 1H), 1.96 (m, 1H), 2.27 (s, 3H), 2.84 (m, 1H), 2.9 (m, 1H), 3.49 (m, 1H), 3.71 (m, 1H), 4.16 (m, 5H), 6.58 (d, 1H), 10.1 (brs, 1H).

Intermediate 72
Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-({[4-methylphenyl)sulfonyl]oxy}methyl)piperidine-1-carboxylate

Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(hydroxymethyl)piperidine-1-carboxylate (Intermediate 71; 1.46 g) was dissolved in dry pyridine (20 ml) and cooled to 0° C. Tosylchloride (822 mg) was added in a single portion. The reaction was allowed to slowly warm to room temperature and stirred overnight. The mixture was diluted with EtOAc and washed with water, dried over Na₂SO₄, filtered and concentrated in vacuo. The foam was purified by flash column chromatography eluting with (40% EtOAc/60% hexanes) to give title compound (1.58 g). MS (ES) (MH⁺): 560 for C₂₄H₃₁Cl₂N₃O₆S; NMR (CDCl₃): 1.46 (brs, 11H), 1.89 (m, 1H), 1.98 (m, 1H), 2.31 (s, 3H), 2.35 (s, 3H), 2.8 (m, 2H), 3.96-4.23 (m, 4H), 6.4 (d, 1H), 7.19 (d, 2H), 7.68 (d, 2H), 10.3 (brs, 1H).

Intermediate 73

Cis(±)-4-[(3,4-Dichloro-5-methyl-1H-pyrrole-2-carbonyl)-amino]-3-methoxymethyl-piperidine-1-carboxylic acid tert-butyl ester.

Cis-tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-({[(4-methylphenyl)sulfonyl]oxy}methyl)piperidine-1-carboxylate (Intermediate 72; 325 mg) was dissolved in 5 ml of a 30 wt % MeOH solution containing NaOMe and an additional 5 ml of dry MeOH. The homogeneous reaction was stirred at room temperature for 2 days. Upon reacting, solids began to precipitate from solution. The reaction was concentrated to a solid residue, re-dissolved in EtOAc and washed with saturated NH₄Cl (2×10 ml). The organic layer was dried over Na₂SO₄, filtered and concentrated. The residual material was purified by flash column chromatography eluting with (1:1 EtOAc/hexanes) to give the title compound (192 mg). MS (ES) (MH⁺): 420 for C₁₉H₂₇Cl₂N₃O₄.

Intermediate 74
Cis(±)3,4-dichloro-N-[3-(methoxymethyl)piperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide hydrochloride

Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(methoxymethyl)piperidine-1-carboxylate (Intermediate 73; 192 mg, 0.45 mmol) was dissolved in 4N HCl in dioxane (10 ml) and 10 ml of MeOH. The mixture was stirred at room temperature for 3 h, concentrated to dryness and azeotroped with MeOH to remove excess HCl (5×20 ml) to yield the title compound which was used without purification. (crude mixture 195 mg). MS (ES) (MH⁺): 320 for C₁₃H₁₉Cl₂N₃O₂.

Intermediates 75-76

The following Intermediates were prepared by the procedure described in Intermediate 74 from the starting materials (SM) indicated.

Int
Compound
Data
SM

75
Cis(±)3,4-Dichloro-5- methyl-1H-pyrrole-2- carboxylic acid (3- methylaminomethyl- piperidin-4-yl)-amide hydrochloride embedded image

MS (ES) MH⁺: 319 for C₁₃H₂₀Cl₂N₄O
Intermediate 77

76
Cis-3,4-dichloro-5-methyl-
MS (ES) MH⁺: 333 for
Intermediate 78

1H-pyrrole-2-carboxylic acid
C₁₄H₂₂Cl₂N₄O

(3-dimethylaminomethyl-

piperidin-4-yl)-amide

hydrochloride

Intermediate 77
Cis(±)-[(3,4-Dichloro-5-methyl-1H-pyrrole-2-carbonyl)-amino]-3-methylaminomethyl-piperidine-1-carboxylic acid tert-butyl ester

Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-({[(4-methylphenyl)sulfonyl]oxy}methyl)-piperidine-1-carboxylate (Intermediate 72; 500 mg, 0.89 mmol) was dissolved in 5 ml of a 2.0 M THF solution containing MeNH₂. The reaction vessel was sealed and heated to 100° C. for 2 h. The mixture was cooled to room temperature and diluted with EtOAc, then washed with water. The organic layer was dried over Na₂SO₄, filtered and concentrated to a crude solid foam which was used without further purification. MS (ES)MH⁺: 419 for C₁₈H₂₈Cl₂N₄O₃.

Intermediate 78

The title compound was prepared in a manner analogous to Intermediate 77 from the starting material indicated.

Int
Compound
MS
SM

78
Cis(±)4-[(3,4-Dichloro-5-
MS (ES)
Intermediate

methyl-1H-pyrrole-2-carbonyl)-
MH⁺: 433 for
72 and

amino]-3-dimethylaminomethyl-
C₁₉H₃₀Cl₂N₄O₃
dimethylamine

piperidine-1-carboxylic acid tert-

butyl ester

Intermediate 79
Cis(±)4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-3-carboxylic acid hydrochloride

THF (10 ml) and MeOH (8 ml) were added to cis(±)1-tert-butyl 3-methyl 4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-1,3-dicarboxylate (Intermediate 46; 2.24 g). The resultant mixture was cooled to 0° C., and a solution of lithium hydroxide (0.37 g) in water (5 ml) at 0° C. was added dropwise via pipette, producing a clear, lightly yellow solution. The reaction was stirred at 0° C. for 2 h, stored overnight in a freezer without stirring, then stirred again at 0° C. for six hours. The reaction was acidified to pH 3 with 2N HCl 9˜7 ml), and was concentrated in vacuo. The resultant mixture was dissolved in EtOAc (125 ml) and a saturated aqueous sodium chloride solution (40 ml), followed by the addition of 2N HCl(˜1 ml) to acidify the aqueous layer to pH 1. The phases were separated and the aqueous layer was washed with EtOAc (2×60 ml). The combined EtOAc layers were dried over anhydrous MgSO₄and concentrated in vacuo. The resultant white solid was suspended in anhydrous THF (35 ml) under an argon atmosphere, cooled to 0° C., followed by the addition of 4 M HCl in 1,4-dioxane (10 ml, 40 mmol). The reaction was warmed to room temperature, producing a clear orange-red solution. The reaction was stirred overnight at room temperature, followed by the addition of 5 ml of 4 M HCl in 1,4-dioxane. The reaction was stirred for two days at room temperature, then heated to 50° C. for two hours, and allowed to slowly cool to room temperature overnight. The reaction was concentrated in vacuo, and carried on to the next reaction without further purification (5.16 mmol). MS (ES) (M+H)'): 320, 322 for C₁₂H₁₅Cl₂N₃O₃.

Intermediate 80
2,2,2-Trichloro-1-(3,4-di fluoro-5-methyl-1H-pyrrol-2-yl)ethanone

embedded image

3,4-Difluoro-2-methyl-1H-pyrrole (Intermediate 8; 3.8 g) was dissolved in anhydrous diethyl ether (100 ml). Anhydrous K₂CO₃(12.5 g) was added followed by trichloroacetyl chloride (10 ml). The mixture was stirred at room temperature under N₂for 2 h, poured into a cold saturated solution of NaHCO₃, stirred for 10 min, and extracted with ether. The combined organic layers were dried over Na₂SO₄and concentrated in vacuo to give a red brown oil. Trituration with pentane (50 ml)/DCM (2 ml), at −20° C. overnight to gave the title compound as a brown powder (1.3 g). MS (ES) MH⁺: 262 for C₇H₄Cl₃F₂NO; NMR (CDCl₃): 2.35 (d, 3H), 9.0 (brs, 1H).

Intermediate 81
Cis(±)ethyl-4-[(tert-butoxycarbonyl)amino]-3-(propyoxypiperidine-1-carboxylate

Cis(±)ethyl-3-(allyloxy)-4-[(tert-butoxycarbonyl)amino]piperidine-1-carboxylate (Intermediate 27; 528 mg) was dissolved in MeOH (20 ml). 10% Pd—C (100 mg) was added and the mixture was evacuated and replaced with H₂gas twice. The mixture was stirred under an atmosphere of H₂gas for 12 h. The catalyst was removed over a bed of celite and solvent was removed in vacuo to give the title compound as an oil (445 mg). NMRE: 0.94 (m, 3H), 1.25 (m, 3H), 1.43 (s, 9H), 1.53 (m, 2H), 1.71 (m, 1H), 3.04 (m, 2H), 3.37 (m, 2H), 3.50 (m, 2H), 3.69 (m, 1H), 3.89 (m, 1H), 4.15 (m, 2H), 6.5 (d, 1H).

Intermediate 82
Cis(±)tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate

Examples 87-193

The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

87
Cis(±)-methyl 2-[4-{[(3,4-
MS (ES) MH⁺:H447, 449 for
Intermediatel 15 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₇H₂₀Cl₂N₄O₄S.
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-5-

(hydroxymethyl)piperidin-1-yl]-

carboxylate

1,3-thiazole-5-carboxylate.

88
Cis(±)-methyl 2-{4-{[(3,4-
MS (ES) MH⁺: 477, 479 for
Intermediatel 16 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₂Cl₂N₄O₃S₂.
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-5-

[(methylthio)methyl]piperidin-1-

carboxylate

y1}-1,3-thiazole-5-carboxylate.

89
Cis(±)-methyl 2-{4-{[(3,4-
MS (ES) MH⁺: 493, 495 for
Example 88 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₂Cl₂N₄O₄S₂.
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-5-

[(methylsulfinyl)methyl]piperidin-

carboxylate

1-yl}-1,3-thiazole-5-carboxylate

90
Cis(±)-methyl 2-{4-{[(3,4-
MS (ES) MH⁺: 509, 511 for
Example 88 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₂Cl₂N₄O₅S₂.
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-5-

[(methylsulfonyl)methyl]piperidin-

carboxylate

1-yl}-1,3-thiazole-5-

carboxylate

embedded image

91
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 463, 465 for
Intermediate 36 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₁Cl₂FN₄O₃S.
Intermediate 179

yl)carbonyl]amino}-3-

fluoropiperidin-1-yl)-5-methyl-

1,3-thiazole-4-carboxylate.

92
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 475, 477 for
Intermediate 51 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₄Cl₂N₄O₄S.
Intermediate 179

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-5-

methyl-1,3-thiazole-4-

carboxylate

93
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 477, 479 for
Intermediate 36 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₁₉Cl₂FN₄O₄S.
Intermediate 181

yl)carbonyl]amino}-3-

fluoropiperidin-1-yl)-5-formyl-

1,3-thiazole-4-carboxylate

94
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 506, 508 for
Intermediate 93 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₂Cl₂FN₅O₄S; ¹H NMR
methoxyamine

yl)carbonyl]amino}-3-
(CDCl₃): 1.41 (m, 6H), 2.0
hydrochloride

fluoropiperidin-1-yl)-5-
(m, 4H), 2.3 (s,6H), 3.2 (m,

[(methoxyimino)methyl]-1,3-
4H), 3.9 (s, 3H), 4.0 (s, 3H),

thiazole-4-carboxylate
4.4 (m, 10H), 4.8 (s, 1H), 4.9

(s, 1H), 7.0 (s, 2H), 8.5 (s,

1H), 8.8 (s, 1H), 9.6 (s, 2H)

95
Cis(±)-methyl 2-[(-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- (methylthio)piperidin-1-yl]-1,3- thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 463.1 for C₁₇H₂₀Cl₂N₄O₃S₂; NMR: 1.90 (m, 2H); 2.14 (s, 3H); 2.28 (s, 3H); 3.28-3.45 (m, 2H); 3.74 (s, 3H); 3.77 (m, 1H); 3.95 (m, 2H); 4.44 (m, 1H); 7.25 (d, 1H); 7.85 (s, 1H); 12.14 (s, 1H)
Intermediate 117 and Intermediate 1

96
Cis(±)-methyl 2-[4-{[(3,4-
MS (ES) MH⁺: 495 for
Intermediate 95

dichloro-5-methyl-1H-pyrrol-2-
C₁₇H₂₀Cl₂N₄O₅S₂; NMR: 1.88

yl)carbonyl]amino}-3-
(m, 2H); 2.18 (s, 3H); 3.07 (s,

(methylsulfonyl)piperidin-1-yl]-
3H); 3.45 (t, 1H); 3.61 (t,

1,3-thiazole-5-carboxylate
1H); 3.60-3.85 (m, 2H); 3.77

(s, 3H); 4.48 (m, 1H); 4.68

(m, 1H); 7.52 (d, 1H); 7.93 (s,

1H); 12.07 (s, 1H)

97
Cis(±)methyl 2-(3-(benzyloxy)-4-
MS (ES) MH⁺: 523 for
Intermediate 118 and

{[(3,4-dichloro-5-methyl-1H-
C₂₃H₂₄Cl₂N₄O₄S; NMR: 1.73
methyl 2-bromo-1,3-

pyrrol-2-
(m, 2H); 2.12 (s, 3H); 3.36
thiazole-5-

yl)carbonyl]amino}piperidin-1-
(m, 2H); 3.68 (s, 3H); 3.71
carboxylate

yl)-1,3-thiazole-5-carboxylate
(m, 2H); 3.90 (m, 1H); 4.25

(m, 1H); 4.40 (d, 1H); 4.65

(d, 1H); 7.02 (d, 1H); 7.19 (s,

5H); 7.79 (s, 1H); 12.06 (s,

1H)

98
Cis(±)-methyl 2-[4-{[(3,4-
MS (ES) MH⁺: 471 for
Intermediate 119 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₀Cl₂N₄O₄S; NMR: 1.76
methyl-2-bromo-1,3-

yl)carbonyl]amino}-3-(prop-2-
(m, 2H); 2.18 (s, 3H); 3.36
thiazole-5-

yn-1-yloxy)piperidin-1-yl]-1,3-
(m, 2H); 3.44 (t, 1H); 3.74 (s,
carboxylate

thiazole-5-carboxylate
3H); 3.87 (s, 1H); 3.98 (m,

1H); 4.22-4.36 (m, 4H); 7.15

(d, 1H); 7.83 (s, 1H); 12.15

(s, 1H)

99
Trans-(±)methyl 2-(4-{[(3,4-
MS (ES) MH⁺: 433 for
Intermediate 120 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₆H₁₈Cl₂N₄O₄S; NMR: 1.62
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-
(m, 1H), 2.02 (m, 1H), 2.18
thiazole-5-

hydroxypiperidin-1-yl)-1,3-
(s, 3H), 3.12 (m, 1H), 3.63
carboxylate

thiazole-5-carboxylate
(m, 1H), 3.75 (s, 3H), 3.87

(m, 2H), 4.02 (m, 1H), 5.37

(d, 1H), 5.76 (s, 1H), 7.19 (d,

1H), 7.87 (s, 1H), 11.99 (s,

1H)

100
methyl 2-((3S,4R)-4-{[(3-chloro- 5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image

1.87 (m, 2H); 2.17 (s, 3H); 3.34 (m 1H); 3.60 (m 1H); 3.75 (s, 3H); 4.01 (m, 1H); 4.33 (m, 2H); 4.96 (d, br, 1H); 5.95 (s, 1H); 7.10 (d, 1H); 7.85 (s, 1H); 11.63 (s,
Intermediate 121 and methyl 2-bromo-1,3- thiazole-5- carboxylate

101
ethyl 2-((3S,4R)-4-{[(3-chloro-5-
1.37 (t, 3H); 2.00 (m, 2H);
Intermediate 121 and

methyl-1H-pyrrol-2-
2.26 (s, 3H); 3.31 (m 2H);
ethyl 2-bromo-1,3-

yl)carbonyl]amino}-3-
4.21 (m, 1H); 4.34 (q, 2H);
thiazole-4-

fluoropiperidin-1-y1)-1,3-
4.45 (m, 2H); 4.90 (d, br,
carboxylate

thiazole-4-carboxylate
1H); 5.93 (s, 1H); 6.97 (d,

1H); 7.46 (s, 1H); 8.98 (s, br,

1H)

102
ethyl 2-((3S,4R)-4-{[(3-chloro-5-
MS (ES) MH⁺: 465 for
Intermediate 121 and

methyl-1H-pyrrol-2-
C₂₁H₂₂ClFN₄O₃S
ethyl 2-bromo-1,3-

yl)carbonyl]amino}-3-
NMR δ: 1.44 (t, 3H); 2.03
benzothiazole-7-

fluoropiperidin-1-yl)-1,3-
(m, 2H); 2.27 (s, 3H); 3.40
carboxylate

benzothiazole-7-carboxylate
(m 2H); 4.36 (m, 2H); 4.44

(q, 2H); 4.67 (m, 1H); 4.90

(d, br, 1H); 5.93 (s, 1H); 7.05

(d, 1H); 7.37 (t, 1H); 7.71 (d,

1H); 7.79 (d, 1H); 9.89 (s, br,

1H)

103
methyl 2-((3S,4R)-4-{[(4-bromo-
MS (ES) MH⁺: 446 for
Intermediate 122 and

5-methyl-1H-pyrrol-2-
C₁₆H₁₈BrFN₄O₃S; NMR: 1.97
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-
(m, 2H); 2.23 (s, 3H); 3.34
thiazole-5-

fluoropiperidin-1-yl)-1,3-
(m 2H); 3.80 (s, 3H); 4.26
carboxylate

thiazole-5-carboxylate
(m, 2H); 4.55 (m, 1H); 4.86

(d, br, 1H); 6.0 (d, 1H); 6.53

(s, 1H); 7.82 (s, 1H); 9.83 (s,

br, 1H)

104
methyl 2-((3S,4R)-4-{[(4-bromo-
MS (ES) MH⁺: 480 for
Intermediate 123 and

3-chloro-5-methyl-1H-pyrrol-2-
C₁₆H₁₇BrClFN₄O₃S; NMR δ:
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-
1.86 (m, 2H); 2.19 (s, 3H);
thiazole-5-

fluoropiperidin-1-yl)-1,3-
3.44 (m 1H); 3.60 (m 1H);
carboxylate

thiazole-5-carboxylate
3.75 (s, 3H); 4.01 (m, 1H);

4.33 (m, 2H); 4.96 (d, br,

1H); 7.28 (d, 1H); 7.85 (s,

1H); 12.18 (s, 1H)

105
ethyl 2-((3S,4R)-4-{[(4-bromo-3- chloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-4-carboxylate embedded image

MS (ES) MH⁺: 494 for C₁₇H₁₉BrClFN₄O₃S; NMR δ: 1.22 (t, 3H); 1.81 (m, 2H); 2.15 (s, 3H); 3.41 (m 2H); 3.90 (m, 1H); 4.20 (q, 2H); 4.30 (m, 1H); 4.92 (d, br, 1H); 5.72 (s, 1H); 7.24 (d, 1H); 7.65 (s, 1H); 12.13 (s, 1H)
Intermediate 123 and ethyl 2-bromo-1,3- thiazole-4- carboxylate

106
isopropyl 2-((3S,4R)-4-{[(4-
1.32 (d, 6H); 1.80 (m, 2H);
Intermediate 123 and

bromo-3-chloro-5-methyl-1H-
2.19 (s, 3H); 3.07 (m 1H);
isopropyl 2-bromo-

pyrrol-2-yl)carbonyl]amino}-3-
3.27 (m, 1H); 4.37 (m, 2H);
isonicotinate

fluoropiperidin-1-yl)isonicotinate
4.71 (m, 1H); 4.97 (d, br,

1H); 5.15 (m, 1H); 6.70 (d,

1H); 7.22 (d, 1H); 7.25 (s,

1H); 8.17 (d, 1H); 12.11 (s,

br, 1H)

107
methyl 2-((3S,4R)-4-{[(4-bromo-
MS (ES) MH⁺: 524 for
Intermediate 123 and

3-chloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₁BrClFN₄O₄S; NMR δ:
Intermediate 17

yl)carbonyl]amino}-3-
1.86 (m, 2H); 2.19 (s, 3H);

fluoropiperidin-1-yl)-4-
3.29 (s, 2H); 3.60 (m 2H);

(methoxymethyl)-1,3-thiazole-5-
3.73 (s, 3H); 4.04 (m, 1H);

carboxylate
4.30 (m, 2H); 4.57 (s, 3H);

4.90 (d, br, 1H); 7.27 (d, 1H);

12.17 (s, 1H)

108
ethyl 2-((3S,4R)-4-{[(3-chloro-5-
MS (ES) MH⁺: 409 for
Intermediate 121 and

methyl-1H-pyrrol-2-
C₁₉H₂₂ClFN₄O₃
ethyl 2-bromo-

yl)carbonyl]amino}-3-
NMR: 1.40 (t, 3H); 1.98 (m,
isonicotinate

fluoropiperidin-1-yl)isonicotinate
2H); 2.27 (s, 3H); 3.09 (m

2H); 4.38 (q, 2H); 4.47 (m,

2H); 4.84 (m, 1H); 4.90 (d,

br, 1H); 5.92 (s, 1H); 7.03 (d,

1H); 7.15 (d, 1H); 7.30 (s,

1H); 8.27 (d, 1H); 9.88 (s, br,

1H)

109
ethyl 2-((3S,4R)-4-{[(4-bromo-5-
MS (ES) MH⁺: 409 for
Intermediate 122 and

methyl-1H-pyrrol-2-
C₁₉H₂₂BrFN₄O₃
ethyl 2-bromo-

yl)carbonyl]amino}-3-
NMR: 1.40 (t, 3H); 1.98 (m,
isonicotinate

fluoropiperidin-1-yl)isonicotinate
2H); 2.27 (s, 3H); 3.09 (m

2H); 4.38 (q, 2H); 4.43 (m,

2H); 4.84 (m, 1H); 4.90 (d,

br, 1H); 6.16 (d, 1H); 6.59 (s,

1H); 7.15 (d, 1H); 7.29 (s,

1H); 8.27 (d, 1H); 9.76 (s, br,

1H)

110
Cis(±)-Methyl 2-+4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3-(2- methoxyethoxy)piperidin-1-yl]- 1,3-thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 491 for C₁₉H₂₄Cl₂N₄O₅S; NMR: 1.72- 1.80 (m, 2H), 2.17 (s, 3H), 3.13 (s, 3H), 3.25-3.42 (m, 4H), 3.52-3.60 (m, 1H), 3.65- 3.75 (m, 2H), 3.73 (s, 3H); 3.85-4.05 (m, 1H); 4.20-4.35 (m, 2H), 7.14 (d, 1H), 7.82 (s, 1H), 12.14 (brs, 1H)
Intermediate 124 and methyl 2-bromo-1,3- thiazole-5- carboxylate

111
Cis(±)-Ethyl 2{[-4-{[(3,4-
MS (ES) MH⁺: 505 for
Intermediate

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₆Cl₂N₄O₅S
124 and

yl)carbonyl]amino}-3-(2-

ethyl 2-bromo-1,3-

methoxyethoxy)piperidin-1-yl]-

thiazole-4-

1,3-thiazole-4-carboxylate

carboxylate

112
Cis(±)-Ethyl 2-[4-{[(3,4-
MS (ES) MH⁺: 519 for
Intermediate

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₈Cl₂N₄O₅S; NMR: 1.22
124 and

yl)carbonyl]amino }-3-(2-
(t, 3H), 1.70-1.75 (m, 2H),
ethyl 2-chloro-1,3-

methoxyethoxy)piperidin-1-yl]-
2.17 (s, 3H), 2.41 (s, 3H),
thiazole-5-

4-methyl-1,3-thiazole-5-
3.14 (s, 3H), 3.32-3.40 (m,
carboxylate

carboxylate
buried under water peak),

3.45-3.62 (m, 1H), 3.67-3.73

(m, 2H), 3.86-3.98 (m, 1H),

4.16 (q, 2H), 4.19-4.30 (m, 2

H), 7.13 (d, 1H), 12.14 (s,

1H)

113
Cis(±)-Ethyl 2-[4-{[(3,4-
MS (ES) MH⁺: 499 for
Intermediate 124 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₈Cl₂N₄O₅
ethyl 2-

yl)carbonyl]amino}-3-(2-

fluoroisonicotinate

methoxyethoxy)piperidin-1-

(Konno, Akinori J.

yl]isonicotinate

Fluorine Chemistry

(1998), 87(2), 137-

140)

114
Cis(±)-Ethyl 2-[4-{[(3,4-
MS (ES) MH⁺: 555 for
Intermediate 124 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₄H₂₈Cl₂N₄O₅S
ethyl 2-bromo-1,3-

yl)carbonyl]amino}-3 -(2-

benzothiazole-7-

methoxyethoxy)piperidin-1-yl]-

carboxylate

1,3-benzothiazole-7-carboxylate

115
Methyl 2-((3S,4R)-4-{[(4-chloro- 1H-pyrrol-2-yl)carbonyl]amino}- 3-fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 387 for C₁₅H₁₆ClFN₄O₃S; NMR: 1.55-1.76 (m, 1H), 1.85-2.00 (m, 1H), 3.36-3.45 (m, 1H), 3.50 (dd, 1H), 3.74 (s, 3H), 4.02-4.10 (m, 1H), 4.15-4.36 (m, 2H), 4.90 (d, 1H), 6.94- 6.97 (m, 2H), 7.85 (s, 1H), 8.10 (d, 1H), 11.82 (s, 1H)
Intermediate 95 and methyl 2-bromo-1,3- thiazole-5- carboxylate

116
Ethyl 2-((3S,4R)-4-{[(4-chloro-5-
MS (ES) MH⁺: 429 for
Intermediate 260 and

methyl-1H-pyrrol-2-
C₁₈H₂₂ClFN₄O₃S; NMR: 1.23
ethyl 2-chloro-4-

yl)carbonyl]amino }-3-
(t, 3H), 1.62-1.77 (m, 1H),
methy1-1,3-thiazole-

fluoropiperidin-1-yl)-4-methyl-
1.83-2.00 (m, 1H), 2.13 (s,
5-carboxylate

1,3-thiazole-5-carboxylate
3H), 2.43 (s, 3H), 3.33-

3.41(m, 1H), 3.50 (dd, 1H),

3.98-4.02 (m, 1H), 4.16 (q,

2H), 4.23-4.35 (m, 2H), 4.86

(d, 1H), 6.89 (d, 1H), 7.97 (d,

1H), 11.65 (s, 1H)

117
Ethyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH⁺: 415 for
Intermediate 95 ethyl

1H-pyrrol-2-yl)carbonyl]amino}-
C₁₇H₂₀ClFN₄O₃S; NMR: 1.23
2-chloro-4-methy1-

3-fluoropiperidin-1-yl)-4-methyl-
(t, 3H), 1.69-1.74 (m, 1H),
1,3-thiazole-5-

1,3-thiazole-5-carboxylate
1.86-2.03 (m, 1H), 2.43 (s,
carboxylate

3H), 3.27-3.35 (m, 1H), 3.51

(dd, 1H), 3.98-4.05 (m, 1H),

4.16 (q, 2H), 4.23-4.33 (m, 2

H), 4.88 (d, 1H), 6.94-6.98

(m, 2H), 8.85 (d, 1H), 11.81

(s, 1H)

118
Ethyl 2-((3S,4R)-4-{[(4,5-
MS (ES) MH⁺: 449 for
Intermediate

dichloro-1H-pyrrol-2-
C₁₇H₁₉Cl₂FN₄O₃S; NMR:
128 and ethyl 2-

yl)carbonyl]amino}-3-
1.23 (t, 3H), 1.65-1.74 (m,
chloro-4-methyl-1,3-

fluoropiperidin-1-yl)-4-methyl-
1H), 1.85-2.00 (m, 1H),
thiazole-5-

1,3-thiazole-5-carboxylate
2.43(s, 3H), 3.30-3.40 (m,
carboxylate

1H), 3.51 (dd, 1H), 3.98-4.05

(m, 1H), 4.16 (q, 2H), 4.21-

4.35 (m, 2H), 4.88 (d, 1H),

7.06 (d, 1H), 8.15 (d, 1H),

12.78 (s, 1H)

119
Methyl 2-((3S,4R)-4-{[(4,5-
MS (ES) MH⁺: 421 for
Intermediate

dichloro-1H-pyrrol-2-
C₁₅H₁₅Cl₂FN₄O₃S
128 and methyl 2-

yl)carbonyl]amino}-3-

bromo-1,3-thiazole-

fluoropiperidin-1-yl)-1,3-

5-carboxylate

thiazole-5-carboxylate

120
Cis(±)-Methyl 2-{[4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3 -(2- hydroxypropoxy)piperidin-1-yl]- 1,3-thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 491 for C₁₉H₂₄Cl₂N₄O₅S; NMR: 0.95 (d, 3H), 1.75-1.90 (m, 2H), 2.17 (s, 3H), 3.15-3.47 (peaks overlapping with H₂O signal), 3.55-3.68 (m, 2H), 3.73 (s, 3H), 3.94-3.97 (m, 1H), 4.23- 4.35 (m, 2H), 7.17 (d, 1H), 7.82 (s, 1H), 12.11 (s, 1H)
Intermediate 126 and methyl 2-bromo-1,3- thiazole-5- carboxylate

121
Cis(±)-Methyl 2-[(4-{[(3,4-
MS (ES) MH⁺: 505 for
Intermediate

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₆Cl₂N₄O₅S
125 and

yl)carbonyl]amino}-3-(2-

methyl 2-bromo-1,3-

methoxypropoxy)piperidin-1-yl]-

thiazole-5-

1,3-thiazole-5-carboxylate

carboxylate

122
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 511 for
Intermediate 51 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₄Cl₂N₄O₄S; NMR: 1.36
2-bromo-1,3-

yl)carbonyl]amino}-3-
(t, 3H), 1.79 (m, 2H), 2.18 (s,
benzothiazole-7-

methoxypiperidin-1-yl)-1,3-
3H), 3.32-3.59 (m, 4H), 4.21
carboxylate (U.S. Pat.

benzothiazole-7-carboxylate
(m, 1H), 4.37 (m, 1H), 4.37
No. 5770758)

(q, 2H), 7.19 (d, 1H), 7.41 (t,

1H), 7.66 (m, 2H), 12.17 (s,

1H)

123
ethyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH⁺: 511 for
Intermediate 52 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₄Cl₂N₄O₄S; NMR: 1.36
2-bromo-1,3-

yl)carbonyl]amino}-3-
(t, 3H), 1.79 (m, 2H), 2.18 (s,
benzothiazole-7-

methoxypiperidin-1-yl)-1,3-
3H), 3.32-3.59 (m, 4H), 4.21
carboxylate (U.S. Pat.

benzothiazole-7-carboxylate
(m, 1H), 4.37 (m, 1H), 4.37
No.5,770,758)

(q, 2H), 7.19 (d, 1H), 7.41 (t,

1H), 7.66 (m, 2H), 12.17 (s,

1H)

124
Cis (±)ethyl 2-(4-{[(3,4-dichloro-
MS (ES) MH⁺: 448 for
Intermediate 32 and

5-methyl-1H-pyrrol-2-
C₁₇H₁₉Cl₂FN₄O₃S
ethyl 2-bromo-1,3-

yl)carbonyl] amino}-3-

thiazole-4-

fluoropiperidin-l-y1)-1,3-

carboxylate

thiazole-4-carboxylate

125
ethyl 2-((3S,4R)-4-{[(4-chloro-5-
MS (ES) MH⁺: 475 for
Intermediate 129 and

methyl-1H-pyrrol-2-
C₂₂H₂₄ClN₄O₄S
2-bromo-1,3-

yl)carbonyl]amino}-3-

benzothiazole-7-

methoxypiperidin-1-yl)-1,3-

carboxylate (U.S. Pat.

benzothiazole-7-carboxylate

No. 5,770,758)

embedded image

126
Cis(±)methyl 2-4-{[(4-chloro-
MS (ES) MH⁺: 427 for
Intermediate 130 and

3,5-dimethyl-1H-pyrrol-2-
C₁₈H₂₃ClN₄O₄S
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-5-

methoxypiperidin-1-yl)-1,3-

carboxylate

thiazole-5-carboxylate

127
Cis(±)ethyl 2-4-{[(3,4-dichloro-
MS (ES) MH⁺: 513 for
Intermediate 51 and

5-methyl-1H-pyrrol-2-
C₂₁H₂₃Cl₂N₅O₄S
Intermediate 204

yl)carbonyl]amino}-3-

methoxypiperidin-1-

yl)[1,3]thiazolo[4,5-b]pyridine-7-

carboxylate

128
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 448 for
Intermediate 31 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₇H₁₉Cl₂FN₄O₃S
ethyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-4-

fluoropiperidin-1-yl)-1,3-

carboxylate

thiazole-4-carboxylate

129
ethyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH⁺: 448 for
Intermediate 130 and

3,5-dimethyl-1H-pyrrol-2-
C₁₈H₂₂ClFN₄O₃S
ethyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-4-

fluoropiperidin-1-yl)-1,3-

carboxylate

thiazole-4-carboxylate

130
ethyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH⁺: 448 for
Intermediate 33 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₇H₁₉Cl₂FN₄O₃S
ethyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-4-

fluoropiperidin-1-yl)-1,3-

carboxylate

thiazole-4-carboxylate

embedded image

131
Cis(±)methyl 2-3-Chloro-4-
MS (ES) MH⁺: 451 for
Intermediate 131 and

{[(3,4-dichloro-5-methyl-1H-
C₁₆H₁₇Cl₃N₄O₃S; NMR: 1.17
2-bromo-1,3-

pyrrol-2-
(t, 3H), 1.84 (m, 1H), 1.93
thiazole-5-

yl)carbonyl]amino}piperidin-1-
(m, 1H), 2.20 (s, 3H), 3.45
carboxylate

yl)-1,3-thiazole-5-carboxylate
(m, 1H), 3.75 (s, 3H), 3.82 (d,

1H), 4.02 (m, 1H), 4.26 (m,

1H), 4.50 (m, 1H), 4.76 (s,

1H), 7.15 (d, 1H), 7.85 (s,

1H), 12.12 (s, 1H)

132
methyl 2-{(3S,4R)-4-[({4-chloro-
MS (ES) MH⁺: 456 for
Intermediate 132 and

3-[(E)-(methoxyimino)methyl]-5-
C₁₈H₂₁ClFN₅O₄S;
methyl-2-bromo-1,3-

methyl-1H-pyrrol-2-

thiazole-5-

yl}carbonyl)amino]-3-

carboxylate

fluoropiperidin-1-yl}-1,3-

thiazole-5-carboxylate

133
Cis(±)-ethyl 2-3-chloro-4-{[(3,4-
MS (ES) MH⁺: 515 for
Intermediate 131 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₁Cl₃N₄O₃S
2-bromo-1,3-

yl)carbonyl]amino}piperidin-1-

benzothiazole-7-

y1)-1,3-benzothiazole-7-

carboxylate (U.S. Pat.

carboxylate

No. 5,770,758)

134
Cis(±)-ethyl 2-(3-chloro-4-{[(3,4-
MS (ES) MH⁺: 495 for
Intermediate 131 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₁Cl₃N₄O₄S
Intermediate 215

yl)carbonyl]amino}piperidin-1-

yl)-4-(hydroxymethyl)-1,3-

thiazole-5-carboxylate

135
Cis(±)-methyl 2-(3-chloro-4-
MS (ES) MH⁺: 417 for
Intermediate 133 and

{[(4-chloro-5-methyl-1H-pyrrol-
C₁₆H₁₈Cl₂N₄O₃S
methyl 2-bromo-1,3-

2-yl)carbonyl]amino}piperidin-1-

thiazole-5-

yl)-1,3-thiazole-5-carboxylate

carboylate

embedded image

136
Cis(±)-methyl 2-(3-chloro-4-
MS (ES) MH⁺: 495 for
Intermediate 131 and

{[(3,4-dichloro-5-methyl-1H-
C₁₈H₂₁Cl₃N₄O₄S
Intermediate 17

pyrrol-2-

yl)carbonyl]amino}piperidin-1-

yl)-4-(methoxymethyl)-1,3-

thiazole-5-carboxylate

137
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-
MS (ES) MH⁺: 500 for
Intermediate 226 and

5-methyl-1H-pyrrol-2-
C₂₀H₂₃Cl₂N₅O₆; NMR: 1.3 (t,
Intermediate 50

yl)carbonyl]amino}-3-
3H), 1.65 (m, 1H), 1.8 (m,

methoxypiperidin-1-yl)-5-
1H), 2.2 (s, 3H), 3.2-3.3 (m

nitroisonicotinate
6H), 3.6 (m 1H), 4.3 (m, 3H),

7.1 (m, 2H), 8.9 (s, 1H), 12.1

(s, 1H)

138
Cis(±)-methyl 2-(4-{[(3,4-
MS (ES) MH⁺: 431 for
methyl 2-bromo-1,3-

dichloro-5-methyl-1H-pyrrol-2-
C₁₇H₂₀Cl₂N₄O₃S; NMR: 0.9
thiazole-5-

yl)carbonyl]amino}-3-
(d, 3H), 1.8 (m, 2H), 2.2 (m,
carboxylate and

methylpiperidin-1-yl)-1,3-
4H), 3.2 (m 3H), 3.4-3.7 (m,
Intermediate 134

thiazole-5-carboxylate
3H), 3.7 (s, 3H), 4.1 (m, 1H),

4.25 (m, 1H), 7.1 (d, 1H), 7.9

(s, 1H), 12.0 (s, 1H)

139
Cis(±)-methyl 2-(4-{[(3,4-
MS (ES) MH⁺: 431 for
methyl 2-bromo-1,3-

dichloro-5-methyl-1H-pyrrol-2-
C₁₇H₂₀Cl₂N₄O₃S; NMR: 1.3
thiazole-5-

yl)carbonyl]amino}-2-
(d, 1H), 1.8-2.1 (m, 4H), 2.2
carboxylate and

methylpiperidin-1-yl)-1,3-
(s, 3H), 3.5 (m, 1H), 3.7 (m,
Intermediate 135

thiazole-5-carboxylate
4H), 4.1 (m, 2H), 7.3 (s, 1H),

7.9 (s, 1H), 12.0 (s, 1H)

140
Cis(±)-isopropyl 2-(4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-6- methylisonicotinate embedded image

MS (ES) MH⁺: 483 for C₂₂H₂₈Cl₂N₄O₄; NMR: 0.9 (m, 1H),1.3 (d, 6H), 1.7, (m, 1H), 2.2 (s, 3H), 2.4 (s, 3H), 3.1 (m, 2H), 3.5 (m, 1H), 4.2 (m, 2H), 4.7 (d, 1H), 5.1 (m, 1H), 6.8 (s, 1H), 7.0 (s, 1H), 7.15 (s, 1H), 12.1 (s, 1H)
Intermediate 227 and Intermediate 50

141
Cis(±)-isopropyl 5-chloro-4-(4-
MS (ES) MH⁺: 503 for
Intermediate 226 and

{[(3,4-dichloro-5-methyl-1H-
C₂₁H₂₅Cl₃N₄O₄
Intermediate 50

pyrrol-2-yl)carbonyl]amino}-3 -

methoxypiperidin-1-yl)pyridine-

2-carboxylate

142
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 479 for
Intermediate 215 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₁Cl₂FN₄O₄S; NMR: 1.2
Intermediate 36

yl)carbonyl]amino}-3-
(t, 3H), 1.9 (m, 2H), 2.2 (s,

fluoropiperidin-1-yl)-4-
3H), 3.6 (dd, 1H), 4.0-4.2 (m,

(hydroxymethyl)-1,3-thiazole-5-
1H), 4.2 (q, 2H), 4.25-4.45

carboxylate
(m, 1H), 4.6 (s, 2H), 4.9 (m,

1H), 5.05 (m, 1H), 7.2 (d,

1H), 12.1 (s, 1H)

143
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-
MS (ES) MH⁺: 491 for
Intermediate 215 and

5-methyl-1H-pyrrol-2-
C₁₉H₂₄Cl₂N₄O₅S; NMR: 1.2
Intermediate 50

yl)carbonyl]amino}-3-
(t, 3H), 1.7 (m, 2H), 2.2 (s,

methoxypiperidin-1-yl)-4-
3H), 3.4 (s, 3H), 3.55 (m,

(hydroxymethyl)-1,3-thiazole-5-
1H), 4.0 (m, 1H), 4.1-4.4 (m,

carboxylate
4H), 4.6 (s, 2H), 7.1 (d, 1H),

12.1 (s, 1H)

144
Cis(±)-ethyl 2-(4-{[(4-chloro-3-
MS (ES) MH⁺: 438 for
Intermediate 136 and

cyano-5-methyl-1H-pyrrol-2-
C₁₈H₂₀ClN₅O₄S; NMR: 1.6-
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-
1.9 (m, 2H), 2.2 (s, 3H), 3.3
thiazole-5-

methoxypiperidin-1-yl)-1,3-
(s, 3H), 3.6 (m, 1H), 3.7 (s,
carboxylate

thiazole-5-carboxylate
3H), 3.9 (m, 1H), 4.3 (m,

3H), 7.75 (d, 1H), 12.7 (s,

1H)

145
Cis(±)-ethyl 2-(4-{[(4-chloro-3- cyano-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- benzothiazole-7-carboxylate embedded image

MS (ES) MH⁺: 502 for C₂₃H₂₄ClN₅O₄S ; NMR: 1.35 (t, 3H), 1.6-2.0 (m, 2H), 2.2 (s, 3H), 3.3 (s, 3H), 3.4 (m, 1H), 3.6 (s, 3H), 4.1 (m, 1H), 4.3 (m, 1H), 4.4 (q, 2H), 7.7 (m, 2H), 7.8 (m, 1H), 7.9 (t, 1H), 12.7 (s, 1H)
Intermediate 136 and ethyl 2-bromo-1,3- benzothiazole-7- carboxylate (U.S. Pat. No. 5,770,758)

146
Cis(±)-ethyl 2-(4-{[(4-chloro-3-
MS (ES) MH⁺: 460 for
Intermediate 136 and

cyano-5-methyl-1H-pyrrol-2-
C₂₂H₂₆ClN₅O₄NMR: 1.3 (d,
Intermediate 230

yl)carbonyl]amino}-3-
6H), 1.7 (m, 2H), 2.2 (s, 3H),

methoxypiperidin-1-yl)-1,3-
3.1 (s, 2H), 3.3 (s, 3H), 3.5 (s,

thiazole-5-carboxylate
3H), 4.2 (m, 1H), 4.6 (d, 1H),

5.1 (m, 1H), 7.0 (s, 1H), 7.2

(s, 1H), 7.7 (d, 1H), 8.2 (d,

1H), 12.7 (s, 1H)

147
methyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH⁺: 426 for
Intermediate 137 and

3-cyano-5-methyl-1H-pyrrol-2-
C₁₇H₁₇ClFN₅O₃S; NMR: 1.9
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-
(m, 2H), 2.2 (s, 3H), 3.3 (s,
thiazole-5-

fluoropiperidin-1-yl)-1,3-
3H), 3.5 (dd, 1H), 3.75 (s,
carboxylate

thiazole-5-carboxylate
3H), 4.0 (m, 1H), 4.2-4.5 (m,

2H), 5.0 (d, 1H), 7.9 (s, 1H),

8.15 (m, 1H), 12.6 (s, 1H)

148
ethyl 2-((3S,4R)-4-{[(4-chloro-3-
MS (ES) MH⁺: 490 for
Intermediate 137 and

cyano-5-methyl-1H-pyrrol-2-
C₂₂H₂₁ClFN₅O₃S ; NMR: 1.35
ethyl 2-bromo-1,3-

yl)carbonyl] amino}-3-
(t, 3H), 1.6-2.0 (m, 2H), 2.2
benzothiazole-7-

fluoropiperidin-1-yl)-1,3-
(s, 3H), 3.3 (m), 3.4 (m, 1H),
carboxylate (U.S. Pat.

benzothiazole-7-carboxylate
3.6 (s, 3H), 4.1 (m, 1H), 4.3
No. 5,770,758)

(m, 1H), 4.4 (q, 2H), 7.7 (m,

2H), 7.8 (m, 1H), 7.9 (t, 1H),

12.7 (s, 1H)

149
isopropyl 2-((3S,4R)-4-{[(4-
MS (ES) MH⁺: 460 for
Intermediated 137

chloro-3-cyano-5-methyl-1H-
C₂₁H₂₃ClFN₅O₃NMR: 1.3 (d,
and Intermediate 230

pyrrol-2-yl)carbonyl]amino}-3-
6H), 1.8 (m, 2H), 2.2 (s, 3H),

fluoropiperidin-1-yl)isonicotinate
3.0 (m, 2H), 3.3 (m), 4.1-4.2

(m, 1H), 4.45 (d, 1H), 4.9 (d,

1H), 5.0 (m, 1H), 5.1 (m,

1H), 7.0 (d, 1H), 7.3 (s, 1H),

8.1 (d, 1H), 8.3 (d, 1H), 12.6

(s, 1H)

150
ethyl 2-((cis-3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-5- (morpholin-4-ylcarbonyl)-1,3- thiazole-4-carboxylate embedded image

MS (ES) MH⁺: 579 for C₂₃H₂₉Cl₂N₅O₆S; NMR: 1.2 (m, 3H), 1.75 (m, 2H), 2.2 (s, 3H), 3.3 (s, 3H), 3.4 (m, 1H), 3.5-3.6 (m, 4H), 3.8 (m, 1H), 4.2 (m, 4H), 7.15 (d, 1H), 12.1 (s, 1H)
Intermediate 231 and Intermediate 50

151
Cis(±)-isopropyl 6-cyano-4-(4-
MS (ES) MH⁺: 494 for
Intermediate 231 and

{[(3,4-dichloro-5-methyl-1H-
C₂₂H₂₅Cl₂N₅O₄; NMR: 1.3 (s,
Intermediate 50.

pyrrol-2-yl)carbonyl]amino}-3-
6H), 1.8 (m, 2H), 2.25 (s,

methoxypiperidin-1-yl)pyridine-
3H), 3.4 (s, 3H), 3.6 (m, 1H),

2-carboxylate
4.1 (d, 1H), 4.3 (m, 1H), 4.5

(d, 1H), 5.2 (m, 1H), 7.2 (d,

1H), 7.65 (s, 1H), 7.8 (s, 1H),

12.2 (s, 1H)

152
Cis(±)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 475 for
2-chloro-1,3-

methyl-1H-pyrrol-2-
C₁₇H₂₀Cl₂N₆O₄S; NMR: 1.7
thiazole-4,5-

yl)carbonyl]amino}-3-
(m, 2H), 2.2 (s, 3H), 3.3 (s,
dicarboxamide

methoxypiperidin-1-yl)-1,3-
3H), 3.5 (m, 1H), 4.0 (m,
(Robba, M.; Le

thiazole-4,5-dicarboxamide
1H), 4.2 (m, 1H), 4.4 (m,
Guen, Y. Bulletin de

1H), 7.1 (d, 1H), 7.6 (s, 1H),
la Societe Chimique

8.1 (s, 1H), 8.2 (s, 1H), 10.4
de France (1969),

(s, 1H), 12.1 (s, 1H)
(6), 2152-7) and

Intermediate 50.

153
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 463 for
2-chloro-1,3-

methyl-1H-pyrrol-2-
C₁₆H₁₇Cl₂N₆O₃S; NMR: 1.8-
thiazole-4,5-

yl)carbonyl]amino}-3-
1.9 (m, 2H), 2.2 (s, 3H), 3.3
dicarboxamide

methoxypiperidin-1-yl)-1,3-
(s, 3H), 3.4 (dd, 1H), 4.1 (m,
(Robba, M.; Le

thiazole-4,5-dicarboxamide
1H), 4.4 (m, 2H), 4.95 (d,
Guen, Y. Bulletin de

1H), 7.3 (d, 1H), 7.6 (s, 1H),
la Societe Chimique

8.1 (s, 1H), 8.2 (s, 1H), 10.4
de France (1969),

(s, 1H), 12.1 (s, 1H)
(6), 2152-7) and

Intermediate 36.

154
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-
MS (ES) MH⁺: 483 for
Intermediate 202 and

5-methyl-1H-pyrrol-2-
C₂₁H₂₄Cl₂N₄O₅
Intermediate 50

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-5-

formylisonicotinate

155
ethyl 2-((3S,4R)-4-{[(3,5- dichloro-4-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 449 for C₁₇H₁₉Cl₂FN₄O₃S: NMR: 1.25 (m, 5H), 1.9 (s, 3H), 3.6 (dd, 1H), 3.9 (m, 1H), 4.3 (m, 2H), 5.0 (d, 1H), 7.3(d, 1H), 7.8 (s, 1H), 12.6 (s, 1H)
Intermediate 138 and ethyl 2-bromo-1,3- thiazole-5- carboxylate

156
2-((3S,4R)-4-{[(3,5-dichloro-4-
MS (ES) MH⁺: 465 for
Intermediate 138 and

methyl-1H-pyrrol-2-
C₁₈H₁₉Cl₂FN₄O₅S; NMR:
Intermediate 252

yl)carbonyl]amino}-3-
1.25 (t, 3H), 1.8 (m, 2H), 1.9

fluoropiperidin-1-yl)-5-
(s, 3H), 3.5-3.8 (m, 2H), 3.9

(ethoxycarbonyl)-1,3-thiazole-4-
(m, 1H), 4.2 (q, 2H),4.3 (m,

carboxylic acid
2H), 5.0 (d, 1H), 7.4(d, 1H),

12.6 (s, 1H), 13.6 (s, 1H)

157
methyl 4-acetyl-2-((3S,4R)-4-
MS (ES) MH⁺: 489 for
Intermediate 212 and

{[(3,4-dichloro-5-methyl-1H-
C₁₉H₂₄Cl₂N₄O₅S; NMR: 1.75
Intermediate 51

pyrrol-2-yl)carbonyl]amino}-3-
(m, 2H), 2.2 (s, 3H), 2.45 (s,

methoxypiperidin-1-yl)-1,3-
3H), 3.2-3.4 (m), 3.9 (m, 1H),

thiazole-5-carboxylate
4.3 (m, 2H), 7.15 (d, 1H),

12.15 (s, 1H)

158
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 505 for
Intermediate 214 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₆Cl₂N₄O₅S;
Intermediate 51

yl)carbonyl]amino}-3-
NMR: 1.5 (s, 6H), 1.75 (m,

methoxypiperidin-1-yl)-4-(1-
2H), 2.2 (s, 3H), 3.3 (s, 3H),

hydroxy-1-methylethyl)-1,3-
3.55 (m, 1H), 3.8 (s, 3H), 3.8-

thiazole-5-carboxylate
4.0 (m, 2H), 4.2 (m, 1H), 4.5

(m, 1H), 7.15 (d, 1H), 12.2 (s,

1H)

159
methyl 1 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 503 for
Intermediate 213 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₀Cl₂N₄O₄S₂; NMR: 1.8
Intermediate 51.

yl)carbonyl]amino}-3-
(m, 2H), 2.2 (s, 3H), 3.3 (m),

methoxypiperidin-1-
3.6 (m, 1H), 3.95 (m, 1H), 4.3

yl)thieno[2,3-d][1,3]thiazole-6-
(m, 2H), 7.2 (d, 1H), 8.0 (s,

carboxylate
1H), 12.2 (s, 1H)

160
Cis(±)-methyl 2-(3- (cyclopropylmethoxy)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}piperidin-1- yl)-1,3-thiazole-5-carboxylate embedded image

MS (ESI) M: 487 for C₂₀H₂₄Cl₂N₄O₄S; NMR 0.11 (m, 2H), 0.38 (m, 2H), 0.91 (m, 1H), 1.76 (m, 2H), 2.17 (s, 3H), 3.24-3.45 (m, 4H), 3.68 (bs, 1H), 3.73 (s, 3H), 3.94 (m, 1H), 4.25 (m, 2H), 7.14 (d, 1H), 7.82 (s, 1H), 12.16 (s, 1H)
Intermediate 139 and methyl 2-bromo-1,3- thiazole-5- carboxylate

161
Cis(±)-methyl 2-[4-{[(3,4-
MS (ESI) M: 530 for
Intermediate140 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₁Cl₂N₅O₄S₂; NMR 1.66
methyl 2-bromo-1,3-

yl)carbonyl]amino}-3-(1,3-
(s, 2H), 1.91 (m, 1H), 2.10
thiazole-5-

thiazol-2-ylmethoxy)piperidin-1-
(qd, 1H), 2.27 (s, 3H), 3.20-
carboxylate

yl]-1,3-thiazole-5-carboxylate
3.37 (m, 2H), 3.82 (s, 3H),

3.96 (m, 2H), 4.40 (m, 1H),

4.64 (d, 1H), 4.96 (dd, 2H),

7.19 (d, 1H), 7.28 (d, 1H),

9.67 (bs, 1H)

162
Cis(±)-Methyl 2-(4-{[(3,4-
MS (ES) MH⁺: 461, 463 for
Intermediate

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₂Cl₂N₄O₄S; ¹H-NMR:
141 and methy1-2-

yl)carbonyl]amino}-3-
1.04 (t, 3H); 1.75 (m, 2H);
bromo-1,3-thiazole-5

ethoxypiperidin-1-yl)-1,3-
2.17 (s, 3H); 3.35-3.45 (m,
carboxylate

thiazole-5-carboxylate
3H); 3.63 (m, 2H); 3.73 (s,

3H); 3.96 (m, 1H); 4.25 (m,

2H); 7.11 (d, 1H); 7.82 (s,

1H); 12.12 (s, IH)

163
Cis(±)-Methyl 2-(4-{[(3,4-
MS (ES) MH⁺: 505, 507 for
Intermediate 141 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₆Cl₂N₄O₅S; 1H-NMR:
Intermediate 17

yl)carbonyl]amino}-3-
1.05 (t, 3H); 1.74 (m, 2H);

ethoxypiperidin-1-yl)-4-
2.17 (s, 3H); 3.27 (s, 3H);

(methoxymethyl)-1,3-thiazole-5-
3.39-3.47 (m, 3H); 3.63 (m,

carboxylate
2H); 3.71 (s, 3H); 3.96 (m,

1H); 4.23 (m, 2H); 4.55 (s,

2H); 7.12 (d, 1H); 12.16 (br s,

1H)

164
Cis(±)-Ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 475, 477 for
Intermediate 50 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₄Cl₂N₄O₄S; ¹H-NMR:
Intermediate 236

yl)carbonyl]amino}-3-
1.22 (t, 3H); 1.72 (m, 2H);

methoxypiperidin-1-yl)-4-
2.17 (s, 3H); 2.42 (s, 3H);

methyl-1,3-thiazole-5-
3.31(m, 5H); 3.52 (m, 1H);

carboxylate
3.90 (m, 1H); 4.16 (q, 2H);

4.26 (m, 2H); 7.14 (d, 1H);

12.14 (br s, 1H)

165
Ethyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-4-methyl- 1,3-thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 463 465 for C₁₈H₂₁Cl₂FN₄O₃S; NMR: 1.23 (t, 3H); 1.85 (m, 2H); 2.18 (s, 3H); 2.43 (s, 3H); 3.35 (m, 1H overlapping water) 3.53 (dd, 1H). 4.00 (m, 1H); 4.16 (q, 2H); 4.30 (m, 2H); 4.94 (d, 1H); 7.24 (d, 1H); 12.09 (s, 1H)
Intermediate 36 and Intermediate 236

166
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 475, 477 for
Intermediate 51 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₄Cl₂N₄O₄S; NMR: 1.22
Intermediate 236

yl)carbonyl]amino}-3-
(t, 3H); 1.72 (m, 2H); 2.17 (s,

methoxypiperidin-1-yl)-4-
3H); 2.42 (s, 3H); 3.31(m,

methyl-1,3-thiazole-5-
5H); 3.52 (m, 1H); 3.90 (m,

carboxylate
1H); 4.16 (q, 2H); 4.26 (m,

2H); 7.14 (d, 1H); 12.14 (br s,

1H)

167
Trans(±)methyl 2-[4-{[(3,4-
MS (ES) MH⁺: 530, 532 for
Intermediate 142

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₅Cl₂N₅O₅S ; NMR: 1.89

yl)carbonyl]amino}-3-
(m, 1H), 2.14 (m, 1H), 2.17

(morpholin-4-
(s, 3H), 3.73 (s, 3H), 3.23-

ylcarbonyl)piperidin-1-yl]-1,3-
3.79 (m, 12H), 3.93 (dd, 1H),

thiazole-5-carboxylate
4.51 (m, 1H), 7.33 (d, 1H),

7.84 (s, 1H), 12.08 (s, 1H)

168
Cis(±)methyl 2-[4-{[(3,4-
MS (ES) MH⁺: 530, 532 for
Intermediate 143

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₅Cl₂N₅O₅S ; NMR: 1.79

yl)carbonyl]amino}1-3-
(dq, 1H), 1.90 (m, 1H), 2.15

(morpholin-4-
(s, 3H), 3.22-3.42 (m, 6H),

ylcarbonyl)piperidin-1-yl]-1,3-
3.51-3.71 (m, 5H), 3.74 (s,

thiazole-5-carboxylate
3H), 3.96 (m, 1H), 4.02 (m,

1H), 4.40 (m, 1H), 7.17 (d,

1H), 7.88 (s, 1H), 12.02 (s,

1H)

169
Cis(±)({4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 491, 493 for
Intermediate 144

methyl-1H-pyrrol-2-
C₁₈H₂₀Cl₂N₄O₆S; NMR: 1.61

yl)carbonyl]amino}-1-[5-
(dq, 1H), 2.03 (m, 1H), 2.17

(methoxycarbonyl)-1,3-thiazol-2-
(s, 3H), 3.25 (dd, 1H), 3.35

yl]piperidin-3-yl}oxy)acetic acid
(m, 1H), 3.63 (m, 1H), 3.74

(s, 3H), 3.88 (m, 1H), 4.06

(m, 1H), 4.17 (s, 2H), 4.23

(dd, 1H), 7.58 (d, 1H), 7.86

(s, 1H), 11.99 (s, 1H), 12.76

(s, 1H)

170
Cis(±)methyl 2-[(3S,4R)-4- {[(3,4-dichloro-5-methyl-1H- pyrrol-2-yl)carbonyl]amino}-3- (2-morpholin-4-yl-2- oxoethoxy)piperidin-1-yl]-1,3- thiazole-5-carboxylate embedded image

MS (ES) MH⁺: 560, 562 for C₂₂H₂₇Cl₂N₅O₆S; NMR: 1.59 (dq, 1H), 2.07 (m, 1H), 2.17 (s, 3H), 3.24 (dd, 1H), 3.27- 3.56 (m, 8H), 3.61 (m, 1H), 3.74 (s, 3H), 3.85 (m, 1H), 4.05 (m, 1H), 4.24 (dd, 2H), 4.35 (q, 2H), 7.78 (d, 1H), 7.86 (s, 1H), 11.95 (s, 1H)
Example 169

171
Methyl 2-(4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 433, 435 for
Intermediate 244

methyl-1H-pyrrol-2-
C₁₆H₁₈Cl₂N₄O₄S

yl)carbonyl]amino}-3-

hydroxypiperidin-1-yl)-1,3-

thiazole-5-carboxylate

172
Methyl 2-(4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 504, 506 for
Example 171

methyl-1H-pyrrol-2-
C₁₉H₂₃Cl₂N₅O₅S

yl)carbonyl]amino}-3-

{[(ethylamino)carbonyl]oxy}

piperidin-1-yl)-1,3-thiazole-5-

carboxylate

173
Methyl 2-(3-
MS (ES) MH⁺: 516, 518 for
Example 171

{[(allylamino)carbonyl]oxy}-4-
C₂₀H₂₃Cl₂N₅O₅S

{[(3,4-dichloro-5-methyl-1H-

pyrrol-2-

yl)carbonyl]amino}piperidin-1-

yl)-1,3-thiazole-5-carboxylate

174
ethyl 4-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 443 for
Intermediate 32 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₁Cl₂FN₄O₃; NMR: 1.31
ethyl 4-

yl)carbonyl]amino}-3-
(t, 3 H) 1.81 (s, 2 H) 2.19 (s,
chloropyridine-2-

fluoropiperidin-1-yl)pyridine-2-
3 H) 2.69 (s, 1 H) 3.33 (s, 3
carboxylate (WO

carboxylate
H) 4.05 (s, 1 H) 4.30 (q, 2 H)
2004007657)

4.40 (s, 1 H) 4.86 (d, 1 H)

7.07 (dd, 2.73 Hz, 1 H) 7.21

(d, 1 H) 7.46 (d, 1 H) 8.23 (d,

1 H) 12.09 (s, 1 H)

175
Cis(±)-diethyl 2-(4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-4,5-dicarboxylate embedded image

MS (ES) MH⁺: 533 for C₂₁H₂₆Cl₂N₄O₆S; NMR: 1.22 (t, 3 H) 1.28 (t, 3 H) 1.76 (d, 2 H) 2.15-2.21 (m, 3 H) 3.29- 3.34 (m, 3 H) 3.36 (s, 3 H) 3.42 (s, 1 H) 3.56 (s, 1 H) 3.95 (s, 1 H) 4.19 (q, 2 H) 4.23-4.32 (m, 3 H) 7.19 (d, 1 H) 12.20 (s, 1 H)
Intermediate 50 and Intermediate 244

176
diethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 521 for C₂₀
Intermediate 32 and

dichloro-5-methyl-1H-pyrrol-2-
H₂₃Cl₂FN₄O₅S; NMR: 1.22
Intermediate 247

yl)carbonyl]amino}-3-
(t, 3 H) 1.28 (t, 3 H) 1.86 (d,

fluoropiperidin-1-yl)-1,3-
2 H) 2.19 (s, 3 H) 3.31 (s, 1

thiazole-4,5-dicarboxylate
H) 3.41 (s, 2 H) 3.68-3.71

(dd, 1 H) 3.99 (s, 1 H) 4.20

(q, 2 H) 4.29 (q, 2 H) 4.89-

5.05 (d, 1 H) 7.27 (d, 1 H)

12.09 (s, 1 H)

177
Cis(±)-ethyl 4-(4-{[(4-chloro-5-
MS (ES) MH⁺: 521 for
Intermediate 55 and

methyl-1H-pyrrol-2-
C₂₀H₂₅ClN₄O₄
ethyl 4-

yl)carbonyl]amino}-3-
NMR: 1.31 (t, 3 H) 1.62 (s, 1
chloropyridine-2-

methoxypiperidin-1-yl)pyridine-
H) 1.79-1.95 (m, 1 H) 2.10-
carboxylate (WO

2-carboxylate
2.19 (m, 3 H) 3.07-3.19 (m,
2004007657)

2 H) 3.23 (s, 3 H) 3.45 - 3.54

(m, 1 H) 3.89 (s, 1 H) 4.18 (s,

1 H) 4.22 (d, 1 H) 4.30 (q, 2

H) 6.89 (d, 1 H) 7.04 (dd, 1

H) 7.44 (d, 1 H) 7.67 (d, 1 H)

8.20 (d, 1 H) 11.63 (s, 1 H)

178
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-
MS (ES) MH⁺: 622 for
Intermediate 50 and

5-methyl-1H-pyrrol-2-
C₂₈H₃₃Cl₂N₅O₅S
Intermediate 55

yl)carbonyl]amino}-3 -

methoxypiperidin-1-yl)-4-{[(1-

methyl-1-

phenylethyl)amino]carbonyl}-

1,3-thiazole-5-carboxylate

179
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 443 for
Intermediate 32 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₁Cl₂FN₄O₃
ethyl 2-

yl)carbonyl]amino}-3-

fluoroisonicotinate

fluoropiperidin-1-yl)isonicotinate

(Konno, Akinori J.

Fluorine Chemistry

(1998), 87(2), 137-

140)

180
methyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-4- (methoxymethyl)-1,3-thiazole-5- carboxylate embedded image

MS (ES) MH⁺: 479 for C₁₈H₂₁Cl₂FN₄O₄S NMR: 1.86 (s, 2 H) 2.19 (s, 3 H) 3.25-3.31 (s, 3 H) 3.53- 3.67 (dd, 1 H) 3.73 (s, 3 H) 4.00 (s, 2 H) 4.33 (s, 2 H) 4.57 (s, 2 H) 4.89-5.05 (d, 1 H) 7.27 (d, 1 H) 12.10 (s, 1 H)
Intermediate 32 and Intermediate 17

181
ethyl 4-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 493 for
Intermediate 32 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₂₃Cl₂FN₄O₃
Intermediate 10

yl)carbonyl]amino}-3-

fluoropiperidin-1-yl)quinoline-2-

carboxylate

182
ethyl 2-((3S,4R)-4-{[(4-chloro-5-
MS (ES) MH⁺: 421 for
Intermediate 55 and

methyl-1H-pyrrol-2-
C₂₀H₂₅ClN₄O₄
ethyl 2-

yl)carbonyl]amino}-3-
NMR: 1.32 (t, 3 H) 1.60 (d, 1
fluoroisonicotinate

methoxypiperidin-1-
H) 1.84 (s, 1 H) 2.14 (s, 3 H)
(Konno, Akinori J.

yl)isonicotinate
3.13 (d, 2 H) 3.20-3.24 (m,
Fluorine Chemistry

3 H) 3.49 (s, 1 H) 4.20 (d, 2
(1998), 87(2), 137-

H) 4.33 (q, 2 H) 4.56 (s, 1 H)
140)

6.89 (d, 1 H) 6.97 (d, 1 H)

7.23 (s, 1 H) 7.64 (d, 1 H)

8.24 (d, 1 H) 11.62 (s, 1 H)

183
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺:491 for
Intermediate 51 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₄Cl₂N₄O₅S
Intermediate 17

yl)carbonyl]amino}-3-
NMR: 1.86-1.95 (m, 1 H)

methoxypiperidin-1-yl)-4-
1.97-2.04 (m, 1 H) 2.26-

(methoxymethyl)-1,3-thiazole-5-
2.31 (m, 3 H) 3.16-3.31 (m,

carboxylate
2 H) 3.47 (s, 3 H) 3.48 (s, 2

H) 3.50-3.55 (m, 1 H) 3.82

(s, 3 H) 4.05 (d, 1 H) 4.25 -

4.37 (m, 1 H) 4.54 (s, 1 H)

4.69-4.81 (m, 2 H) 7.19-

7.27 (m, 1 H) 9.54 (s, 1 H)

184
methyl 2-((3R,45)-4-{[(3,4-
MS (ES) MH⁺:491 for
Intermediate 52 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₄Cl₂N₄O₅S
Intermediate 17

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-4-

(methoxymethyl)-1,3-thiazole-5-

carboxylate

185
Cis(±)-isopropyl 4-(4-{[(3,4-
MS (ES) MH⁺: 582 for
Intermediate 50 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₆H₃₃Cl₂N₅O₆
Intermediate 249

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-6-

(morpholin-4-

ylcarbonyl)pyridine-2-

carboxylate

embedded image

186
isopropyl 4-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 570 for
Intermediate 32 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₅H₃₀Cl₂FN₅O₅
Intermediate 249

yl)carbonyl]amino}-3-
NMR: 1.32 (d, 6 H) 1.78-

fluoropiperidin-1-yl)-6-
1.93 (m, 2 H) 2.19 (s, 3 H)

(morpholin-4-
3.27-3.33 (m, 4 H) 3.39 (d, 2

ylcarbonyl)pyridine-2-
H) 3.53-3.60 (m, 2 H) 3.65

carboxylate
(d, 4 H) 4.12 (s, 1 H) 4.39 (s,

1 H) 5.07-5.19 (m, 1 H) 7.16-

7.26 (m, 2 H) 7.47 (d, 1 H)

12.08 (s, 1 H)

187
isopropyl 4-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 528 for
Intermediate 32 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₂₈Cl₂FN₅O₄
Intermediate 250

yl)carbonyl]amino}-3-

fluoropiperidin-1-yl)-6-

[(dimethylamino)carbonyl]

pyridine-2-carboxylate

188
Cis(±±+0)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 505 for
Intermediate 50 and

methyl-1H-pyrrol-2-
C₁₉H₂₂Cl₂N₄O₆S
Intermediate 252

yl)carbonyl]amino}-3-
NMR: 1.24 (t, 3 H) 1.74 (s, 2

methoxypiperidin-1-yl)-5-
H) 2.18 (s, 3 H) 3.36 (s, 4 H)

(ethoxycarbonyl)-1,3-thiazole-4-
3.56 (s, 1 H) 3.93 (s, 1 H)

carboxylic acid
4.19 (s, 3 H) 4.29 (s, 2 H)

7.13 (s, 1 H) 12.11 (s, 1 H)

13.51 (s, 1 H)

189
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 493 for
Intermediate 32 and

methyl-1H-pyrrol-2-
C₁₈H₁₉Cl₂FN₄O₅S
Intermediate 252

yl)carbonyl]amino}-3-
NMR: 1.19-1.27 (m, 3 H)

fluoropiperidin-1-yl)-5-
1.85 (d, 2 H) 2.18 (s, 3 H)

(ethoxycarbonyl)-1,3-thiazole-4-
3.26-3.35 (m, 1 H) 3.53 (d, 1

carboxylic acid
H) 3.98 (s, 2 H) 4.18 (q, 1 H)

4.31 (s, 2 H) 4.88-5.04 (s, 1

H) 7.26 (d, 1 H) 12.08 (s, 1

H) 13.55 (s, 1 H)

190
2-((3R,4S)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 505 for
Intermediate 52 and

methyl-1H-pyrrol-2-
C₁₉H₂₂Cl₂N₄O₆S
Intermediate 252

yl)carbonyl]amino}-3-
NMR: 1.16 (t, 3 H) 1.69 (s, 2

methoxypiperidin-1-yl)-5-
H) 2.12 (s, 2 H) 3.30 (s, 3 H)

(ethoxycarbonyl)-1,3-thiazole-4-
3.50 (s, 2 H) 3.89 (s, 2 H)

carboxylic acid
4.13 (q, 2 H) 4.17-4.29 (m, 2

embedded image

191
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 505 for
Intermediate 51 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₂Cl₂N₄O₆S
Intermediate 252

yl)carbonyl]amino}-3-
NMR: 1.22 (t, 3 H) 1.75 (s, 2

methoxypiperidin-1-yl)-4-{[(1-
H) 2.18 (s, 3 H) 3.31 (d, 1 H)

methyl-1-
3.36 (s, 3 H) 3.42 (s, 1 H)

phenylethyl)amino]carbonyl}-
3.56 (s, 1 H) 3.95 (s, 1 H)

1,3-thiazole-5-carboxylate
4.14-4.22 (m, 2 H) 4.29 (s, 1

H) 7.16 (d,1 H) 12.16 (s, 2 H)

13.56 (s, 1 H)

192
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 461 for
Intermediate 51 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₈H₂₂Cl₂N₄O₄S
ethyl 2-bromo-1,3-

yl)carbonyl]amino}-3-

thiazole-4-

methoxypiperidin-1-yl)-1,3-

carboxylate

thiazole-4-carboxylate

193
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 455 for
Intermediate 51 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₄Cl₂N₄O₄
ethyl 2-

yl)carbonyl]amino}-3-
NMR: 1.32 (s, 3 H) 1.84 (s, 2
fluoroisonicotinate

methoxypiperidin-1-
H) 2.22 (s, 3 H) 3.36 (s, 3 H)
(Konno, Akinori J.

yl)isonicotinate
3.45 (s, 1 H) 4.16 (s, 1 H)
Fluorine Chemistry

4.25 (s, 1 H) 4.31 (s, 2 H)
(1998), 87(2), 137-

4.81 (s, 1 H) 7.04 (s, 1 H)
140)

7.26 (s, 1 H) 8.21 (s, 1 H)

10.53 (s, 1 H)

Example 194
Cis(±)-ethyl 5-amino-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate

A solution of SnCl₂dihydrate (870 mg, 3.8 mmol) in 5 ml concentrated HCl was added to a solution of 436 mg (0.87 mmol) of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-nitroisonicotinate (Example 308) in 30 ml acetic acid. The mixture was stirred at room temperature overnight. Solvent was removed and the residue was partitioned between water and EtOAc. The EtOAc was separated and washed with brine. Drying (MgSO₄), removal of solvent and chromatography on silica gel (100% CH₂Cl₂followed by gradient elution to 100% EtOAc and then to 10% MeOH in EtOAc) gave 230 mg of product. MS (ES) (MH⁺): 470 for C₂₀H₂₅Cl₂N₅O₄; NMR (CDCl₃): 1.5 (t, 3H), 2.1 (m, 2H) 2.4 (s, 3H), 3.2 (m, 2H), 3.6 (s, 3H), 3.65 (m, 1H), 4.0 (m, 1H), 4.4 (m, 1H), 4.5 (q, 2H), 7.3 (s, 1H), 8.0 (s, 1H), 9.5 (s, 1H).

Example 195
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-[(methoxycarbonyl)amino]isonicotinate

embedded image

Methylchlorofomate (15 μl, 0.19 mmol) was added to a solution of 60 mg (0.13 mmol) of Cis(±)-ethyl 5-amino-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate (Example 194) in 3 ml pyridine. After stirring at room temperature overnight, 7 μl more methylchloroformate was added. Solvent was removed and the residue was partitioned between EtOAc and NaHCO₃(aqueous). The EtOAc was separated and washed with water and brine. Drying (MgSO₄) and removal of solvent gave 43 mg of product. NMR (d₆-DMSO): 1.3 (t, 3H), 1.7 (m, 2H) 2.2 (s, 3H), 3.1 (m, 2H), 3.3 (s, 3H), 3.5 (m, 1H), 3.6 (s, 3H), 4.0-4.3 (m, 4H), 4.6 (m, 1H), 7.05 (m, 1H), 7.15 (m, 1H), 8.2 (s, 1H), 9.1 (s, 1H), 12.2 (s, 1H).

Example 196
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-[(methylsulfonyl)amino]isonicotinate

Methanesulfonyl chloride (16 μl, 21 mmol) was added to 66 mg (0.14 mmol) of Cis(±)-ethyl 5-amino-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate (Example 194) in 3 ml pyridine. After stirring for 1 h, 5 μl more methanesulfonyl chloride was added. Stirred at room temperature overnight. Solvent was removed, and the residue was partitioned between EtOAc and Na₂CO₃(aqueous). The EtOAc was separated and washed with water and brine. Drying (MgSO₄) and removal of solvent gave 63 mg of product. MS (ES) (MH⁺): 534 for C₂₁H₂₇Cl₂N₅O₆S, NMR (d₆-DMSO): 1.4 (t, 3H), 1.8 (m, 2H) 2.2 (s, 3H), 2.9 (s, 3H), 3.1-3.2 (m, 2H), 3.3-3.5 (m), 3.6 (m, 1H), 4.2-4.3 (m, 2H), 4.4 (q, 2H), 4.7 (m, 1H), 7.1 (s, 1H), 7.2 (d, 1H), 8.2 (s, 1H), 12.2 (s, 1H).

Example 197
Cis(±)-6-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(ethoxycarbonyl)nicotinic acid

A solution of 133 mg (0.84 mmol) KMnO₄in 5 ml water was added to a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-formylisonicotinate (Example 154) in 20 ml acetone, and the mixture was stirred at room temperature for 4 h. After quenching with aqueous NaHSO₃, the mixture was acidified to about pH=4 with 1N HCl and extracted twice with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO₄) and concentrated to give a solid that was triturated with MeOH to give 175 mg of product. MS (ES) MH⁺: 499 for C₂₁H₂₄Cl₂N₄O₆; NMR: 1.25 (t, 3H), 1.5-1.8, (m, 3H), 2.1 (s, 3H), 3.1 (m, 3H), 3.3 (s, 3H), 3.5 (m, 1H), 4.2 (m, 2H), 4.4 (m, 1H), 4.9 (m, 1H), 6.9 (s, 1H), 7.1 (d, 1H), 8.6 (s, 1H), 12.1 (s, 1H), 13.3 (s, 1H).

Example 198
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-{[(1-methyl-1-phenylethyl)amino]carbonyl} isonicotinate

HATU (87 mg, 24 mmol) was added to a solution of 118 mg (0.24 mmol) Cis(±)-6-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(ethoxycarbonyl)nicotinic acid (Example 197), 0.040 ml (28 mmol) Et₃N and 33 mg (0.24 mmol) cumylamine in 3 ml DMF. After stirring at room temperature overnight, the mixture was diluted with water and extracted with EtOAc. The EtOAc was washed 2 times with water and once with brine before being dried (MgSO₄) and concentrated to give 103 mg of a solid. MS (ES) MH⁺: 616 for C₃₀H₃₅Cl₂N₅O₅.

Examples 199-200

The following Examples were prepared by the procedure described in Example 198 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

199
ethyl 2-((3S,4R)-4-{[(3,5-
MS (ES) MH⁺: 610 for
Example 156 and

dichloro-4-methyl-1H-pyrrol-2-
C₂₇H₃₀Cl₂FN₅O₄S;
cumylamine

yl)carbonyl]amino}-3-
NMR: 1.2 (t, 3H), 1.5 (s,

fluoropiperidin-1-yl)-4-{[(1-
6H), 1.65 (m, 2H), 1.9

methyl-1-
(s, 3H), 3.6 (m, 1H), 4.0

phenylethyl)amino]carbonyl}-
(m, 1H), 4.1-4.3 (m,

1,3-thiazole-5-carboxylate
4H), 4.3 (dd, 1H), 4.95

(d, 1H), 7.0-7.5 (m, 5H),

8.6 (s, 1H), 12.6 (s, 1H)

200

embedded image

MS (ES) MH⁺: 605 for C₂₄H₃₁Cl₂FN₆O₆S; NMR: 1.2 (t, 3H), 1.8 (m, 2H), 1.9 (s, 3H), 2.3 (m, 4H), 3.6 (m, 5H), 4.0 (m, 1H), 4.2 (q, 2H), 4.3 (m, 2H), 4.95 (d, 1H), 7.35 (d, 1H), 8.4 (t, 1H), 12.6 (s, 1H)
Example 156 and (2- morpholin-4- ylethyl)amine

Example 201
Cis(±)-ethyl 5-(aminocarbonyl)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate

A solution of 103 mg (0.17 mmol) of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-{[(1-methyl-1-phenylethyl)amino]carbonyl} isonicotinate (Example 198) in 10 ml TFA was heated at 40° C. overnight and at 50° C. for 6 h. Solvent was removed and the residue was triturated with MeOH to give 62 mg of a white solid. MS (ES) MH⁺: 498 for C₂₁H₂₅Cl₂N₅O₅.

Example 202

The following Examples were prepared by the procedure described in Example 201 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

202
5-thiazolecarboxylic acid, 4-
MS (ES)
Example

(aminocarbonyl)-2-[(3S,4R)-4-
MH⁺: 492 for
199

[[(3,5-dichloro-4-methyl-1H-
C₁₈H₂₀Cl₂FN₅O₄SE

pyrrol-2-yl)carbonyl]amino]-3-

fluoro-1-piperidinyl]-, ethyl ester

Example 203
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(dimethylamino)carbonyl]-1,3-thiazole-5-carboxylate

A solution of Cis(±)-2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-(ethoxycarbonyl)-1,3-thiazole-4-carboxylic acid (0.062 g, 0.12 mmol, Example 188), dimethylamine (0.06 mL, 2M solution in THF, Aldrich), HATU (0.05 g, 0.13 mmol) and triethylamine (0.018 mL, 0.13 mmol) was stirred at room temperature until complete by LCMS (about 30 min). The crude reaction mixture was slowly poured into water and the resulting white precipitate was filtered, washed with water and dried under vacuum to yield pure product (0.028 g). MS (ES) MH⁺: 532 for C₂₁H₂₇Cl₂N₅O₅S; NMR: 1.20 (t, 3H) 1.76 (s, 2H) 2.18 (s, 3H) 2.78 (s, 3H) 2.93 (s, 3H) 3.29 (d, 1H) 3.36 (s, 3H) 3.39-3.43 (m, 1H) 3.55 (s, 1H) 3.91 (s, 1H) 4.15 (q, 2H) 4.29 (s, 2H) 7.15 (d, 1H) 12.14 (s, 1H)

Examples 204-241

The following Examples were prepared by the procedure described in Example 203 from the starting materials (SM) indicated

Ex
Compound
Data
SM

204
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 574 for
Example 188 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₂₉Cl₂N₅O₆S;
morpholine

yl)carbonyl]amino}-3-
NMR: 1.21 (t, 3 H) 1.74 (s, 2

methoxypiperidin-1-yl)-4-
H) 2.17 (s, 3 H) 3.11-3.17 (m,

(morpholin-4-ylcarbonyl)-1,3-
2 H) 3.34 (s, 3 H) 3.38 (s, 1 H)

thiazole-5-carboxylate
3.47-3.59 (m, 5 H) 3.62 (s, 2

H) 3.87 (s, 1 H) 4.17 (q, 2 H)

4.29 (s, 2 H) 7.13 (d, 1 H)

12.13 (s, 1 H)

205

embedded image

MS (ES) MH⁺: 562 for C₂₂H₂₆Cl₂FN₅O₅S; NMR: 1.16 (t, 3 H) 1.80 (s, 2 H) 2.12 (s, 3 H) 3.09 (d, 2 H) 3.45 (s, 2 H) 3.50 (s, 2 H) 3.57 (s, 2 H) 3.92 (s, 1 H) 4.12 (q, 2 H) 4.26 (s, 3 H) 4.82 (s, 1 H) 4.99 (s, 1 H) 7.19 (s, 1 H) 12.02 (s, 1 H)
Example 189 and morpholine

206
Cis(±)-ethyl-2-(4-{[(3,4-
MS (ES) MH⁺: 534 for
Example 188 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₅Cl₂N₅O₆S; NMR: 1.18-
methoxylamine

yl)carbonyl]amino}-3-
1.25 (m, 3 H) 1.75 (s, 2 H)
hydrochloride

methoxypiperidin-1-yl)-4-
2.17 (s, 3 H) 3.35 (s, 3 H) 3.54

[(methoxyamino)carbonyl]-1,3-
(s, 2 H) 3.67 (s, 3 H) 3.95 (s, 2

thiazole-5-carboxylate
H) 4.14-4.22 (m, 2 H) 4.28 (s,

2 H) 7.13 (d, 1 H) 11.48 (s, 1

H) 12.13 (s, 1 H)

207
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 522 for
Example 189 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₂Cl₂FN₅O₅S; NMR: 1.16
methoxylamine

yl)carbonyl]amino}-3-
(t, 3 H) 1.79 (s, 2 H) 2.12 (s, 3
hydrochloride

fluoropiperidin-1-yl)-4-
H) 3.29 (s, 2 H) 3.62 (s, 3 H)

[(methoxyamino)carbonyl]-1,3-
3.94 (s, 1 H) 4.12 (q, 2 H) 4.25

thiazole-5-carboxylate
(s, 2 H) 4.82-4.98 (s, 1 H) 7.18

(d, 1 H) 11.44 (s, 1 H) 12.03

(s, 1 H)

208
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 572 for
Example 188 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₄H₃₁Cl₂N₅O₅S; NMR: 1.22
piperidine

yl)carbonyl]amino}-3-
(s, 3 H) 1.43 (s, 2 H) 1.56 (s, 4

methoxypiperidin-1-yl)-4-
H) 1.74 (s, 2 H) 2.17 (s, 3 H)

(piperidin-1-ylcarbonyl)-1,3-
3.12 (s, 2 H) 3.36 (s, 3 H) 3.52

thiazole-5-carboxylate
(s, 3 H) 4.16 (s, 2 H) 4.27 (s, 2

H) 7.15 (s, 1 H) 12.18 (s, 1 H)

209
ethyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH⁺: 622 for
Example 190 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₈H₃₃Cl₂N₅O₅S; NMR: 1.18
cumylamine

yl)carbonyl]amino}-3-
(t, 3 H) 1.53 (s, 3 H) 1.56 (s, 3

methoxypiperidin-1-yl)-4-{[(1-
H) 1.71 (s, 2 H) 2.13 (s, 3 H)

methyl-1-
3.34 (s, 3 H) 3.51 (s, 2 H) 3.92

phenylethyl)amino]carbonyl}-
(s, 2 H) 4.15 (q, 2 H) 4.26 (s, 2

1,3-thiazole-5-carboxylate
H) 7.12 (dd, 2 H) 7.23 (t,2 H)

7.40 (d, 2 H) 8.56 (s, 1 H)

12.11 (s, 1 H)

210

embedded image

MS (ES) MH⁺: 610 for C₂₇H₃₀Cl₂FN₅O₄S; NMR: 1.23 (t, 3 H) 1.61 (s, 6 H) 1.86 (s, 2 H) 2.19 (s, 3 H) 3.31 (s, 3 H) 3.55 (s, 1 H) 4.04 (s, 1 H) 4.22 (q, 1 H) 4.32 (s, 2 H) 4.90-5.06 (d, 1H) 7.20 (d, 1 H) 7.31 (t, 3 H) 7.47 (d, 2 H) 8.63 (s, 1 H) 12.12 (s, 1H)
Example 189 and cumylamine

211
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 506 for
Example 189 and

dichloro-5-methyl-1H-pyrrol-2-
C₁₉H₂₂Cl₂FN₅O₄S; NMR: 1.14
methylamine

yl)carbonyl]amino}-3-
(t, 3 H) 1.77 (s, 2 H) 2.12 (s, 3

fluoropiperidin-1-yl)-4-
H) 2.62 (d,3 H) 3.33 (s, 1 H)

[(methylamino)carbonyl]-1,3-
3.43-3.63 (s, 1 H) 3.94 (s, 1 H)

thiazole-5-carboxylate
4.09 (q, 2 H) 4.23 (s, 2 H)

4.82-4.98 (s, 1 H) 7.20 (d, 1 H)

8.27 (d, 1 H) 12.03-12.12 (m,

1 H)

212
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 548 for
Example 188 and 2-

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₇Cl₂N₅O₆S
aminoethanol

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-4-{[(2-

hydroxyethyl)amino]carbonyl}-

1,3-thiazole-5-carboxylate

213
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 622 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₈H₃₃Cl₂N₅O₅S;
cumylamine

yl)carbonyl]amino}-3-
NMR: 1.23 (t, 3 H) 1.59 (s, 3

methoxypiperidin-1-yl)-4-{[(1-
H) 1.62 (s, 3 H) 1.77 (s, 2 H)

methyl-1-
2.19 (s, 3 H) 3.31 (s, 1 H) 3.36

phenethyl)amino]carbonyl}-
(s, 1 H) 3.40 (s, 3 H) 3.57 (s, 1

1,3-thiazole-5-carboxylate
H) 3.96 (s, 1 H) 4.21 (q, 2 H)

4.32 (s, 2 H) 7.12-7.22 (m, 2

H) 7.29 (t, 2 H) 7.46 (d, 2 H)

8.62 (s, 1 H)

214
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 518 for
Example 188 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₅Cl₂N₅O₅S;
methylamine

yl)carbonyl]amino}-3-
NMR: 1.20 (s, 3 H) 1.74 (s, 2

methoxypiperidin-1-yl)-4-
H) 2.17 (s, 3 H) 2.68 (s, 3 H)

[(methylamino)carbonyl]-1,3-
3.30 (s, 2 H) 3.36 (s, 3 H) 3.55

thiazole-5-carboxylate
(s, 1 H) 3.99 (s, 1 H) 4.15 (s, 2

H) 4.26 (s, 2 H) 7.14 (s, 1 H)

8.32 (s, 1 H) 12.18 (s, 1 H)

215

embedded image

MS (ES) MH⁺: 562 for C₂₂H₂₉Cl₂N₅O₆S; NMR: 1.15-1.25 (m, 3 H) 1.74 (s, 2H) 2.18 (s, 3 H) 3.26 (s, 3 H) 3.30 (s, 1 H) 3.36 (s, 3 H) 3.41 (d, 3 H) 3.55 (s, 1 H) 4.00 (s, 1 H) 4.10-4.19 (m, 2 H) 4.26 (s, 2 H) 7.15 (d, 1 H) 8.44-8.56 (m, 1 H) 12.16 (s, 1 H)
Example 188 and (2- methoxyethyl)amine

216
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 562 for
Example 188 and 2-

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₉Cl₂N₅O₆S;
aminopropan-1-ol

yl)carbonyl]amino}-3-
NMR: 1.08 (d, 2 H) 1.22 (t, 3

methoxypiperidin-1-yl)-4-{[(2-
H) 1.75 (s, 2 H) 2.18 (s, 3 H)

hydroxy-1-
3.37 (s, 3 H) 3.47 (d, 1 H) 3.55

methylethyl)amino]carbonyl}-
(s, 1 H) 3.81-3.92 (m, 1 H)

1,3-thiazole-5-carboxylate
3.99 (s, 1 H) 4.17 (q, 2 H) 4.27

(s, 2 H) 4.62 (s, 2 H) 7.15 (d, 1

H) 8.20 (d, 1 H) 12.17 (s, 1 H)

217
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 562 for
Example 188 and 1-

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₉Cl₂N₅O₆S;
aminopropan-2-ol

yl)carbonyl]amino}-3-
NMR: 1.07 (d, 3 H) 1.21 (t, 3

methoxypiperidin-1-yl)-4-{[(2-
H) 1.75 (s, 2 H) 2.18 (s, 3 H)

hydroxypropyl)amino]carbonyl}-
3.03-3.18 (m, 2 H) 3.36 (s, 3

1,3-thiazole-5-carboxylate
H) 3.41 (s, 1 H) 3.55 (s, 1 H)

3.74 (s, 1 H) 3.98 (s, 1 H) 4.11-

4.19 (m, 2 H) 4.19 (s, 1 H)

4.30 (s, 1 H) 4.61 (s, 1 H) 7.15

(d, 1 H) 8.33-8.43 (m, 1 H)

12.16 (s, 1 H)

218
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 518 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₅Cl₂N₅O₅S;
methylamine

yl)carbonyl]amino}-3-
NMR: 1.21 (s, 3 H) 1.74 (s, 2
hydrochloride

methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3 H) 2.69 (s, 3 H)

[(methylamino)carbonyl]-1,3-
3.17 (s, 2 H) 3.36 (s, 3 H) 3.55

thiazole-5-carboxylate
(s, 1 H) 3.98 (s, 1 H) 4.14 (s, 2

H) 4.27 (s, 2 H) 7.13 (s, 1 H)

8.33 (s, 1 H) 12.17 (s, 1 H)

219
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 562 for
Example 191 and (2-

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₉Cl₂N₅O₆S
methoxyethyl)amine

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-4-{[(2-

methoxyethyl)amino]carbonyl}-

1,3-thiazole-5-carboxylate

220

embedded image

MS (ES) MH⁺: 562 for C₂₂H₂₉Cl₂N₅O₆S
Example 191 and (2S)-2-aminopropan- 1-ol

221
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 562 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₉Cl₂N₅O₆S
[(1R)-2-methoxy-1-

yl)carbonyl]amino}-3-

methylethyl]amine

methoxypiperidin-1-yl)-4-

({[(1R)-2-hydroxy-1-

methylethyl]amino}carbonyl)-

1,3-thiazole-5-carboxylate

222
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 568 for
Example 188 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₅Cl₂F₂N₅O₅S;
difluoroethylamine

yl)carbonyl]amino}-3-
NMR: 1.21 (t, 3 H) 1.75 (s, 2

methoxypiperidin-1-yl)-4-{[(2,2-
H) 2.18 (s, 3 H) 3.36 (s, 3 H)

difluoroethyl)amino]carbonyl}-
3.44 (s, 1 H) 3.55 (s, 3 H) 3.98

1,3-thiazole-5-carboxylate
(s, 1 H) 4.16 (q, 2 H) 4.26 (s, 2

H) 5.88-6.26 (t, 1H) 7.15 (d,1

H) 8.88 (s, 1 H) 12.16 (s, 1 H)

223
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 571 for
Example 188 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₄Cl₂N₆O₆S;
isoxazol-3-amine

yl)carbonyl]amino}-3-
NMR: 1.12 (t, 3 H) 1.77 (d, 2

methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3 H) 3.38 (s, 3 H)

[(isoxazol-3-ylamino)carbonyl]-
3.56 (s, 2 H) 3.98 (s, 2 H) 4.14

1,3-thiazole-5-carboxylate
(q, 2 H) 4.19-4.34 (m, 2 H)

6.99 (d, 1 H) 7.16 (d, 1 H) 8.86

(d, 1 H) 11.59 (s, 1 H) 12.17

(s, 1 H)

224
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 574 for
Example 188 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₂₉Cl₂N₅O₆S;
(3R)-

yl)carbonyl]amino}-3-
NMR: 1.21 (t,3 H) 1.75 (d, 2
tetrahydrofuran-3-

methoxypiperidin-1-yl)-4-
H) 1.87 (s, 1 H) 2.09 (s, 1 H)
amine 4-

{[(3R)-tetrahydrofuran-3-
2.18 (s, 3 H) 3.36 (s, 3 H) 3.42
methylbenzenesulfon-

ylamino]carbonyl}-1,3-thiazole-
(s, 1 H) 3.55 (s, 2 H) 3.69 (s, 1
ate

5-carboxylate
H) 3.78 (s, 2 H) 4.01 (s, 1 H)

4.17 (d, 2 H) 4.28 (s, 3 H) 7.15

(d, 1 H) 8.67 (d, 1 H) 12.17 (s,

1 H)

225

embedded image

MS (ES) MH⁺: 562 for C₂₂H₂₆Cl₂FN₅O₅S; NMR: 1.07 (s, 2 H) 1.21 (t, 3 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 2.73 (s, 1 H) 3.36 (s, 3 H) 3.41 (s, 1 H) 3.55 (s, 1 H) 3.99 (s, 1 H) 4.17 (s, 2 H) 4.26 (s, 3 H) 4.62-4.84 (d, 1H) 7.16 (s, 1 H) 8.64 (s, 1 H) 12.17 (s, 1 H)
Example 188 and (1R,2S)-2- fluorocyclopropan- amine 4- methylbenzenesulfon- ate

226
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 576 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₃₁Cl₂N₅O₆S;
[(1S)-2-methoxy-1-

yl)carbonyl]amino}-3-
NMR: 1.09 (d, 3 H) 1.22 (t, 3
methylethyl]amine

methoxypiperidin-1-yl)-4-
H) 1.75 (s, 2 H) 2.18 (s, 3 H)

({[(1S)-2-methoxy-1-
3.17 (s, 2 H) 3.26 (s, 3 H) 3.37

methylethyl]amino}carbonyl)-
(s, 3 H) 3.55 (s, 1 H) 4.01 (d, 1

1,3-thiazole-5-carboxylate
H) 4.17 (d, 2 H) 4.27 (s, 2 H)

7.16 (s, 1 H) 8.32 (d, 1 H)

12.16 (s, 1 H)

227
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 542 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₅Cl₂N₅O₅S;
propargylamine

yl)carbonyl]amino}-3-
NMR: 1.22 (s, 3 H) 1.74 (s, 2

methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3 H) 3.16 (s, 1 H)

[(prop-2-yn-1-
3.40 (m, 5 H) 3.55 (d, 1 H)

ylamino)carbonyl]-1,3-thiazole-
3.96 (s, 3 H) 4.17 (s, 2 H) 4.28

5-carboxylate
(s, 2 H) 7.14 (s, 1 H) 8.87 (s, 1

H) 12.16 (s, 1 H)

228
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 576 for
Example 191 and 2-

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₃₁Cl₂N₅O₆S
amino-2-

yl)carbonyl]amino}-3-
NMR: 1.26 (s, 6 H) 1.75 (s, 2
methylpropan-1-ol

methoxypiperidin-1-yl)-4-{[(2-
H) 2.18 (s, 3 H) 3.37 (s, 3 H)

hydroxy-1,1-
3.44 (s, 3 H) 3.56 (s, 1 H) 4.03

dimethylethyl)amino]carbonyl}-
(s, 1 H) 4.19 (s, 2 H) 4.28 (s, 2

1,3-thiazole-5-carboxylate
H) 4.67 (s, 1 H) 7.16 (s, 1 H)

7.87 (s, 1 H) 12.17 (s, 1 H)

229
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 562 for
Example 191 and

methyl-1H-pyrrol-2-
C₂₂H₂₆Cl₂FN₅O₅S;
(1R,2S)-2-

yl)carbonyl]amino}-3-
NMR: 1.08 (s, 3 H) 1.21 (t, 3
fluorocyclopropan-

methoxypiperidin-1-yl)-4-{[(2-
H) 1.76 (s, 2 H) 2.18 (s, 3H)
amine 4-

hydroxy-1,1-
3.36 (s, 3 H) 3.41 (s, 1 H) 3.55
methylbenzenesulfon-

dimethylethyl)amino]carbonyl}-
(s, 1 H) 3.97 (s, 1 H) 4.09-
ate

1,3-thiazole-5-carboxylic acid
4.19 (m, 2 H) 4.27 (s, 2 H)

4.61-4.83 (s, 1 H) 7.15 (d, 1 H)

8.64 (s, 1 H) 12.16 (s, 1 H)

230

embedded image

MS (ES) MH⁺: 569 for C₂₃H₂₆Cl₂N₆O₅S; NMR: 1.21 (q, 5 H) 1.50-1.61 (m, 2 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.36 (s, 3 H) 3.40 (s, 1 H) 3.55 (s, 1 H) 4.01 (s, 1 H) 4.13- 4.22 (m, 2 H) 4.28 (s, 2 H) 7.14 (d, 1 H) 9.36 (s, 1 H) 12.17 (s, 1 H)
Example 191 and 1- aminocyclopropane- carbonitrile

231
ethyl 4-
MS (ES) MH⁺: 544 for
Example 191 and

[(cyclopropylamino)carbonyl]-2-
C₂₂H₂₇Cl₂N₅O₅S;
cyclopropylamine

((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 0.49 (s, 2 H) 0.66 (d, 2

methyl-1H-pyrrol-2-
H) 1.22 (s, 3 H) 1.75 (s, 2 H)

yl)carbonyl]amino}-3-
2.18 (s, 3 H) 2.72 (s, 1 H) 3.38

methoxypiperidin-1-yl)-1,3-
(m, 4 H) 3.55 (s, 1 H) 3.99 (s,

thiazole-5-carboxylate
1 H) 4.17 (s, 2 H) 4.27 (s, 2 H)

7.16 (s, 1 H) 8.44 (s, 1 H)

12.17 (s, 1 H)

232
ethyl 4-{[(1-cyano-1-
MS (ES) MH⁺: 571 for
Example 191 and 2-

methylethyl)amino]carbonyl}-2-
C₂₃H₂₈Cl₂N₆O₅S;
amino-2-

((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.23 (t, 3 H) 1.62 (s, 6
methylpropanenitrile

methyl-1H-pyrrol-2-
H) 1.76 (s, 2 H) 2.18 (s, 3 H)

yl)carbonyl]amino}-3-
3.37 (s, 3 H) 3.56 (s, 1 H) 4.04

methoxypiperidin-1-yl)-1,3-
(s, 1 H) 4.15-4.22 (m, 2 H)

thiazole-5-carboxylate
4.23 (s, 2 H) 7.15 (d, 1 H) 9.07

(s, 1 H) 12.17 (s, 1 H)

233
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 606 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₂₉Cl₂N₅O₈S
methyl serinate

yl)carbonyl]amino}-3-
NMR: 1.21 (t, 3 H) 1.75 (s, 2

methoxypiperidin-1-yl)-4-({[1-
H) 2.18 (s, 3 H) 3.37 (s, 3 H)

(hydroxymethyl)-2-methoxy-2-
3.56 (s, 1 H) 3.66 (s, 2 H) 3.69-

oxoethyl]amino}carbonyl)-1,3-
3.75 (m, 1 H) 4.00 (s, 1 H)

thiazole-5-carboxylate
4.16 (q, 2 H) 4.27 (s, 2 H) 4.42-

4.54 (m, 1 H) 4.98 (s, 1 H)

7.16 (d, 1 H) 8.75 (dd, 1 H)

12.17 (s, 1 H)

234
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 617 for
Example 191 and (2-

dichloro-5-methyl-1H-pyrrol-2-
C₂₅H₃₄Cl₂N₆O₆S;
morpholin-4-

yl)carbonyl]amino}-3-
NMR: 1.22 (d, 3 H) 1.75 (s, 2
ylethyl)amine

methoxypiperidin-1-yl)-4-{[(2-
H) 2.18 (s, 3 H) 3.34 (m, 5H)

morpholin-4-
3.36 (s, 3 H) 3.55 (s, 1 H) 3.80

ylethyl)amino]carbonyl}-1,3-
(s, 2 H) 3.91 (s, 2 H) 4.02 (s, 1

thiazole-5-carboxylate
H) 4.16 (s, 2 H) 4.27 (s, 2 H)

4.94 (s, 1 H) 7.14 (s, 1 H) 8.59

(s, 1 H) 12.16 (s, 1 H)

235

embedded image

MS (ES) MH⁺: 590 for C₂₃H₂₉Cl₂N₅O₇S NMR: 1.22 (d, 3 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.36 (s, 4 H) 3.55 (s, 1 H) 3.80 (s, 2 H) 3.91 (s, 2 H) 4.00 (s, 1 H) 4.16 (s, 3 H) 4.28 (s, 2 H) 4.94 (s, 1 H) 7.14 (s, 1 H) 8.59 (s, 1 H) 12.16 (s, 1 H)
Example 191 and (1,3-dioxolan-2- ylmethyl)amine

236
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 629 for
Example 191 and 1-

dichloro-5-methyl-1H-pyrrol-2-
C₂₆H₃₄Cl₂N₆O₆S
(3-

yl)carbonyl]amino}-3-

aminopropyl)pyrroli-

methoxypiperidin-1-yl)-4-({[3-

din-2-one

(2-oxopyrrolidin-1-

yl)propyl]amino}carbonyl)-1,3-

thiazole-5-carboxylate

237
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 595 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₅H₂₈Cl₂N₆O₅S;
(pyridin-2-

yl)carbonyl]amino}-3-
NMR: 1.18 (t, 3 H) 1.76 (s, 2
ylmethyl)amine

methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3 H) 3.46 (s, 2 H)

{[(pyridin-2-
3.57 (s, 1 H) 3.99 (s, 1 H) 4.16

ylmethyl)amino]carbonyl}-1,3-
(q, 2 H) 4.28 (s, 2 H) 4.50 (d, 2

thiazole-5-carboxylate
H) 7.16 (d, 1 H) 7.34 (s, 1 H)

7.53 (d, 1 H) 7.81-7.93 (m, 1

H) 8.53 (s, 1 H) 9.07 (t, 1 H)

12.17 (s, 1 H)

238
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 578 for
Example 191 and [2-

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₉Cl₂N₅O₅S₂
(methylthio

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-4-({[2-

(methylthio)ethyl]amino}carbon-

yl)-1,3-thiazole-5-carboxylate

239
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 585 for
Example 191 and 1-

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₂₆Cl₂N₆O₆S;
(1,3-oxazol-2-

yl)carbonyl]amino}-3-
NMR: 1.17 (t, 3 H) 1.74 (s, 2
yl)methanamine

methoxypiperidin-1-yl)-4-{[(1,3-
H) 2.18 (s, 3 H) 3.37 (s, 3 H)
hydrochloride

oxazol-2-
3.55 (s, 1 H) 4.00 (s, 1 H) 4.13

ylmethyl)amino]carbonyl}-1,3-
(d, 2 H) 4.26 (s, 2 H) 4.49 (d, 2

thiazole-5-carboxylate
H) 7.11-7.25 (m, 2 H) 8.08 (s,

1 H) 9.07 (s, 1 H) 12.16 (s, 1

H)

240

embedded image

MS (ES) MH⁺: 550 for C₂₁H₂₆Cl₂FN₅O₅S; NMR: 1.21 (t, 3 H) 1.74 (d, 2 H) 2.18 (s, 3 H) 3.40 (s, 3 H) 3.55 (s, 3 H) 3.99 (s, 1 H) 4.17 (d, 2 H) 4.27 (s, 2 H) 4.42 (s, 1 H) 4.58 (s, 1 H) 7.14 (s, 1 H) 8.70 (s, 1 H) 12.17 (s, 1 H)
Example 191 and 2- fluoroethanamine hydrochloride

241
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 576 for
Example 191 and 1-

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₃₁Cl₂N₅O₆S;
amino-2-

yl)carbonyl]amino}-3-
NMR: 1.11 (s, 6 H) 1.22 (d, 3
methylpropan-2-ol

methoxypiperidin-1-yl)-4-{[(2-
H) 1.75 (s, 2 H) 2.18 (s, 3 H)

hydroxy-2-
3.14 (s, 3 H) 3.38 (s, 3 H) 3.55

methylpropyl)amino]carbonyl}-
(s, 1 H) 3.95 (s, 1 H) 4.17 (s, 2

1,3-thiazole-5-carboxylate
H) 4.27 (s, 2 H) 4.39 (s, 1 H)

7.14 (s, 1 H) 8.28 (s, 1 H)

12.17 (s, 1 H)

Examples 242-245

The following Examples were prepared by the procedure described in Example 34 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

242
Cis(±)-ethyl 4-(aminocarbonyl)-
MS (ES) MH⁺: 504 for
Example 178

2-(4-{[(3,4-dichloro-5-methyl-
C₁₉H₂₃Cl₂N₅O₅S

1H-pyrrol-2-

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-1,3-

thiazole-5-carboxylate

243
ethyl 4-(aminocarbonyl)-2-
MS (ES) MH⁺: 504 for
Example 209

((3R,4S)-4-{[(3,4-dichloro-5-
C₁₉H₂₃Cl₂N₅O₅S

methyl-1H-pyrrol-2-

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-1,3-

thiazole-5-carboxylate

244
ethyl 4-(aminocarbonyl)-2-
MS (ES) MH⁺: 492 for
Example 210

((3S,4R)-4-{[(3,4-dichloro-5-
C₁₈H₂₀Cl₂FN₅O₄S

methyl-1H-pyrrol-2-

yl)carbonyl]amino}-3-

fluoropiperidin-1-yl)-1,3-

thiazole-5-carboxylate

245

embedded image

MS (ES) MH⁺: 504 for C₁₉H₂₃Cl₂N₅O₅S NMR: 1.22 (t, 3H) 1.74 (d, 2 H) 2.18 (s, 3 H) 3.31 (s, 1 H) 3.37 (s, 3 H) 3.38-3.43 (m, 1 H) 3.55 (s, 1 H) 3.95 (s, 1 H) 4.17 (q, 2 H) 4.27 (s, 2 H) 7.15 (d, 1 H) 7.53 (s, 1 H) 7.82 (s, 1 H) 12.17 (s, 1 H)
Example 213

Example 246
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(morpholin-4-ylmethyl)-1,3-thiazole-5-carboxylate

To a solution of ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate (0.15 g, 0.31 mmol, Example 252) in methylene chloride (20 mL) was added sodium triacetoxyborohydride (0.1 g, 0.47 mmol) and morpholine (0.03 mL, 0.34 mmol). Reaction was stirred at room temperature and monitored by LCMS. Upon completion, the reaction mixture was diluted with 1N HCl and then partitioned with EtOAc/sat. sodium bicarbonate. Washing with brine, drying with MgSO₄and concentrating yielded a solid. Purification by silica gel flash column (gradient elution 70-100% EtOAc/CH₂Cl₂) afforded pure product (0.091 g) MS (ES) M+H⁺: 560 for C₂₃H₃₁Cl₂N₅O₅S; NMR: 1.24 (t, 3H) 1.75 (s, 2H) 2.18 (s, 3H) 3.32 (s, 2H) 3.36 (s, 3H) 3.52 (s, 2H) 3.54 (d, 4H) 3.65-3.75 (m, 2H) 3.76-3.86 (m, 2H) 3.93 (s, 1H) 4.18 (q, 2H) 4.27 (s, 1H) 7.16 (d, 1H) 12.16 (s, 1H)

Examples 247-249

The following Intermediate was prepared by the procedure described in Example 246 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

247
Cis(±)-ethyl 4-[(tert-
MS (ES) MH⁺: 546 for
Example 252

butylamino)methyl]-2-(4-{[(3,4-
C₂₃H₃₃Cl₂N₅O₄S;
and tert-

dichloro-5-methyl-1H-pyrrol-2-
NMR: 1.04 (s, 9 H) 1.22 (t, 3 H)
butylamine

yl)carbonyl]amino}-3-
1.72 (d, 2 H) 2.17 (s, 3 H) 3.32

methoxypiperidin-1-yl)-1,3-
(s, 1 H) 3.35 (s, 3 H) 3.53 (s, 1

thiazole-5-carboxylate
H) 3.78-3.92 (m, 2 H) 4.17 (q,

2 H) 4.23 (d, 2 H) 7.14 (d, 1 H)

248
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH⁺: 558 for
Example 252

dichloro-5-methyl-1H-pyrrol-2-
C₂₄H₃₃Cl₂N₅O₄S
and piperidine

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-4-

(piperidin-1-ylmethyl)-1,3-

thiazole-5-carboxylate

249
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 560 for
Example 252

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₃₁Cl₂N₅O₅S
and pyrrolidin-

yl)carbonyl]amino}-3-

3-ol

methoxypiperidin-1-yl)-4-[(3-

hydroxypyrrolidin-1-yl)methyl]-

1,3-thiazole-5-carboxylate

Example 250
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(E)-(hydroxyimino)methyl]-1,3-thiazole-5-carboxylate

embedded image

A solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate (0.10 g, 0.2 mmol, Example 252), sodium acetate (0.041 g, 0.5 mmol) and hydroxylamine hydrochloride (0.028 g, 0.4 mmol) were heated to reflux in absolute ethanol for 3 hours. After cooling to room temperature the ethanol was removed under reduced pressure followed by EtOAc/H₂O partitioning, drying with MgSO₄and concentrating to a yellow solid (0.081 g) MS (ES): 504 NMR: 1.25 (t, 3H) 1.75 (s, 2H) 2.18 (s, 3H) 3.31 (s, 3H) 3.36 (s, 3H) 3.55 (s, 1H) 3.95 (s, 1H) 4.18-4.26 (m, 2H) 4.26 (d, 2H) 7.16 (d, 1H) 8.61 (s, 1H) 11.72 (s, 1H) 12.16 (s, 1H)

Examples 251

The following Intermediate was prepared by the procedure described in Example 250 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

251
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 518 for
Example 252

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₅Cl₂N₅O₅S;
and

yl)carbonyl]amino}-3-
NMR: 1.25 (t, 3 H) 1.76 (s, 2 H)
methoxylamine

methoxypiperidin-1-yl)-4-[(E)-
2.19 (s, 3 H) 3.30-3.32 (m, 2 H)
hydrochloride

(methoxyimino)methyl]-1,3-
3.35-3.39 (m, 3 H) 3.57 (s, 1 H)

thiazole-5-carboxylate
3.92 (s, 3 H) 4.04 (s, 1 H) 4.19-

4.25 (m, 2 H) 4.25-4.33 (m, 2

H) 7.16 (d, 1 H) 8.66 (s, 1 H)

12.16 (s, 1 H)

Example 252
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate

To a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate (0.63 g, 1.3 mmol, Example 143) in methylene chloride was added Dess-Martin periodinane (0.61 g, 1.4 mmol). After 1 hr stirring at room temperature the reaction was complete. The crude reaction mixture was washed with water (×2) and brine, followed by drying with MgSO4 and concentrating to a minimal volume of methylene chloride after which it was directly deposited on a silica gel flash column (gradient elution to 1:1 EtOAc in CH₂Cl₂). Pure fractions concentrated to clean, yellow solid (0.56 g). NMR: 1.29 (t, 3H) 1.75 (s, 2H) 2.18 (s, 3H) 3.38 (s, 4H) 3.44 (s, 1H) 3.57 (s, 1H) 4.03 (d, 1H) 4.22-4.35 (m, 4H) 7.15 (d, 1H) 10.31 (s, 1H) 12.16 (s, 1H).

Example 253
ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(difluoromethyl)-1,3-thiazole-5-carboxylate

Diethylaminosulfurtrifluoride (0.03 mL, 0.22 mmol) was added to a solution of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate (0.10 g, 0.2 mmol, Example 252) in methylene chloride. The reaction was complete after heating at reflux overnight. Upon cooling to room temperature, the reaction was washed with water (×3) and brine (×1), dried with MgSO₄and concentrated to a yellow solid which, upon trituration, yielded a clean white solid (0.021 g). MS (ES) M+H: 511 for C₁₉H₂₂Cl₂F₂N₄O₄S; NMR: 1.26 (t, 3H) 1.75 (s, 2H) 2.18 (s, 3H) 3.37 (s, 3H) 3.43 (s, 1H) 3.56 (s, 1H) 3.96 (s, 1H) 4.25 (s, 1H) 4.36 (s, 2H) 7.16 (s, 1H) 7.31 (s, 1H) 12.17 (s, 1H).

Example 254
ethyl 4-(azidomethyl)-2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate

To a suspension of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate (0.10 g, 0.2 mmol, Example 143) in anhydrous toluene was added diphenylphosphorylazide (0.053 mL, 0.24 mmol). The reaction was cooled to 0 deg and DBU was added slowly. After stirring at 0 deg for 30 min the reaction was warmed to room temperature and stirred overnight. The biphasic reaction mixture was washed with water (×3), 1N HCl (×1), brine (×1), dried with MgSO₄and concentrated (0.048 g). MS (ES) M+H: 516 for C₁₉H₂₃Cl₂N₇O₄S.

Example 255
Cis(±)-ethyl 4-[cyano(morpholin-4-yl)methyl]-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate

embedded image

A solution of sodium cyanide (0.011 g, 0.22 mmol) and morpholine (0.018 mL, 0.21 mmol) in water (5 mL) was cooled to 0 deg. 1N HCl (0.22 mL, 0.22 mmol) was added slowly. After warming to room temperature, a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate (0.10 g, 0.2 mmol, Example 252) in methanol (10 mL) was added. After stirring at room temperature for six weeks the reaction was complete. The reaction mixture was concentrated to remove methanol and the residue was diluted with water and extracted with EtOAc (×3), washed with brine (×1), dried with MgSO₄and concentrated to a pink solid (0.055 g). MS (ES) M+H: 585 for C₂₄H₃₀Cl₂N₆O₅S.

Example 256
ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[(2-(methylsulfonyl)ethyl]amino}carbonyl)-1,3-thiazole-5-carboxylate

m-CPBA (0.091 g, 0.37 mmol) was added to a cold solution of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[2-(methylthio)ethyl]amino}carbonyl)-1,3-thiazole-5-carboxylate (0.107 g, 0.18 mmol, Example 238) in methylene chloride. After stirring at room temperature for 2 hours, the reaction mixture was washed with sat. sodium bicarbonate (×3), dried with MgSO4, and concentrated to a white solid (0.092 g). MS (ES) M+H: 610 for C₂₂H₂₉Cl₂N₅O₇S₂; NMR: 1.21 (q, 3H) 1.66-1.80 (m, 2H) 2.18 (s, 3H) 3.04 (s, 3H) 3.29 (s, 4H) 3.36 (s, 3H) 3.51-3.62 (m, 3H) 3.99 (s, 1H) 4.17 (q, 2H) 4.28 (s, 2H) 7.15 (d, 1H) 8.72 (t, 1H) 12.17 (s, 1H).

Examples 257-381

The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.

Ex
Compound
NMR
m/z
SM

257
Cis(±)-2-{4-{[(3,4-dichloro-5-
1.85 (m, 2H), 2.16 (s, 3H), 2.2 (m,
479
Example

methyl-1H-pyrrol-2-
1H), 2.5 (s, 3H), 2.6-2.9 (m, 2H),

89

yl)carbonyl]amino}-3-
3.0 (m, 1H), 3.2 (m, 1H), 3.9 (m,

[(methylsulfinyl)methyl]piperidin-
2H), 4.17 (m, 1H), 7.4 (s, 1H), 7.7

1-yl}-1,3-thiazole-5-
(dd. 1H), 7.9 (broad s, 1H).

carboxylic acid

258
Cis(±)-2-{4-{[(3,4-dichloro-5-
1.71 (m, 2H), 2.12 (s, 3H), 2.96 (s,
495
Example

methyl-1H-pyrrol-2-
3H), 2.99 (m, 2H), 3.12 (m, 3H),

90

yl)carbonyl]amino}-3-
3.95 (m, 2H), 4.3 (m, 1H), 7.37 (d,

[(methylsulfonyl)methyl]piperidin-
1H), 7.7 (s, 1H), 12 (broad s, 1H),

1-yl}-1,3-thiazole-5-
12.6 (broad s, 1H).

carboxylic acid

259
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.75 (m, 2H), 2.12 (s, 3H), 2.45 (s,
435
Example

methyl-1H-pyrrol-2-
3H), 3.14 (m, 1H), 3.27 (dd, 1H),

91

yl)carbonyl]amino}-3-
3.8 (d, 1H), 4.0 (m, 2H), 4.78 (d,

fluoropiperidin-1-yl)-5-methyl-
1H), 5.9 (broad s, 1H), 7.16 (d,

1,3-thiazole-4-carboxylic acid
1H), 12 (s, 1H).

260

embedded image

1.67 (m, 2H), 2.1 (s, 3H), 2.45 (s, 3H), 3.1 (m, 2H), 3.3 (s, 3H), 3.7 (d, 2H), 4.0 (dd, 2H), 4.4 (broad s, 1H), 7.0 (d, 1H), 12.1 (s, 1H).
447
Example 92

261
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.86 (m, 4H), 2.2 (s, 6H), 3.4 (m,
478
Example

methyl-1H-pyrrol-2-
4H), 3.8 (s, 3H), 3.9 (s, 3H), 4.0

94

yl)carbonyl]amino}-3-
(m, 2H), 4.3 (m, 4H), 4.9 (s, 1H),

fluoropiperidin-1-yl)-5-
5.0 (s, 1H), 7.2 (d, 2H), 8.4 (s,

[(methoxyimino)methyl]-1,3-
1H), 8.7 (s, 1H), 12.1 (s, 2H), 13.2

thiazole-4-carboxylic acid
(s, 2H).

262
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.93 (m, 2H), 2.16 (s, 3H), 3.3-3.8
566
Example

methyl-1H-pyrrol-2-
(m, 11H), 4.0 (m, 2H), 4.4 (m,

93

yl)carbonyl]amino}-3-
1H), 7.2 (d, 1H), 7.4 (t, 1H), 7.6

(morpholin-4-
(d, 1H), 7.7 (d, 1H), 9.8 (broad s,

ylcarbonyl)piperidin-1-yl]-1,3-
1H), 12.0 (s, 1H).

benzothiazole-7-carboxylic acid

263
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.65-1.90 (m, 2H); 2.14 (s, 3H);
449
Example

methyl-1H-pyrrol-2-
2.19 (s, 3H); 3.20-3.45 (m, 2H);

95

yl)carbonyl]amino}-3-
3.73 (d, 1H); 3.94 (d, 1H); 4.02

(methylthio)piperidin-1-yl]-1,3-
(dd, 1H); 4.43 (m, 1H); 7.24 (d,

thiazole-5-carboxylic acid
1H); 7.75 (s, 1H); 12.13 (s, 1H);

12.66 (s, 1H).

264
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.70 (m, 1H); 1.90 (m, 1H); 2.11
481
Example

methyl-1H-pyrrol-2-
(s, 3H); 3.00 (s, 3H); 3.30-3.45

96

yl)carbonyl]amino}-3-
(m, 2H); 3.45 (m, 1H); 3.62 (m,

(methylsulfonyl)piperidin-1-yl]-
2H); 4.30 (bd, 1H); 7.39 (s, 1H);

1,3-thiazole-5-carboxylic acid
8.20 (m, 1H); 12.10 (s, 1H); 12.60

(s, 1H).

265

embedded image

1.79 (m, 2H); 2.18 (s, 3H); 3.35 (m, 2H); 3.81 (s, 1H); 3.95 (d, 1H); 4.29 (m, 1H); 4.46 (m, 2H); 4.71 (d, 1H); 7.09 (d, 1H); 7.25 (s, 5H); 7.75 (s, 1H); 12.12 (s, 1H); 12.63 (s, 1H).
509
Example 97

266
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.76 (m, 2H); 2.18 (s, 3H); 3.30
457
Example

methyl-1H-pyrrol-2-
(m, 2H); 3.44 (t, 1H); 3.87 (s, 1H);

98

yl)carbonyl]amino}-3-(prop-2-
3.96 (m, 1H); 4.22-4.36 (m, 4H);

yn-1-yloxy)piperidin-1-yl]-1,3-
7.15 (d, 1H); 7.73 (s, 1H); 12.15

thiazole-5-carboxylic acid
(s, 1H); 12.62 (s, 1H).

267
Trans(±)2-(3-(benzyloxy)-4-
1.72 (m, 1H), 1.98 (m, 1H), 2.17
509
Example

{[(3,4-dichloro-5-methyl-1H-
(s, 3H), 3.26 (m, 1H), 3.67 (m,

99 and

pyrrol-2-
1H), 3.82 (m, 1H), 4.14 (m, 2H),

benzyl

yl)carbonyl]amino}piperidin-1-
4.63 (dd, 2H), 7.28 (m, 5H), 7.34

bromide

yl)-1,3-thiazole-5-carboxylic
(d, 2H), 7.76 (s, 1H), 12.00 (s,

acid
1H), 12.66 (br s, 1H)

268
Trans(±)2-(3-(allyloxy)-4-
1.67 (m, 1H), 1.98 (m, 1H), 2.17
459
Example

{[(3,4-dichloro-5-methyl-1H-
(s, 3H), 3.22 (m, 1H), 3.37 (m,

99 and

pyrrol-2-
1H), 3.57 (m, 1H), 3.79 (m, 1H),

allyl

yl)carbonyl]amino}piperidin-1-
4.09 (m, 4H), 5.10 (d, 1H), 5.23

bromide

yl)-1,3-thiazole-5-carboxylic
(dd, 1H), 5.85 (m, 1H), 7.31 (d,

acid
2H), 7.76 (s, 1H), 11.99 (s, 1H)

269
Trans(±)2-(4-{[(3,4-dichloro-5-
1.60 (m, 1H), 2.01 (m, 1H), 2.17
419
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.07 (m, 1H), 3.30 (m,

99

yl)carbonyl]amino}-3-
1H), 3.61 (m, 1H), 3.82 (m, 1H),

hydroxypiperidin-1-yl)-1,3-
3.90 (m, 1H) 3.99 (m, 1H), 4.58

thiazole-5-carboxylic acid
(m, 1H), 7.18 (d, 1H), 7.31 (m,

1H), 7.75 (s, 1H), 11.97 (s, 1H)

270

embedded image

1.74 (m, 1H), 2.00 (m, 1H), 2.16 (s, 3H), 3.36 (m, 2H), 3.79 (m, 2H), 4.18 (m, 2H), 4.80 (dd, 2H), 7.41 (brd, 1H), 7.46 (brt, 2H), 7.54 (brd, 1H), 7.76 (s, 1H), 7.94 (brt, 1H), 8.58 (brd, 1H), 11.99 (s, 1H)
510
Example 99 and 2- chloro- methyl- pyridine

271
2-((3S,4R)-4-{[(3-chloro-5-
1.85 (m, 2H); 2.17 (s, 3H); 3.48
387
Example

methyl-1H-pyrrol-2-
(m 2H); 4.0 (m, 1H); 4.33 (m,

100

yl)carbonyl]amino}-3-
2H); 4.96 (d, br, 1H); 5.95 (s, 1H);

fluoropiperidin-1-yl)-1,3-
7.10 (d, 1H); 7.76 (s, 1H); 11.63

thiazole-5-carboxylic acid
(s, 1H); 12.68 (s, br, 1H)

272
2-((3S,4R)-4-{[(3-chloro-5-
1.88 (m, 2H); 2.17 (s, 3H); 3.31
387
Example

methyl-1H-pyrrol-2-
(m 2H); 3.94 (m, 1H); 4.23 (m,

101

yl)carbonyl]amino}-3-
2H); 4.90 (d, br, 1H); 5.93 (s, 1H);

fluoropiperidin-1-yl)-1,3-
7.10 (d, 1H); 7.62 (s, 1H); 11.62

thiazole-4-carboxylic acid
(s, 1H)

273
2-((3S,4R)-4-{[(3-chloro-5-
1.88 (m, 2H); 2.17 (s, 3H); 3.31
437
Example

methyl-1H-pyrrol-2-
(m 2H); 4.19 (m, 1H); 4.46 (m,

102

yl)carbonyl]amino}-3-
2H); 4.97 (d, br, 1H); 5.93 (s, 1H);

fluoropiperidin-1-yl)-1,3-
7.10 (d, 1H); 7.41 (t, 1H); 7.68 (d,

benzothiazole-7-carboxylic acid
1H); 7.69 (d, 1H); 11.62 (s, 1H)

274
2-((3S,4R)-4-{[(3-chloro-5-
1.80 (m, 2H); 2.16 (s, 3H); 3.06
381
Example

methyl-1H-pyrrol-2-
(m 2H); 4.40 (m, 2H); 4.71 (m,

108

yl)carbonyl]amino}-3-
1H); 4.90 (d, br, 1H); 5.94 (s, 1H);

fluoropiperidin-1-yl)isonicotinic
7.03 (m, 2H); 7.26 (s, 1H); 8.22

acid
(d, 1H); 11.61 (s, br, 1H)

275

embedded image

1.94 (m, 1H); 1.98 (m, 1H); 2.14 (s, 3H); 3.31 (m 2H); 4.01 (m, 1H); 4.28 (m, 2H); 4.86 (d, br, 1H); 6.94 (s, 1H); 7.75 (s, 1H); 8.02 (d, 1H); 11.73 (s, 1H).
432
Example 103

276
2-((3S,4R)-4-{[(4-bromo-5-
1.72 (m, 1H); 1.92 (m, 1H); 2.15
426
Example

methyl-1H-pyrrol-2-
(s, 3H); 3.10 (m, 1H); 3.30 (m,

109

yl)carbonyl]amino}-3-
1H); 4.24 (m, 1H); 4.44 (m, 1H);

fluoropiperidin-1-yl)isonicotinic
4.69 (m, 1H); 4.86 (d, br, 1H);

acid
6.96 (s, 1H); 7.05 (d, 1H); 7.33 (s,

1H); 7.95 (d, 1H); 8.24 (d, 1H);

11.74 (s, br, 1H).

277
2-((3S,4R)-4-{[(4-bromo-3-
1.86 (m, 2H); 2.19 (s, 3H); 3.48
466
Example

chloro-5-methyl-1H-pyrrol-2-
(m 1H); 3.53 (m, 1H); 4.01 (m,

104

yl)carbonyl]amino}-3-
1H); 4.33 (m, 2H); 4.96 (d, br,

fluoropiperidin-1-yl)-1,3-
1H); 7.32 (d, 1H); 7.76 (s, 1H);

thiazole-5-carboxylic acid
12.24 (s, 1H); 12.69 (br, 1H).

278
2-((3S,4R)-4-{[(4-bromo-3-
1.85 (m, 2H); 2.19 (s, 3H); 3.31
466
Example

chloro-5-methyl-1H-pyrrol-2-
(m 2H); 3.95 (m, 1H); 4.23 (m,

105

yl)carbonyl]amino}-3-
2H); 4.90 (d, br, 1H); 7.45 (d, 1H);

fluoropiperidin-1-yl)-1,3-
7.63 (s, 1H); 12.39 (s, br, 1H).

thiazole-4-carboxylic acid

279
2-((3S,4R)-4-{[(4-bromo-3-
1.86 (m, 2H); 2.19 (s, 3H); 3.29
510
Example

chloro-5-methyl-1H-pyrrol-2-
(s, 2H); 3.60 (m 2H); 4.04 (m,

107

yl)carbonyl]amino}-3-
1H); 4.30 (m, 2H); 4.57 (s, 3H);

fluoropiperidin-1-yl)-4-
4.90 (d, br, 1H); 7.32 (d, 1H);

(methoxymethyl)-1,3-thiazole-
12.25 (s, 1H); 12.78 (br, 1H)

5-carboxylic acid

280

embedded image

1.86 (m, 2H); 2.19 (s, 3H); 3.07 (m, 1H); 4.04 (m, 1H); 4.28 (m, 2H); 4.69 (m, 1H); 4.90 (d, br, 1H); 7.01 (d, 1H); 7.27 (s, 1H); 7.82 (m, 1H); 8.02 (m, 1H); 13.38 (s, br, 1H)
460
Example 106

281
Cis(±)-2-[(4-{[(3,4-Dichloro-5-
1.74-1.76 (m, 2H), 2.17 (s, 3H),
477
Example

methyl-1H-pyrrol-2-
3.14 (s, 3H), 3.25-3.42 (m, 4H),

110

yl)carbonyl]amino}-3-(2-
3.50-3.60 (m, 1H), 3.67-3.73 (m,

methoxyethoxy)piperidin-1-yl]-
2H), 3.75-4.00 (m, 2H), 4.20-4.35

1,3-thiazole-5-carboxylic acid
(m, 2H), 7.14 (d, 1H), 7.72 (s,

1H), 12.14 (brs, 1H)

282
Cis(±)-2-[(4-{[(3,4-Dichloro-5-
1.74-1.80 (m, 2H), 2.17 (s, 3H),
477
Example

methyl-1H-pyrrol-2-
3.14 (s, 3H), 3.25-3.42 (peaks

111

yl)carbonyl]amino}-3-(2-
overlapping with H₂O signal),

methoxyethoxy)piperidin-1-yl]-
3.50-3.60 (m, 1H), 3.67-3.73 (m,

1,3-thiazole-4-carboxylic acid
2H), 3.86-3.90 (m, 1H), 4.12-4.35

(m, 2H), 7.15 (d, 1H), 7.57 (s,

1H), 12.13 (brs, 1H), 12.55 (brs,

1H)

283
Cis(±)-2-[(4-{[(3,4-Dichloro-5-
1.70-1.75 (m, 2H), 2.17 (s, 3H),
471
Example

methyl-1H-pyrrol-2-
3.05-3.20 (m, 2H), 3.09 (s, 3H),

113

yl)carbonyl]amino}-3-(2-
3.25-3.35 (m, 2H), 3.45--3.73

methoxyethoxy)piperidin-1-
(peaks overlapping with H₂O

yl]isonicotinic acid
signal), 4.20-4.25 (m, 2H), 4.60-

4.70 (m, 1H), 6.97 (d, 1H), 7.13

(d, 1H), 7.26 (s, 1H), 8.19 (d, 1H),

12.13 (s, 1H)

284
Cis(±)-2-[(4-{[(3,4-Dichloro-5-
1.79-1.75 (m, 2H), 2.19 (s, 3H),
527
Example

methyl-1H-pyrrol-2-
3.12 (s, 3H), 3.27-3.45 (peaks

114

yl)carbonyl]amino}-3-(2-
overlapping with H₂O signal),

methoxyethoxy)piperidin-1-yl]-
3.51-3.62 (m, 1H), 3.72-3.80 (m,

1,3-benzothiazole-7-carboxylic
2H), 4.05-4.13 (m, 1H), 4.24-4.42

acid
(m, 2H), 7.18 (d, 1H), 7.39 (t, 1H),

7.65 (t, 2H), 12.16 (s, 1H), 13.48

(brs, 1H)

285

embedded image

1.70-1.75 (m, 2H), 2.17 (s, 3H), 2.39(s, 3H), 3.15 (s, 3H), 3.32- 3.40 (m, buried under water peak), 3.50-3.60 (m, 1H), 3.68-3.75 (m, 2H), 3.86-3.98 (m, 1H), 4.20-4.30 (m, 2 H), 7.14 (d, 1H), 12.14 (s, 1H), 12.38 (brs, 1H)
490
Example 112

286
2-((3S,4R)-4-{[(4-chloro-1H-
1.62-1.76 (m, 1H), 1.85-2.03 (m,
373
Example

pyrrol-2-yl)carbonyl]amino}-3-
1H), 3.22 (s, 3H), 3.36-3.45 (m,

115

fluoropiperidin-1-yl)-1,3-
1H), 3.50 (dd, 1H), 3.75 (s, 1H),

thiazole-5-carboxylic acid
4.02-4.10 (m, 1H), 4.15-4.36 (m,

2H), 4.90 (d, 1H), 6.94-6.97 (m,

2H), 7.85 (s, 1H), 8.10 (d, 1H),

11.82 (s, 1H)

287
2-((3S,4R)-4-{[(4-chloro-5-
1.62-1.74 (m, 1H), 1.84-2.05 (m,
401
Example

methyl-1H-pyrrol-2-
1H), 2.13 (s, 3H), 2.41 (s, 3H),

116

yl)carbonyl]amino}-3-
3.19-3.30 (m, 1H), 3.50 (dd, 1H),

fluoropiperidin-1-yl)-4-methyl-
3.96-4.02 (m, 1H), 4.20-4.31 (m,

1,3-thiazole-5-carboxylic acid
2H), 4.87(d, 1H), 6.89 (d, 1H),

7.97 (d, 1H), 11.65 (s, 1H)

288
2-((3S,4R)-4-{[(4-chloro-1H-
1.68-1.74 (m, 1H), 1.85-2.00 (m,
387
Example

pyrrol-2-yl)carbonyl]amino}-3-
1H), 2.39 (s, 3H), 3.30-3.54 (peaks

117

fluoropiperidin-1-yl)-4-methyl-
buried under water peak), 3.94-

1,3-thiazole-5-carboxylic acid
4.00 (m, 1H), 4.10-4.32 (m, 2H),

4.82 (d, 1H), 6.94-6.97 (m, 2H),

8.11 (d, 1H), 11.84 (s, 1H)

289
2-((3S,4R)-4-{[(4,5-dichloro-
1.69-1.74 (m, 1H), 1.86-2.00 (m,
419
Example

1H-pyrrol-2-
1H), 2.40 (s, 3H), 3.25-3.35 (m,

118

yl)carbonyl]amino}-3-
1H, buried under water peak), 3.51

fluoropiperidin-1-yl)-4-methyl-
(dd, 1H), 3.96-4.00 (m, 1H), 4.16-

1,3-thiazole-5-carboxylic acid
4.31 (m, 2H), 4.87 (d, 1H), 7.06

(d, 1H), 8.15 (d, 1H), 12.48 (brs,

1H), 12.78 (s, 1H)

290

embedded image

1.64-1.74 (m, 1H), 1.85-2.00 (m, 1H), 3.30-3.40 (m, 1H, buried under water peak), 3.53 (dd, 1H), 4.00-4.08 (m, 1H), 4.12-4.40 (m, 2H), 4.89 (d, 1H), 7.06 (d, 1H), 7.75 (s, 1H), 8.16 (d, 1H), 12.78 (s, 1H)
405
Example 119

291
Cis(±)-2-[4-{[(3,4-dichloro-5-
0.95 (d, 3H), 1.73-1.85 (m, 2H),
477
Example

methyl-1H-pyrrol-2-
2.16 (s, 3H), 3.19-3.36 (m, 6 H,

120

yl)carbonyl]amino}-3-(2-
broad peaks), 3.61-3.67 (m, 3 H),

hydroxypropoxy)piperidin-1-
3.94-4.30 (m, difficult to integrate

yl]-1,3-thiazole-5-carboxylic
as the peaks are buried under

acid
water peak), 7.16 (d, 1H), 7.71 (s,

1H), 12.11 (s, 1H)

292
Cis(±)-2-[4-{[(3,4-dichloro-5-
0.96 (d, 3H), 1.73-1.76 (m, 2H),
491
Example

methyl-1H-pyrrol-2-
2.17 (s, 3H), 3.14 (s, 1H), 3.28-

121

yl)carbonyl]amino}-3-(2-
3.67 (difficult to integrate as the

methoxypropoxy)piperidin-1-
peaks are buried under water

yl]-1,3-thiazole-5-carboxylic
peak), 3.89-3.92 (m, 1H), 4.20-

acid
4.45 (m, 2 H), 7.12(d, 1H), 7.72(s,

1H), 12.15 (s, 1H)

293
2-((3R,4S)-4-{[(3,4-dichloro-5-
1.85 (m, 2H), 2.25 (s, 3H), 3.41-
483
Example

methyl-1H-pyrrol-2-
3.48 (m, 6H), 4.16 (m, 1H), 5.35

123

yl)carbonyl]amino}-3-
(m, 1H), 4.41 (m, 1H), 7.26 (d,

methoxypiperidin-1-yl)-1,3-
1H), 7.49 (t, 1H), 7.72 (t, 2H0,

benzothiazole-7-carboxylic acid
12.23 (s, 1H)

294
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.85 (m, 2H), 2.25 (s, 3H), 3.41-
483
Example

methyl-1H-pyrrol-2-
3.48 (m, 6H), 4.16 (m, 1H), 5.35

122

yl)carbonyl]amino}-3-
(m, 1H), 4.41 (m, 1H), 7.26 (d,

methoxypiperidin-1-yl)-1,3-
1H), 7.49 (t, 1H), 7.72 (t, 2H),

benzothiazole-7-carboxylic acid
12.23 (s, 1H)

295

embedded image

1.74 (m, 2H), 2.10 (s, 3H), 3.29 (m, 1H), 3.48 (d, 1H), 3.85 (d, 1H0, 4.14 (m, 1H), 4.29 (m, 1H), 4.83 (d, 1H), 7.18 (d, 1H), 7.53 (s, 1H), 12.03 (s, 1H)
421
Example 124

296
2-((3S,4R)-4-{[(4-chloro-5-
1.85 (m, 1H), 2.14 (m, 1H), 2.23
449
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.33 (s, 3H), 3.62-3.81

125

yl)carbonyl]amino}-3-
(m, 2H), 4.29 (m, 1H), 4.43 (m,

methoxypiperidin-1-yl)-1,3-
1H), 4.51 (m, 1H). 7.09 (s, 1H),

benzothiazole-7-carboxylic acid
7.59 (t, 1H), 7.82-7.90 (m, 2H),

11.84 (s, 1H)

297
Cis(±)2-4-{[(4-chloro-3,5-
1.47 (m, 1H), 1.62 (m, 1H), 1.95
413
Example

dimethyl-1H-pyrrol-2-
(s, 3H0, 1.98 (s, 3H), 3.13 (m,

126

yl)carbonyl]amino}-3-
1H), 3.32 (m, 1H), 3.42 (s, 3H),

methoxypiperidin-1-yl)-1,3-
3.68 (m, 1H), 4.04 (m, 2H), 6.89

thiazole-5-carboxylic acid
(d, 1H), 7.53 (s, 1H), 11.22 (s, 1H)

299
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.74 (m, 2H), 2.10 (s, 3H), 3.29
421
Example

methyl-1H-pyrrol-2-
(m, 1H), 3.48 (d, 1H), 3.85 (d,

128

yl)carbonyl]amino}-3-
1H0, 4.14 (m, 1H), 4.29 (m, 1H),

fluoropiperidin-1-yl)-1,3-
4.83 (d, 1H), 7.18 (d, 1H), 7.53 (s,

thiazole-4-carboxylate
1H), 12.03 (s, 1H)

300
2-((3S,4R)-4-{[(4-chloro-3,5-
1.69 (m, 1H), 1.82 (m, 1H), 2.09
401
Example

dimethyl-1H-pyrrol-2-
(s, 3H), 2.13 (s, 3H), 3.19-3.30 (m,

129

yl)carbonyl]amino}-3-
2H), 3.89 (m, 1H), 4.14 (m, 2H),

fluoropiperidin-1-yl)-1,3-
4.83 (d, 1H), 7.38 (d, 1H), 7.56 (s,

thiazole-4-carboxylic acid
1H), 11.29 (s, 1H)

301

embedded image

1.74 (m, 2H), 2.10 (s, 3H), 3.29 (m, 1H), 3.48 (d, 1H), 3.85 (d, 1H0, 4.14 (m, 1H), 4.29 (m, 1H), 4.83 (d, 1H), 7.18 (d, 1H), 7.53 (s, 1H), 12.03 (s, 1H)
421
Example 130

302
Cis(±)2-3-chloro-4-{[(3,4-
1.87 (m, 1H), 1.93 (m, 1H), 2.20
437
Example

dichloro-5-methyl-1H-pyrrol-2-
(s, 3H), 3.41 (m, 1H), 3.82 (d,

131

yl)carbonyl]amino}piperidin-1-
1H), 4.01 (d, 1H), 4.27 (d, 1H),

yl)-1,3-thiazole-5-carboxylic
4.75 (s, 1H), 7.18 (d, 1H), 7.75 (s,

acid
1H), 12.15 (s, 1H)

303
2-{(3S,4R)-4-[({4-chloro-3-
1.86 (m, 2H), 2.35 (s, 3H), 3.33
444
Example

[(E)-(methoxyimino)methyl]-5-
(m, 1H), 3.61 (dd, 1H), 3.82 (s,

132

methyl-1H-pyrrol-2-
3H), 4.00 (d, 1H), 4.34 (m, 2H),

yl}carbonyl)amino]-3-
4.93 (d, 1H), 7.28 (d, 1H), 7.76 (s,

fluoropiperidin-1-yl}-1,3-
1H), 8.02 (s, 1H), 12.14 (s, 1H),

thiazole-5-carboxylic acid
12.66 (s, 1H)

304
Cis(±)-2-(3-chloro)-4-{[(3,4-
1.82(m, 2H), 2.25 (s, 3H), 3.41
489
Example

dichloro-5-methyl-1H-pyrrol-2-
(m, 1H), 3.42 (m, 2H), 4.19 (m,

133

yl)carbonyl]amino}piperidin-1-
1H), 5.35 (m, 1H), 4.41 (m, 1H),

yl)[1,3]thiazolo[4,5-b]pyridine-
7.28 (d, 1H), 7.43(t, 1H), 7.72 (t,

7-carboxylic acid
2H), 12.23 (s, 1H)

305

embedded image

1.84 (m, 1H), 1.91 (m, 1H), 2.20 (s, 3H), 3.33 (m, 1H), 3.79 (m, 1H), 4.04 (m, 1H), 4.21 (m, 1H), 4.48 (m, 1H), 4.59 (m, 2H), 4.75 (s, 1H), 7.20 (d, 1H), 12.17 (s, 1H)
468
Example 134

306
Cis(±)-2-(3-chloro-4-{[(4-
1.72 (m, 1H), 2.07 (m, 1H), 2.14
403
Example

chloro-5-methyl-1H-pyrrol-2-
(s, 3H), 3.34 (t, 1H), 3.81 (d, 1H),

135

yl)carbonyl]amino}piperidin-1-
4.03 (d, 1H), 4.22 (d, 1H), 4.36

yl)-1,3-thiazole-5-carboxylic
(m, 1H), 4.73 (s, 1H), 6.91 (s, 1H),

acid
7.75 (s, 1H), 7.95 (d, 1H), 11.70

(s, 1H)

307
Cis(±)-2-(3-chloro-4-{[(3,4-
1.83 (m, 1H), 1.92 (m, 1H), 2.20
481
Example

dichloro-5-methyl-1H-pyrrol-2-
(s, 3H), 3.28 (s, 3H0, 3.35 (m,

136

yl)carbonyl]amino}piperidin-1-
1H), 3.80 (d, 1H), 4.01 (m, 1H),

yl)-4-(methoxymethyl)-1,3-
4.22 (m, 1H), 4.43 (m, 1H), 4.56

thiazole-5-carboxylic acid
(m, 2H), 4.75 (s, 1H), 7.18 (d,

1H), 12.15 (s, 1H)

308
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.78 (m, 1H), 1.91 (m, 1H), 2.19
470
Intermediate

methyl-1H-pyrrol-2-
(s, 3H), 3.32 (m, 2H), 3.55 (d,

131

yl)carbonyl]amino}-3-
1H), 3.90 (s, 1H), 4.03 (m, 1H),

and 2-

hydroxypiperidin-1-yl)-1,3-
4.17 (m, 1H), 5.53 (d, 1H), 7.15

bromo-

benzothiazole-7-carboxylic acid
(d, 1H), 7.41 (t, 1H), 7.64 (t, 2H),

1,3-

12.15 (s, 1H), 13.47 (s, 1H)

benzthia-

zole-7-

carboxylate

309
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.65 (m, 1H), 1.8 (m, 1H), 2.2 (s,
500
Example

methyl-1H-pyrrol-2-
3H), 3.3 (m), 3.55 (s, 1H), 4.3 (m,

137

yl)carbonyl]amino}-3-
1H), 7.1 (m 2H), 8.9 (s, 1H), 12.2

methoxypiperidin-1-yl)-5-
(s, 1H), 13.9 (s, 1H)

nitroisonicotinic acid

310

embedded image

1.7 (m, 2H), 2.2 (s, 3H), 2.4-2.5 (m), 3.0-3.2 (m 2H), 3.3 (s, 3H), 3.5 (m 1H), 3.6 (s, 3H), 4.1 (m, 1H), 4.2 (m, 1H), 4.5 (m, 1H), 7.1 (m, 2H), 8.6 (s, 1H), 12.1 (s, 1H), 13.7 (s, 1H)
500
Example 195

311
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.7 (m, 2H) 2.2 (s, 3H), 2.9 (s,
506
Example

methyl-1H-pyrrol-2-
3H), 3.1 (m, 2H), 3.3-3.5 (m), 3.5

196

yl)carbonyl]amino}-3-
(m, 1H), 4.2 (m, 2H), 4.6 (d, 1H),

methoxypiperidin-1-yl)-5-
7.1 (m, 2H), 8.1 (s, 1H), 12.1 (s,

[(methylsulfonyl)amino]isonico-
1H).

tinic acid

312
Cis(±)-2-(4-{[(3,4-dichloro-5-
0.9 (d, 3H), 1.8 (m, 2H), 2.2 (m,
431
Example

methyl-1H-pyrrol-2-
4H), 3.3-3.8 (m, 4H), 4.25 (m,

138

yl)carbonyl]amino}-3-
1H), 4.25 (m, 1H), 7.2 (d, 1H), 7.8

methylpiperidin-1-yl)-1,3-
(s, 1H), 12.0 (s, 1H), 12.6 (s, 1H)

thiazole-5-carboxylic acid

313
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.3 (d, 1H), 1.8-2.1 (m, 4H), 2.2
417;
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.6 (m, 1H), 3.8 (m 1H),

139

yl)carbonyl]amino}-2-
4.1 (m, 2H), 7.3 (s, 1H), 7.8 (s,

methylpiperidin-1-yl)-1,3-
1H), 12.1 (s, 1H)

thiazole-5-carboxylic acid

314
Cis(±)-2-(4-{[(3,4-dichloro-5-
0.9 (m, 1H), 1.3 (d, 6H), 1.7, (m,
441
Example

methyl-1H-pyrrol-2-
1H), 2.2 (s, 3H), 2.4 (s, 3H), 3.1

140

yl)carbonyl]amino}-3-
(m, 2H), 3.5 (m, 1H), 4.2 (m, 2H),

methoxypiperidin-1-yl)-6-
4.7 (d, 1H), 5.1 (m, 1H), 6.8 (s,

methylisonicotinic acid
1H), 7.0 (s, 1H), 7.15 (s, 1H), 12.1

(s, 1H).

315

embedded image

NMR: 1.8, (m, 3H), 2.2 (s, 3H), 3.3 (s, 3H), 3.6 (m, 2H), 4.0 (m, 1H), 4.2 (m, 1H), 7.2 (s, 1H), 7.7 (s, 1H), 8.5 (s, 1H), 12.1 (s, 1H), 12.4 (s, broad, 1H).
461
Example 141

316
2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.85 (m, 2H), 2.2 (s, 3H),
451
Example

methyl-1H-pyrrol-2-
3.3-3.7 (m, 2H), 4.0 (m, 1H), 4.3

142 and

yl)carbonyl]amino}-3-
(m, 2H), 4.6 (s, 2H), 4.95 (d, 1H),

Intermediate

fluoropiperidin-1-yl)-4-
7.3 (d, 1H), 12.1 (s, 1H), 12.7 (s,

215

(hydroxymethyl)-1,3-thiazole-5-
1H).

carboxylic acid

317
Cis(±)-2-(4-{[(3,4-dichloro-5-
NMR: 1.2 (t, 3H), 1.7 (m, 2H), 2.2
463
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.4 (s, 3H), 3.55 (m, 1H),

143

yl)carbonyl]amino}-3-
4.0 (m, 1H), 4.1-4.4 (m, 4H), 4.6

methoxypiperidin-1-yl)-4-
(s, 2H), 7.1 (d, 1H), 12.1 (s, 1H).

(hydroxymethyl)-1,3-thiazole-5-

carboxylic acid

318
Cis(±)-2-(4-{[(4-chloro-3-
NMR: 1.6-1.9 (m, 2H), 2.2 (s,
424
Example

cyano-5-methyl-1H-pyrrol-2-
3H), 3.3 (s, 3H), 3.6 (m, 1H), 3.7

144

yl)carbonyl]amino}-3-
(s, 3H), 3.9 (m, 1H), 4.3 (m, 2H),

methoxypiperidin-1-yl)-1,3-
7.75 (m, 2H), 12.6 (2 s, 2H).

thiazole-5-carboxylic acid

319
Cis(±)-2-(4-{[(4-chloro-3-
NMR: 1.6-2.0 (m, 2H), 2.2 (s,
479
Example

cyano-5-methyl-1H-pyrrol-2-
3H), 3.3 (s, 3H), 3.4 (m, 1H), 3.6

145

yl)carbonyl]amino}-3-
(s, 3H), 4.1 (m, 1H), 4.2-4.4 (m,

methoxypiperidin-1-yl)-1,3-
2H), 7.4 (t, 1H), 7.65 (m, 2H), 7.8

benzothiazole-7-carboxylic acid
(m, 1H), 12.6 (s, 1H), 13.5 (s, 1H).

320

embedded image

NMR: 1.7 (m, 2H), 2.2 (s, 3H), 3.0-3.7 (m), 4.2 (m, 2H), 4.6 (m, 1H), 7.0 (s, 1H), 7.25 (s, 1H), 7.7 (s, 1H), 8.2 (s, 1H), 12.6 (s, 1H), 13.5 (s, 1H).
418
Example 146

322
2-((3S,4R)-4-{[(4-chloro-3-
NMR: 1.9 (m, 2H), 2.2 (s, 3H), 3.4
462
Example

cyano-5-methyl-1H-pyrrol-2-
(m, 1H), 3.4 (m, 1H), 3.6 (s, 3H),

148

yl)carbonyl]amino}-3-
4.1 (m, 1H), 4.3 (m, 1H), 4.4 (q,

fluoropiperidin-1-yl)-1,3-
2H), 7.7 (m, 2H), 7.8 (m, 1H), 7.9

benzothiazole-7-carboxylic acid
(t, 1H), 12.7 (s, 1H), 13.5 (s, 1H).

323
2-((3S,4R)-4-{[(4-chloro-3-
NMR: 1.8 (m, 2H), 2.2 (s, 3H), 3.0
406
Example

cyano-5-methyl-1H-pyrrol-2-
(m, 2H), 3.3 (m), 4.0-4.5 (m, 2H),

149

yl)carbonyl]amino}-3-
4.7 (m, 1H), 4.95 (d, 1H), 7.0 (d,

fluoropiperidin-1-yl)isonicotinic
1H), 7.3 (s, 1H), 8.05 (m, 1H),

acid
8.25 (d, 1H), 12.6 (s, 1H), 13.4 (s,

1H).

324
Cis(±)-2-(4-{[(3,4-dichloro-5-
NMR: 1.7 (m, 2H), 2.2 (s, 3H), 3.3
546
Example

methyl-1H-pyrrol-2-
(m), 3.4 (m, 4H), 3.5 (m, 4H), 3.8-

150

yl)carbonyl]amino}-3-
3.9 (m, 1H), 4.0-4.2 (m, 4H), 7.3

methoxypiperidin-1-yl)-5-
(s, 1H), 12.3 (s, 1H), 12.9 (s, 1H).

(morpholin-4-ylcarbonyl)-1,3-

thiazole-4-carboxylic acid

325

embedded image

NMR: 1.7 (m, 2H), 2.1 (s, 3H), 3.3 (s, 3H), 3.45 (m, 1H), 4.0 (d, 1H), 4.2 (m, 1H), 4.4 (d, 1H), 7.0 (d, 1H), 7.5 (s, 1H), 7.7 (s, 1H), 12.1 (s, 1H), 13.3 (s, 1H).
452
Example 151

326
2-((3S,4R)-4-{[(3,5-dichloro-4-
NMR: 1.8 (m, 2H), 1.9 (s, 3H), 3.3
421
Example

methyl-1H-pyrrol-2-
(m, 1H), 3.5 (dd, 1H), 4.0 (m, 1H),

155

yl)carbonyl]amino}-3-
4.3 (m, 2H), 5.0 (d, 1H), 7.35(d,

fluoropiperidin-1-yl)-1,3-
1H), 7.8 (s, 1H), 12.6 (s, 1H) 12.7

thiazole-5-carboxylic acid
(s, 1H).

327
4-acetyl-2-((3S,4R)-4-{[(3,4-
NMR: 1.7 (m, 2H), 2.2 (s, 3H), 3.3
475
Example

dichloro-5-methyl-1H-pyrrol-2-
(s, 3H), 3.9 (m, 2H), 4.3 (m, 2H),

157

yl)carbonyl]amino}-3-
7.15 (m, 1H), 12.2 (s, 1H), 13.2 (s,

methoxypiperidin-1-yl)-1,3-
1H).

thiazole-5-carboxylic acid

328
2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.5 (s, 6H), 1.7 (m, 2H), 2.2
491
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.3 (s, 3H), 3.5 (m, 1H),

158

yl)carbonyl]amino}-3-
3.8 (m, 2H), 4.3 (m, 1H), 4.4 (m,

methoxypiperidin-1-yl)-4-(1-
1H), 7.15 (d, 1H), 12.2 (s, 1H).

hydroxy-1methylethyl)-1,3-

thiazole-5-carboxylic acid

329
2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.8 (m, 2H), 2.2 (s, 3H), 3.3
489
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.6 (m, 1H), 4.0 (m, 1H),

159

yl)carbonyl]amino}-3-
4.3 (m, 2H), 7.2 (d, 1H), 7.9 (s,

methoxypiperidin-1-
1H), 12.2 (s, 1H), 13.1 (s, 1H).

yl)thieno[2,3-d][1,3]thiazole-6-

carboxylic acid

330

embedded image

0.10 (m, 2H), 0.38 (m, 2H), 0.91 (m, 1H), 1.75 (m, 1H), 2.17 (s, 3H), 3.15-3.43 (m, 4H), 3.67 (m, 1H), 3.92 (m, 1H), 4.26 (m, 2H), 7.14 (d, 1H), 7.72 (s, 1H), 12.16 (s, 1H), 12.60 (bs, 1H).
473
Example 160

331
2-[4-{[(3,4-dichloro-5-methyl-
1.80 (m, 2H), 2.16 (s, 3H), 3.40 (d,
515
Example

1H-pyrrol-2-
2H), 3.94 (m, 2H), 4.33 (td, 1H),

161

yl)carbonyl]amino}-3-(1,3-
4.46 (d, 1H), 4.81-4.99 (dd, 2H),

thiazol-
7.13 (d, 1H), 7.65 (d, 1H), 7.69 (s,

2-ylmethoxy)piperidin-1-yl]-
1H), 7.71 (d, 1H), 12.12 (s, 1H),

1,3-thiazole-5-carboxylic acid
12.60 (bs, 1H).

332
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.05 (t, 3H); 1.74 (m, 2H); 2.17 (s,
447,
Example

methyl-1H-pyrrol-2-
3H); 3.35-3.45 (m, 3H); 3.63-3.73
449
162

yl)carbonyl]amino}-3-
(m, 2H); 3.97 (m, 1H); 4.25 (m,

ethoxypiperidin-1-yl)-1,3-
2H); 7.12 (d, 1H); 7.72 (s, 1H);

thiazole-5-carboxylic acid
12.16 (s, 1H); 12.55 (br s, 1H).

333
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.06 (t, 3H); 1.74 (m, 2H); 2.17 (s,
435,
Example

methyl-1H-pyrrol-2-
3H); 3.27 (m, 4H); 3.42 (m, 1H);
437
163

yl)carbonyl]amino}-3-
3.62-3.71 (m, 2H); 3.82 (m, 1H);

ethoxypiperidin-1-yl)-4-
4.08-4.21 (overlapping m, 3H);

(methoxymethyl)-1,3-thiazole-
4.55 (s, 2H); 6.64 (s, 1H); 7.11 (d,

5-carboxylic acid
1H); 12.16 (s, 1H).

334
2-((3S,4R)-4-{[(3,4-Dichloro-
1.83 (m, 2H); 2.18 (s, 3H); 2.40 (s,
435,
Example

5-methyl-1H-pyrrol-2-
3H); 3.32 (m, overlapping water);
437
165

yl)carbonyl]amino}-3-
3.50 (dd, 1H); 3.97 (m, 1H); 4.21-

fluoropiperidin-1-yl)-4-methyl-
4.31 (m, 2H); 4.93 (d, 1H); 7.26

1,3-thiazole-5-carboxylic acid
(d, 1H); 12.11 (s, 1H); 12.44 br s,

1H).

335

embedded image

1.72 (m, 2H); 2.17 (s, 3H); 2.39 (s, 3H); 3.26-3.35 (m overlapping with water, 5H); 3.52 (m, 1H); 3.90 (m, 1H); 4.25 (m, 2H); 7.14 (d, 1H); 12.15 (s, 1H); 12.40 (s, 1H).
447, 449
Example 166

337
Trans(±)2-[4-{[(3,4-dichloro-5-
1.89 (m, 1H), 2.14 (m, 1H), 2.17
516
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.24-3.70 (m, 11H [under

167

yl)carbonyl]amino}-3-
H₂O peak]), 3.74 (dd, 1H), 3.90

(morpholin-4-
(dd, 1H), 4.51 (m, 1H),_7.33 (d,

ylcarbonyl)piperidin-1-yl]-1,3-
1H), 7.74 (s, 1H), 12.09 (s, 1H),

thiazole-5-carboxylic acid
12.64 (s, 1H)

338
Cis(±)2-[4-{[(3,4-dichloro-5-
1.79 (dq, 1H), 1.89 (m, 1H), 2.15
516
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.21-3.42 (m, 6H), 3.49-

168

yl)carbonyl]amino}-3-
3.72 (m, 5H), 3.95 (m, 1H), 4.02

(morpholin-4-
(m, 1H), 4.40 (m, 1H), 7.17 (d,

ylcarbonyl)piperidin-1-yl]-1,3-
1H), 7.78 (s, 1H), 12.02 (s, 1H),

thiazole-5-carboxylic acid
12.69 (s, 1H)

339
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.51 (dq, 1H), 1.98 (m, 1H), 2.18
546
Example

methyl-1H-pyrrol-2-
(s, 3H), 3.18 (m, 2H), 3.23-3.56

169

yl)carbonyl]amino}-3-(2-
(m, 10H [under H₂O peak]), 3.77

morpholin-4-yl-2-
(m, 1H), 4.04 (m, 2H), 4.32 (q,

oxoethoxy)piperidin-1-yl]-1,3-
2H), 7.36 (s, 1H), 8.26 (broad s,

thiazole-5-carboxylic acid
2H)

340

embedded image

MS (ES) MH⁺: 490, 492 for C₁₈H₂₁Cl₂N₅O₅S; NMR: 0.96 (t, 3H), 1.82 (m, 2H), 2.17 (s, 3H), 2.96 (m, 2H), 3.19-3.40 (m, 2H [under H₂O peak]), 3.47 (d, 1H), 3.95 (m, 1H), 4.08 (m, 1H), 4.33 (m, 1H), 4.83(m, 1H), 6.84 (broad s, 1H), 7.14 (d, 1H), 7.21 (t, 1H), 7.46 (s, 1H)
490
Example 172

341
2-(3-
NMR: 1.22 (s, 1H), 1.84 (m, 2H),
502
Example

{[(allylamino)carbonyl]oxy}-4-
2.17 (s, 3H), 3.52 (m, 1H), 3.57,

173

{[(3,4-dichloro-5-methyl-1H-
(m, 1H), 4.03 (m, 1H), 4.14 (m,

pyrrol-2-
1H), 4.36 (m, 1H), 4.78-4.91 (m,

yl)carbonyl]amino}piperidin-1-
2H), 4.99 (dd, 1H), 5.07 (dd, 1H),

yl)-1,3-thiazole-5-carboxylic
5.52 (broad s, 1H), 5.73 (m 1H),

acid
7.00 (d, 1H), 7.10 (broad s, 1H),

7.44 (t, 1H), 7.62 (s, 1H)

342
Cis(±)-4-(4-{[(4-chloro-5-
1.56-1.72 (m, 2 H) 2.08-2.20
393
Example

methyl-1H-pyrrol-2-
(m, 3 H) 3.24 (s, 3 H) 3.55 (s, 2 H)

177

yl)carbonyl]amino}-3-
3.71-3.86 (m, 2 H) 4.16 (s, 2 H)

methoxypiperidin-1-yl)pyridine-
6.88 (d, 1 H) 7.44 (s, 1 H) 7.68 (s,

2-carboxylic acid
1 H) 7.97 (d, 1 H) 11.69 (s, 1 H)

343
Cis(±)-4-(aminocarbonyl)-2-(4-
1.74 (s, 2 H) 2.19 (s, 3 H) 3.38 (s,
476
Example

{[(3,4-dichloro-5-methyl-1H-
3 H) 3.55 (s, 2 H) 4.01 (s, 1 H)

242

pyrrol-2-yl)carbonyl]amino}-3-
4.25 (s, 3 H) 4.49 (s, 1 H) 7.16 (d,

methoxypiperidin-1-yl)-1,3-
1 H) 8.93 (s, 2 H) 12.16 (s, 1 H

thiazole-5-carboxylic acid

344
4-((3S,4R)-4-{[(3,4-dichloro-5-
1.81-1.95 (m, 2 H) 2.14-2.21
415
Example

methyl-1H-pyrrol-2-
(m, 3 H) 3.73 (s, 2 H) 4.26 (t, 2 H)

174

yl)carbonyl]amino}-3-
4.62 (s, 1 H) 4.93 (s, 1 H) 7.22 (s,

fluoropiperidin-1-yl)pyridine-2-
1 H) 7.36 (s, 1 H) 7.49 (s, 1 H)

carboxylic acid
7.69 (s, 1 H) 8.04 (d, 1 H) 12.30

(s, 1 H)

345

embedded image

1.80 (m, 2 H) 2.13-2.26 (s, 3 H) 4.14 (dd, 1 H) 4.27 (s, 1 H) 4.41 (s, 2 H) 4.72 (s, 1 H) 4.84-5.00 (d, 1 H) 7.02 (d, 1H) 7.17-7.32 (m, 1 H) 7.66-7.78 (m, 1 H) 8.24 (d, 1 H) 12.11 (s, 1 H)
415
Example 179

346
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.85 (s, 2 H) 2.19 (s, 3 H) 3.28 (s,
465
Example

methyl-1H-pyrrol-2-
3 H) 3.50-3.64 (dd, 1 H) 3.98 (s, 1

180

yl)carbonyl]amino}-3-
H) 4.32 (s, 2 H) 4.57 (s, 2 H) 4.88-

fluoropiperidin-1-yl)-4-
5.04 (d, 1 H) 7.29 (d, 1 H) 12.12

(methoxymethyl)-1,3-thiazole-
(s, 1 H) 12.79 (s, 1 H)

5-carboxylic acid

347
4-((3S,4R)-4-{[(3,4-dichloro-5-
2.00 (s, 2 H) 2.21 (s, 3 H) 3.33 (s,
465
Example

methyl-1H-pyrrol-2-
1 H) 3.78 (d, 1 H) 4.08 (s, 2 H)

181

yl)carbonyl]amino}-3-
4.32-4.42 (m, 1 H) 4.95-5.11 (d, 1

fluoropiperidin-1-yl)quinoline-
H) 7.34 (d, 1 H) 7.60 (s, 2 H) 7.69

2-carboxylic acid
(t, 1 H) 7.84 (t, 1H) 8.08-8.22 (m,

2 H) 12.15 (s, 1 H)

348
Cis(±)-2-(4-{[(4-chloro-5-
1.57 (d, 1 H) 1.86 (d, 1 H) 2.14 (s,
393
Example

methyl-1H-pyrrol-2-
3 H) 3.04-3.18 (m, 2 H) 3.19-

182

yl)carbonyl]amino}-3-
3.25 (s, 3 H) 3.49 (s, 1 H) 4.19 (s,

methoxypiperidin-1-
1 H) 4.21 (d, 1 H) 4.55 (d, 1 H)

yl)isonicotinic acid
6.89 (d, 1 H) 6.96 (d, 1 H) 7.23 (s,

1 H) 7.64 (d, 1 H) 8.22 (d, 1 H)

11.62 (s, 1 H) 13.39 (s, 1 H)

349
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.68 (s, 2 H) 2.12 (s, 3 H) 3.21 (s,
477
Example

methyl-1H-pyrrol-2-
3 H) 3.33 (m, 5 H) 3.48 (s, 1 H)

183

yl)carbonyl]amino}-3-
3.85 (s, 1 H) 4.19 (s, 2 H) 4.49 (s,

methoxypiperidin-1-yl)-4-
2 H) 7.08 (s, 1 H) 12.09 (s, 1 H)

(methoxymethyl)-1,3-thiazole-

5-carboxylic acid

350

embedded image

1.68 (s, 2 H) 2.12 (s, 3 H) 3.21 (s, 3 H) 3.25 (m, 2H) 3.30 (s, 3 H) 3.48 (s, 1 H) 3.84 (s, 1 H) 4.19 (s, 2 H) 4.49 (s, 2 H) 7.09 (d, 1 H) 12.09 (s, 1 H)
477
Example 184

351
Cis(±)-4-(4-{[(3,4-dichloro-5-
1.68 (s, 1 H) 1.77 (s, 1 H) 2.18 (s,
471
Example

methyl-1H-pyrrol-2-
3 H) 3.21 (s, 2 H) 3.31 (s, 3 H)

185

yl)carbonyl]amino}-3-
3.55 (s, 1 H) 4.02 (s, 1 H) 4.28 (s,

methoxypiperidin-1-yl)pyridine-
1 H) 4.41 (s, 1 H) 7.13 (s, 1 H)

2,6-dicarboxylic acid
7.61 (s, 2 H) 12.13 (s, 1 H)

352
4-((3S,4R)-4-{[(3,4-dichloro-5-
1.71-1.86 (m, 2 H) 2.22 (s, 3 H)
486
Example

methyl-1H-pyrrol-2-
2.93-3.04 (m, 3 H) 3.04-3.15

187

yl)carbonyl]amino}-3-
(m, 3 H) 3.80-3.96 (m, 1 H) 4.08

fluoropiperidin-1-yl)-6-
(s, 1 H) 4.28-4.43 (m, 2 H) 4.77

[(dimethylamino)carbonyl]pyri-
(s, 1 H) 4.94 (s, 1 H) 6.87 (d,1 H)

dine-2-carboxylic acid
7.10 (d, 1 H) 7.58 (d, 1 H) 9.33 (s,

2 H)

353
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.75 (s, 2 H) 2.18 (s, 3 H) 3.33 (s,
477
Example

methyl-1H-pyrrol-2-
2 H) 3.37 (s, 3 H) 3.55 (s, 1 H)

175

yl)carbonyl]amino}-3-
3.92 (s, 1 H) 4.26 (s, 2 H) 7.15 (d,

methoxypiperidin-1-yl)-1,3-
1 H) 12.14 (s, 1 H)

thiazole-4,5-dicarboxylic acid

354
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.85 (s, 2 H) 2.19 (s, 3 H) 3.33 (s,
465
Example

methyl-1H-pyrrol-2-
1 H) 3.60 (s, 1 H) 3.99 (s, 1 H)

176

yl)carbonyl]amino}-3-
4.31 (s, 2 H) 4.88-5.04 (s, 1 H)

fluoropiperidin-1-yl)-1,3-
7.28 (s, 1 H) 12.09 (s, 1 H)

thiazole-4,5-dicarboxylic acid

355

embedded image

1.75 (s, 2 H) 2.18 (s, 3 H) 3.17 (s, 1 H) 3.36 (s, 3 H) 3.56 (s, 1 H) 4.01 (s, 2 H) 4.25 (s, 2 H) 7.15 (d, 1 H) 10.35 (s, 1 H) 12.15 (s, 1 H)
461
Example 252

356
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.69 (s, 2 H) 2.12 (s, 3 H) 2.72 (s,
504
Example

methyl-1H-pyrrol-2-
3 H) 2.82-2.88 (m, 3 H) 3.22 (s, 1

203

yl)carbonyl]amino}-3-
H) 3.29 (s, 3 H) 3.32 (s, 1 H) 3.48

methoxypiperidin-1-yl)-4-
(d, 1 H) 3.81 (s, 1 H) 4.21 (s, 2 H)

[(dimethylamino)carbonyl]-1,3-
7.09 (d, 1 H) 12.03-12.13 (m, 1

thiazole-5-carboxylic acid
H) 12.68 (s, 1 H)

357
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.75 (s, 2 H) 2.18 (s, 3 H) 3.12-
546
Example

methyl-1H-pyrrol-2-
3.22 (m, 2 H) 3.35 (s, 3 H) 3.53 (d,

204

yl)carbonyl]amino}-3-
6 H) 3.60 (d, 2 H) 3.85 (s, 2 H)

methoxypiperidin-1-yl)-4-
4.27 (s, 2 H) 7.14 (d, 1 H) 12.13

(morpholin-4-ylcarbonyl)-1,3-
(s, 1 H) 12.81 (s, 1 H)

thiazole-5-carboxylic acid

358
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.84 (s, 2 H) 2.18 (s, 3 H) 3.16 (s,
534
Example

methyl-1H-pyrrol-2-
2 H) 3.51 (s, 2 H) 3.52-3.64 (m, 5

205

yl)carbonyl]amino}-3-
H) 3.96 (s, 1 H) 4.29 (s, 2 H) 4.37

fluoropiperidin-1-yl)-4-
(s, 1 H) 4.87-5.04 (d, 1 H) 7.26 (d,

(morpholin-4-ylcarbonyl)-1,3-
1 H) 12.07 (s, 2 H)

thiazole-5-carboxylic acid

359
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.79 (s, 2 H) 2.19 (s, 3 H) 3.38 (s,
506
Example

methyl-1H-pyrrol-2-
3 H) 3.56 (s, 2 H) 3.64 (s, 1 H)

206

yl)carbonyl]amino}-3-
3.75 (s, 3 H) 4.03 (s, 1 H) 4.25 (s,

methoxypiperidin-1-yl)-4-
2 H) 7.16 (d, 1 H) 12.16 (s, 1 H)

[(methoxyamino)carbonyl]-1,3-

thiazole-5-carboxylic acid

trifluoroacetate

360

embedded image

1.83-1.92 (m, 2 H) 2.19 (s, 3 H) 3.50-3.63 (dd, 1 H) 3.76 (s, 3 H) 4.11 (s, 1 H) 4.30 (s, 1 H) 4.42 (s, 2 H) 4.90-5.07 (s, 1 H) 7.29 (d, 1 H) 12.11 (s, 1 H) 12.39 (s, 1 H)
494
Example 207

361
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.51 (s, 3 H) 1.57 (s, 1 H) 1.75 (s,
544
Example

methyl-1H-pyrrol-2-
2 H) 2.18 (s, 3 H) 3.07-3.17 (m, 2

208

yl)carbonyl]amino}-3-
H) 3.35 (s, 3 H) 3.54 (d, 2 H) 3.87

methoxypiperidin-1-yl)-4-
(s, 1 H) 4.27 (s, 2 H) 7.16 (d, 1 H)

(piperidin-1-ylcarbonyl)-1,3-
12.16 (s, 1 H) 12.76 (s, 1 H)

thiazole-5-carboxylic acid

362
4-(aminocarbonyl)-2-((3S,4R)-
1.74 (d, 2 H) 2.19 (s, 3 H) 3.32 (s,
476
Example

4-{[(3,4-dichloro-5-methyl-1H-
2 H) 3.38 (s, 3 H) 3.55 (s, 1 H)

243

pyrrol-2-yl)carbonyl]amino}-3-
4.25 (s, 2 H) 4.49 (s, 1 H) 7.17 (d,

methoxypiperidin-1-yl)-1,3-
1 H) 8.87 (s, 1 H) 12.17 (s, 1 H)

thiazole-5-carboxylic acid

363
4-(aminocarbonyl)-2-((3S,4R)-
1.84 (s, 2 H) 2.19 (s, 3 H) 3.19 (s,
464
Example

4-{[(3,4-dichloro-5-methyl-1H-
1 H) 3.95 (s, 2 H) 4.24 (s, 2 H)

244

pyrrol-2-yl)carbonyl]amino}-3-
4.86-5.02 (s, 1 H) 7.28 (s, 1 H)

fluoropiperidin-1-yl)-1,3-
12.12 (s, 1 H)

thiazole-5-carboxylic acid

364
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.60-1.73 (m, 2 H) 2.12 (s, 3 H)
520
Example

methyl-1H-pyrrol-2-
3.14-3.25 (m, 2 H) 3.30 (s, 3 H)

212

yl)carbonyl]amino}-3-
3.41 (t, 2 H) 3.86 (s, 2 H) 4.19 (s,

methoxypiperidin-1-yl)-5-{[(2-
2 H) 7.09 (d,1 H) 9.66 (t, 1 H)

hydroxyethyl)amino]carbonyl}-
12.09 (s, 1 H)

1,3-thiazole-4-carboxylic acid

trifluoroacetate (salt)

365

embedded image

1.69 (s, 2 H) 2.12 (s, 3 H) 3.25 (s, 2 H) 3.31 (s, 3 H) 3.43-3.53 (m, 2 H) 4.03 (s, 1 H) 4.23 (s, 2 H) 4.80 (s, 1 H) 7.07-7.22 (m, 1 H) 9.23 (s, 1 H) 12.09 (s, 1 H)
520
Example 212

366
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.84 (s, 2 H) 2.18 (s, 3 H) 2.76 (s,
478
Example

methyl-1H-pyrrol-2-
3 H) 3.31 (s, 1 H) 3.40 (s, 1 H)

211

yl)carbonyl]amino}-3-
3.61 (s, 1 H) 3.98 (s, 1 H) 4.29 (s,

fluoropiperidin-1-yl)-5-
1 H) 4.87-5.03 (s, 1 H) 7.26 (s, 1

[(methylamino)carbonyl]-1,3-
H) 9.43 (s, 1 H) 12.11 (s, 1 H)

thiazole-4-carboxylic acid

367
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.87 (s, 2 H) 2.19 (s, 3 H) 2.87 (s,
478
Example

methyl-1H-pyrrol-2-
3 H) 3.53 (s, 1 H) 4.13 (s, 1 H)

211

yl)carbonyl]amino}-3-
4.30 (s, 1 H) 4.43 (s, 2 H) 4.91-

fluoropiperidin-1-yl)-4-
5.07 (d, 1 H) 7.31 (s, 1 H) 9.40 (s,

[(methylamino)carbonyl]-1,3-
1 H) 12.11 (s, 1 H)

thiazole-5-carboxylic acid

368
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.76 (s, 2 H) 2.19 (s, 3 H) 2.91 (q,
476
Example

methyl-1H-pyrrol-2-
1 H) 3.03 (d, 1 H) 3.35-3.38 (m,

355

yl)carbonyl]amino}-3-
3 H) 3.53 (s, 1 H) 3.93 (s, 1 H)

methoxypiperidin-1-yl)-4-
4.03 (d, 1 H) 4.23 (s, 1 H) 7.20 (d,

[(hydroxyimino)methyl]-1,3-
1 H) 7.54 (s, 1 H) 7.83 (s, 1 H)

thiazole-5-carboxylic acid
8.76 (s, 1 H)

369
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.70-1.82 (m, 2 H) 2.19 (s, 3 H)
490
Example

methyl-1H-pyrrol-2-
3.32 (s, 3H) 3.38 (s, 3 H) 3.41 (s, 1

214

yl)carbonyl]amino}-3-
H) 3.56 (s, 1 H) 4.09 (s, 1 H) 4.29

methoxypiperidin-1-yl)-4-
(d, 2 H) 4.46 (s, 1 H) 7.17 (d,1 H)

[(methylamino)carbonyl]-1,3-
9.38 (s, 1 H) 12.17 (s, 1 H)

thiazole-5-carboxylic acid

370

embedded image

1.69 (s, 2 H) 2.12 (s, 3 H) 3.31 (s, 3 H) 3.49 (s, 2 H) 3.84 (s, 3 H) 3.96 (s, 2 H) 4.21 (s, 2 H) 7.10 (d, 1 H) 8.62 (s, 1 H) 12.10 (s, 1 H)
490
Example 251

371
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.61-1.71 (m, 2 H) 2.10-2.14
532
Example

methyl-1H-pyrrol-2-
(m, 3 H) 2.68 (s, 3 H) 3.29 (s, 3 H)

246

yl)carbonyl]amino}-3-
3.47 (d, 1 H) 3.58 (s, 4 H) 3.67-

methoxypiperidin-1-yl)-4-
3.80 (m, 2 H) 3.84 (d, 2 H) 4.19 (t,

(morpholin-4-ylmethyl)-1,3-
2 H) 7.10 (d, 1 H) 12.12 (s, 1 H)

thiazole-5-carboxylic acid

372
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.60-1.74 (m, 2 H) 2.12 (s, 3 H)
483
Example

methyl-1H-pyrrol-2-
3.27 (s, 1 H) 3.30 (s, 3 H) 3.34 (s,

253

yl)carbonyl]amino}-3-
1 H) 3.49 (s, 1 H) 3.87 (s, 1 H)

methoxypiperidin-1-yl)-4-
4.21 (s, 2 H) 7.10 (d, 1 H) 7.27 (s,

(difluoromethyl)-1,3-thiazole-5-
1 H) 12.10 (s, 1 H)

carboxylic acid

373
Cis(±)-4-[(tert-
1.26 (s, 9 H) 1.72 (s, 2 H) 2.18 (s,
518
Example

butylamino)methyl]-2-(4-
3 H) 3.32 (m, 3H) 3.36 (s, 3 H)

247

{[(3,4-dichloro-5-methyl-1H-
3.52 (s, 1 H) 3.95 (s, 2 H) 4.18 (s,

pyrrol-2-yl)carbonyl]amino}-3-
2 H) 7.15 (d, 1 H) 12.18 (s, 1 H)

methoxypiperidin-1-yl)-1,3-

thiazole-5-carboxylic acid

374
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.11-1.20 (m, 3 H) 1.76 (s, 2 H)
534
Example

methyl-1H-pyrrol-2-
2.19 (s, 3 H) 3.38 (s, 3 H) 3.48 (d,

216

yl)carbonyl]amino}-3-
3 H) 3.57 (s, 1 H) 4.04 (s, 1 H)

methoxypiperidin-1-yl)-4-{[(2-
4.27 (s, 2 H) 4.91 (s, 2 H) 7.17 (d,

hydroxy-1-
1 H) 8.83 (s, 1 H) 12.16 (s, 1 H)

methylethyl)amino]carbonyl}-

1,3-thiazole-5-carboxylic acid

375

embedded image

1.79 (s, 3 H) 2.19 (s, 3 H) 3.23- 3.28 (m, 3 H) 3.38 (s, 3 H) 3.42 (s, 2 H) 3.46-3.52 (m, 2 H) 3.57 (s, 1 H) 4.30 (d, 2 H) 7.17 (d, J = 8.48 Hz, 1 H) 9.38 (s, 1 H) 12.16 (s, 1 H)
534
Example 215

376
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.06 (d, 3 H) 1.69-1.79 (m, 3 H)
534
Example

methyl-1H-pyrrol-2-
2.18 (s, 3 H) 3.37 (s, 3 H) 3.54 (s,

217

yl)carbonyl]amino}-3-
2 H) 3.71 (s, 1 H) 3.94 (s, 1 H)

methoxypiperidin-1-yl)-5-{[(2-
4.25 (s, 3 H) 4.79 (s, 1 H) 6.55 (s,

hydroxypropyl)amino]carbonyl}-
1 H) 7.17 (s, 1 H) 9.78 (s, 1 H)

1,3-thiazole-4-carboxylic acid
12.16 (s, 1 H)

377
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.06 (dd, 3 H) 1.75 (s, 2 H) 2.19
534
Example

methyl-1H-pyrrol-2-
(s, 3 H) 3.24 (s, 2 H) 3.38 (s, 3 H)

217

yl)carbonyl]amino}-3-
3.43 (s, 1 H) 3.56 (s, 1 H) 3.83 (s,

methoxypiperidin-1-yl)-4-{[(2-
1 H) 4.05 (s, 1 H) 4.26 (s, 2 H)

hydroxypropyl)amino]carbonyl}-
4.90 (s, 1 H) 7.17 (d, 1 H) 9.21 (s,

1,3-thiazole-5-carboxylic acid
1 H) 12.16 (s, 1 H)

378
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.69 (s, 6 H) 2.18 (s, 3 H) 3.34 (s,
530
Example

methyl-1H-pyrrol-2-
3 H) 3.40 (m, 3H) 3.54 (s, 5 H)

248

yl)carbonyl]amino}-3-
4.24 (s, 4 H) 7.14 (d, 1H) 12.16 (s,

methoxypiperidin-1-yl)-4-
1H)

(piperidin-1-ylmethyl)-1,3-

thiazole-5-carboxylic acid

379
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.75 (s, 2 H) 2.19 (s, 3 H) 3.17
433
Example

methyl-1H-pyrrol-2-
(d,1 H) 3.27 (s, 1 H) 3.36 (s, 3 H)

192

yl)carbonyl]amino}-3-
3.54 (s, 1 H) 3.85 (s, 1 H) 4.21 (d,

methoxypiperidin-1-yl)-1,3-
2 H) 7.16 (d, 1 H) 7.58 (s, 1 H)

thiazole-4-carboxylic acid
12.16 (s, 1 H) 12.57 (s, 1 H)

380

embedded image

1.73 (d, 3 H) 2.07 (s, 1 H) 2.18 (s, 3 H) 2.95 (s, 2 H) 3.26 (s, 2 H) 3.36 (s, 3 H) 3.53 (s, 1 H) 3.85 (s, 1 H) 4.15 (s, 4 H) 4.35 (s, 1 H) 5.20 (s, 1 H) 7.16 (d, 1 H) 12.16 (s, 1 H)
532
Example 249

381
4-{[(1-
1.25 (s, 2 H) 1.48 (s, 2 H) 1.75 (s,
560
Example

carboxycyclopropyl)amino]carbon-
2 H) 2.19 (s, 3 H) 3.39 (s, 4 H)

402

yl}-2-((3S,4R)-4-{[(3,4-
3.56 (s, 2 H) 4.26 (s, 2 H) 4.42 (s,

dichloro-5-methyl-1H-pyrrol-2-
1 H) 7.15 (s, 1 H) 9.80 (s, 1 H)

yl)carbonyl]amino}-3-
12.15 (s, 1 H) 12.78 (s, 1 H) 16.05

methoxypiperidin-1-yl)-1,3-
(s, 1 H)

thiazole-5-carboxylic acid

Example 382
Cis(±)-5-(aminocarbonyl)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-4-carboxylic acid

A solution of 55 mg (23 mmol) of Cis(±)-3,4-dichloro-N-[3-methoxypiperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide (Intermediate 50), 55 mg (0.23 mmol) of ethyl 5-(aminocarbonyl)-2-chloro-1,3-thiazole-4-carboxylate (Intermediate 220) and 33 mg (0.23 mmol) K₂CO₃in 3 ml NMP was heated at 150° C. for 1 h in a microwave reactor. Water (0.1 ml) was added and the mixture was heated at 150° C. for another hour. The solution was diluted with water and acidified with 1N HCl before being extracted 2 times with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO₄) and concentrated to give a solid that was triturated with MeOH to give 41 mg of a white solid. MS (ES) MH⁺: 479 for C₁₇H₁₉Cl₂N₅O₅S; NMR: 1.75 (m, 2H), 2.2 (s, 3H), 3.3 (s), 3.5 (s, 1H), 3.9 (m, 1H), 4.2 (m, 2H), 7.15 (d 1H), 7.8 (s, 1H), 8.9 (s, 1H), 12.2 (s, 1H).

Example 383
Cis(±)-5-(amino carbonyl)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinic acid

A mixture of 85 mg (0.17 mmol) of Cis(±)-ethyl 5-(aminocarbonyl)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate (Example 198) and 86 mg (0.50 mmol) Ba(OH)₂in 3 ml MeOH and 2 ml water was heated at 120° C. for 1 h. The mixture was acidified to about pH=4 with 1N HCl and extracted 4 times with EtOAc. The EtOAc was concentrated and the residue was purified by reverse phase HPLC (20-40% CH₃CN gradient in water with 0.1% TFA) to afford 8 mg of product as a white solid. MS (ES) MH⁺: 470 for C₁₉H₂₁Cl₂N₅O₅; NMR: 1.5-1.8, (m, 3H), 2.2 (s, 3H), 3.0-3.2 (m, 2H), 3.3 (s, 3H), 3.5 (m, 2H), 4.2-4.5 (m, 2H), 4.9 (d, 1H), 6.9 (s, 1H), 7.1-7.3 (m, 2H), 7.8 (s, 1H), 8.4 (s, 1H), 12.1 (s, 1H), 13.1 (s, 1H).

Examples 384-385

The following Examples were synthesized by an analogous method to Example 383 from the starting materials (SM) given in the table below.

Ex
Compound
NMR
m/z
SM

384
2-((3S,4R)-4-{[(3,5-dichloro-4-
NMR: 1.8 (m,
MS (ES) MH⁺: 577
Intermediate

methyl-1H-pyrrol-2-
2H), 1.9 (s, 3H),
for
138

yl)carbonyl]amino}-3-
3.5-4.0 (m, 8H),
C₂₂H₂₇Cl₂FN₆O₅S

fluoropiperidin-1-yl)-4-{[(2-
4.0-4.4 (m, 3H),

morpholin-4-
5.0 (d, 1H), 7.4

ylethyl)amino]carbonyl}-1,3-
(d, 1H), 9.5 (s,

thiazole-5-carboxylic acid
1H), 12.6 (s,

1H).

385

embedded image

NMR: 1.8 (m, 2H), 1.9 (s, 3H), 3.5-4.0 (m, 8H), 4.0-4.4 (m, 3H), 5.0 (d, 1H), 7.4 (d, 1H), 9.5 (s, 1H), 12.6 (s, 1H).
MS (ES) MH⁺: 464 for C₁₆H₁₆Cl₂FN₅O₄S
Example 202

Example 386
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(methylamino)carbonyl]-1,3-thiazole-5-carboxylic acid

To a suspension/solution of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(methylamino)carbonyl]-1,3-thiazole-5-carboxylate (0.078 g, 0.15 mmol, Example 218) in methanol (2 mL) was added barium hydroxide (0.052 g, 0.30 mmol) and water (0.5 mL). After stirring several hours the reaction was complete. The reaction was acidified with 1N HCl and then concentrated to remove methanol. The residue was extracted with EtOAc (×3), dried with MgSO₄and concentrated to a white solid (0.059 g). MS (ES) M+H⁺: 490 for C₁₈H₂₁Cl₂N₅O₅S; NMR: 1.76 (s, 2H) 2.18 (s, 3H) 2.86 (s, 3H) 3.38 (s, 3H) 3.56 (s, 2H) 4.02 (s, 1H) 4.27 (s, 2H) 4.40 (s, 1H) 7.15 (s, 1H) 9.38 (s, 1H) 12.15 (s, 1H)

Examples 387-412

The following Intermediate was prepared by the procedure described in Example 386 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

387
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 534 for
Example 219

methyl-1H-pyrrol-2-
C₂₀H₂₅Cl₂N₅O₆S;

yl)carbonyl]amino}-3-
NMR: 1.72 (s, 2H) 2.18 (s, 3H)

methoxypiperidin-1-yl)-4-{[(2-
3.24 (s, 3H) 3.36 (s, 3H) 3.51

methoxyethyl)amino]carbonyl}-
(s, 2H) 3.84 (s, 2H) 4.15(s, 2H)

1,3-thiazole-5-carboxylic acid
7.15 (s, 1H) 12.16 (s, 1H)

13.18 (s, 1H)

388
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 534 for
Example 220

methyl-1H-pyrrol-2-
C₂₀H₂₅Cl₂N₅O₆S;

yl)carbonyl]amino}-3-
NMR: 1.19 (s, 3H) 1.77 (s, 2H)

methoxypiperidin-1-yl)-4-
2.19 (s, 3H) 3.38 (s, 3H)

({[(1S)-2-hydroxy-1-
3.47 (s, 3H) 3.58 (s, 1H) 4.04

methylethyl]amino}carbonyl)-
(s, 1H) 4.29 (s, 2H) 4.91 (s, 1H)

1,3-thiazole-5-carboxylic acid
7.18 (s, 1H) 8.79-8.94 (m, 1H)

12.16 (s, 1H)

389
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 534 for
Example 221

methyl-1H-pyrrol-2-
C₂₀H₂₅Cl₂N₅O₆S

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-4-

({[(1R)-2-hydroxy-1-

methylethyl]amino}carbonyl)-

1,3-thiazole-5-carboxylic acid

390

embedded image

MS (ES) MH⁺: 540 for C₁₉H₂₁Cl₂F₂N₅O₅S; NMR: 1.76(s, 2H) 2.19 (s, 3H) 3.38 (s, 3H) 3.44 (s, 1H) 3.57 (s, 2H) 3.73 (s, 3H) 4.10 (s, 1H) 4.27 (d, 2H) 4.43 (s, 1H) 7.17 (d, 1H) 9.60 (s, 1H) 12.16 (s, 1H) 15.77 (s, 1H)
Example 222

391
Cis(±)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 543 for
Example 223

methyl-1H-pyrrol-2-
C₂₀H₂₀Cl₂N₆O₆S;

yl)carbonyl]amino}-3-
NMR: 1.74 (s, 2H) 2.19 (s, 3H)

methoxypiperidin-1-yl)-4-
3.22 (s, 2H) 3.38 (s, 3H)

[(isoxazol-3-ylamino)carbonyl]-
3.52 (s, 1H) 3.88 (s, 1H) 4.24

1,3-thiazole-5-carboxylic acid
(s, 2H) 6.99 (d, 1H) 7.16 (s, 1H)

8.75 (s, 1H) 12.16 (s, 1H)

392
Cis(±)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 546 for
Example 224

methyl-1H-pyrrol-2-
C₂₁H₂₅Cl₂N₅O₆S;

yl)carbonyl]amino}-3-
NMR: 1.76 (s, 3H) 1.94-2.08

methoxypiperidin-1-yl)-4-
(m, 1H) 2.19 (s, 3H) 3.38 (s, 3H)

{[(3R)-tetrahydrofuran-3-
3.44 (s, 1H) 3.56 (s, 1H)

ylamino]carbonyl}-1,3-thiazole-
3.63-3.76 (m, 2H) 3.81-3.92

5-carboxylic acid
(m, 2H) 4.12 (s, 1H) 4.26 (s, 1H)

4.51 (s, 1H) 7.16 (d, 1H)

9.17 (d, 1H) 12.15 (s, 1H)

15.97 (s, 1H)

393
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 534 for
Example 225

methyl-1H-pyrrol-2-
C₂₀H₂₂Cl₂FN₅O₅S;

yl)carbonyl]amino}-3-
NMR: 1.23 (dd, 2H) 1.75 (s, 2H)

methoxypiperidin-1-yl)-4-
2.19 (s, 3H) 2.87 (s, 1H)

({[(1R,2S)-2-
3.37 (d, 3H) 3.42 (s, 1H) 3.56

fluorocyclopropyl]amino}
(s, 2H) 4.10 (s, 1H) 4.26 (s, 3H)

carbonyl)-
4.45 (s, 1H) 4.73 (d, 1H)

1,3-thiazole-5-carboxylic
4.96 (s, 1H) 7.16 (d, 1H) 9.29

acid
(dd, 1H) 12.15 (s, 2H) 16.02 (d,

1H)

394
4-(azidomethyl)-2-((3S,4R)-4-
MS (ES) MH⁺: 488 for
Example 254

{[(3,4-dichloro-5-methyl-1H-
C₁₇H₁₉Cl₂N₇O₄S;

pyrrol-2-yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.18 (s, 3H)

methoxypiperidin-1-yl)-1,3-
3.37 (s, 5H) 3.56 (s, 1H)

thiazole-5-carboxylic acid
3.92 (s, 1H) 4.28 (s, 2H) 4.54

(d, 2H) 7.18 (s, 1H) 12.16 (s, 1H)

12.97 (s, 1H)

395

embedded image

MS (ES) MH⁺: 548 for C₂₁H₂₇Cl₂N₅O₆S; NMR: 1.18 (d, 3H) 1.76 (s, 2H) 2.18 (s, 3H) 3.24 (s, 3H) 3.38 (s, 3H) 3.49 (s, 2H) 3.57 (s, 1H) 4.06 (s, 1H) 4.26 (s, 2H) 7.15 (s, 1H) 8.95 (s, 1H) 12.16 (s, 1H) 16.33 (s, 1H)
Example 226

396
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 514 for
Example 227

methyl-1H-pyrrol-2-
C₂₀H₂₁Cl₂N₅O₅S;

yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.19 (s, 3H)

methoxypiperidin-1-yl)-4-
3.26 (s, 2H) 3.38 (s, 3H)

[(prop-2-yn-1-
3.57 (s, 2H) 4.10 (d, 2H) 4.27

ylamino)carbonyl]-1,3-thiazole-
(s, 2H) 7.17(d, 1H) 9.78 (s, 1H)

5-carboxylic acid
12.16 (s, 1H) 15.96 (s, 1H)

397
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 548 for
Example 228

methyl-1H-pyrrol-2-
C₂₁H₂₇Cl₂N₅O₆S;

yl)carbonyl]amino}-3-
NMR: 1.29 (s, 6H) 1.73 (s, 2H)

methoxypiperidin-1-yl)-4-{[(2-
2.17 (s, 3H) 3.37 (m, 6H)

hydroxy-1,1-
3.46 (s, 2H) 3.54 (s, 1H) 3.91

dimethylethyl)amino]carbonyl}-
(s, 1H) 4.23 (s, 2H) 7.16 (s, 1H)

1,3-thiazole-5-carboxylic acid
12.19 (s, 1H)

398
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 546 for
Example 224

methyl-1H-pyrrol-2-
C₂₁H₂₅Cl₂N₅O₆S;

yl)carbonyl]amino}-3-
NMR: 1.23 (s, 1H) 1.76 (s, 2H)

methoxypiperidin-1-yl)-4-
2.00 (d, 1H) 2.19 (s, 3H)

{[(3R)-tetrahydrofuran-3-
3.38 (s, 6H) 3.43 (s, 1H) 3.56

ylamino]carbonyl}-1,3-thiazole-
(s, 1H) 3.64-3.77 (m, 2H) 3.79-

5-carboxylic acid
3.94 (m, 2H) 4.26 (s, 1H) 4.51

(s, 1H) 7.16 (d, 1H) 9.17 (s, 1H)

12.16 (s, 1H) 15.98 (s, 1H)

399
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 534 for
Example 229

methyl-1H-pyrrol-2-
C₂₀H₂₂Cl₂FN₅O₅S;

yl)carbonyl]amino}-3-
NMR: 1.21 (d, 1H) 1.40 (s, 1H)

methoxypiperidin-1-yl)-4-
1.76 (s, 2H) 2.19 (s, 3H)

({[(1R,2S)-2-
2.85 (s, 1H) 3.38 (s, 3H) 3.43

fluorocyclopropyl]amino}
(s, 3H) 3.56 (s, 1H) 4.26 (s, 1H)

carbonyl)-
4.74-4.97 (d, 1H) 7.17 (d, 1H)

1,3-thiazole-5-carboxylic
9.27 (d, 1H) 12.16 (s, 2H)

acid
16.01 (s, 2H)

400

embedded image

MS (ES) MH⁺: 427 for C₁₈H₂₀Cl₂N₄O₄ NMR: 1.72 (s, 2H) 2.18 (s, 3H) 3.13 (d, 2H) 3.30 (s, 3H) 3.49 (s, 1H) 4.17-4.31 (m, 2H) 4.68 (d, 1H) 6.97 (d, 1H) 7.15 (d, 1H) 7.23 (s, 1H) 8.22 (d, 1H) 12.16 (s, 1H) 13.39 (s, 1H)
Example 193

401
4-[(cyclopropylamino)carbonyl]-
MS (ES) MH⁺: 516 for
Example 231

2-((3S,4R)-4-{[(3,4-dichloro-5-
C₂₀H₂₃Cl₂N₅O₅S;

methyl-1H-pyrrol-2-
NMR: 0.77 (d, 2H) 0.80 (s, 2H)

yl)carbonyl]amino}-3-
1.76 (s, 2H) 2.19 (s, 3H)

methoxypiperidin-1-yl)-1,3-
2.86-2.99 (m, 1H) 3.30 (s, 1H)

thiazole-5-carboxylic acid
3.37 (s, 3H) 3.56 (s, 1H) 4.16

(s, 1H) 4.26 (d,2H) 4.41 (s, 1H)

7.16 (d, 1H) 9.22 (d, 1H)

12.15 (s, 1H)

402
l-({[2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 574 for
Example 230

dichloro-5-methyl-1H-pyrrol-2-
C₂₂H₂₅Cl₂N₅O₇S;

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-5-

(methoxycarbonyl)-1,3-thiazol-

4-

yl]carbonyl(amino)cyclopropane

carboxylic acid

403
4-{[(1-carboxy-2-
MS (ES) MH⁺: 564 for
Example 233

hydroxyethyl)amino]carbonyl}-
C₂₀H₂₃Cl₂N₅O₈S;

2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.78 (s, 2H) 2.19 (s, 3H)

methyl-1H-pyrrol-2-
3.39 (s, 3H) 3.47 (s, 2H)

yl)carbonyl]amino}-3-
3.59 (s, 1H) 3.87 (s, 2H) 4.30

methoxypiperidin-1-yl)-1,3-
(s, 2H) 4.53 (s, 1H) 7.16 (s, 1H)

thiazole-5-carboxylic acid
9.03 (s, 1H) 12.16 (s, 1H)

15.97 (s, 1H)

404
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 589 for
Example 234

methyl-1H-pyrrol-2-
C₂₃H₃₀Cl₂N₆O₆S;

yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.19 (s, 3H)

methoxypiperidin-1-yl)-4-{[(2-
3.14 (d, 2H) 3.39 (s, 4H) 3.57

morpholin-4-
(s, 3H) 3.72 (s, 3H) 3.78 (s, 1H)

ylethyl)amino]carbonyl}-1,3-
3.96 (s, 2H) 4.27 (s, 2H)

thiazole-5-carboxylic acid
7.18 (d, 1H) 9.59 (s, 1H) 12.21

(s, 1H)

405

embedded image

MS (ES) MH⁺: 562 for C₂₁H₂₅Cl₂N₅O₇S; NMR: 1.77 (s, 2H) 2.19 (s, 3H) 3.39 (s, 9H) 3.44-3.52 (m, 2H) 3.58 (s, 1H) 3.79-3.87 (m, 2H) 3.89-3.97 (m, 2H) 4.27 (s, 2H) 5.05 (t, 1H) 7.17 (d, 1H) 9.39 (t, 1H) 12.16 (s, 1H) 16.20 (s, 1H)
Example 235

406
2-((3S,4R)-4-{[(3,4-dichloro-5
MS (ES) MH⁺: 567 for
Example 237

methyl-1H-pyrrol-2-
C₂₃H₂₄Cl₂N₆O₅S;

yl)carbonyl]amino}-3-
NMR: 1.77 (s, 2H) 2.19 (s, 3H)

methoxypiperidin-1-yl)-4-
3.40 (s, 3H) 3.58 (s, 2H)

{[(pyridin-2-
4.28 (s, 2H) 4.67 (s, 2H) 7.16

ylmethyl)amino]carbonyl}-1,3-
(s, 1H) 7.31-7.45 (m, 2H) 7.85

thiazole-5-carboxylic acid
(s, 1H) 8.56 (s, 1H) 9.97 (s, 1H)

12.17 (s, 1H) 16.14 (s, 1H)

407
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 601 for
Example 236

methyl-1H-pyrrol-2-
C₂₄H₃₀Cl₂N₆O₆S;

yl)carbonyl]amino}-3-
NMR: 1.71 (s, 1H) 1.74 (d, 3H)

methoxypiperidin-1-yl)-4-({[3-
1.85-2.00 (m, 2H) 2.19(s, 3H)

(2-oxopyrrolidin-1-
2.20-2.27 (m, 2H) 3.19-3.35

yl)propyl]amino}carbonyl)-1,3-
(m, 11H) 3.39 (s, 4H) 3.56 (s, 1H)

thiazole-5-carboxylic acid
4.20-4.34 (m, 1H) 7.17 (d,

1H) 9.45 (t, 1H) 12.16 (s, 1H)

408
Cis(±)-4-[cyano(morpholin-4-
MS (ES) MH⁺: 557 for
Example 255

yl)methyl]-2-(4-{[(3,4-dichloro-
C₂₂H₂₆Cl₂N₆O₅S;

5-methyl-1H-pyrrol-2-
NMR: 1.75 (s, 2H) 2.18 (s, 3H)

yl)carbonyl]amino}-3-
2.71 (s, 3H) 3.39 (s, 2H)

methoxypiperidin-1-yl)-1,3-
3.43 (s, 5H) 3.59 (s, 4H) 3.80

thiazole-5-carboxylic acid
(s, 2H) 4.27 (s, 2H) 4.44 (s, 1H)

7.14 (s, 1H) 12.15 (s, 1H)

409
2-((3s,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 582 for
Example 256

methyl-1H-pyrrol-2-
C₂₀H₂₅Cl₂N₅O₇S₂

yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.19 (s, 3H)

methoxypiperidin-1-yl)-4-({[2-
3.06 (s, 3H) 3.38 (s, 5H)

(methylsulfonyl)ethyl]amino}
3.44 (t, 3H) 3.57 (s, 1H) 3.68-

carbonyl)-
3.81 (m, 2H) 4.26 (s, 2H) 7.16

1,3-thiazole-5-carboxylic
(d, 1H) 9.45-9.56 (m, 1H)

acid
12.15 (s, 1H)

410

embedded image

MS (ES) MH⁺: 557 for C₂₁H₂₂Cl₂N₆O₆S; NMR: 1.76 (s, 2H) 2.19 (s, 3H) 3.38 (s, 3H) 3.45 (s, 1H) 3.57 (s, 1H) 4.26 (d, 2H) 4.65 (s, 2H) 7.11-7.24 (m, 2H) 8.09 (s, 1H) 9.98 (s, 1H) 12.16 (s, 1H) 15.92 (s, 1H)
Example 239

411
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 522 for
Example 240

methyl-1H-pyrrol-2-
C₁₉H₂₂Cl₂FN₅O₅S;

yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.19 (s, 3H)

methoxypiperidin-1-yl)-4-{[(2-
3.38 (s, 4H) 3.45 (s, 1H)

fluoroethyl)amino]carbonyl}-
3.58 (s, 2H) 3.68 (s, 1H) 4.14

1,3-thiazole-5-carboxylic acid
(s, 1H) 4.27 (s, 2H) 4.47-4.54

(m, 1H) 4.67 (t, 1H) 7.26 (d,

J = 8.29 Hz, 1H) 9.55 (s, 1H)

12.29 (s, 1H) 16.19 (s, 1H)

412
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 548 for
Example 241

methyl-1H-pyrrol-2-
C₂₁H₂₇Cl₂N₅O₆S;

yl)carbonyl]amino}-3-
NMR: 1.11 (d, 6H) 1.77 (s, 2H)

methoxypiperidin-1-yl)-4-{[(2-
2.18 (s, 3H) 3.23 (s, 3H)

hydroxy-2-
3.38 (s, 3H) 3.57 (s, 1H) 4.29

methylpropyl)amino]carbonyl}-
(s, 1H) 4.76 (s, 1H) 7.18 (s, 1H)

1,3-thiazole-5-carboxylic acid
8.94 (s, 1H) 12.16 (s, 1H)

Example 413
4-{[(1-cyanocyclopropyl)amino]carbonyl}-2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid

To a solution of ethyl 4-{[(1-cyanocyclopropyl)amino]carbonyl}-2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate (0.09 g, 0.16 mmol, Example 230) in methanol (2 mL) was added potassium carbonate (0.022 g, 0.16 mmol) and water (0.5 mL). After heating in the microwave for 30 min at 80°, reaction was complete by LCMS analysis. The reaction mixture was diluted with water and acidified with 1N HCl. After concentrating to remove methanol, the resulting white precipitate was filtered, washed with water and dried (0.071 g). MS (ES) M+H': 541 for C₂₁H₂₂Cl₂N₆O₅S; NMR: 1.33-1.41 (m, 2H) 1.64 (s, 2H) 1.75 (s, 2H) 2.19 (s, 3H) 3.37 (s, 3H) 3.43 (s, 1H) 3.57 (s, 1H) 4.08 (s, 1H) 4.27 (d, 2H) 4.40 (s, 1H) 7.16 (d, 1H) 9.87 (s, 1H) 12.17 (s, 1H)

The following Intermediate was prepared by the procedure described in Example 413 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

414
4-{[(1-cyano-1-
MS (ES) MH⁺: 543 for
Example 232

methylethyl)amino]carbonyl}-2-
C₂₁H₂₄Cl₂N₆O₅S;

((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.68 (s, 6 H) 1.76 (s, 2 H)

methyl-1H-pyrrol-2-
2.19 (s, 3 H) 3.38 (s, 4 H) 3.44

yl)carbonyl]amino}-3-
(s, 1 H) 3.56 (s, 1 H) 4.11 (s, 1

methoxypiperidin-1-yl)-1,3-
H) 4.25 (s, 2 H) 7.14 (s, 1 H)

thiazole-5-carboxylic acid
9.10 (s, 1 H) 12.17 (s, 1 H)

Example 415
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-N-methoxy-N-methyl-1,3-thiazole-5-carboxamide

embedded image

2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (10 mg, 0.024 mmol) was dissolved in dry DMF (10 ml), HATU (9.1 mg, 0.024 mmol), triethylamine (7.27 mg, 0.072 mmol) and N,O-dimethylhydroxyamine (4.65 mg, 0.048 mmol) were added. The mixture was stirred at room temperature for 30 minutes, then was poured into cold water (30 ml), the precipitate was filtered, washed with water and collected as the desired product (off white solid, 10 mg). MS (ESP): 465 (MH⁺) for C₁₇H₂₀Cl₂FN₅O₃S NMR (CDCl₃) δ: 1.87 (m, 2H); 2.19 (s, 3H); 3.07 (m, 2H); 3.21 (s, 3H); 3.72 (s, 3H); 4.01 (m, 1H); 4.30 (m, 2H); 4.96 (d, br, 1H); 7.28 (d, 1H); 7.85 (s, 1H); 12.09 (s, 1H).

The following compound was produced following the procedure described for Example 415 from Example 334 and N-methoxy amine hydrochloride.

Example 416
2-((3S,4R)-4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-N-methoxy-4-methyl-1,3-thiazole-5-carboxamide

MS (ES) MH⁺: 476 for C₁₈H₂₃Cl₂N₅O₄S; NMR: 1.66-1.79 (m, 1H), 2.17 (s, 3H), 2.37 (s, 3H), 3.20-3.35 (m, buried under water peak), 3.35 (s, 3H), 33.50-3.55 (m, 1H), 3.61 (s, 3H), 3.82-3.91 (m, 1H), 4.15-4.31 (m, 2H), 7.14 (d, 1H), 10.79 (s, 1H), 12.14 (s, 1H)

Example 417
sodium 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylate

Sodium hydroxide (0.056 mL, 0.056 mmol, Acros 1N) was added to a suspension of 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylic acid (0.03 g, 0.056 mmol, Example 387) in methanol (5 mL). After stirring five minutes the reaction was homogeneous. The reaction mixture was concentrated and the resulting white solid was dried overnight (0.030 g). MS (ES) MH⁺: 534 for C₂₀H₂₄Cl₂N₅O₆SNa; NMR: 1.73 (s, 2H) 2.19 (s, 3H) 3.24 (s, 3H) 3.32 (s, 2H) 3.36 (s, 3H) 3.51 (s, 1H) 3.84 (s, 1H) 4.22 (d, 2H) 7.17 (d, 1H) 12.17 (s, 1H) 13.26 (s, 1H)

Examples 419-423

The following Examples were prepared by the procedure described in Example 417 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

419
sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 548 for
Example 395

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₆Cl₂N₅O₆SNa

yl)carbonyl]amino}-3-
NMR: 1.04-1.15 (m, 3H) 1.71

methoxypiperidin-1-yl)-4-
(s, 2H) 2.18 (s, 3H) 3.08-3.21

({[(1S)-2-methoxy-1-
(m, 3H) 3.25 (s, 3H) 3.36 (s, 4H)

methylethyl]amino}carbonyl)-
3.50 (s, 1H) 3.87 (d, 1H)

1,3-thiazole-5-carboxylate
3.99 (dt, 1H) 4.11 (s, 1H) 4.22

(s, 1H) 7.21 (d, 1H) 13.17 (d, 1H)

420

embedded image

MS (ES) MH⁺: 582 for C₂₀H₂₄Cl₂N₅O₇S₂Na NMR: 1.67-1.78 (m, 2H) 2.18 (s, 3H) 3.00 (s, 3H) 3.10-3.21 (m, 2H) 3.24-3.31 (m, 3H) 3.36 (s, 3H) 3.47-3.60 (m, 3H) 3.85 (s, 1H) 4.10 (s, 1H) 4.17 (s, 2H) 7.17(d, 1H) 12.16 (s, 1H) 13.71 (s, 1H)
Example 409

421
sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 556 for
Example 410

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₁Cl₂N₆O₆SNa

yl)carbonyl]amino}-3-
NMR: 1.71 (d, 2H) 2.15 (s, 3H)

methoxypiperidin-1-yl)-4-{[(1,3-
3.09-3.24 (m, 2H) 3.35 (s, 3H)

oxazol-2-
3.49 (s, 1H) 3.84 (s, 1H)

ylmethyl)amino]carbonyl}-1,3-
4.16 (s, 2H) 4.48 (d, 2H) 7.12

thiazole-5-carboxylate
(s, 12H) 7.18 (d, 1H) 8.01 (s, 1H)

12.17 (s, 1H) 13.95-14.07

(m, 1H)

422
sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 534 for
Example 399

dichloro-5-methyl-1H-pyrrol-2-
C₂₀H₂₁Cl₂FN₅O₅SNa

yl)carbonyl]amino}-3-

methoxypiperidin-1-yl)-4-

({[(1R,2S)-2-

fluorocyclopropyl]amino}

carbonyl)-

1,3-thiazole-5-carboxylate

423
Sodium-2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 435,437 for
Example 42

dichloro-5-methyl-1H-pyrrol-2-
C₁₆H₁₇Cl₂FN₄O₃S; NMR: 1.77-

yl)carbonyl]amino}-3-
1.79 (m, 1H), 1.99 (m, 1H), 2.24

fluoropiperidin-1-yl)-1,3-
(s, 3H), 3.25-3.27 (m, 1H), 3.74

thiazole-5-carboxylate
(d, 1H), 4.16 (m, 1H), 4.22 (m,

1H), 4.38 (t, 1H), 4.83 (d, 1H),

7.19 (s, 1H), 8.13 (br d, 1H)

Example 424
N-ethylethanaminium 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylate

Diethylamine (0.0058 mL, 0.056 mmol, Aldrich) was added to a suspension of 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylic acid (0.03 g, 0.056 mmol, Example 387) in methanol (5 mL). After stirring five minutes, methylene chloride was added until solution was homogeneous. The reaction was concentrated and the resulting solid was dried overnight (0.024 g). MS (ES) MH⁺: 534 for C₂₄H₃₇Cl₂N₆O₆S; NMR: 1.16 (t, 3H) 1.74 (s, 2H) 2.19 (s, 3H) 2.91 (q, 3H) 3.25 (s, 3H) 3.32 (s, 4H) 3.37 (s, 3H) 3.42 (d, 2H) 3.53 (s, 1H) 3.94 (s, 1H) 4.22 (s, 2H) 7.17 (d, 1H)

The following compound was synthesized according to the procedure described for Example 424.

Ex
Compound
Data
SM

425

embedded image

MS (ES) MH⁺: 435,437 for C₁₆H₁₇Cl₂FN₄O₃S; NMR: 1.14 (t, 3H), 1.81 (m, 2H), 2.21 (s, 3H), 2.84 (q, 2H), 3.34 (m, 2H), 3.86 (m, 1H), 4.30 (m, 1H), 4.89 (d, 1H), 7.32 (s, 1H), 7.61 (d, 1H)
Example 42

Example 426
Potassium 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylate

An aqueous solution of potassium hydroxide (0.1 M, 4.75 ml, 0.475 mmol) was added to a solution of 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (Example 42, 200 mg, 0.475 mmol) in methanol (35 ml). The mixture was stirred for 1 h and then concentrated under reduced pressure to provide the crude salt (230 mg). The salt was dissolved in acetone/water (50 ml; 48:2) and acetone was added slowly to the stirred mixture until it became cloudy. Stirring was continued and more acetone was added very slowly over 20 min. The mixture was stored at 4° C. overnight. The solid was collected by filtration and air dried for 24 h to provide the salt (160 mg).

MS (ESP): 421 (M+H) for C₁₅H₁₅Cl₂FN₄O₃S

¹H NMR (300 MHz, DMSO-d₆) δ: 1.75 (d, 1H); 2.04 (m, 1H); 2.24 (s, 3H); 3.34 (m, 2H); 3.75 (d, 1H); 4.20 (m, 1H); 4.39 (t, 1H); 4.83 (d, 1H); 7.17 (s, 1H); 8.18 (s, 1H); 14.12 (s, 1H).

Example 427
1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylate

Tromethamine (43 mg, 0.36 mmol), 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (Example 42, 150 mg, 0.36 mmol), methanol (50 ml) and water (5 ml) were combined and stirred at 60° C. until the mixture was a homogeneous solution (30 min). The mixture was cooled to room temperature and concentrated under reduced pressure. The crude salt (80 mg) was dissolved in ethyl acetate/methanol (8 ml; 50:50) and ethyl acetate was added slowly to the stirred solution until it became cloudy. Stirring was continued and additional ethyl acetate (˜15 ml) was added slowly to the mixture. The mixture was stored at 4° C. overnight. The solid was collected by filtration and air dried for 24 h to provide the salt (64 mg).

MS (ESP): 421 (M+H) for C₁₅H₁₅Cl₂FN₄O₃S

¹H NMR (300 MHz, Methanol-d₄) δ: 2.00 (m, 2H); 2.25 (s, 3H); 3.33 (m, 2H); 3.30-3.55 (m, 2H); 3.67 (s, 6H); 4.10 (d, 1H); 4.35 (m, 2H); 4.90 (d, 1H); 7.57 (s, 1H).

The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated in the table below.

Ex
Compound
Data
SM

428
methyl 2-((3S,4R)-4-{[(4-chloro-
MS (ESP): 419 (MH⁺) for
Intermediate

3-fluoro-5-methyl-1H-pyrrol-2-
C₁₆H₁₇ClF₂N₄O₃S
261

yl)carbonyl]amino}-3-

¹H-NMR (CDCl₃) δ: 1.96

fluoropiperidin-1-yl)-1,3-
(m, 2H); 2.25 (s, 3H); 3.37

thiazole-5-carboxylate
(m 2H); 3.84 (s, 3H); 4.17

(m, 1H); 4.38 (m, 1H); 4.56

(m, 1H); 4.87 (d, br, 1H);

6.21 (m, 1H); 7.87 (s, 1H);

9.35 (s, br, 1H);

¹⁹F-NMR (CDCl₃) δ: −158(s)

The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.

Ex
Compound
NMR
m/z
SM

429
2-((3S,4R)-4-{[(4-chloro-3-
1.85 (m, 2H); 2.15 (s, 3H); 3.31
405
Example

fluoro-5-methyl-1H-pyrrol-2-
(m 2H); 4.0 (m, 1H); 4.31 (m,

428

yl)carbonyl]amino}-3-
2H); 4.90 (d, br, 1H); 7.43 (d, 1H);

fluoropiperidin-1-yl)-1,3-
7.75 (s, 1H); 11.95 (s, br, 1H);

thiazole-5-carboxylic acid

¹⁹F-NMR (CDCl₃) δ: −158(s)ppm

Example 430-433

The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated in the table below.

Ex
Compound
Data
SM

430

embedded image

MS (ES) MH: 575 for C₂₃H₃₁Cl₂N₅O₆S; NMR: 1.08 (d, 3H), 1.20 (t, 3H), 1.68-1.76 (m, 2H), 2.17 (s, 3H), 3.14-3.19 (m, 1H), 3.25 (s, 3H), 3.35 (s, 3H), 3.54 (brs, 1H), 3.90-4.05 (m, 2H), 4.15 (q, 2H), 4.20-4.30 (m, 2H), 7.15 (d, 1H), 8.32 (d, 1H), 12.16 (s, 1H)
Example 191 and Intermediate 1725- 162

431
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH: 575 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₃₁Cl₂N₅O₆S;
(2S)-2-

yl)carbonyl]amino}-3-
NMR: 1.09 (d, 3H), 1.21 (t,
methoxypropan-1-

methoxypiperidin-1-yl)-4-
3H), 1.68-1.76 (m, 2H), 2.18
amine hydrochloride

({[(2S)-2-
(s, 3H), 3.15-3.21 (m, 1H),
(1725-163)

methoxypropyl]amino}
3.26 (s, 3H), 3.36 (s, 3H),

carbonyl)-
3.54 (brs, 1H), 3.95-4.05 (m,

1,3-thiazole-5-carboxylate
2H), 4.16 (q, 2H), 4.20-4.30

(m, 2H), 7.15 (d, 1H), 8.32

(d, 1H), 12.16 (s, 1H)

432
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 576 for
Example 191 and

dichloro-5-methyl-1H-pyrrol-2-
C₂₃H₃₁Cl₂N₅O₆S;
(2R)-1-

yl)carbonyl]amino}-3-
NMR: 1.08 (d, 3H), 1.21 (t,
methoxypropan-2-

methoxypiperidin-1-yl)-4-
3H), 1.68-1.76 (m, 2H), 2.17
amine hydrochloride

({[(1R)-2-methoxy-1-
(s, 3H), 3.14-3.20 (m, 1H),
(1725-177)

methylethyl]amino}carbonyl)-
3.25 (s, 3H), 3.35 (s, 3H),

1,3-thiazole-5-carboxylate
3.54 (brs, 1H), 3.95-4.05 (m,

2H), 4.16 (q, 2H), 4.20-4.30

(m, 2H), 7.14 (d, 1H), 8.30

(d, 1H), 12.15 (s, 1H)

433
Cis(±)-methyl 2-(3-azido-4-
1.8 (m, 2H), 2.19 (s, 3H),
Intermediate 272 and

{[(3,4-dichloro-5-methyl-1H-
3.35 (m, 1H), 3.6 (d, 1H),
methyl 2-bromo-1,3-

pyrrol-2-
3.75 (s, 3H), 3.95 (d, 1H),
thiazole-5-carboxylate

yl)carbonyl]amino}piperidin-1-
4.24 (m, 3H), 7.23 (d, 1H),

yl)-1,3-thiazole-5-carboxylate
7.86 (s, 1H), 12.1 (s, 1H).

Examples 434-437

The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.

Ex
Compound
NMR
m/z
SM

434
2-((3S,4R)-4-{[(3,4-Dichloro-5-
1.07 (d, 3H), 1.70-1.76 (m, 2H),
546
Example

methyl-1H-pyrrol-2-
2.17 (s, 3H), 3.25 (s, 3H), 3.36 (s,

430

yl)carbonyl]amino}-3-
3H), 3.37-3.50 (m, 2H), 3.55 (brs,

methoxypiperidin-1-yl)-4-
1H), 4.20-4.30 (m, 2H), 4.45 (brs.

({[(2R)-2-
1H), 7.16 (d, 1H), 8.98 (d, 1H),

methoxypropyl]amino}
12.13 (s, 1H), 16.30 (s, 1H)

carbonyl)-

1,3-thiazole-5-carboxylic acid

435

embedded image

1.16 (d, 3H), 1.70-1.76 (m, 2H), 2.18 (s, 3H), 3.23 (s, 3H), 3.37 (s, 3H), 3.44-3.50 (m, 2H), 3.55 (brs, 1H), 4.20-4.30 (m, 2H), 4.45 (brs, 1H), 7.16 (d, 1H), 8.98 (d, 1H), 12.14 (s, 1H), 16.31 (s, 1H)
546
Example 431

436
2-(3S,4R)-4-{[(3,4-Dichloro-5-
1.16 (d, 3H), 1.70-1.76 (m, 2H),
547
Example

methyl-1H-pyrrol-2-
2.17 (s, 3H), 3.26 (s, 3H), 3.38 (s,

432

yl)carbonyl]amino}-3-
3H), 3.46-3.52 (m, 2H), 3.55 (brs,

methoxypiperidin-1-yl)-4-
1H), 4.20-4.30 (m, 2H), 4.45 (brs,

({[(1R)-2-methoxy-1-
1H), 7.16 (d, 1H), 8.96 (d, 1H),

methylethyl]amino}carbonyl)-
12.14 (s, 1H), 16.31 (s, 1H)

1,3-thiazole-5-carboxylic

acid

437
Cis(±)-2-(3-azido-4-{[(3,4-
.8 (m, 2H), 2.2 (s, 3H), 3.3 (m,
444
Example

dichloro-5-methyl-1H-pyrrol-2-
1H), 3.6 (d, 1H), 3.9 (d, 1H), 4.24

433

yl)carbonyl]amino}piperidin-1-
(m, 3H), 7.23 (d, 1H), 7.7 (s, 1H),

yl)-1,3-thiazole-5-carboxylic
12.1 (s, 1H), 12.7 (S, 1H)

acid

Examples 438-440

The following Examples were prepared by the procedure described in Example 417 from the starting materials (SM) indicated

Ex
Compound
Data
SM

438
sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 547 for
Example 434

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₆Cl₂N₅O₆S; NMR: 1.07 (d,

yl)carbonyl]amino}-3-
3H), 1.60-1.75 (m, 2H), 2.14 (s,

methoxypiperidin-1-yl)-4-
3H), 3.10-3.19 (m, 3H), 3.24 (s,

({[(2R)-2-
3H), 3.34 (s, 3H), 3.47 (brs, 1H),

methoxypropyl]amino}
3.81-3.85 (m, 1H), 3.90-4.00 (m,

carbonyl)-
1H), 4.05-4.20 (m, 2H), 7.17 (d,

1,3-thiazole-5-carboxylate
1H), 12.16 (brs, 1H), 13.22 (d,

1H)

439
Sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 547 for
Example 435

dichloro-5-methyl-1H-pyrrol-2-
C₂₁H₂₆Cl₂N₅O₆S; NMR: 1.07 (d,

yl)carbonyl]amino}-3-
3H), 1.60-1.75 (m, 2H), 2.17 (s,

methoxypiperidin-1-yl)-4-
3H), 3.10-3.22 (m, 3H), 3.24 (s,

({[(2S)-2-
3H), 3.35 (s, 3H), 3.49 (brs, 1H),

methoxypropyl]amino}
3.81-3.85 (m, 1H), 3.90-4.00 (m,

carbonyl)-
1H), 4.05-4.20 (m, 2H), 7.15 (d,

1,3-thiazole-5-carboxylate
1H), 12.15 (brs, 1H), 13.22 (d,

1H)

440

embedded image

MS (ES) MH⁺: 547 for C₂₁H₂₆Cl₂N₅O₆S; NMR: 1.07 (d, 3H), 1.65-1.73 (m, 2H), 2.17 (s, 3H), 3.10-3.22 (m, 3H), 3.24 (s, 3H), 3.35 (s, 3H), 3.49 (brs, 1H), 3.81-3.85 (m, 1H), 3.90-4.00 (m, 1H), 4.05-4.20 (m, 2H), 7.17 (d, 1H), 12.18 (brs, 1H), 13.19 (d, 1H)
Example 436

Preparation of Starting Materials
Intermediate 83
Cis(±)-ethyl(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methylpiperidine-1-carboxylate

A solution of 167 mg (0.9 mmol) of Cis(±)-ethyl(4-amino-3-methylpiperidine-1-carboxylate (Intermediate 152), 235 μl (1.25 mmol) diisopropylethylamine and 280 mg (1.35) of 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride (Intermediate 202) was stirred at room temperature for 1 h. The mixture was diluted with EtOAc and washed with aqueous Na₂CO₃and brine. Drying MgSO₄and removal of solvent gave an oil that was purified by chromatography (100% CH₂Cl₂followed by gradient elution to 100% EtOAc) to afford 145 mg of product. MS (ES) (MH⁺): 362 for C₁₅H₂₁Cl₂N₃O₃; NMR (d₆-DMSO): 0.8 (d, 3H), 1.2 (t, 3H), 1.65 (m, 2H), 1.9 (m, 1H), 2.2 (s, 3H), 3.5 (m, 1H), 4.0 (m, 2H), 4.1 (m, 1H), 7.1 (d, 1H), 12.0 (s, 1H).

Intermediates 84-114

The following Intermediates were synthesized by an analogous method to Intermediate 37 or Intermediate 83 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

84
Cis(±)-tert-butyl 4-{[(3,4-dichloro-
N/A
Intermediate 72

5-methyl-1H-pyrrol-2-

yl)carbonyl]amino}-3-

[(methylthio)methyl]piperidine-1-

carboxylate

85

embedded image

MS (ESP): 420.1 (M − H) for C₁₇H₂₅Cl₂N₃O₃S; NMR: 1.40 (s, 9H); 1.45- 1.70 (m, 2H); 2.10 (s, 3H); 2.18 (s, 3H); 2.80- 3.20 (m, 2H); 3.31 (m, 1H); 3.90 (m, 2H); 4.30 (m, 1H); 7.15 (d, 1H); 12.13 (s, 1H)
Intermediate 184 and Intermediate 1

86
Cis(±)-ethyl 3-(benzyloxy)-4-{[(3,4-
MS (ESP): 454 (M + H)
Intermediate 158

dichloro-5-methyl-1H-pyrrol-2-
for C₂₁H₂₅Cl₂N₃O₄;
and Intermediate

yl)carbonyl]amino}piperidine-1-
NMR: 1.20 (q, 3H); 1.70
1

carboxylate
(m, 2H); 2.15 (s, 3H);

3.05 (m, 2H); 3.68 (s,

1H); 4.00 (m, 3H); 4.15

(m, 1H); 4.40(m, 2H);

4.70 (d, 1H); 7.08 (d, 1H);

7.30 (m, 5H); 12.06 (s,

1H).

87
Cis(±)-ethyl 4-{[(3,4-dichloro-5-
MS (ESP): 424 (M + Na)
Intermediate 256

methyl-1H-pyrrol-2-
for C₁₇H₂₁Cl₂N₃O₄; ¹H
and Intermediate

yl)carbonyl]amino}-3-(prop-2-yn-1-
NMR (300 MHz,
1

yloxy)piperidine-1-carboxylate
CDCl₃) δ: 1.27 (t, 3H);

1.79 (m, 2H); 2.27 (s,

3H); 2.40 (t, 1H); 2.90

(m, 2H); 3.85 (m, 1H);

4.10-4.55 (m, 7H); 7.25

(m, 1H); 9.53 (s, 1H).

88
Trans-(±)tert-butyl 4-{[(3,4-
MS (ES) MH⁺: 392 for
Intermediate 185

dichloro-5-methyl-1H-pyrrol-
C₁₆H₂₃Cl₂N₃O₄; NMR:
and Intermediate

2yl)carbonyl]amino}3-
1.45 (s, 9H), 1.54 (m,
1

hydroxypiperidine-1-carboxylate
1H), 2.02 (m, 1H), 2.27

(s, 3H), 2.67 (dd, 1H),

2.84 (brt, 1H), 3.34 (m,

1H), 3.50 (m, 1H), 3.90

(m, 1H), 4.11 (m, 1H),

4.27 (m, 1H), 6.75 (brd,

1H), 10.06 (br s, 1H)

89
tert-butyl (3S,4R)-4-{[(3-chloro-5-
MS (ES) MH⁺: 360 for
Intermediate 196

methyl-1H-pyrrol-2-
C₁₆H₂₃ClFN₃O₃
and Intermediate

yl)carbonyl]amino}-

64

3-fluoropiperidine-1-carboxylate

90

embedded image

MS (ESN): 404(M − 1) for C₁₆H₂₃BrN₃O₃ NMR (CDCl₃) δ: 1.47 (t, 9H); 1.80 (m, 2H); 2.26 (s, 3H); 2.81 (s, 3H); 2.96 (m, 1H); 4.27 (m, 1H); 4.65 (d, br, 1H); 6.11 (d, 1H); 6.59 (s, 1H); 9.97 (s, br, 1H)
Intermediate 197 and Intermediate 64

91
tert-butyl (3S,4R)-4-{[(4-bromo-3-
MS (ES) MH⁺: 440 for
Intermediate 198

chloro-5-methyl-1H-pyrrol-2-yl)
C₁₆H₂₂BrClFN₃O₃
and Intermediate

carbonyl]amino}-3-
NMR (CDCl₃) δ: 1.47 (s,
64

fluoropiperidine-1-carboxylate
9H); 1.85 (m, 2H); 2.29

(s, 3H); 2.85 (m, 2H);

4.24 (m, 2H); 4.50 (m,

1H); 4.72 (d, br, 1H); 6.96

(d, 1H); 9.30 (s, br, 1H)

92
Cis(±)-Ethyl (4-{[(3,4-dichloro-5-
MS (ES) MH⁻: 420 for
Intermediate 159

methyl-1H-pyrrol-2-
C₁₇H₂₅Cl₂N₄O₅
and Intermediate

yl)carbonyl]amino}-3-(2-

1

methoxyethoxy)piperidine-1-

carboxylate

93
Cis(±)-Ethyl 4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 436 for
Intermediate

methyl-1H-pyrrol-2-
C₁₈H₂₇Cl₂N₃O₅
160 and

yl)carbonyl]amino}-3-(2-

Intermediate 1

methoxypropoxy)piperidine-1-

carboxylate

94
Cis(±)-Ethyl 4-{[(3,4-dichloro-5-
MS (ES) MH⁺: 422 for
Intermediate

methyl-1H-pyrrol-2-
C₁₇H₂₅Cl₂N₃O₅
161 and

yl)carbonyl]amino}-3-(2-

Intermediate 1

hydroxypropoxy)piperidine-1-

carboxylate

95

embedded image

C₁₅H₂₁ClFN₃O₃ NMR: 1.39 (s, 9H), 1.50- 1.60 (m, 1H), 1.69-1.80 (m, 1H), 2.73-3.11 (m, 2H), 3.95-4.23 (m, 3H), 4.71 (d, 1H), 6.94- 6.96 (m, 2H), 8.03 (d, 1H), 11.78 (s, 1H)
Intermediates 2,2,2-trichloro-1- (4-chloro-1H- pyrrol-2- yl)ethanone (Tett lett. 27, 2505- 2508, 1979) and Intermediate 64

96
tert-Butyl (3S,4R)-4-{[(4,5-
C₁₅H₂₁ClFN₃O₃
Intermediates 203

dichloro-1H-pyrrol-2-
NMR: 1.39 (s, 9H), 1.50-
and Intermediate

yl)carbonyl]amino}-3-
1.60 (m, 1H), 1.69-1.80
64

fluoropiperidine-1-carboxylate
(m, 1H), 2.73-3.11 (m,

2H), 3.95-4.23 (m, 3H),

4.71 (d, 1H), 6.94-6.96 (m,

2H), 8.03 (d, 1H), 11.78

(s, 1H)

97
Ethyl (3S,4R)-4-{[(4-chloro-5-
MS (ES) MH⁺: for
Intermediate 6

methyl-1H-pyrrol-2-
C₁₅H₂₂ClN₃O₄; NMR:
and intermediate

yl)carbonyl]amino}-3-
1.18 (t, J = 7.06 Hz, 3H),
25

methoxypiperidine-1-carboxylate
1.48 (d, J = 3.58 Hz, 1H),

1.75 (td, J = 12.29, 7.82

Hz, 1H), 2.10-2.18 (m,

3H), 2.95 (d, J = 13.38 Hz,

2H), 3.20-3.27 (m, 3H),

3.27-3.35 (m, 2H), 3.38

(s, 1H), 3.97-4.09 (m,

J = 10.53, 7.08, 7.08, 3.39

Hz, 2H), 4.19 (s, 1H),

6.88 (d, J = 2.64 Hz, 1H),

7.62 (d, J = 7.91 Hz, 1H),

11.60 (s, 1H)

98
Cis(±)-ethyl-4-{[(4-chloro-3,5-
MS (ES) MH⁺: 358 for
Intermediate 195

dimethyl-1H-pyrrol-2-
C₁₆H₂₄ClN₃O₄.
and Intermediate

yl)carbonyl]amino}-3-

26

methoxypiperidine-1-carboxylate

99
tert-butyl (Cis(±)-3-chloro-4-{[(3,4-
1.40 (s, 9H), 1.67 (m,
Intermediate 1 and

dichloro-5-methyl-1H-pyrrol-2-
2H), 2.19 (s, 3H), 2.68
Intermediate 162

yl)carbonyl]amino}piperidine-1-
(m, 1H), 3.43 (m, 1H),

carboxylate
4.02 (m, 1H), 4.17 (m,

1H), 4.36 (m, 1H), 4.58

(s, 1H), 7.05 (d, 1H),

12.12 (s, 1H)

100

embedded image

MS (ES) MH⁺: 415 for C₁₈H₂₆ClFN₄O₄; NMR: 1.40 (s, 9H), 1.70 (m, 2H), 2.34 (s, 3H), 3.29 (m, 1H), 3.31 (s, 3H), 3.35 (m, 1H), 3.99 (m, 1H), 4.24 (m, 2H), 4.78 (d, 1H), 7.19 (d, 1H), 8.02 (s, 1H), 12.11 (s, 1H)
Intermediate 199 and Intermediate 64

101
tert-butyl Cis(±)-3-chloro-4-{[(4-
1.40 (s, 9H), 1.54 (m,
162 and

chloro-5-methyl-1H-pyrrol-2-
1H), 1.83 (m, 1H), 2.14
Intermediate 6

yl)carbonyl]amino}piperidine-1-
(s, 3H), 3.28 (m, 1H),

carboxylate
3.41 (m, 1H), 4.02-4.22

(m, 3H), 4.56 (s, 1H),

6.89 (s, 1H), 7.80 (d, 1H),

11.63 (s, 1H)

102a
Cis(±)-ethyl (4-{[(3,4-dichloro-5-
MS (ES) (MH⁺): 362 for
Intermediate 202

methyl-1H-pyrrol-2-
C₁₅H₂₁Cl₂N₃O₃; NMR
and Intermediate

yl)carbonyl]amino}-2-
(d₆-DMSO): 0.8 (d, 3H),
164

methylpiperidine-1-carboxylate
1.2 (t, 3H), 1.65 (m, 2H),

1.9 (m, 1H), 2.2 (s, 3H),

3.5 (m, 1H), 4.0 (m, 2H),

4.1 (m, 1H), 7.1 (d, 1H),

12.0 (s, 1H)

102b
Cis(±)-ethyl (4-{[(4-chloro-3-
MS (ES) (MH⁺): 369 for
Intermediate 200

cyano-5-methyl-1H-pyrrol-2-
C₁₆H₂₁ClN₄O₄; NMR (d₆-
and Intermediate

yl)carbonyl]amino}-3-
DMSO): 1.2 (t, 3H), 2.2
21

methoxypiperidine-1-carboxylate
(s, 3H), 2.8-3.1 (m, 2H),

3.3 (s, 3H), 3.4 (m, 1H),

3.8-4.3 (m, 5H), 7.7 (d,

1H), 12.7 (s, 1H)

103
tert-butyl (3S,4R)-4-{[(4-chloro-3-
MS (ES) (MH⁺): 383 for
Intermediate 200

cyano-5-methyl-1H-pyrrol-2-
C₁₇H₂₂ClFN₄O₃; NMR
and Intermediate

yl)carbonyl]amino}-3-
(d₆-DMSO): 1.4 (s, 9H),
59

fluoropiperidine-1-carboxylate
1.7 (m, 2H), 2.2 (s, 3H),

3.8-4.2 (m, 4H), 4.8 (d,

1H), 8.0 (d, 1H), 12.5 (s,

1H)

104
tert-butyl (3S,4R)-4-{[(3,5-dichloro-
MS (ES) (MH⁺): 394 for
Intermediate 201

4-methyl-1H-pyrrol-2-
C₁₆H₂₂Cl₂FN₃O₃; NMR
and Intermediate

yl)carbonyl]amino}-3-
(d₆-DMSO): 1.4(s, 9H),
59

fluoropiperidine-1-carboxylate
1.6-1.8 (m, 2H), 1.9 (s,

3H), 2.9 (m, 2H), 4.0-4.3

(m, 3H), 4.8 (d, 1H), 7.3

(d, 1H), 12.5 (s, 1H)

105

embedded image

MS (ESI) M: 418 for C₁₈H₂₅Cl₂N₃O₄; NMR: 0.22 (m, 2H), 0.50 (m, 2H), 1.04 (m, 1H), 1.24 (t, 3H), 1.69 (m, 2H), 2.24 (s, 3H), 2.87-3.09 (m, 2H), 3.28 (m, 1H), 3.59 (bs, 1H), 3.92-4.36 (m, 5H), 7.20 (m, 1H), 12.21 (bs, 1H)
Interemdiate 165 and Intermediate 1

106
Cis(±)-ethyl 4-{[(3,4-dichloro-5-
MS (ESI) M: 461 for
Intermediate 166

methyl-1H-pyrrol-2-
C₁₈H₂₂Cl₂N₄O₄S; NMR
and Intermediate

yl)carbonyl]amino}-3-(1,3-thiazol-
(DMSO): 1.10 (m, 3H),
1

2-ylmethoxy)piperidine-1-
1.65 (m, 2H), 2.16 (s,

carboxylate
3H), 2.82-3.10 (m, 2H),

3.79 (bs, 1H), 3.97 (m,

3H), 4.21 (dt, 1H), 4.35 (t,

1H), 4.78 (d, 1H), 4.95 (d,

1H), 7.10 (d, 1H), 7.72

(dd, 2H), 12.12 (bs, 1H)

107
Cis(±)-Ethyl (rel 3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 392, 394
Intermediate 257

dichloro-5-methyl-1H-pyrrol-2-
for C₁₆H₂₃Cl₂N₃O₄;
and Intermediate

yl)carbonyl]amino}-3-
NMR: 1.04-1.21 (m, 6H);
1

ethoxypiperidine-1-carboxylate
1.60 (m, 2H); 2.17 (s,

3H); 2.95 (m, 2H); 3.48

(br s, 1H); 3.65 (m, 1H);

3.92 (br s, 1H); 3.98-4.05

(m, 2H); 4.09-4.25 (m,

2H); 7.09 (d, 1H) 12.14

(s, 1H)

108
1-tert-butyl 3-methyl 4-{[(3,4-
MS (ES) MH⁺: 434, 436
Intermediate 167

dichloro-5-methyl-1H-pyrrol-2-
for C₁₈H₂₅Cl₂N₃O₅; NMR
and Intermediate

yl)carbonyl]amino}piperidine-1,3-
(CDCl₃): 1.45 (s, 9H),
1

dicarboxylate
1.60 (m, 1H), 2.16 (m,

1H), 2.27 (s, 3H), 2.45

(dt, 1H), 2.93 (m, 1H),

3.10 (m, 1H), 3.66 (s,

3H), 4.05 (m, 1H), 4.29

(m, 2H), 6.68 (d, 1H),

9.66 (s, 1H)

109
1-(tert-butoxycarbonyl)-4-{[(3,4-
MS (ES) MH⁺: 420, 422
Intermediate 108

dichloro-5-methyl-1H-pyrrol-2-
for C₁₇H₂₃Cl₂N₃O₅.
and Intermediate

yl)carbonyl]amino}piperidine-3-

1

carboxylic acid

110

embedded image

MS (ES) MH⁺: 489, 491 for C₂₁H₃₀Cl₂N₄O₅; NMR: 1.40 (s, 9H), 1.54 (m, 1H), 1.82 (m, 1H), 2.15 (s, 3H), 2.81 (broad s, 2H), 3.14 (dt, 1H), 3.24-3.40 (m, 2H [under H₂O peak]), 3.41-3.68 (m, 6H), 3.93 (m, 2H), 4.24 (m, 1H), 7.14 (d, 1H), 11.98 (s, 1H)
Intermediate 109 and Intermediate 1

111
Trans(±)tert-butyl 4-{[(3,4-
MS (ES) MH⁺: 489, 491
Intermediate 109

dichloro-5-methyl-1H-pyrrol-2-
for C₂₁H₃₀Cl₂N₄O₅;
and Intermediate

yl)carbonyl]amino}-3-(morpholin-
NMR: 1.37 (s, 9H), 1.64
1

4-ylcarbonyl)piperidine-1-
(m, 1H), 2.11 (m, 1H),

carboxylate
2.16 (s, 3H), 3.14 (m,

1H), 3.18-3.68 (m, 11H

[under H₂O peak]), 3.73

(dd, 1H), 4.37 (m, 1H),

7.24 (d, 1H), 12.08 (s,

1H)

112
Cis(±)ethyl 3-(2-tert-butoxy-2-
MS (ES) MH⁺: 478, 480
Intermediate 240

oxoethoxy)-4-{[(3,4-dichloro-5-
for C₂₀H₂₉Cl₂N₃O₆;
and Intermediate

methyl-1H-pyrrol-2-
NMR: 1.17 (t, 3H), 1.41
1

yl)carbonyl]amino}piperidine-1-
(s, 9H), 1.90 (m, 1H),

carboxylate
2.16 (s, 3H), 2.78-3.06

(m, 3H), 3.46 (m, 1H),

3.74 (m, 1H), 3.94 (m,

1H), 4.03 (q, 2H), 4.09 (s,

2H), 4.12 (m, 1H), 7.39

(d, 1H), 11.97 (s, 1H)

113
Trans(±)ethyl 3-(2-tert-butoxy-2-
NMR: 1.17 (t, 3H), 1.38
Intermediate 240

oxoethoxy)-4-{[(3,4-dichloro-5-
(s, 9H), 1.58 (m, 1H),
and Intermediate

methyl-1H-pyrrol-2-
1.68 (m, 1H), 2.17 (s,
1

yl)carbonyl]amino}piperidine-1-
3H), 2.81-3.02 (m, 2H),

carboxylate
3.66 (m, 1H), 3.86-4.27

(m, 7H), 7.40 (d, 1H),

12.07 (s, 1H)

114
Ethyl 3-{[tert-
MS (ES) MH⁺: 478, 480
Intermediate 112

butyl(dimethyl)silyl]oxy}-4-{[(3,4-
for C₂₀H₃₃Cl₂N₃O₄Si;
and Intermediate

dichloro-5-methyl-1H-pyrrol-2-
NMR: −0.07 (s, 3H), 0.07
1

yl)carbonyl]amino}piperidine-1-
(s, 3H), 0.83 (s, 9H), 1.16

carboxylate
(t, 3H), 1.56 (m, 1H), 1.72

(m, 1H), 2.17 (s, 3H),

3.04 (m, 2H), 3.85-4.11

(m, 6H), 6.66 (m, 1H),

12.12 (s, 1H)

Intermediates 115-144

The following Intermediates were synthesized by an analogous method to Intermediate 50 or Intermediate 74 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

115
Cis(±)-3,4-dichloro-N-[3- (hydroxymethyl)piperidin- 4-yl]-5-methyl-1H- pyrrole-2-carboxamide hydrochloride embedded image

MS (ES) MH⁺: 306, 308 for C₁₂H₁₇Cl₂N₃O₂.
Intermediate 71

116
Cis(±)-3,4-dichloro-5-
MS (ES) MH⁺: 336, 338 for
Intermediate 84

methyl-N-{3-
C₁₃H₁₉Cl₂N₃OS.

[(methylthio)methyl]

piperidin-4-yl}-1H-

pyrrole-2-carboxamide

hydrochloride

117
Cis(±)-3,4-dichloro-5-
MS (ESP): 463.1 (M + H) for
Intermediate 85

methyl-N-[3-
C₁₇H₂₀Cl₂N₄O₃S₂; NMR: 1.90

(methylthio)piperidin-4-
(m, 2H); 2.14 (s, 3H); 2.28 (s,

yl]-1H-pyrrole-2-
3H); 3.28-3.45 (m, 2H); 3.74

carboxamide
(s, 3H); 3.77 (m, 1H); 3.95

(m, 2H); 4.44 (m, 1H); 7.25

(d, 1H); 7.85 (s, 1H); 12.14

(s, 1H)

118
Cis(±)-N-[3-
MS (ESP): 382 (M + H) for
Intermediate 86

(benzyloxy)piperidin-4-
C₁₈H₂₁Cl₂N₃O₂

yl]-3,4-dichloro-5-methyl-

1H-pyrrole-2-carboxamide

119
Cis(±)-3,4-dichloro-5-
MS (ESP): 330 (M + H) for
Intermediate 87

methyl-N-[3-(prop-2-yn-1-
C₁₄H₁₇Cl₂N₃O₂

yloxy)piperidin-4-yl]-1H-

pyrrole-2-carboxamide

120
Trans-(±)3,4-dichloro-N- [3-hydroxypiperidin-4-yl]- 5-methyl-1H-pyrrole-2- carboxamide trifluoroacetate embedded image

MS (ES) MH⁺: 292 for C₁₁H₁₅Cl₂N₃O₂
Intermediate 88

121
3-chloro-N-[(3S,4R)-3-
MS (ES) MH⁺: 260 for
Intermediate 89

fluoropiperidin-4-yl]-5-
C₁₁H₁₅ClFN₃O; 1.91 (m, 2H);

methyl-1H-pyrrole-2-
2.17 (s, 3H); 3.13 (m, 1H);

carboxamide
3.35 (m, 2H); 3.57 (s, 1H);

4.35 (m, 1H); 5.05 (d, br,

1H); 5.96 (s, 1H); 7.26 (d,

1H); 8.67 (br, 1H); 9.16 (br,

1H); 11.70 (s, br, 1H)

122
4-bromo-N-[(3S,4R)-3-
MS (ES) MH⁺: 306 for
Intermediate 90

fluoropiperidin-4-yl]-5-
C₁₁H₁₅BrN₃O

methyl-1H-pyrrole-2-

carboxamide

123
4-bromo-3-chloro-N-
MS (ES) MH⁺: 340 for
Intermediate 91

[(3S,4R)-3-
C₁₁H₁₄BrN₃O

fluoropiperidin-4-yl]-5-
NMR δ: 1.91 (m, 2H); 2.20

methyl-1H-pyrrole-2-
(s, 3H); 3.13 (m, 1H); 3.35

carboxamide
(m, 2H); 3.62 (m, 1H); 4.35

(m, 1H); 5.05 (d, br, 1H);

7.39 (d, 1H); 8.60 (s, br, 1H);

8.99 (s, br, 1H); 12.17 (s, br,

1H)

124
Cis(±)-3,4-dichloro-N-[(3-
MS (ES) MH⁺: 350 for
Intermediate 92

(2-
C₁₄H₂₁Cl₂N₃O₃

methoxyethoxy)piperidin-

4-yl]-5-methyl-1H-

pyrrole-2-carboxamide

125
Cis(±)-3,4-Dichloro-N-[3- (2-methoxypropoxy) piperidin- 4-yl]-5-methyl-1H- pyrrole-2-carboxamide embedded image

MS (ES) MH⁺: 364 for C₁₅H₂₃Cl₂N₃O₃
Intermediate 93

126
Cis(±)-3,4-Dichloro-N-3-
MS (ES) MH⁺: 350 for
Intermediate 94

(2-
C₁₄H₂₁Cl₂N₃O₃;

hydroxypropoxy)piperidin-

4-yl]-5-methyl-1H-

pyrrole-2-carboxamide

127
4-Chloro-N-[(3S,4R)-3-
MS (ES) MH⁺: 246 for
Intermediate 95

fluoropiperidin-4-yl]-1H-
C₁₀H₁₃ClFN₃O

pyrrole-2-carboxamide

hydrochloride

128
4,5-dichioro-N-[(3S,4R)-3-
MS (ES) MH⁺: 280 for
Intermediate 96

fluoropiperidin-4-yl]-1H-
C₁₀H₁₂Cl₂FN₃O

pyrrole-2-carboxamide

hydrochloride

129
4-chloro-N--[(3S,4R)-(3-
1.41 (s, 1H), 1.67 (s, 1H),
Intermediate 97

methoxypiperidin-4-yl)]1-
2.13 (s, 3H), 2.47 (s, 1H),

5-methyl-1H-pyrrole-2-
2.55 (s, 1H), 2.86 (s, 1H),

carboxamide
3.08 (d, J = 13.19 Hz, 1H),

3.25 (s, 3H), 3.31 (s, 1H),

6.89 (d, J = 2.45 Hz, 1H), 7.52

(s, 1H), 11.59 (s, 1H)

130
Cis(±)-4-chloro-N- [(3S,4R)-3- methoxypiperidin-4-yl]- 3,5-dimethyl-1H-pyrrole- 2-carboxamide embedded image

MS (ES) MH⁺: 287 for C₁₃H₂₀ClN₃O₂.
Intermediate 98

131
3,4-dichloro-N-[Cis(±)-3-
MS (ES) MH⁺: 310 for
Intermediate 99

chloropiperidin-4-yl]-5-
C₁₁H₁₄Cl₃N₃O

methyl-1H-pyrrole-2-

carboxamide

hydrochloride

132
4-chloro-N-[(3S,4R)-3-
MS (ES) MH⁺: 317 for
Intermediate 100

fluoropiperidin-4-yl]-3-
C₁₇H₁₈ClFN₄O₂

[(E)-

(methoxyimino)methyl]-5-

methyl-1H-pyrrole-2-

carboxamide

hydrochloride

133
Cis(±)-3-chloro-N-[3-
MS (ES) MH⁺: 276 for
Intermediate 101

chloropiperidin-4-yl]-5-
C₁₁H₁₅Cl₂N₃O

methyl-1H-pyrrole-2-

carboxamide

hydrochloride

134
Cis(±)-3,4-dichloro-5-
MS (ES) (MH⁺): 290 for
Intermediate 83

methyl-N-[(3-
C₁₂H₁₇Cl₂N₃O.

methylpiperidin-4-yl]-1H-

pyrrole-2-carboxamide

135
Cis(±)-3,4-dichloro-5- methyl-N-[2- methylpiperidin-4-yl]-1H- pyrrole-2-carboxamide embedded image

MS (ES) (MH⁺): 290 for C₁₂H₁₇Cl₂N₃O. NMR: 1.0 (d, 3H), 1.2-1.4 (m, 1H), 1.7-1.9 (m, 1H), 2.2 (s, 3H), 2.5-2.7 (m, 2H), 3.0 (m, 1H), 3.3 (m, 1H), 3.7-3.8 (m, 1H), 7.1 (d, 1H)
Intermediate 101

136
Cis(±)-4-chloro-3-cyano-
MS (ES) (MH⁺): 297 for
Intermediate 102

N-[(3-methoxypiperidin-4-
C₁₂H₁₇Cl₂N₃O₂.

yl]-5-methyl-1H-pyrrole-
NMR: 1.6-1.9 (m, 2H), 2.2 (s,

2-carboxamide
3H), 2.8 (m, 2H), 3.0 (m,

1H), 3.3 (s, 3H), 3.5 (s, 1H),

4.15 (m, 1H), 7.7 (d, 1H), 8.7

(s, broad, 1H)

137
4-chloro-3-cyano-N-
MS (ES) (MH⁺): 285 for
Intermediate 103

[(3S,4R)-3-fluoropiperidin-
C₁₁H₁₄Cl₂FN₃O.

4-yl]-5-methyl-1H-
NMR: 1.6 (m, 2H), 2.2 (s,

pyrrole-2-carboxamide
3H), 2.3 (m, 1H), 2.3 (m,

1H), 2.5-3.0 (m, 2H), 3.1-3.3

(m, 1H), 3.5 (s, 1H), 4.0-4.2

(dd, 1H), 4.7 (d, 1H), 7.9 (d,

2H)

138
(3S,4R)-4-{[(3,5-dichloro-
MS (ES) (MH⁺): 294 for
Intermediate 104

4-methyl-1H-pyrrol-2-
C₁₁H₁₄Cl₂FN₃O.

yl)carbonyl]amino}-3-
NMR: 1.9 (s, 3H), 3.0-3.7 (m,

fluoropiperidinium
4H), 4.3 (m, 1H), 5.0 (d, 1H),

chloride
7.65 (d, 1H), 8.7 (s, broad,

1H), 9.4 (s, broad, 1H), 12.7

(s, 1H)

139
Cis(±)-3,4-dichloro-N-[3-
MS (ES) MH⁺: 347 for
Intermediate 105

(cyclopropylmethoxy)
C₁₅H₂₁Cl₂N₃O₂; NMR: 0.17

piperidin-4-yl]-5-methyl-
(m, 2H), 0.44 (m, 2H), 1.01

1H-pyrrole-2-carboxamide
(m, 1H), 1.34 (s, 1H), 1.62

(m, 2H), 2.17 (s, 3H), 2.55-

2.70 (m, 2H), 2.89 (m, 2H),

3.10-3.23 (m, 2H), 3.38-3.49

(m, 1H), 4.09 (m, 1H), 7.12

(d, 1H), 12.10 (bs, 1H).

140
Cis(±)-3,4-dichloro-5- methyl-N-[3-(1,3-thiazol- 2-ylmethoxy)piperidin-4- yl]-1H-pyrrole- 2-carboxamide embedded image

MS (ESI) M: 389 for C₁₅H₁₈Cl₂N₄O₂S
Intermediate 106

141
Cis(±)-3,4-Dichloro-N-
MS (ES) MH⁺: 320 for
Intermediate 107

[(rel 3S,4R)-3-
C₁₃H₁₉Cl₂N₃O₂; NMR: 1.14

ethoxypiperidin-4-yl]-5-
(t, 3H); 1.60 (br s, 2H);

methyl-1H-pyrrole-2-
2.17 (s, 3H); 2.62 (m, 2H);

carboxamide
2.89 (m, 2H); 3.14 (m, 2H);

3.64 (m, 2H); 4.05 (m, 2H);

7.10 (d, 1H)

142
Trans(±)3,4-dichloro-5-
MS (ES) MH⁺: 389, 391 for
Intermediate 111

methyl-N-[3-(morpholin-4-
C₁₆H₂₂Cl₂N₄O₃

ylcarbonyl)piperidin-4-yl]-

1H-pyrrole-2-carboxamide

hydrochloride

143
Cis(±)3,4-dichloro-5-
MS (ES) MH⁺: 389, 391 for
Intermediate 110

methyl-N-[3-(morpholin-4-
C₁₆H₂₂Cl₂N₄O₃

ylcarbonyl)piperidin-4-yl]-

1H-pyrrole-2-carboxamide

hydrochloride

144
Cis(±)[(4-{[(3,4-dichloro-
MS (ES) [(M + H)⁺]: 350, 352
Intermediate 112

5-methyl-1H-pyrrol-2-
for C₁₃H₁₇Cl₂N₃O₄

yl)carbonyl]amino}

piperidin-3-yl)oxy]

acetic acid

Intermediates 145-157

The following Intermediates were synthesized by an analogous method to Intermediate 59 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

145
Cis(±)-ethyl 3-(benzyloxy)-4- [(tert- butoxycarbonyl)amino] piperidine-1-carboxylate embedded image

MS (ESP): 401 (M + Na) for C₂₀H₃₀N₂O₅; NMR (CDCl₃) δ: 1.25 (m, 3H); 1.43 (s, 9H); 1.65- 1.85 (m, 2H); 2.81 (m, 2H); 3.58 (s, 1H); 3.71 (m, 1H); 4.05-4.30 (m, 3H); 4.30 (m, 2H); 4.76 (t, 1H); 4.94 (m, 1H); 7.26-7.38 (m, 5H)
cis(±)ethyl 4- [(tert- butoxycarbonyl) amino]-3- hydroxypiperidine- 1-carboxylate (WO9412494) and Benzyl bromide

146
Cis(±)-ethyl 4-[(tert-
NMR: (CDCl₃) 1.26 (t, 3H); 1.45
cis(±)ethyl 4-

butoxycarbonyl)amino]-3-
(s, 9H); 1.67 (m, 2H); 2.43 (t,
[(tert-

(prop-2-yn-1-yloxy)piperidine-
1H); 2.79 (m, 2H); 3.74 (m, 2H);
butoxycarbonyl)

1-carboxylate
4.00-4.45 (m, 6H); 5.00 (s, 1H)
amino]-3-

hydroxypiperidine-

1-carboxylate

(WO9412494) and

Propargyl

bromide

147
Cis(±)-Ethyl (4-benzylamino)-
MS (ES) MH⁺: 337 for
Intermediate 169

3-(2-
C₁₈H₂₈N₂O₄

methoxyethoxy)piperidine-1-

carboxylate

148
Cis(±)-Ethyl 4-[(tert-
MS (ES) M + Na: 383 for
Intermediate 149 and

butoxycarbonyl)amino]-3-(2-
C₁₇H₃₂N₂O₆
methyl iodide

methoxypropoxy)piperidine-1-

carboxylate

149
Cis(±)-Ethyl 4-[(tert-
MS (ES) M + Na: 369 for
Intermediate 150

butoxycarbonyl)amino]-3-(2-
C₆H₃₀N₂O₆
(J.Org.Chem, 60,

hydroxypropoxy)piperidine-1-

4922-4924, 1995)

carboxylate

150
Cis(±)-Ethyl 4-[(tert- butoxycarbonyl)amino]-3- (oxiran-2- ylmethoxy)piperidine-1- carboxylate embedded image

MS (ES) M + Na: 367 for C₁₆H₂₈N₂O₆
Intermediate 27 and m-CPBA

151
tert-butyl (Cis(±)-4-
1.39 (s, 9H), 1.54 (m, 2H), 1.93
Intermediate 170

(benzylamino)-3-
(m, 1H), 2.80 (m, 2H), 3.20 (m,

chloropiperidine-1-carboxylate
1H), 3.75 (q, 2H), 4.06 (m, 1H),

4.57 (s, 1H), 7.22-7.36 (m, 5H).

152
Cis(±)-ethyl 4-(benzylamino)-
NMR (CDCl₃): 0.9 (d, 3H), 1.2
ethyl 3-methyl-4-

3-methylpiperidine-1-
(t, 3H), 1.6 (m, 2H), 2.0 (m, 1H),
oxopiperidine-1-

carboxylate
2.8 (m, 1H), 2.9-3.2 (m, 2H), 3.7
carboxylate

(m, 1H), 3.8 (s, 2H), 4.1 (m, 2H),
(Ebnoether, A.;

7.2-7.4 (m, 5H).
Niklaus. P.;

Suess, R.

Helvetica

Chimica
Acta

(1969), 52(3),

629-38)

153
Cis(±)-ethyl (4-(benzylamino)-
MS (ES) (MH⁺): 277 for
Intermediate 164

2-methylpiperidine-1-
C₁₆H₂₄N₂O₂:

carboxylate
NMR (d₆-DMSO): 1.25 (t, 3H),

1.3 (d, 3H), 1.3-1.5 (m, 2H), 1.65

(s, broad, 2H), 1.8-2.0 (m, 2H),

3.2-3.4 (m, 2H), 3.8 (m, 1H), 4.1

(3, 3H)

154
Cis(±)-Ethyl 4-(benzylamino)-
MS (ES) MH⁺: 333 for
Intermediate 171

3-(cyclopropylmethoxy)
C₁₉H₂₈N₂O₃; NMR: 0.14 (m, 2H),

piperidine-1-carboxylate
0.42 (m, 2H), 0.97 (m, 1H), 1.15

(t, 3H), 1.51 (m, 2H), 2.67 (m,

1H), 2.79-3.01 (m, 2H), 3.19 (m,

1H), 3.53 (m, 1H), 3.73 (m, 3H),

3.88-4.02 (m, 3H), 7.18-7.35 (m,

5H)

155
Cis(±)-ethyl 4-[(tert- butoxycarbonyl)amino]-3- (1,3-thiazol-2- ylmethoxy)piperidine-1- carboxylate embedded image

MS (ES) MH⁺: 386 for C₁₇H₂₇N₃O₅S; NMR (CDCl₃): 1.24 (t, 3H), 1.42 (s, 9H), 1.63 (s, 1H), 1.69-1.81 (m, 2H), 2.82 (m, 2H), 3.67 (m, 2H), 4.10 (q, 2H), 4.40-4.60 (m, 1H), 4.76 (d, 1H), 4.94-5.25 (m, 2H), 7.31 (d, 1H), 7.74 (d, 1H)
Intermediate 235

156
Cis(±)-Ethyl (4-
MS (ES) MH⁺: 307 for
Intermediate 172

(benzylamino)-3-
C₁₇H₂₆N₂O₃; NMR: 1.08 (t, 3H);

ethoxypiperidine-1-
1.15 (t, 3H); 1.50 (m, 2H); 1.75

carboxylate
(br s, 1H); 2.65 (br s, 1H); 2.92

(m, 2H); 3.47 (br s, 1H); 3.55 (m,

1H); 3.71 (m, 3H); 3.88 (br s,

1H); 3.98-4.05 (m, 2H); 7.18-

7.34 (m 5H)

157
Cis(±)-ethyl 4-(benzylamino)-
MS (ES) MH⁺: 293 for
Intermediate 168

3-methoxypiperidine-1-
C₁₆H₂₄N₂O₃. NMR: 1.16 (t, 3H),

carboxylate
1.50 (m, 2H), 1.89 (s, 2H), 2.66

(m, 1H), 2.89 (dd, 2H), 3.26 (s,

3H), 3.67-3.83 (m, 3H), 3.99 (m,

3H), 7.18-7.37 (m, 5H)

Intermediates 158-167

The following Intermediates were synthesized by an analogous method to Intermediate 28 or Intermediate 59 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

158
Cis(±)-ethyl 4-amino-3-
MS (ESP): 279 (M + H) for
Intermediate 145

(benzyloxy)piperidine-1-
C₁₅H₂₂N₂O₃

carboxylate

160
Cis(±)-Ethyl 4-amino-3-(2- methoxypropoxy)piperidine-1- carboxylate hydrochloride embedded image

MS (ES) MH⁺: 261 for C₁₂H₂₄N₂O₄
Intermediate 148

161
Cis(±)-Ethyl 4-amino-3-(2-
MS (ES) MH⁺: 247 for
Intermediate 149

hydroxypropoxy)piperidine-1-
C₁₁H₂₂N₂O₄

carboxylate hydrochloride

162
tert-butyl Cis(±)-4-amino-3-
1.39 (s, 9H), 1.45 (m, 1H), 1.58
Intermediate 151

chloropiperidine-1-carboxylate
(m, 2H), 2.95 (m, 1H), 3.31 (m,

1H), 3.82 (m, 1H), 4.03 (m, 1H),

4.26 (m, 1H)

163
ethyl Cis(±)-4-amino-3-
NMR (CDCl₃): 0.9 (d, 3H), 1.2
Intermediate 152

methylpiperidine-1-
(t, 3H), 1.5 (m, 2H), 1.6 (m, 1H),

carboxylate
2.2 (s, broad, 2H), 3.0 (m, 1H),

3.2 (m, 2H), 3.4 (m, 1H), 4.0-4.2

(m, 2H)

164
Cis(±)-ethyl (4-amino-2-
NMR: 1.25 (t, 3H), 1.3 (d, 3H),
ethyl 2-methyl-4-

methylpiperidine-1-
1.3-1.5 (m, 2H), 1.65 (s, broad,
oxopiperidine-1-

carboxylate
2H), 1.8-2.0 (m, 2H), 3.2-3.4 (m,
carboxylate (EP

2H), 3.8 (m, 1H), 4.1 (3, 3H)
121972 A2)

165
Cis(±)-Ethyl 4-amino-3- (cyclopropylmethoxy) piperidine-1-carboxylate embedded image

MS (ES) MH⁺: 243 for C₁₂H₂₂N₂O₃; NMR (CDCl₃): 0.19 (m, 2H), 0.49 (m, 2H), 1.05 (m, 1H), 1.24 (t, 3H), 1.65-1.84 (m, 2H), 2.93 (d, 2H), 3.09 (m, 1H), 3.25-3.44 (m, 2H), 3.52 (bs, 1H), 3.85-4.21 (m, 6H)
Intermediate 154

166
Cis(±)-ethyl 4-amino-3-(1,3-
MS (ES) MH⁺: 286 for
Intermediate 155

thiazol-2-
C₁₂H₁₉N₃O₃S; NMR (DMSO):

ylmethoxy)piperidine-1-
1.00 (t, 1.8H), 1.15 (t, 1.2H), 1.70

carboxylate
(m, 2H), 2.79-3.03 (m, 2H), 3.44

(m, 1H), 3.74-4.02 (m, 4H), 4.29

(m, 1H), 4.91

(t, 2H), 7.25 (bs, 1H), 7.77 (dd,

2H), 8.34 (s, 1H)

167
1-tert-butyl 3-methyl 4-
MS (GC-EI)[(M)⁺]: 258 for
Intermediate 237

aminopiperidine-1,3-
C₁₂H₂₂N₂O₄

dicarboxylate

Intermediate 168
ethyl 3-methoxy-4-oxopiperidine-1-carboxylate

To a stirred solution of the methoxyketal (Intermediate 173, 55.15 g, 223 mmol, crude) in dry THF (30 mL), at room temperature and under ambient atmosphere, was added an aqueous solution of H₂SO₄(5%, v/v, 190 mL). Temperature was increased to 60° C.; the reaction was stirred at this temperature. Complete conversion was suggested after 2 hours by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf˜0.43). The reaction mixture was allowed to come to room temperature. THF was removed under vacuum. To the aqueous solution was added solid sodium bicarbonate until basic, and solid sodium chloride until saturated, with the addition of more water necessary. Crude product was extracted with methylene chloride (3×300 mL); the organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification; yield was assumed quantitative.

MS (ESI) M: 201 for C₉H₁₅NO₄. ¹H NMR (CDCl₃): 1.28 (t, 3H), 2.38-2.60 (m, 2H), 3.30-3.41 (m, 2H), 3.45 (s, 3H), 3.69 (m, 1H), 4.05 (m, 2H), 4.17 (q, 2H).

Intermediates 169-172

The following Intermediates were synthesized by an analogous method to Intermediate 168 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

169
Ethyl 3-(2-methoxyethoxy)-4-
MS (ES) MH⁺: 246 for
Intermediate 174

oxopiperidine-1-carboxylate
C₁₁H₁₉NO₅

170
tert-butyl 3-chloro-4- oxopiperidine-1-carboxylate embedded image

1.30 (m, 1H), 1.34 (s, 9H), 2.45 (t, 2H), 3.34 (m, 1H), 3.17 (m, 1H), 4.10 (m, 1H), 4.66 (m, 1H)

J.
Org.
Chem., 1994, 59, 6955- 6964.

171
Ethyl 3-(cyclopropylmethoxy)-
MS (ES) MH⁺: 242 for
Intermediate 255 and

4-oxopiperidine-1-carboxylate
C₁₂H₁₉NO₄; NMR (CDCl₃):
cyclopropylmethyl

0.21 (m, 2H), 0.53 (m, 2H),
bromide

1.07 (m, 1H), 1.28 (t, 3H),

2.37-2.58 (m, 2H), 3.32-3.51

(m, 4H), 3.85 (bs, 1H), 4.04-

4.41 (m, 4H)

172
Ethyl 3-ethoxy-4-
MS (ES) MNa⁺: 238 for
Intermediate 175

oxopiperidine-1-carboxylate
C₁₀H₁₇NO₄—Na adduct; NMR:

1.09 (t, 3H); 1.20 (t, 3H); 2.31

(m, 1H); 3.12 (br s, 1H); 3.45

(m, 1H); 3.59 (m, 1H); 3.94

(m, 2H); 4.03-4.11 (m, 4H).

Intermediate 173
ethyl 3,4,4-trimethoxypiperidine-1-carboxylate

To a stirred solution of sodium hydride (6.96 g, 290 mmol) in dry THF (100 mL), at 0° C. and under an atmosphere of N₂, was added a solution of the hydroxyketal (Intermediate 255, 223 mmol) in THF (125 mL) over approximately 30 minutes, via addition funnel. The resulting solution was stirred at 0° C. under an atmosphere of N₂for approximately 15 minutes; to it was then added methyl iodide (18.0 mL, 41.0 g, 290 mmol) portionwise, via syringe, over approximately 5 minutes. The reaction was stirred overnight under an atmosphere of N₂, gradually reaching room temperature. Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf˜0.57) in the morning. The reaction was quenched with a small volume of water, then concentrated under vacuum. To the residue was added approximately 50 mL of water; from this mixture was extracted the crude product with ethyl acetate (3×150 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification; yield was assumed quantitative.

MS (ESI) M: 247 for C₁₁H₂₁NO₅. ¹H NMR (CDCl₃): 1.24 (t, 3H), 1.72-1.83 (m, 2H), 2.82 (m, 2H), 2.98 (t, 1H), 3.20 (s, 3H), 3.21 (s, 3H), 3.41 (s, 3H), 4.10 (q, 2H), 4.20-4.37 (m, 2H).

Intermediates 174-175

The following Intermediates were synthesized by an analogous method to Intermediate 173 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

174
Ethyl 4,4-dimethoxy-3-
NMR (CDCl₃): 1.23 (t, 3H),
Intermediate 255 and 1-

(2-
1.73-1.85 (m, 2H), 2.75-2.88
bromo-2-methoxyethane

methoxyethoxy)
(m, 1H), 2.93-3.10 (m, 1H),

piperidine-1-carboxylate
3.19 (s, 3H), 3.23 (s, 3H), 3.34

(s, 3H), 3.40-3.60 (m, 4H),

3.68-3.80 (m, 2H), 4.11 (q, 2H),

3.98-4.30 (m, 1 H)

175
Ethyl 3-ethoxy-4,4- dimethoxypiperidine-1- carboxylate embedded image

MS (ES) MNa⁺: 284 for C₁₂H₂₃NO₅—Na adduct; NMR: 1.07 (t, 3H); 1.15 (t, 3H); 1.52 (m, 1H); 1.66 (m, 1H); 3.08 (s, 3H); 3.10 (s, 3H); 3.59 (m, 1H); 3.81 (m, 2H); 3.96-4.07 (m, 4H); 4.12 (m, 1H)
Intermediate 255 and ethyl iodide

Intermediate 176
Ethyl 2-oxobutanoate

Diethyl oxalate (10 g; 68 mmol) was dissolved in Et₂O (100 ml) and cooled to −78 C. Ethyl magnesium bromide (1.0 M in THF; 72 ml; 71.8 mmol; 1.05 equiv.) was added slowly via syringe. The dry ice/acetone bath was allowed to melt and warm to 10 C. Monitored the reaction by ¹H NMR. The reaction was cooled to 0 C and quenched with saturated NH₄Cl. Dilute with H₂O and separate phases. The organic layer was dried over Na₂SO₄, filtered and concentrated. Isolation gave 7.6 g of a crude yellow oil in 86% yield. No further purification.

Intermediate 177
Ethyl 3-bromo-2-oxobutanoate

CuBr₂(39.3 g; 176 mmol; 3 equiv.) was suspended in EtOAc (160 ml). A CHCl₃solution containing ethyl 2-oxobutanoate (Intermediate 176, 7.6 g; 58.7 mmol) was added dropwise. The suspension was then heated to reflux for 6 hours and monitored by ¹H NMR. The solids were filtered through a pad of Celite and the mother liquor was concentrated. The crude oil was passed through a short plug of silica gel and eluted with a 1:1 mixture of EtOAc/hexanes. The yellow band was collected and concentrated to give 12.2 g of product. No further purification.

Intermediate 178
Ethyl 2-amino-5-methyl-1,3-thiazole-4-carboxylate

Ethyl 3-bromo-2-oxobutanoate (Intermediate 177, 12.2 g; 58.7 mmol) and thiourea (4.46 g; 76.1; 58.7 mmol) were combined and heated to reflux. The solution was allowed to cool to room temperature and stir for 12 hours. The reaction was monitored by LC/MS. The base was precipitated with 20% NH₄OH (10 ml) and then redissolved with 1N HCl (100 ml) and then finally reprecipitated with 20% NH₄OH. The precipitate was collected and washed with H₂O. The crude product was then crystallized from 9:1 ethanol/water to give 5.95 g of product in 55% yield. MS (ES) MH⁺: 187 for C₇H₁₀N₂O₂S.

Intermediate 179
Ethyl 2-chloro-5-methyl-1,3-thiazole-4-carboxylate

Ethyl 2-amino-5-methyl-1,3-thiazole-4-carboxylate (Intermediate 178, 3 g; 16.1 mmol) and anhydrous CuCl₂(3.25 g; 24.2 mmol; 1.5 equiv.) were combined in dry acetonitrile (28 ml). t-butyl nitrite (90% tech; 2.77 g; 24.2 mmol; 1.5 equiv.) was added dropwise. The suspension was stirred at room temperature for 12 hours and monitored by LC/MS. The acetonitrile was removed in vacuo and the solid was redissolved in CHCl₃and H₂O. The aqueous layer was acidified with 2N HCl and the phases were separated. Back extracted the aqueous with CHCl₃. The organic extracts were combined, dried over Na₂SO₄and decolorizing carbon for 1 hour. Filtered through a pad of Celite and concentrated to an oil. Isolation gave 2.62 g of the title compound in 80% yield. The compound can be further purified via flash column chromatography and crystallization. MS (ES) MH⁺: 206, 208 for C₇H₈ClNO₂S.

Intermediate 180
Ethyl 5-(bromomethyl)-2-chloro-1,3-thiazole-4-carboxylate

embedded image

Ethyl 2-chloro-5-methyl-1,3-thiazole-4-carboxylate (Intermediate 179, 2.8 g; 13.6 mmol) was dissolved in CCl₄(25 ml). NBS (2.3 g; 13 mmol) and AIBN (2.12 g; 13 mmol) were added in a single portion and the resultant reaction mixture was heated to reflux for 24 hours. Additional NBS (690 mg; 0.3 equiv.) and AIBN (636 mg; 0.3 mmol) were added to push the reaction to completion. Continued to heat for another 4 hours. Cooled to room temperature, filtered and concentrated the mother liquor. Redissolved in minimal DMSO (7 ml) and purified by Gilson HPLC (5-95% ACN/0.1% TFA; run time=35 min). Isolated 1.15 g of desired product in 29% yield MS (ES) MH⁺: 284, 286, 288 for C₇H₇BrClNO₂S.

Intermediate 181
Ethyl 2-chloro-5-formyl-1,3-thiazole-4-carboxylate

Ethyl 5-(bromomethyl)-2-chloro-1,3-thiazole-4-carboxylate (Intermediate 180, 920 mg; 3.2 mmol) was dissolved in acetonitrile dried over molecular sieves. The solution was cooled to 0 C and NMO (570 mg; 1.5 equiv.) was added in a single portion. The reaction was monitored by LC/MS. An additional 1.5 equivalents of NMO was added in two portions over two hours. The reaction was concentrated to a solid residue, redissolved in EtOAc and washed with H₂O. Dried the organic over Na₂SO₄, filtered and concentrated. No further purification. MS (ES) MH⁺: 220,222 for C₇H₆ClNO₃S.

Intermediate 182
tert-Butyl 3-bromo-4-oxopiperidine-1-carboxylate

Chlorotrimethylsilane (5.6 ml, 44 mmol) was added slowly to a solution of tert-butyl 4-oxopiperidine-1-carboxylate (commercial, 8 g, 40 mmol), triethylamine (12.3 ml, 88 mmol) and DMF (40 ml) at room temperature. The resultant solution was heated to 75° C. and stirred overnight under nitrogen. The reaction mixture was cooled to room temperature and then in an ice bath. Cold hexane (250 ml) was added slowly to the reaction mixture followed by cold (saturated) aqueous sodium bicarbonate (50 ml). The organic phase was separated and washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude silyl enolether was dissolved in THF (15 ml) and cooled to 0° C. N-Bromosuccinimide (7.1 g, 40 mmol) was dissolved in THF (120 ml) and added slowly (45 min.) to the reaction mixture. The resultant mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography (hexanes/ethyl acetate, 5:1) to provide the title compound as a white solid (11 g).

MS (ESP): 222.1 (M-tBu) for C₁₀H₁₆BrNO₃

¹H NMR (300 MHz, DMSO-d₆) δ: 1.25 (s, 9H); 2.30 (m, 1H); 2.55 (m, 1H); 3.42-3.80 (m, 3H); 3.93 (m, 1H); 4.60 (m, 1H).

Intermediate 183
tert-Butyl 3-(methylthio)-4-oxopiperidine-1-carboxylate

Sodium thiomethoxide (805 mg, 11.5 mmol) was added to a solution of tert-butyl 3-bromo-4-oxopiperidine-1-carboxylate (Intermediate 182, 3.20 g, 11.5 mmol) and THF (15 ml) at 0° C. The resultant mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction was quenched with water (15 ml) and diluted with ethyl acetate (150 ml). The organic phase was separated and washed with brine. The combined aqueous phase was back extracted with ethyl acetate (50 ml). The combined organic layer was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (hexanes/ethyl acetate, 7:1) to provide the title compound (2.4 g).

MS (ESP): 190.2 (M-tBu) for C₁₁H₁₉NO₃S

¹H NMR (300 MHz, CDCl₃) δ: 1.43 (s, 9H); 2.02 (s, 3H); 2.23 (dt, 1H); 2.95 (m, 1H); 3.20-3.40 (m, 2H); 3.65 (m, 1H); 3.90-4.20 (m, 2H).

Intermediate 184
Cis(±)-tert-butyl-4-amino-3-(methylthio)piperidine-1-carboxylate

Sodium cyanoborohydride (344 mg, 5.48 mmol) was added to a solution of tert-butyl 3-(methylthio)-4-oxopiperidine-1-carboxylate (Intermediate 183, 1.07 g, 4.40 mmol), ammonium acetate (3.24 g, 42 mmol) and methanol (15 ml). The resultant mixture was stirred for 4 h. The reaction was quenched by addition of 1N HCl (3 ml). Aqueous sodium bicarbonate (saturated, 50 ml) was added slowly to the reaction mixture followed by extraction with ethyl acetate (3×75 ml). The combined organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to yield the crude amine.

MS (ESP): 247.3 (M+H) for C₁₁H₂₂N₂O₂S.

Intermediate 185
Trans(±)tert-butyl 4-amino-3-hydroxypiperidine-1-carboxylate

embedded image

The title compound was prepared as described in Marquis R. W. et al. J. Med. Chem. 1998, 41,3563-3567 and/or WO 9805336. MS (ES) MH⁺: 217 for C₁₀H₂₀N₂O₃; NMR: 1.45 (s, 9H), 1.80 (m, 1H), 1.95 (m, 1H), 2.21 (m, 1H), 2.62 (m, 1H), 2.75 (m, 1H), 3.28 (m, 1H), 3.47 (m, 1H), 3.81 (m, 1H), 4.11 (m, 1H), 4.28 (m, 1H), 8.20 (m, 1H)

Intermediate 186
Ethyl 3-chloro-5-methyl-1H-pyrrole-2-carboxylate

The compound was prepared by the procedure described for Intermediate 2.

MS (ESP): 188 (MH⁺) for C₈H₁₀ClNO₂

¹H-NMR (CDCl₃) δ: 1.37 (t, 3H); 2.26 (s, 3H); 4.32 (q, 2H); 5.96 (s, 1H); 8.81 (br, 1H).

Intermediate 187
Ethyl 4-bromo-5-methyl-1H-pyrrole-2-carboxylate

The compound was prepared by the procedure described for Intermediate 2.

MS (ESP): 234 (MH⁺) for C₈H₁₀BrNO₂

¹H-NMR δ: 1.27 (t, 3H); 2.17 (s, 3H); 4.22 (q, 2H); 6.74 (s, 1H); 12.10 (s, br, 1H).

Intermediate 188
4 Ethyl 4-bromo-3-chloro-5-methyl-1H-pyrrole-2-carboxylate

Ethyl 4-bromo-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 187, 2.87 g, 12.4 mmol) was dissolved in dry DMF (30 ml), N-chlorosuccinimide (1.66 g, 12.4 mmol) was added and resulting mixture was stirred at room temperature over night, more N-chlorosuccinimide (0.83 g, 6.2 mmol) was added and the reaction temperature was increased to 35° C., stirred for 4 hours. The mixture was poured into cold sodium hydroxide aqueous solution (2M) (50 ml), extracted with diethyl ether (2×50 ml). The organic phase was then washed with water (20 ml) and brine (20 ml), dried over anhydrous sodium sulfate and purified by column chromatography(hexanes/ethyl acetate, gradient) to give the desired product as a white crystal. (1.2 g).

MS (ESP): 268 (MH⁺) for C₈H₉BrClNO₂

¹H-NMR (CDCl₃) δ: 1.38 (t, 3H); 2.30 (s, 3H); 4.34 (q, 2H); 9.0 (br, 1H)

Intermediate 189
ethyl 4-chloro-3,5-dimethyl-1H-pyrrole-2-carboxylate

N-Chlorosuccinimide (1.77 g, 13.25 mmol) was added to a solution of ethyl 3,5-dimethyl-2-pyrrole carboxylate (2.11 g, 12.62 mmol) in chloroform (45 mL). The reaction mixture was stirred at room temperature for 24 h and then poured into 2 N NaOH. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a crude solid. The crude solid was dissolved in hot MeOH, cooled to room temperature, and the precipitate was collected by filtration (493 mg, 19%). MS (ES) MH⁺: 174 for C₉H₁₂ClNO₂.

Intermediate 190
ethyl 4-chloro-3-[(E)-(methoxyimino)methyl]-5-methyl-1H-pyrrole-2-carboxylate

embedded image

A solution of Intermediate 191 (300 mg, 1.39 mmol) in MeOH (5 mL) and pyridine (1.5 mL) with methylamine hydrochloride (255 mg, 3.06 mmol) was heated to 60° C. overnight. The reaction was cooled to room temperature and then partitioned between methylene chloride and 10% HCl. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give an off-white solid.

MS (ES) MH⁺: 245 for C₁₀H₁₃ClN₂O₃;

NMR (DMSO-d₆): 1.29 (t, 3H), 2.36 (s, 3H), 3.83 (s, 3H), 4.27 (q, 2H), 8.03 (s, 1H), 12.31 (s, 1H).

Intermediate 191
ethyl 4-chloro-3-formyl-5-methyl-1H-pyrrole-2-carboxylate

POCl₃in 1,2-dichloroethane (14 mL) was slowly added to a solution of DMF (4.37 mL, 59.79 mmol) in 1,2-dichloroethane (10 mL). The reaction mixture was stirred for 15 min and then Intermediate 7 (2.04 g, 10.87 mmol) was added. The reaction mixture was heated at reflux for 3 h and then cooled to room temperature. The reaction mixture was treated with sodium acetate (10 g) in water (25 mL) and stirred for 1 h. The mixture was extracted with methylene chloride, washed with water, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 2:1 hexanes/ethyl acetate) gave the desired compound (720 mg).

MS (ES) MH⁺: 216 for C₉H₁₀ClNO₃.

Intermediate 192
ethyl 3-bromo-4-chloro-5-methyl-1H-pyrrole-2-carboxylate

Bromine (0.56 ml, 11 mmol) was added to a solution of 1 g (5.3 mmol) of ethyl 4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 7) and 0.8 ml (5.7 mmol) Et₃N in CH₂Cl₂. After stirring at room temperature for 2 h, aqueous NaHSO₃was added and the CH₂Cl₂was removed and the aqueous residue was partitioned between water and EtOAc. The EtOAc was separated and washed with brine. Drying (MgSO₄) and removal of solvent gave 1.5 g of product as a solid. MS (ES) (MH⁺): 240 for C₈H₉BrClNO₂; NMR (d₆-DMSO): 1.3 (t, 3H), 2.2 (s, 3H), 4.2 (q, 2H), 12.3 (s, 1H).

Intermediate 193
ethyl 4-chloro-3-cyano-5-methyl-1H-pyrrole-2-carboxylate

Nitrogen gas was bubbled through a mixture of 1.4 g (5.25 mmol) of ethyl 3-bromo-4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 192), 470 g (4 mol) Zn(CN)₂, 250 mg (0.26 mmol) Pd₂(dba)₃and 302 mg (0.26 mmol) dppf in 15 ml DMF for 15 min. The mixture was heated at 130° C. for 1 h. Additional Zn(CN)₂(1 g), Pd₂(dba)₃(500 mg) and dppf (604 mg) were added. After bubbling through N₂for 15 min and heating at 130° C. for 2 h, additional Zn(CN)₂(0.5 g), Pd₂(dba)₃(250 mg) and dppf (302 mg) were added. Heating was continued at 130° C. for 2 h. Solvent was removed and the residue was partitioned between EtOAc and water. The EtOAc was separated and washed with brine. Combined aqueous layers were extracted again with EtOAc, which was washed with brine. Combined EtOAc extracts were dried (MgSO₄) and concentrated. The residue was purified by silica gel chromatography (100% CH₂Cl₂followed by gradient elution to 5% MeOH in CH₂Cl₂) to afford 750 mg of product as a solid. MS (ES) (MH⁺): 213 for C₉H₉ClN₂O₂; NMR (d₆-DMSO): 1.3 (t, 3H), 2.2 (s, 3H), 4.3 (q, 2H), 13.1 (s, 1H).

Intermediate 194
ethyl 3,5-dichloro-4-methyl-1H-pyrrole-2-carboxylate

Et₃N (5.5 ml, 39 mmol) was added slowly to a solution of 2.0 g (13 mmol) of ethyl 4-methyl-1H-pyrrole-2-carboxylate and 3.1 ml SO₂Cl₂in 30 ml CH₂Cl₂cooled in an ice water bath. The mixture was warmed to room temperature with stirring overnight. After treatment with aqueous NaHSO₃, the CH₂Cl₂was removed and the aqueous residue was diluted with water and extracted twice with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO₄) and concentrated. The solid residue was twice recrystallized from 50% aqueous EtOH to afford 1.38 g of product as a white solid. MS (ES) (M−H⁻): 222 for C₈H₉Cl₂NO₂; NMR (d₆-DMSO): 1.3 (t, 3H), 1.9 (s, 3H), 4.25 (q, 2H), 12.8 (s, 1H).

Intermediate 195
4-chloro-3,5-dimethyl-1H-pyrrole-2-carboxylic acid

embedded image

Prepared using the procedure described for Intermediate 1 using Intermediate 189 as the starting material.

MS (ES) MH⁺: 174 for C₇H₈ClNO₂

Intermediate 196
3-chloro-5-methyl-1H-pyrrole-2-carboxylic acid

Prepared using the procedure described for Intermediate 1 using Intermediate 186 as the starting material.

MS (ESP): 160 (MH⁺) for C₆H₆ClNO₂

¹H-NMR (CDCl₃) δ: 2.29 (s, 3H); 6.02 (s, 1H); 8.83 (br, 1H).

Intermediate 197
4-bromo-5-methyl-1H-pyrrole-2-carboxylic acid

Prepared by the procedure described for Intermediate 1 using Intermediate 187 as the starting material.

MS (ESP): 206 (MH⁺) for C₆H₆BrNO₂

NMR (CDCl₃) δ: 2.31 (s, 3H); 6.97 (s, 1H); 9.08 (s, br, 1H).

Intermediate 198
4-bromo-3-chloro-5-methyl-1H-pyrrole-2-carboxylic acid

Prepared using the procedure described for Intermediate 1 and Intermediate 188. MS (ESP): 240 (MH⁺) for C₆H₅BrClNO₂

Intermediate 199
4-chloro-3-[(E)-(methoxyimino)methyl]-5-methyl-1H-pyrrole-2-carboxylic acid

Synthesized as described for Intermediate 1 from Intermediate 190.

MS (ES) MH⁺: 217 for C₉H₉ClN₂O₃.

Intermediate 200
4-chloro-3-cyano-5-methyl-1H-pyrrole-2-carboxylic acid

embedded image

A solution of 670 mg (3.2 mmol) of ethyl 4-chloro-3-cyano-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 193) and 3.2 ml (3.2 mmol) 1N NaOH in 20 ml MeOH was heated at 100° C. in a microwave reactor for 2 h. The mixture was diluted with water and extracted with EtOAc. The EtOAc was washed with 1N NaOH. The combined aqueous layers were acidified with concentrated HCl and extracted 2 times with EtOAc, each extract being washed with brine. Drying (MgSO₄) and removal of solvent gave 535 mg of product as a solid. MS (ES) (M−H⁻): 183 for C₇H₅ClN₂O₂; NMR (d₆-DMSO): 2.2 (s, 3H), 12.9 (s, 1H), 13.3 (s, 1H).

Intermediate 201
3,5-dichloro-4-methyl-1H-pyrrole-2-carboxylic acid

A solution of 1.1 gm (4.95 mmol) of ethyl 3,5-dichloro-4-methyl-1H-pyrrole-2-carboxylate (Intermediate 194) and 1.7 g (9.9 mmol) of Ba(OH)₂in 50 ml 1:1 EtOH—H₂O was heated at 85° C. for 9 h. The mixture was diluted with water, acidified with 20 ml 1N HCl and extracted 3 times with ether. The ether was washed with water, dried (MgSO₄) and concentrated to give 1.0 g of product as a solid. MS (ES) (M−H⁻): 194 for C₆H₅Cl₂NO₂; NMR (d₆-DMSO): 1.9 (s, 3H), 12.7 (s, 1H), 12.8 (s, 1H).

Intermediate 202
3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride

A solution of 10.4 g (54 mmol) of 3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (Intermediate 1) in 100 ml SOCl₂was heated at reflux for 30 min. Solvent was removed to afford product. NMR (CDCl₃): 2.3 (s, 1H), 8.8 (s, 1H).

Intermediate 203
2,2,2-trichloro-1-(4,5-dichloro-1H-pyrrol-2-yl)ethanone

To a solution of 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethanone (1.00 g, 47.06 mmol) in dichloromethane (8 mL), sulfuryl chloride (1.60 mL, 0.188 mol) was added slowly at room temperature. The reaction was stirred overnight and quenched with water and extracted with dichloromethane. The extract was washed with saturated sodium bicarbonate, water and brine. Then it was dried over magnesium sulfate and concentrated to give the desired product as a white solid (0.90 g).

MS (ES) M⁻: 279 for C₆H₂Cl₅O

Intermediate 204
ethyl 2-bromo[1,3]thiazolo[4,5-b]pyridine-7-carboxylate

To a 0° C. mixture of CuBr₂(229 mg, 1.02 mmol) in acetonitrile (3 mL) was slowly added t-Butyl nitrite (0.15 mL, 1.28 mmol). The reaction mixture was stirred for 15 min and then added Intermediate 205 (250 mg, 0.85 mmol). The reaction mixture was stirred for 2 h, partitioned between diethyl ether and water, and filtered through diatomaceous earth. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:1 hexanes/ethyl acetate) gave the desired product (38 mg, 16%).

MS (ES) MH⁺: 174 for C₉H₇BrN₂O₂S.

Intermediate 205
ethyl 2-amino[1,3]thiazolo[4,5-b]pyridine-7-carboxylate

To a solution of Intermediate 206 (944 mg, 4.20 mmol) in acetic acid (12 mL) was added benzyltrimethyl ammonium tribromide (1.67 g, 4.28 mmol). The reaction mixture was stirred at room temperature for 2 h and the solid that formed was collected by filtration to provide the desired compound as the acetic acid salt (1.20 g).

MS (ES) MH⁺: 224 for C₉H₉N₃O₂5.

Intermediate 206
ethyl 2-[(aminocarbonothioyl)amino]isonicotinate

A solution of Intermediate 207 (2.10 g, 6.38 mmol) in ethanol (20 mL) and potassium carbonate (882 mg, 6.38 mmol) was heated to 80° C. for 2 h. The reaction mixture was cooled to room temperature and the solid that formed was collected by filtration to give the desired compound.

MS (ES) MH⁺: 226 for C₉H₁₁N₃O₂S;

NMR (DMSO-d₆): 1.17 (t, 3H), 4.18 (q, 2H), 7.29 (m, 1H), 7.59 (s, 1H), 8.25 (m, 1H), 8.87 (s, 1H), 10.24 (s, 1H), 10.63 (s, 1H).

Intermediate 207
ethyl 2-{[(benzoylamino)carbonothioyl]amino}isonicotinate

To a 0° C. solution of benzyl isothiocyanate (1.25 mL, 9.27 mmol) in acetone (15 mL) was slowly added ethyl 2-aminoisonicotinate (1.4 g, 8.43 mmol). The reaction mixture was stirred for 1 h and then poured onto ice. The solid that formed was collected by filtration and washed with water to give the desired product (2.10 g).

MS (ES) MH⁺: 330 for C₁₆H₁₅N₃O₃S.

Intermediate 208
2-chloro-5-nitroisonicotinic acid

A solution of 13.7 g (46 mmol) of Na₂Cr₂O₃in 100 ml concentrated H₂SO₄was added slowly to a solution of 3.0 g (17.4 mmol) of 2-chloro-4-methyl-5-nitropyridine dissolved in 100 ml concentrated H₂SO₄while cooling in ice water. Allowed to warm to room temperature and stir overnight. The solution was poured onto 600 ml ice and extracted twice with EtOAc, each extract being washed with brine. The combined organic extracts were dried (MgSO₄) and concentrated to afford product as a gummy oil. MS (ES) MH⁺: 203 for C₆H₃ClN₂O₄.

Intermediate 209
ethyl 2-amino-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate

A solution of 5.0 g (37 mmol) of 3-chlorofuran-2,4(3H,5H)-dione and 3.3 g (43 mmol) of thiourea in 50 ml EtOH was heated at reflux for 4 h. Solvent was removed and the residue was dissolved in water with 1N HCl added. The aqueous solution was basified with aqueous Na₂CO₃. Thick solids that formed were filtered, rinsed with water and dried in vacuo. NMR: 1.2 (t, 3H), 4.2 (q, 2H), 4.6 (s, 2H), 4.9 (s, broad, 1H), 7.8 (s, 2H).

Intermediate 210
ethyl 2-amino-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1,3-thiazole-5-carboxylate

embedded image

To a solution of 2.0 g (9.8 mmol) of ethyl 2-amino-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate (Intermediate 209) and 1.3 g (19.4 mmol) of imidazole in 20 ml DMF was added 1.6 g (10.6 mmol) of t-butyldimethylsilyl chloride. After stirring for 2 h, solvent was removed and the residue was taken up in water. Insoluble solids were collected, ground up, washed with water and dried in vacuo to afford 2.95 g of product. MS (ES) (MH⁺): 317 for C₁₃H₂₄N₂O₃SSi; NMR (d₆-DMSO): 0.03 (s, 6H), 0.86 (s, 9H), 1.2 (t, 3H), 4.1 (q, 2H), 4.8 (s, 2H), 7.8 (s, 2H).

Intermediate 211
ethyl 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazole-5-carboxylate

t-Butylnitrite (1.8 ml (14 mmol) was added slowly to a mixture of 2.9 g (9.2 mmol) of ethyl 2-amino-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1,3-thiazole-5-carboxylate (Intermediate 210) and 1.95 g (14 mmol) CuCl₂in CH₃CN. After stirring at room temperature for 2 h, solvent was removed and the residue was taken up in EtOAc, which was washed 2 times with 1NHCl and once with brine. Drying (MgSO₄) and removal of solvent gave 2.95 g of product as an oil. NMR (CDCl₃): 0.1 (s, 6H), 0.9 (s, 9H), 1.35 (t, 3H), 4.3 (q, 2H), 5.0 (s, 2H).

Intermediates 212

The following Intermediates were synthesized by an analogous method to Intermediate 211 from the starting materials (SM) given in the table below

Int
Compound
Data
SM

212
ethyl 4-acetyl-2-
NMR (CDCl₃): 2.6 (s,
Intermediate

chloro-1,3-thiazole-
3H), 3.9 (s, 3H)
222

5-carboxylate

Intermediate 214
methyl 2-chloro-4-(1-hydroxy-1-methylethyl)-1,3-thiazole-5-carboxylate

A solution of 5.6 ml (11.2 mmol) 2N AlMe₃in toluene was added to a dry ice-acetone bath of 1.14 g (5.2 mol) of methyl 4-acetyl-2-chloro-1,3-thiazole-5-carboxylate (Intermediate 212) in 20 ml dry CH₂Cl₂. The mixture was allowed to warm to room temperature slowly before being quenched with MeOH. After stirring at room temperature overnight, the mixture was diluted with 1N HCl and stirred 15 min before being diluted with water and extracted twice with EtOAc. The EtOAc was washed with brine, dried (MgSO₄) and concentrated to give an oil that was purified by chromatography (50% hexanes in CH₂Cl₂with gradient elution to 100% CH₂Cl₂) affording 720 mg of product as an oil. NMR (CDCl₃): 1.5 (s, 6H), 3.8 (s, 3H), 5.7 (s, broad, 1H).

Intermediate 215
ethyl 2-chloro-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate

embedded image

A solution of 17.7 g (53 mmol) of ethyl 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazole-5-carboxylate (Intermediate 211) and 53 ml (53 mmol) of 1N HCl in dioxane was stirred at room temperature for 1 h. The mixture was extracted 3 times with EtOAc, which was dried (MgSO₄) and concentrated to give 11.3 g of an orange oil. Purification by silica gel chromatography affords a solid. NMR (CDCl₃): 1.2 (t, 3H), 3.1 (s, broad, 1H), 4.2 (q, 2H), 4.8 (s, 2H).

Intermediate 216
4-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazol-5-yl]carbonyl}morpholine

A solution of 2N Me₃Al in hexanes (0.91 ml, 1.82 mmol) was added slowly to a solution of 0.16 ml (1.8 mmol) of morpholine in 4 ml CH₂Cl₂. After stirring for 15 min, a solution of 0.5 g (1.5 mmol) of ethyl 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazole-5-carboxylate (Intermediate 218) in 4 ml CH₂Cl₂was added. The solution was heated at 80° C. in a microwave reactor for 1 hour before pouring into dilute aqueous HCl. The mixture was extracted 3 times with CH₂Cl₂, which was washed with brine, dried (MgSO₄) and concentrated. The residue was purified by silica gel chromatography (100% CH₂Cl₂followed by gradient elution to 30% EtOAc in CH₂Cl₂to give 315 mg of product. MS (ES) (MH⁺): 377 for C₁₅H₂₅ClN₂O₃SSi; NMR (d₆-DMSO): 0.1 (s, 6H), 0.9 (s, 9H), 3.6 (m, 4H), 3.7 (m, 4H), 4.1 (q, 2H), 4.75 (s, 2H).

The following Examples were synthesized by an analogous method to Intermediate 216 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

217
4-({[tert-
NMR (d₆-DMSO): 0.04
Intermediate

butyl(dimethyl)silyl]oxy}methyl)-
(s, 6H), 0.8 (s, 9H), 1.6 (s,
211 and

2-chloro-N-(1-methyl-1-
6H), 4.9 (s, 2H), 7.2 (7,
cumylamine

phenylethyl)-1,3-miazole-5-
1H), 7.3 (t, 2H), 7.4 (d,

carboxamide
2H), 8.6 (s, 1H).

Intermediate 218
2-chloro-5-(morpholin-4-ylcarbonyl)-1,3-thiazole-4-carboxylic acid

A solution of 173 mg (1.7 mmol) CrO₃in 1 ml of 4:1 water/H₂SO₄was added to as solution of 310 mg (0.82 mmol) of 4-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazol-5-yl]carbonyl}morpholine (Intermediate 216) in 3 ml acetone cooled in an ice water bath. The mixture was stirred with warming room temperature over 90 min. A few drops of isopropanol were added, and the mixture was diluted with water and extracted 2 times with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO₄) and concentrated to give 190 mg of a white solid. MS (ES) (MH⁺): 277 for C₉H₉ClN₂O₄S; NMR (d₆-DMSO): 3.3 (m, 4H), 3.6 (m, 4H), 13.7 (s, 1H).

The following Examples were synthesized by an analogous method to Intermediate 218 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

219
2-chloro-5-{[(1-
MS (ES) (M − H⁻): 323 for
Intermediate

methyl-1-
C₁₄H₁₃ClN₂O₂S
217

phenylethyl)amino]

carbonyl}-1,3-

thiazole-4-

carboxylic acid

Intermediate 220
ethyl 5-(aminocarbonyl)-2-chloro-1,3-thiazole-4-carboxylate

embedded image

A solution of 210 mg of ethyl 2-chloro-5-{[(1-methyl-1-phenylethyl)amino]carbonyl}-1,3-thiazole-4-carboxylate (Intermediate 233) in 5 ml TFA was stirred at room temperature overnight. Solvent was removed and the residue was dissolved in 5 ml MeOH. Solvent was again removed and the residue was triturated with ether to give 57 mg of a white solid. NMR (d₆-DMSO): 1.3 (t, 3H), 4.3 (q, 2H), 8.2 (s, 1H), 8.8 (s, 1H).

Intermediate 221
methyl 2-chloro-4,4-dimethoxy-3-oxopentanoate

SO₂Cl₂(2.2 ml, 27 mmol) was added slowly to a solution of 5.0 g (26 mmol) of methyl 4,4-dimethoxy-3-oxopentanoate in 30 ml CH₂Cl₂cooled in an ice water bath. The solution was warmed to room temperature and stirred for 1 h. Solvent was removed and the residue was taken up in EtOAc, which was washed with water and brine. Drying (MgSO₄) and removal of solvent gave 6.1 g of an oil. NMR: (CDCl₃): 1.5 (s, 3H), 3.25 (2s, 6H), 4.8 (s, 3H), 5.3 (s, 1H).

Intermediate 222
methyl 4-acetyl-2-amino-1,3-thiazole-5-carboxylate

A solution of 4.37 g (19 mmol) methyl 2-chloro-4,4-dimethoxy-3-oxopentanoate (Intermediate 221) and 1.8 g (24 mmol) thiourea in 50 ml EtOH was heated at reflux for 3 h. Solvent was removed and the residue was dissolved in 1:1 acetone-5N HCl and the solution was heated at reflux for 4 h. Acetone was removed and the aqueous residue was neutralized with 50% NaOH and then basified with aqueous Na₂CO₃. Precipitated solids were filtered, washed with water and dried in vacuo. NMR (d₆-DMSO): 2.4 (s, 3H), 3.7 (s, 3H), 8.0 (s, 2H).

Intermediate 223
isopropyl 4-chloropyridine-2-carboxylate 1-oxide

A solution of 2.55 g (14 mmol) of isopropyl 4-chloropyridine-2-carboxylate (Intermediate 232) and 1.4 g (26 mmol) of m-CPBA in 30 ml CH₂Cl₂was stirred at room temperature for 2 d. The mixture was quenched with aqueous NaHSO₃and CH₂Cl₂was removed. The aqueous residue was basified with aqueous Na₂CO₃, saturated with NaCl and extracted repeatedly with EtOAc. The EtOAc was dried (MgSO₄) and concentrated. The residue was taken up in ether and insoluble material was filtered off. The filtrate was concentrated and the residue was chromatographed on silica gel (100% CH₂Cl₂with gradient elution to 100% EtOAc) to afford 2.1 g of product as an oil. NMR (d₆-DMSO): 1.3 (d, 6H), 5.3 (septet, 1H), 7.25 (m, 1H), 7.5 (d, 1H), 8.1 (d, 1H).

Intermediate 224
isopropyl 4-chloro-6-cyanopyridine-2-carboxylate

A solution of 200 mg (0.86 mmol) of isopropyl 4-chloropyridine-2-carboxylate 1-oxide (Intermediate 223), 0.14 ml (1 mmol) Et₃N and 0.36 ml (2.7 mmol) of trimethylsilylcyanide in 3 ml CH₃CN was heated at 90° C. overnight. The solution was diluted with EtOAc and washed with water and brine. Drying (MgSO₄) and removal of solvent gave an oil that was purified by chromatography on silica gel (100% CH₂Cl₂followed by gradient elution to 10% EtOAc in CH₂Cl₂) to afford 130 mg of product as a white solid. MS (ES) (MH⁺): 224 for C₁₉H₉ClN₂O₂; NMR (d₆-DMSO): 1.35 (d, 6H), 5.2 (septet, 1H), 8.4 (s, 1H), 8.6 (s, 1H).

Intermediate 225
ethyl 2-chloro-5-formylisonicotinate

embedded image

A solution of 51 ml (128 mmol) of 2.5 N n-butyllithium in hexanes was added slowly to a THF solution of 16 ml (95 mmol) of tetramethylpiperidine cooled in a dry ice-acetone bath. The solution was warmed to −30° C. and cooled to −60° C. before 5.0 g (32 mmol) of 6-chloronicotinic acid was added portion wise. The mixture was warmed to −25° C. and stirred for 30 min. It was then cooled to −70° C. and 10 ml (129 mmol) DMF was added quickly. After quenching with 1N HCl, the solution was warmed to room temperature. The pH was brought to about 4 with additional 1N HCl and the solution was continuously extracted with EtOAc overnight. The EtOAc was dried (MgSO₄) and concentrated. The residue was dissolved in 100 ml EtOH and 2 ml concentrated H₂SO₄was added. The solution was heated at reflux for 24 h. The mixture was brought to about pH=4 with 50% NaOH and was extracted twice with ether. The ether was dried (MgSO₄) and concentrated to gave an oil that was chromatographed on silica gel (50% hexanes in CH₂Cl₂with gradient elution to 100% CH₂Cl₂) to afford 1 g of product as an oil that slowly solidified. NMR (CDCl₃): 1.4 (t, 3H), 4.5 (q, 2H), 7.7 (s, 1H), 9.1 (s, 1H), 10.7 (s, 1H).

Intermediate 226
ethyl 2-chloro-5-nitroisonicotinate

A mixture of 2-chloro-5-nitroisonicotinic acid (Intermediate 208) and 16 ml triethylorthoacetate in 100 ml toluene was heated at reflux for 2 h. The mixture as stirred with 1N HCl for 30 min before being partitioned between EtOAc and water. The EtOAc was separated, washed with water and brine, dried (MgSO₄) and concentrated. Chromatographed on silica gel (100% hexanes with gradient elution to 100% CH₂Cl₂to give product as an oil. MS (ES) (MH⁺): 231 for C₈H₇ClN₂O₄; NMR (d₆-DMSO): 1.3 (t, 3H), 4.4 (m, 2H), 8.1 (s, 1H), 9.2 (s, 1H).

Intermediates 227-233

The following compounds were prepared in a manner analogous to Intermediate 226 from the starting material (SM) indicated.

Int
Compound
Data
SM

227
isopropyl 2-chloro-6-
MS (ES) (MH⁺): 214
2-chloro-6-methylisonicotinate and

methylisonicotinate
for C₁₀H₁₂ClNO₂;
trisopropylorthoformate

NMR (d₆-DMSO): 1.3

(d, 6H), 2.55 (s, 3H),

5.2 (septet, 1H), 7.65

(s, 1H), 7.7 (s, 1H)

228
isopropyl 4-
NMR (CDCl₃): 1.35 (d,
4-chloropyridine-2-carboxylate and

chloropyridine-2-
6H), 5.3 (septet, 1H),
trisopropylorthoformate

carboxylate
7.4 (dd, 1H), 8.05 (d,

1H), 8.6 (d, 1H)

229
isopropyl 4,5-
NMR (CDCl₃): 1.35 (d,
4,5-dichloropyridine-2-

dichloropyridine-2-
6H), 5.3 (septet, 1H),
carboxylate (Graf, R. J.fuer

carboxylate
8.1 (s, 1H), 8.7 (s, 1H)

Prakt.
Chem. (Leipzig) (1932),

133 36-50) and

trisopropylorthoformate

230
isopropyl 2- fluoroisonicotinate embedded image

NMR (CDCl₃): 1.4 (d, 6H), 5.3 (septet, 3H), 7.5 (m, 1H), 7.7 (m, 1H), 8.35 (d, 1H)
2-fluoroisonicotinic acid and trisopropylorthoformate

231
ethyl 2-chloro-5-
NMR: 1.3 (t, 3H), 3.3
Intermediate 218 and

(morpholin-4-
(m, 2H), 3.5 (m, 2H),
triethylorthoacetate

ylcarbonyl)-1,3-thiazole-
3.6 (m, 2H), 3.65 (m

4-carboxylate
2H), 4.3 (q, 2H)

232
isopropyl 4-
NMR (CDCl₃): 1.35 (d,
4-chloropyridine-2-carboxylic

chloropyridine-2-
6H), 5.3 (septet, 1H),
acid and

carboxylate
7.4 (dd, 1H), 8.05 (d,
trisopropylorthoformate

1H), 8.6 (d, 1H)

233
ethyl 2-chloro-5-{[(1-
MS (ES) (MH+⁻): 353
Intermediate 219 and

methyl-1-
for C₁₆H₁₇ClN₂O₂S
triethylorthoacetate

phenylethyl)amino]

carbonyl}-1,3-thiazole-4-

carboxylate

Intermediate 234
1,3-thiazol-2-ylmethanol

To a stirred solution of commercially available 1,3-thiazole-2-carbaldehyde (5.36 g, 47 mmol) in dry methanol (100 mL), at 0° C. and under an atmosphere of N₂, was added sodium borohydride (2.15 g, 57 mmol) as a solid over approximately 20 minutes. The reaction was stirred for an hour at ambient temperature, under an atmosphere of N₂. Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Rf˜0.23). The reaction was concentrated under vacuum. To the residue was added 15 mL of an aqueous solution of ammonium chloride, and 15 mL of an aqueous solution of sodium chloride; from this mixture was extracted the crude product with ethyl acetate (4×50 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification.

MS (ES) MH⁺: 116 for C₄H₅NOS. ¹H NMR (DMSO): 4.72 (d, 2H), 6.03 (t, 1H), 7.61 (d, 1H), 7.71 (d, 1H).

Intermediate 235
2-(bromomethyl)-1,3-thiazole

embedded image

This compound was synthesized from Intermediate 234 above, using the procedure described in Tetrahedron 61 (2005), p. 137. The crude material was purified by column chromatography (silica gel, 15% ethyl acetate in hexanes). A pale orange liquid (57% yield) was obtained; this material decomposed rapidly, and was used immediately in the next step. MS (ES) MH⁺: 179 for C₄H₄BrNS. ¹H NMR (CDCl₃): 4.75 (s, 2H), 7.37 (d, 1H), 7.74 (d, 1H).

Intermediate 236
Ethyl 2-chloro-4-methyl-1,3-thiazole-5-carboxylate

Syntheisized according to the procedure described for Intermediate 17. MS (ES) MH⁺: 206, 208 for C₇H₈ClNO₂S; ¹H-NMR (300 MHz; DMSO-d₆) δ: 1.28 (t, 3H); 2.60 (s, 3H); 4.28 (q, 2H).

Intermediate 237
1-tert-butyl 3-methyl 4-hydroxy-5,6-dihydropyridine-1,3(2H)-dicarboxylate

Methyl 4-oxopiperidine-3-carboxylate hydrochloride (13.0 g) was suspended in anhydrous DCM (100 mL) under an argon atmosphere. DIEA (29.2 mL) was added slowly via syringe, producing a slightly cloudy solution. The reaction was cooled to 0° C., and di-tert-butyl dicarboxylate (16.1 g) was added, resulting in an exothermic reaction. The reaction mixture was left stirring overnight, slowly warming to room temperature. The reaction mixture was then concentrated in vacuo and partitioned between EtOAc (500 mL) and saturated aqueous NH₄Cl (350 mL). The EtOAc layer was washed with brine (125 mL), dried over anhydrous MgSO₄and concentrated in vacuo, producing a yellow oil. The product was purified by silica gel chromatography (1-25% EtOAc in hexanes), producing the title compound as a clear, colourless oil (14.7 g, 85.1%). MS (ES)[(M−H)⁻]: 256 for C₁₂H₁₉NO₅; NMR (CDCl₃): 1.46 (s, 9H), 2.36 (t, 2H), 3.55 (t, 2H), 3.76 (s, 3H) 4.04 (s, 2H), 11.97 (s, 1H).

Intermediate 238
Ethyl 4-azido-3-hydroxypiperidine-1-carboxylate

Ethyl 4-bromo-3-hydroxypiperidine-1-carboxylate (Preparation: Izamanishi, T. et al; 1982, Chem. Pharm. Bull., 30: 3617-3623) (5.1 g) was dissolved in anhydrous DMF (20 mL) under an argon atmosphere, followed by the addition of 18-crown-6 (0.27 g) and sodium azide (2.89 g). The reaction was heated at 90° C. for twenty-three hours, then stirred overnight, slowly cooling to room temperature. The reaction was then added to deionised water (150 mL) to quench it, saturated with solid sodium chloride, and extracted with EtOAc (2×200 mL). The combined EtOAc layers were washed with brine (100 mL), dried over anhydrous MgSO₄and concentrated in vacuo, yielding the title compound (4.3 g, 100%). MS (GC-EI)[(M-N₂)⁺]: 186 for C₈H₁₄BrN₄O₃.

Intermediate 239
Ethyl 4-azido-3-(2-tert-butoxy-2-oxoethoxy)piperidine-1-carboxylate

Ethyl 4-azido-3-hydroxypiperidine-1-carboxylate (Intermediate 238, 1.71 g) was dissolved in anhydrous THF (15 mL) and cooled to 0° C. Sodium hydride (60% in mineral oil) (0.42 g) was added as a shot, stirred for twenty minutes at 0° C., followed by the slow addition of tert-butyl bromo acetate (0.86 mL) via syringe, and stirred for an additional two hours at 0° C. The reaction was partitioned between EtOAc (250 mL) and saturated aqueous NaHCO₃(200 mL), and the aqueous layer was washed with EtOAc (200 mL). The combined EtOAc layers were washed with brine (50 mL), dried over anhydrous MgSO₄and concentrated in vacuo, yielding the title compound as a crude product (1.78 g, 103%). MS (GC-EI)[(M-N₂)⁺]: 300 for C₁₄H₂₄N₄O₅.

Intermediate 240
Ethyl 4-amino-3-(2-tert-butoxy-2-oxoethoxy)piperidine-1-carboxylate

embedded image

Ethyl 4-azido-3-(2-tert-butoxy-2-oxoethoxy)piperidine-1-carboxylate (Intermediate 239, 1.75 g) was dissolved in THF (60 mL), followed by the addition of deionised water (5 mL) and PS-triphenylphosphine resin (10.6 g), and stirred at room temperature over the week-end. The reaction mixture was filtered, and the resin was rinsed repeatedly with MeOH and a 1:5 MeOH:DCM mixture, and the filtrate was concentrated in vacuo, yielding the title compound (1.20 g, 75%). MS (GC-EI)[(M)⁺]: 302 for C₁₄H₂₆N₂O₅.

Intermediate 241
Ethyl 4-bromo-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate

Ethyl 4-bromo-3-hydroxypiperidine-1-carboxylate (Preparation: Izamanishi, T. et al; 1982, Chem. Pharm. Bull., 30: 3617-3623) (10.17 g) was dissolved in anhydrous DCM (100 mL) under an argon atmosphere and cooled to 0° C. tert-Butyldimethylsilyl trifluoromethylsulfonate (10.2 mL) was added dropwise via syringe, followed by 2,6-lutidine (4.7 mL), also added dropwise via syringe. The reaction was stirred overnight, slowly warming to room temperature, then diluted with DCM (200 mL) and washed with saturated aqueous NaHCO₃(150 mL), saturated aqueous NH₄Cl 4150 mL), brine (100 mL), dried over anhydrous MgSO₄and concentrated in vacuo, yielding the title compound as a crude product (15.1 g, 102%). MS (GC-EI)[(M-C₄H₇)⁺]: 310, 312 for C₁₄H₂₈BrNO₃Si; NMR (CDCl₃): 0.10 (s, 3H), 0.12 (s, 3H), 0.88 (s, 9H), 1.24 (t, 3H), 1.87 (m, 1H), 2.34 (m, 1H), 2.84-3.40 (m, 2H), 3.69 (m, 2H), 3.93 (m, 2H), 4.13 (q, 2H).

Intermediate 242
Ethyl 4-azido-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate

The title compound was prepared in a manner analogous to (Intermediate 238) starting with ethyl 4-bromo-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate (Intermediate 241). MS (GC-EI)[(M-N₂)⁺]: 300 for C_1-4H₂₈N₄O₃Si.

Intermediate 243
Ethyl 4-amino-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate

The title compound was prepared in a manner analogous to (Intermediate 240) starting with ethyl 4-azido-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate (Intermediate 242. MS (GC-EI)[(M)⁺]: 302 for C₁₄H₃₀N₂O₃Si.

Intermediate 244
3,4-dichloro-N-(3-hydroxypiperidin-4-yl)-5-methyl-1H-pyrrole-2-carboxamide

Ethyl 3-{[tert-butyl(dimethyl)silyl]oxy}-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-1-carboxylate (Intermediate 114, 0.805 g) was dissolved in a mixture of MeOH (10 mL) and 1,4-dioxane (15 mL), to which was added 1N NaOH (10 mL) and heated to reflux for twenty-four hours. An additional 5 mL of 1N NaOH was added, with 5 mL of 1,4-dioxane, and the reaction was heated for an additional forty-two hours, then cooled to 0° C. and acidified to ˜pH 9 with 2N HCl (6 mL). The cold mixture was filtered and washed with deionised water, yielding the title compound as a crude product. MS (ES) MH⁺: 292, 294 for C₁₁H₁₅Cl₂N₃O₂.

The following Intermediate was prepared by the procedure described in Intermediate 16 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

245
ethyl 4-{[(1-methyl-1- phenylethyl)amino]carbonyl}-2- (methylsulfonyl)-1,3-thiazole-5- carboxylate embedded image

MS (ES) MH⁺: 397 for C₁₇H₂₀N₂O₅S₂ NMR: 1.24-1.32 (m, 3 H) 1.66 (s, 6 H) 3.57 (s, 3 H) 4.36 (q, 2 H) 7.22 (t, 1 H) 7.34 (t, 2 H) 7.41-7.50 (m, 2 H) 8.91 (s, 1 H)
Intermediate 246

Intermediate 246
ethyl 4-{[(1-methyl-1-phenyl ethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylate

Diisopropylamine (5.3 ml) was dissolve in anhydrous THF (100 ml) was cooled to −78° C. and to this was added n-butyl lithium (15 ml) slowly. The solution was slowly warmed to 0° C. and then cooled back to −78° C. A solution of N-(1-methyl-1-phenylethyl)-2-(methylthio)-1,3-thiazole-4-carboxamide (Intermediate 13; 3.7 g) in anhydrous THF was added slowly maintaining the temperature below −70° C. After stirring for 30 min, a solution of ethyl cyano formate (2.5 ml) in anhydrous THF was added in one portion and the reaction was stirred at −78° C. for 30 min followed by slow warming to room temperature. The reaction mixture was diluted with water and extracted with ethyl acetate (×3), dried with MgSO₄and concentrated to a black oil (0.84 g) NMR: 1.22-1.29 (m, 3H) 1.63 (s, 6H) 2.76 (s, 3H) 4.28 (q, 2H) 7.20 (t, 1H) 7.32 (t, 2H) 7.46 (d, 2H) 8.75 (s, 1H)

Intermediate 247
diethyl 2-chloro-1,3-thiazole-4,5-dicarboxylate

To a solution of tert-butyl nitrite (3.4 mL, 28 mmol) and copper (II) chloride (3.7 g, 28 mmol) in acetonitrile (50 mL) was added diethyl 2-amino-1,3-thiazole-4,5-dicarboxylate (4.6 g, 19 mmol, Intermediate 248) all in one portion. Gas evolution was observed. After 45 min of stirring at room temperature LCMS indicated complete product formation. After concentrating to remove acetonitrile the residue was partitioned with chloroform and 1N HCl (Fisher), washed with chloroform, dried with MgSO₄and concentrated to an orange oil. Purification by flash column yielded a pale yellow oil (4.2 g, 85%). MS (ES): 264; NMR: 1.25-1.29 (t, 3H) 1.29-1.33 (t, 3H) 4.28-4.33 (q, 2H) 4.33-4.39 (q, 2H)

Intermediate 248
diethyl 2-amino-1,3-thiazole-4,5-dicarboxylate

A solution of thiourea (1.7 g, 22 mmol) and diethyl 2-chloro-3-oxosuccinate (5.0 g, 22 mmol) in absolute ethanol (50 mL) was heated at reflux for one hour. After cooling to room temperature the solvent was removed leaving a white solid. The solid was dissolved in water (100 mL) and the resulting precipitate was filtered and dried (4.6 g, 87%). MS (ES): 245; NMR: 1.21 (t, 3H) 1.26 (t, 3H) 4.16 (q, 2H) 4.26 (q, 2H) 8.04 (s, 2H)

Intermediate 249
isopropyl 4-chloro-6-(morpholin-4-ylcarbonyl)pyridine-2-carboxylate

n-butyllithium (1.92 mL, 2.5M in hexanes) was added dropwise to a −78° C. solution of morpholine (0.42 mL, 4.8 mmol) in anhydrous THF followed by slow warming to room temperature. The solution was transferred to an addition funnel via cannulation and then added dropwise to a solution of dimethyl 4-chloropyridine-2,6-dicarboxylate (1.0 g, 4.4 mmol, Intermediate 251) in anhydrous THF. A slight precipitate was observed during the addition. After stirring two hrs at room temperature an additional 0.5 equivalence of the morpholino-lithium reagent was added to the reaction and after an additional two hrs of stirring another 0.5 equivalence was added followed by stirring one hour to reach completion. The solvent was removed under reduced pressure and the residue was suspended in methylene chloride and the product was extracted with a sat. sodium bicarbonate solution (×3). The sodium bicarbonate portion was acidified with conc. HCl to pH 3 and then extracted with EtOAc (×10), followed by drying with MgSO₄and concentrating to a solid (0.8 g, 70%). MS (ES) MH⁺: 271 for C₁₁H₁₁ClN₂O₄. The solid was suspended in anhydrous toluene (75 mL) and to this was added triisopropylorthoformate (1.97 mL, 8.9 mmol) slowly followed by heating to reflux for 12 hours. After cooling to room temperature the solvent was removed under reduced pressure and the residue was suspended in 1N HCl. Basification to pH8 with saturated sodium bicarbonate followed by extraction with EtOAc (×3), drying with MgSO₄and removal of solvent yielded a tan solid. Purification by silica gel flash column (gradient elution to 3:1 EtOAc:CH₂Cl₂) yielded a white solid (0.23 g) MS (ES) MH⁺: 313 for C₁₄H₁₇ClN₂O₄; NMR: 1.33 (s, 3H) 1.35 (s, 3H) 3.41 (s, 2H) 3.44 (d, 2H) 3.58 (d, 2H) 3.68 (s, 4H) 5.17 (dt, 1H) 8.01 (d, 1H) 8.13 (d, 1H).

The following Intermediate was prepared by the procedure described in Intermediate 249 from the starting materials (SM) indicated.

Ex
Compound
Data
SM

250
isopropyl 4-chloro-6- [(dimethylamino)carbonyl] pyridine-2-carboxylate embedded image

MS (ES) MH⁺: 271 for C₁₂H₁₅ClN₂O₃ NMR: 1.35 (d, 6 H) 2.93 (s, 3 H) 3.03 (s, 3 H) 5.18 (dt, 1 H) 7.96 (d, 1 H) 8.11 (d, 1 H)
Intermediate 251 and dimethylamine

Intermediate 251
dimethyl 4-chloropyridine-2,6-dicarboxylate

Phosphorus pentachloride (45.5 g, 218 mmol) was weighed into a closed flask and suspended in chloroform. 4-hydroxypyridine-2,6-dicarboxylic acid (10.0 g, 55 mmol) was added and after heating at a gentle reflux for 3 days the reaction was complete (60% conversion). After cooling to 0° C. anhydrous methanol (150 mL) was added dropwise. Once the exotherm subsided the solvent was removed under reduced pressureand the residue was partitioned with EtOAc and water and the insoluble material was filtered, washed with EtOAc and dried (6.7 g). The EtOAc layer was washed with water, dried with MgSO₄and concentrated. Recrystallization with methanol yielded additional pure product (0.64 g). MS (ES) MH⁺: 230 for C₉H₈ClNO₄; NMR: 3.94 (s, 3H) 8.32 (s, 1H).

Intermediate 252
2-chloro-5-(ethoxycarbonyl)-1,3-thiazole-4-carboxylic acid

To a solution of ethyl 2-chloro-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate (2.5 g, 11 mmol, Intermediate 211) in acetone at 0° C. was slowly added a solution of chromium trioxide (2.26 g, 22 mmol) in 20% conc. Sulfuric acid in water (20 mL). After stirring at room temperature for 2 hrs, isopropanol (1 mL) was added to quench unreacted chromium trioxide. The reaction was diluted with water and the acetone was removed. Partitioning with methylene chloride (×3), drying with MgSO4 and concentrating yielded a white solid (2.3 g, 90%). MS (ES) MH⁺: 236 for C₇H₆ClNO₄S; NMR: 1.26 (t, 3H) 4.31 (q, 2H) 13.99-14.15 (m, 1H).

Intermediate 253
3,4-Dichloro-5-chloromethyl-1H-pyrrole-2-carboxylic acid ethyl ester

To a 4-neck 22 L round bottom flask equipped with an overhead stirrer, liquid addition funnel, nitrogen inlet and an internal temperature probe was charged (Intermediate 254, 2000 g, 13.6 mol) and carbon tetrachloride (12 L). The reaction mixture was cooled to −5° C. and sulfuryl chloride was added at a rate that the temperature did not exceed 0° C. (1 h). Resulting reaction mixture became very thick (as precipitate becomes heavy, significant gas evolution was observed) and was allowed to stir at 0° C. for a total of 4 h after addition. Precipitate was filtered and solid azeotroped with toluene to remove excess sulfuryl chloride. The solid was and dried in convection oven at 50° C. yielding 3 (2077 g, 62%) as a dark purple solid.

Intermediate 254
5-Methyl-1H-pyrrole-2-carboxylic acid ethyl ester

To a 4-neck 22 L round bottom flask equipped with an overhead stirrer, liquid addition funnel, nitrogen inlet and an internal temperature probe was charged ethyl 3-oxobutanoate (1952 g, 15.0 mol) and glacial acetic acid (5 L). The resulting solution was cooled to 0° C. with an ice water bath and an aqueous solution of sodium nitrite (1242 g, 18.0 mol, 1.2 eq, in 1875 ml of water) was added slowly (4.5 h) not allowing the internal temperature above 10° C. The homogeneous red solution was allowed to warm to ambient and stirred for 48 h. The solution color changed from light red to yellow. Reaction vessel was then placed in a heating mantle, fitted with a reflux condenser and acetylacetaldehyde dimethyl acetal (1982 g, 15.0 mol, 1 eq) was added in one portion (the top of the reflux condenser was left open to air to allow for the rapid gas evolution during the addition of the zinc). Zinc (dust, 2156 g, 33 mol, 2.2 eq) was added in portions (at a rate such that gas evolution was controlled) over 4 h. The addition of zinc brought the reaction to reflux and after addition the dark red solution was heated at reflux for an additional 1.5 h. Contents of the reaction were poured hot into a 50 L container with 20 kg of ice and allowed to stir for 16 h. Resulting suspension was filtered, dried in convection oven and recrystallized with hot heptane yielding a light yellow solid (312 g, 13.6% yield).

Intermediate 255
ethyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate

embedded image

To a stirred solution of potassium hydroxide (42 g, 752 mmol) in dry methanol (100 mL), at 0° C. and under an atmosphere of N₂, was added a solution of ethyl 4-oxopiperidine-1-carboxylate (26.4 mL, 29.96 g, 175 mmol) in dry methanol (75 mL) via syringe. The resulting solution was stirred for an additional 30 minutes under an atmosphere of N₂at 0° C. To it, in small portions over approximately 90 minutes, was added iodobenzene diacetate (84.6 g, 262 mmol). Temperature was kept near 0° C. throughout this time. The reaction was stirred overnight under an atmosphere of N₂, gradually reaching room temperature. Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf˜0.25) in the morning. The reaction was concentrated under vacuum. To the residue was added approximately 50 mL water; from this mixture was extracted the crude product with ethyl acetate (3×200 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude product was purified using column chromatography (silica gel; 10-65% ethyl acetate in hexanes), yielding 26.74 g (66%) of a pale yellow oil.

MS (ESI) M: 233 for C₁₀H₁₉NO₅. ¹H NMR (CDCl₃): 1.22 (t, 3H), 1.69-1.86 (m, 2H), 2.20 (m, 2H), 2.86 (t, 1H), 3.22 (s, 3H), 3.23 (s, 3H), 3.74 (m, 1H), 3.95 (m, 2H), 4.11 (q, 2H).

The following Intermediates were synthesized by an analogous method to Intermediate 28 or Intermediate 59 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

256
Cis(±)-ethyl 4-amino-3-(prop-
MS (ESP):
Intermediate

2-yn-1-yloxy)piperidine-1-
227 (M + H)
146

carboxylate
for C₁₁H₁₈N₂O₃

257
Cis(±)-Ethyl (4-amino-3-
MS (ES)
Intermediate

ethoxypiperidine-1-
MH⁺: 217
156

carboxylate
for C₁₀H₂₀N₂O₃

The following Intermediates were synthesized by an analogous method to Intermediate 37 or Intermediate 83 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

258
tert-Butyl(3S,4R)-4-{[(4-
MS (ES) MH⁺: 360 for
Intermediate 64 and

chloro-5-methyl-1H-pyrrol-
C₁₆H₂₃ClFN₃O₃;
Intermediate 6

2-yl)carbonyl]amino}-3-

fluoropiperidine-1-

carboxylate

259
tert-butyl(3S,4R)-4-{[(4-
MS (ESP): 530 (MNa⁺) for
Intermediate 263 and

chloro-3-fluoro-5-methyl-1-{[2-
C₂₂H₃₆ClF₂N₃O₄Si
Intermediate 64

(trimethylsilyl)ethoxy]methyl}-

1H-pyrrol-2-

yl)carbonyl]amino}-3-

fluoropiperidine-1-

carboxylate

The following Intermediates were synthesized by an analogous method to Intermediate 50 or Intermediate 74 from the starting materials (SM) given in the table below.

Int
Compound
Data
SM

260
4-Chloro-N-[(3S,4R)-3- fluoroxypiperidin-4-yl]-5- methyl-1H-pyrrole-2- carboxamide embedded image

MS (ES) MH⁺: 260 for C₁₁H₁₅ClFN₃O
Intermediate 258

261
4-chloro-3-fluoro-N-

Intermediate 262

[(3S,4R)-3-fluoropiperidin-

4-yl]-5-methyl-1H-pyrrole-
MS (ESP): 278 (MH⁺) for

2-carboxamide
C₁₁H₁₄ClF₂N₃O

Intermediate 262
tert-butyl(3S,4R)-4-{[(4-chloro-3-fluoro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidine-1-carboxylate

tert-butyl(3S,4R)-4-{[(4-chloro-3-fluoro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidine-1-carboxylate (Intermediate 259, 80 mg, 0.16 mmol) was dissolved in anhydrous THF (6 ml), followed by the addition of tetra-butyl ammonium fluoride (1 ml, 1M in THF) and ethylene diamine (1 mmol), the mixture was then stirred at 50° C. over night. After cooling down to room temperature, the reaction mixture was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium bicarbonate (10 ml) and brine (10 ml), dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (100%-70% hexanes/ethyl acetate) to give the desired product (55 mg).

MS (ESP): 378 (MNa⁺) for C₁₆H₂₂ClF₂N₃O₃

¹H-NMR (CDCl₃) δ: 1.46 (s, 9H); 1.84 (m, 2H); 2.24 (s, 3H); 2.89 (m, 2H); 4.28 (m, 2H); 4.50 (m, 1H); 4.70 (m, br, 1H); 6.32 (m, 1H); 9.36 (br, 1H).

Intermediate 263
4-chloro-3-fluoro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylic acid

tert-butyl 4-chloro-3-fluoro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate (Intermediate 264, 100 mg) was dissolved in N-methylpyrrolidinone (10 ml), heated to 200° C. for 30 minutes. The resulting solution was carried on to the next step without further purification.

MS (ESP): 307 (M⁻) for C₁₂H₁₉ClFNO₃Si

Intermediate 264
tert-butyl 4-chloro-3-fluoro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate

tert-butyl 3-bromo-4-chloro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate (Intermediate 265, 480 mg, 1.13 mmol) was dissolved in dry THF (8 ml), cooled down to −78° C., n-BuLi (2.5M in Hexane, 3.39 mmol) was added dropwise into the mixture via syringe and the mixture was stirred at −78° C. for 30 min followed by a quick addition of N-Fluorobenzensulfonimide (1.25 g, 3.96 mmol in 5 ml of THF/Toluene 1:1), the resulting mixture was then stirred at −78° C. for 30 min and slowly warmed up to room temperature during a period of 12 hrs. The reaction was quenched at 0° C. with drops of saturated NH₄Cl solution and further diluted with EtOAc (50 ml). The organic phase was washed with brine and dried over anhydrous MgSO₄, concentrated to an oil and purified by flash column chromatography eluted with 10% EtOAc in Hexanses. The desired product was obtained as an oil (125 mg).

MS (ESP): 364 (MH⁺) for C₁₆H₂₇ClFNO₃Si

¹H-NMR (CDCl₃) δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.58 (s, 9H); 2.31 (s, 3H); 3.52 (t, 2H); 5.70 (s, 2H).

¹⁹F-NMR (CDCl₃) δ: −148.85

Intermediate 265
tert-butyl 3-bromo-4-chloro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate

embedded image

Ethyl 3-bromo-4-chloro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate (Intermediate 266, 564 mg, 1.42 mmol), t-Butylacetate (330 mg, 2.84 mmol) and potassium t-butoxide (0.14 mmol) were mixed together and stirred at room temperature for 10 minutes, concentrated to an oil under vacuum. t-Butylacetate (330 mg, 2.84 mmol) and potassium t-butoxide (0.14 mmol) were added again into the reaction mixture, repeated the same procedure again. The resulting reaction crude was filtered through a short pass silica gel, washed with ethyl acetate, the combined filtrate was concentrated to an oil and purified by column chromatography (2% ethyl acetate in hexanses) to give the desired product as an oil (485 mg).

¹H-NMR (CDCl₃) δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.58 (s, 9H); 2.33 (s, 3H); 3.52 (t, 2H); 5.75 (s, 2H)

Intermediate 266
Ethyl 3-bromo-4-chloro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate

To a suspension of sodium hydride (76 mg, 3.16 mmol) in dry DMF (5 ml), solution of ethyl 3-bromo-4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 267, 420 mg, 1.58 mg) was added, the resulting mixture was stirred at 0° C. for 30 minutes until gas evolution seized. Trimethylsilyl-ethoylmethyl chloride (315 mg, 1.89 mmol) was added drop wise and stirred over night while allowing the reaction mixture warmed up to room temperature slowly. The reaction was quenched with cold water, diluted with ether (20 ml), washed with water and brine, the organic layer was dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (95% hexanes in ethyl acetate) to give the desired product as an oil (624 mg).

MS (ESP): 397 (MH⁺) for C_1-4H₂₃BrClNO₃Si

¹H-NMR (CDCl₃) δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.43 (t, 3H); 2.38 (s, 3H); 3.55 (t, 2H); 4.34 (q, 2H); 5.75 (s, 2H).

Intermediate 267
Ethyl 3-bromo-4-chloro-5-methyl-1H-pyrrole-2-carboxylate

Ethyl 4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 7, 300 mg, 1.6 mmol) was dissolved in dry dichloromethane (10 ml), N-bromosuccinimide (285 mg, 1.6 mmol) was added at 0° C. and resulting mixture was stirred at room temperature over night. The mixture was poured into cold sodium hydroxide aqueous solution (2M) (20 ml), extracted with diethyl ether (2×20 ml). The organic phase was then washed with water (20 ml) and brine (20 ml), dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (hexanes/ethyl acetate, gradient) to give the desired product as a yellowish solid. (424 mg).

MS (ESP): 266 (MH⁺) for C₈H₉BrClNO₂

¹H-NMR (CDCl₃) δ: 1.39 (t, 3H); 2.32 (s, 3H); 4.34 (q, 2H); 9.04 (s, br, 1H).

Intermediate 268
Trans(±)-tert-butyl-4-[(diphenylmethylene)amino]-3-hydroxypiperidine-1-carboxylate

tert-butyl-4-amino-3-hydroxypiperidine-1-carboxylate (11.9 g; 55 mmol) and benzophenone imine (10 g; 59 mmol; 1.05 eq.) were dissolved in anhydrous toluene and heated to reflux for 18 hrs. Monitored the reaction by TLC (30% EtOAc/hexanes with 0.1% triethylamine). The crude reaction was concentrated and purified by flash column chromatography. Isolation gave 18.4 g of the title compound in an 86% yield. LC/MS (ES⁺)[(M+H)⁺]: 381 for C₂₃H₂₈N₂O₃.

Intermediate 269
Cis(±)-tert-butyl-3-azido-4-[(diphenylmethylene)amino]piperidine-1-carboxylate

In a flame-dried flask triphenylphosphine (3.86 g; 14.7 mmol; 2 eq.) was dissolved in anhydrous THF (15 ml) and cooled to 0 C. DIAD (2.97 g; 14.7 mmol; 2 eq.) was slowly added dropwise. Upon addition a white precipitate formed. A THF solution containing tert-butyl-4-[(diphenylmethylene)amino]-3-hydroxypiperidine-1-carboxylate (Intermediate 268, 2.8 g; 7.36 mmol) was added (amount of THF added was such that the final concentration of alcohol was ca. 0.5-1M). The resultant reaction slurry was stirred at 0 C for 30 minutes. (PhO)₂PON₃(4.05 g; 14.7 mmol; 2 eq.) was then added and the reaction was allowed to warm to RT and stirred for 12 hrs. Monitored by LC/MS. The reaction was concentrated and purified by flash column chromatography (0-30% EtOAc/hexanes with 0.1% triethylamine). Isolation gave 2.13 g of the title compound in 71% yield. LC/MS (ES⁺)[(M+H)⁺]: 406 for C₂₃H₂₇N₅O₂.

Intermediate 270
Cis(±)tert-butyl-4-amino-3-azidopiperidine-1-carboxylate

embedded image

tert-butyl-3-azido-4-[(diphenylmethylene)amino]piperidine-1-carboxylate (Intermediate 269, 1.36 g; 3.3 mmol) was dissolved in 10 ml's of aqueous THF (5% H₂O). PPTS (850 mg; 3.4 mmol; 1.03 eq.) was added in a single portion. The initial cloudy solution became clear within minutes. Upon completion (as determined by LC/MS analysis) the reaction was concentrated and azeotropically dried with acetonitrile. No further purification. (LC/MS: see disappearance of starting material and formation of Ph₂C═O. Product is not observable due to lack of chromophore).

Intermediate 271
Cis(±)tert-butyl-3-azido-4-{[3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-1-carboxylate

Crude tert-butyl-4-amino-3-azidopiperidine-1-carboxylate (Intermediate 270, 3.3 mmol) was dissolved in anhydrous CH₂Cl₂(10 ml) and DIEA (1.27 g; 1.6 ml; 9.9 mmol; 3 eq.). The solution was cooled to 0 C and 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride (736 mg; 3.5 mmol; 1.05 eq.) was added. The reaction was complete within 30 minutes. Dilute with CH₂Cl₂and wash with H₂O (×2), brine and dried over Na₂SO₄. Filter and concentrate. Purify by flash column chromatography (0-60% EtOAc/hexanes). Isolation gave 967 mg in 69% yield over the two-step sequence. LC/MS (ES⁻)[(M−H)⁻]: 415, 417 for C₁₆H₂₂Cl₂N₆O₃.

Intermediate 272
Cis(±)N-(-3-azidopiperidin-4-yl)-3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamide hydrochloride

tert-butyl-3-azido-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-1-carboxylate (Intermediate 271, 967 mg; 2.3 mmol) was dissolved in 4N HCl in dioxanes (20 ml) and methanol (10 ml). The solution was stirred for 2 hours and monitored by LC/MS. Upon completion the solvent was removed and the crude reaction mixture was azeotroped with methanol to remove excess HCl. No further purification. LC/MS (ES⁺)[(M+H)⁺]: 317, 319 for C₁₁H₁₄Cl₂N₆O.

Intermediate 273
(2R)-2-Methoxypropan-1-amine hydrochloride (1725-162) tert-Butyl[(2R)-2-methoxypropyl]carbamate (Intermediate 277, 0.33 g, 1.74 mmol) and Hydrochloric acid (4 M, 1.5 mL) were combined and stirred at room temperature for two 15 hours. Then it was concentrated and triturated with diethyl ether to give white crystalline solid (0.20 g) as the product.

NMR: 1.14 (d, 3H), 3.30 (s, 3H), 3.35-3.45 (m, 2H), 7.99 (brs, 3H)

The following compounds were produced according to the procedure for Intermediate 273 or by hydrogenation using the starting materials listed.

Int
Compound
Data
SM

274
(2S)-2-methoxypropan-1-
NMR: 1.14 (d, 3H), 3.30 (s,
Intermediate

amine hydrochloride
3H), 3.35-3.45 (m, 2H), 7.99
278

(brs, 3H)

275
(2R)-1-Methoxypropan-2-
NMR: 1.14 (d, 3H), 3.29 (s,
Intermediate

amine hydrochloride
3H), 8.07 (brs, 3H), rest of
276

the peaks are buried under

huge water peak

Intermediate 276
Benzyl[(1R)-2-methoxy-1-methylethyl]carbamate

To a solution of benzyl[(1R)-2-hydroxy-1-methylethyl]carbamate (0.5 g, 2.38 mmol) in acetonitrile (20 mL), silver oxide (3.8 g, 13.09 mmol) is added followed by the addition of methyl iodide (1.94 mL, 23.8 mmol). The resultant mixture was stirred overnight at room temperature. The insoluble salt was filtered off and the filtrate was concentrated. The residue was flashed using silica and Ethyl acetate/hexanes system as eluent to give the desired product as clear oil (0.38 g).

MS (ES) MH+Na: 246 for C₁₂H₁₇NO₃;

NMR: 1.01 (d, 3H), 3.12-3.17 (m, 1H), 3.22 (s, 3H), 3.25-3.26 (m, 1H), 3.60-3.75 (m, 1H), 5.00 (s, 2H), 7.16 (d, 1H), 7.29-7.36 (m, 5H)

Intermediate 277
tert-Butyl[(2R)-2-methoxypropyl]carbamate

To a solution of tert-butyl[(2R)-2-hydroxypropyl]carbamate (0.4 g, 2.28 mmol) in THF (5 mL), sodium hydride (0.06 g, 2.51 mmol) was added at 0° C. The resulting solution was stirred for 30 minutes at that temperature and then methyl iodide (0.14 mL, 2.28 mmol) was added. The reaction was warmed to room temperature slowly and allowed to stir for an additional two hours. The reaction was quenched by adding water and extracted with ethyl acetate. The extract was washed with sodium bicarbonate solution, water and brine. It was dried over magnesium sulfate and concentrated. The desired product was obtained as clear oil (0.31 g) and it did not need any further purification.

NMR (CDCl₃): 1.15 (d, 3H), 1.43 (s, 9H), 3.31-3.33 (m, 2H), 3.34 (s, 3H), 3.77-3.81 (m, 1H), 4.66 (brs, 1H)

Intermediate 278
tert-Butyl[(2S)-2-methoxypropyl]carbamate(1725-160)

The title compound was synthesized by using the method analogous to the synthesis of Intermediate 277 starting with tert-butyl[(2S)-2-hydroxypropyl]carbamate and alkylating it with methyl iodide.

NMR (CDCl₃): 1.15 (d, 3H), 1.43 (s, 9H), 3.31-3.33 (m, 2H), 3.34 (s, 3H), 3.77-3.81 (m, 1H), 4.66 (brs, 1H)

The following Intermediate was prepared by the procedure described in Example 203 from the starting materials (SM) indicated

Ex
Compound
Data
SM

441
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH⁺: 605 for
Example 188 and [2-

dichloro-5-methyl-1H-pyrrol-
C₂₄H₃₃Cl₂N₅O₇S;
methoxy-1-

2-yl)carbonyl]amino}-3-

(methoxymethyl)ethyl]amine

methoxypiperidin-1-yl)-4-

(ChemPacific)

({[2-methoxy-1-

(methoxymethyl)ethyl]amino}

carbonyl)-1,3-miazole-5-

carboxylate

The following Intermediate was prepared by the procedure described in Example 383 from the starting materials (SM) indicated

Ex
Compound
Data
SM

442
2-((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-({[2- methoxy-1- (methoxymethyl)ethyl]amino} carbonyl)-1,3-thiazole-5-carboxylic acid embedded image

MS (ES) MH⁺: 578 for C₂₂H₂₉Cl₂N₅O₇S NMR: 1.77 (s, 2 H) 2.19 (s, 3 H) 3.24 (s, 3 H) 3.27 (s, 3 H) 3.38 (s, 5 H) 3.49 (s, 6 H) 4.32 (s, 2 H) 7.18 (s, 1 H) 8.93 (s, 1 H) 12.16 (s, 1 H) 16.17 (s, 1 H)
Example 441

The following Examples were prepared by the procedure described in Example 417 from the starting materials (SM) indicated

Ex
Compound
Data
SM

443
sodium 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-({[2- methoxy-1- (methoxymethyl)ethyl]amino} carbonyl)-1,3-thiazole-5- carboxylate embedded image

MS (ES) MH⁺: 578 for C₂₂H₂₈Cl₂N₅O₇SNa NMR: 1.70 (s, 2 H) 2.17 (s, 3 H) 3.21-3.26 (m, 6 H) 3.34 (s, 4 H) 3.35-3.38 (m, 6 H) 3.49 (s, 1 H) 3.86 (d, 1 H) 4.04-4.16 (m, 3 H) 4.22 (s, 1 H) 7.18 (d, 1 H) 12.17 (s, 1 H) 13.33 (d, 1 H)
Example 442

	Number	Date	Country
Parent	11816612	Nov 2009	US
Child	13759323		US

CHEMICAL COMPOUNDS

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

Provisional Applications (1)

Continuations (1)